Inco Medical: 2025 Annual Report

2 0 2 5

annual report

Yingke Medical Technology Co., Ltd.

Global Intech Health Global

Global INTCO Global Health April 2026

Corporate purpose

Use the crystallization of human wisdom to serve human health needs

Development vision

Become a world-class high-tech manufacturer of medical consumables and equipment

core values

Seek love, kindness and truth

Section 1 Important Tips, Table of Contents and Definitions

The company's board of directors, directors and senior managers guarantee that the contents of the annual report are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability.

The person in charge of the company, Liu Fangyi, the person in charge of accounting work, Feng Jie, and the person in charge of the accounting department (accounting officer) Jiao Yufa declare that they guarantee the authenticity, accuracy and completeness of the financial report in this annual report.

All directors have attended the board meeting where this report was considered.

This annual report involves forward-looking statements such as the company's future plans. Whether they can be realized depends on various factors such as national policies, market demand, organizational construction, etc., and there is a certain degree of uncertainty. These statements do not constitute the company's substantive commitments to investors. Investors and related parties should maintain adequate risk awareness and understand the differences between plans, forecasts and commitments. The company has elaborated on the relevant risk factors that may occur in the future in this annual report. For details, please refer to "11. Prospects for the Company's Future Development" and "(4) Possible Risks" in "Section 3 Management Discussion and Analysis". Investors are kindly requested to pay attention.

2025 is a year when the global economic landscape is reshaped amidst shocks and industry cycles are adjusted to create new opportunities. It is also a key year for Yingke Medical to face multiple challenges and overcome industry cycles with strategic resilience. Faced with multiple pressures such as the in-depth adjustment of the supply and demand pattern of the disposable glove industry and the continuous escalation of tariff barriers in the U.S. market, the company's management, with firm strategic judgment and efficient decision-making and execution, led all employees to face the difficulties and work hard, consolidate core advantages in the change, open up room for growth in innovation, achieve steady repair of operating performance and continuous accumulation of high-quality development momentum, and submitted an answer to shareholders and society that demonstrates resilience and builds strength for the future.

In the past two years, the disposable glove industry has experienced a difficult adjustment period from "oversupply" to "rebalancing supply and demand". On January 1, 2025, the United States further imposed tariffs, which had an impact on the company's original U.S. market. Faced with this severe challenge, the company quickly adjusted its market strategy and increased its resource investment in non-US emerging markets such as Europe and Asia, as well as domestic potential markets. By deepening the local marketing network, expanding strategic customer cooperation, and strengthening brand channel penetration, the company's revenue share in overseas non-U.S. markets will significantly increase in 2025, and domestic market revenue will achieve double-digit growth, demonstrating the company's strong market adaptability and development resilience with practical actions.

With continuous investment in technological innovation and product upgrades, we have opened up a new track for growth through differentiated competition. Facing the industry environment with intensified homogeneous competition, the company adheres to the "innovation-led" strategy. In 2025, the company launched a number of industry-first products such as Syntex™ disposable synthetic latex protective gloves. At the same time, it deepened lean production, comprehensively improved operational efficiency and production management levels, and steadily promoted the upgrading and iteration of the product structure to high-margin areas.

The company deeply implements the development concept of "green manufacturing" and increases the use of green renewable energy such as wind energy and solar energy. While effectively reducing production costs, it continues to improve its ESG core competitiveness and lays a solid foundation for the company's sustainable development. At the same time, the company internally promotes special actions of "cost reduction and efficiency improvement" to further improve resource utilization efficiency and reduce production costs through digital operation upgrades and supply chain strategy optimization.

In 2025, the profitability of the company's main business will significantly improve, and operating cash flow will continue to improve, fully demonstrating the company's stable operating background and broad development space.

The company's profit distribution plan reviewed and approved by the board of directors this time is as follows: based on the total share capital on the equity registration date when the company's equity distribution is implemented, minus the shares repurchased in the company's special repurchase account, a cash dividend of 1.00 yuan (tax included) will be distributed to all shareholders for every 10 shares, 0 bonus shares (tax included) will be given, and 0 shares will be transferred to all shareholders for every 10 shares from the capital reserve.

Directory

CONTENTS

Section 1 Important Tips, Table of Contents and Definitions 01

Section 2 Company Profile and Main Financial Indicators 03

Section 3 Management Discussion and Analysis 07

Section 4 Corporate Governance, Environment and Society 34

Section 5 Important Matters 53

Section 6 Changes in Shares and Shareholders 74

Section 7 Bond-related situations 82

Section 8 Financial Report 87

File directory for reference

1. Financial statements signed and stamped by the person in charge of the company, the person in charge of accounting work, and the person in charge of the accounting department (accounting supervisor).

2. The original audit report containing the seal of the accounting firm and the signature and seal of the certified public accountant.

3. The original copies of all company documents and announcements publicly disclosed during the reporting period.

4. 2025 annual report containing the signature of the legal representative.

5. Other relevant information.

First program heavy

Register to

and mention

explain

righteousness ︑

Section 1 Important Tips, Table of Contents and Definitions

Definition

Interpretation item refers to the interpretation content

Inco Medical, Inco, the Company, the Company, and the parent company refer to Inco Medical Technology Co., Ltd.

Shandong Yingke refers to Shandong Yingke Medical Products Co., Ltd.

Shanghai Yingen refers to Shanghai Yingen International Trading Co., Ltd.

Jiangsu Yingke refers to Jiangsu Yingke Medical Products Co., Ltd.

Anhui Yingke refers to Anhui Yingke Medical Supplies Co., Ltd.

Hong Kong Inco refers to Intco Medical Products (Hong Kong) Co., Ltd. American Inco refers to Intco Medical Industries Inc.

Intco Europe Gmbh

Vietnam Inco refers to Basic International Vie Tnam Co., Ltd (former name: Intco Medical Vietnam Co., Ltd) Vietnam Technology refers to Intco Medical Technology Vietnam Company LimitedVietnam Basic Medical refers to Basic Medical Vietnam Co., LtdSingapore Inco Investment refers to Intco Medical Investment Singapore Pte. Ltd.Singapore Inco refers to Intco Medical Singapore Pte. Ltd. Jiangxi Inco refers to Jiangxi Inco Medical Co., Ltd.

Intco Canada Inc.

Anqing Yingke refers to Anqing Yingke Medical Co., Ltd.

Anhui Yingyi refers to Anhui Yingyi Thermal Power Co., Ltd.

Anhui Kaize refers to Anhui Kaize New Materials Co., Ltd.

Anhui Guoyi refers to Anhui Guoyi Mold Technology Co., Ltd.

Intco Medical International refers to Intco Medical International (Hong Kong) Co., Ltd. Japan Inco refers to Intco Medical Japan Co., Limited Jiangxi Yingcai refers to Jiangxi Yingcai Technology Co., Ltd.

Intco Malaysia refers to Intco Medical Sdn. Bhd.

Warburg Pincus refers to Warburg Pincus Global Growth 14.L.P. Huizhong Fund refers to Horizon Capital investment fund L.P. Yingke Renewable Resources Co., Ltd.

Shanghai Yingcong refers to Shanghai Yingcong Enterprise Management Consulting Partnership (Limited Partnership) China Securities Regulatory Commission refers to China Securities Regulatory Commission

Convertible bonds refer to convertible corporate bonds

Yuan, RMB 10,000, RMB 100 million refers to RMB, RMB 10,000, RMB 100 million Shenzhen Stock Exchange refers to Shenzhen Stock Exchange

The reporting period and the end of the reporting period refer to January 1, 2025 to December 31, 2025, and the same period of the previous year on December 31, 2025. The same period refers to the period from January 1, 2024 to December 31, 2024.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 02

Chapter 2 Lord

important company

financial simplicity

service agency

refers to and

mark

Section 2 Company Profile and Main Financial Indicators

1. Company information

Stock abbreviation Yingke Medical Stock code 300677 Chinese name of the company Yingke Medical Technology Co., Ltd.

The company’s Chinese abbreviation Yingke Medical

The company’s foreign name (if any) INTCO MEDICAL TECHNOLOGY CO.,LTD.

The legal representative of the company Liu Fangyi

Registered address: No. 18, Qingtian Road, Linzi District, Zibo City

Postal code of registered address 255414

Historical changes of company registered address Not applicable

Office address No. 18, Qingtian Road, Linzi District, Zibo City

Postal code for office address 255414

Company website http://www.intcomedical.com.cn

Email [email protected]

2. Contact person and contact information

Secretary of the Board of Directors Securities Affairs Representative

Name Feng Jie Liu Wenjing, Luo Bingqi Contact address No. 18, Qingtian Road, Linzi District, Zibo City No. 18, Qingtian Road, Linzi District, Zibo City Tel 0533-6098999 0533-6098999 Fax 0533-6098966 0533-6098966 Email [email protected] [email protected]

3. Information disclosure and preparation location

The website of the stock exchange where the company discloses its annual report: Shenzhen Stock Exchange (http://www.szse.cn)

Juchao Information Network (http://www.cninfo.com.cn) "China Securities News" and "Shanghai Securities News"

The media name and website where the company discloses its annual report

"Securities Times" "Securities Daily"

The company's annual report is prepared at No. 18, Qingtian Road, Linzi District, Zibo City

4. Other relevant information

Accounting firm hired by the company

Name of accounting firm Tianjian Accounting Firm (Special General Partnership)

Office address of the accounting firm: 28th Floor, T2 Office Building, Runao Business Center, Pinglan Road, Xiaoshan District, Hangzhou City, Zhejiang Province Name of the signing accountant: Fei Fanghua, Li Jingcheng

The sponsor institution hired by the company to perform continuous supervision responsibilities during the reporting period

Applicable √ Not applicable

Financial consultant hired by the company to perform continuous supervision duties during the reporting period

Applicable √ Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 04

Section 2 Company Profile and Main Financial Indicators

5. Main accounting data and financial indicators

Whether the company needs to retroactively adjust or restate previous years’ accounting data

Yes √ No

2025 2024 Increase or decrease this year compared with the previous year 2023

Operating income (yuan) 9,925,819,444.72 9,523,317,123.49 4.23% 6,918,724,492.00 Net profit attributable to shareholders of listed companies (yuan) 1,010,699,970.94 1,465,476,194.01 -31.03% 382,997,569.00

Attributable to shareholders of listed companies

396,851,301.89 1,167,265,063.93 -66.00% 87,167,721.00

Net profit after deducting non-recurring gains and losses (yuan)

Net cash flow generated from operating activities (yuan) 1,885,029,379.56 1,079,057,818.26 74.69% 502,407,486.00 Basic earnings per share (yuan/share) 1.58 2.26 -30.09% 0.58 Diluted earnings per share (yuan/share) 1.57 2.26 -30.53% 0.58 Weighted average return on equity 5.67% 8.76% -3.09% 2.40%

End of 2025 End of 2024 Increase or decrease at the end of this year compared with the end of the previous year End of 2023

Total assets (yuan) 40,090,472,559.57 34,630,896,412.44 15.77% 27,079,441,476.00 Net assets attributable to shareholders of listed companies (yuan) 18,253,839,363.41 17,404,080,149.52 4.88% 16,028,587,817.00

The company's net profit before and after deducting non-recurring gains and losses in the past three fiscal years, whichever is lower, is negative, and the audit report for the most recent year shows that there is uncertainty in the company's ability to continue operating.

Yes √ No

The lower of the company's total audited profit, net profit, and net profit after deducting non-recurring gains and losses during the reporting period is negative.

Yes √ No

Whether the company's share capital has changed from the end of the reporting period to the date of disclosure of the annual report due to the issuance of new shares, additional issuance, rights issue, equity incentive exercise, repurchase, etc., and whether the amount of owner's equity has been affected

√ Yes No

Preferred stock dividends paid 0.00

Perpetual bond interest paid (yuan) 0.00

Fully diluted earnings per share calculated using the latest share capital (yuan/share) 1.5436

6. Main financial indicators by quarter

Unit: Yuan

First quarter Second quarter Third quarter Fourth quarter

Operating income 2,493,933,645.56 2,419,505,397.85 2,511,275,781.81 2,501,104,619.50 Net profit attributable to shareholders of listed companies 352,721,895.21 357,718,088.72 213,970,729.66 86,289,257.35 Net profit after deducting non-recurring gains and losses attributable to shareholders of listed companies 246,606,613.51 153,594,615.49 84,280,208.92 -87,630,136.03 Net cash flow generated from operating activities 406,102,817.23 339,379,743.35 361,199,718.49 778,347,100.49

Are there any significant differences between the above financial indicators or their totals and the relevant financial indicators disclosed by the company in quarterly reports and semi-annual reports?

Yes √ No

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 05

Section 2 Company Profile and Main Financial Indicators

7. Differences in accounting data under domestic and foreign accounting standards

1. Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

Applicable √ Not applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with international accounting standards and Chinese accounting standards.

2. Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

Applicable √ Not applicable

During the reporting period, there was no difference between the net profit and net assets in the financial reports disclosed in accordance with foreign accounting standards and Chinese accounting standards.

8. Non-recurring profit and loss items and amounts

√ Applicable Not applicable

Unit: Yuan

Item Amount in 2025 Amount in 2024 Amount in 2023 Description of gains and losses from disposal of non-current assets

13,554,511.38 -54,634,096.92 -21,101,910.00

(Including the write-off portion of asset impairment provisions that have been provided)

Government subsidies included in current profits and losses

(Closely related to the company’s normal business operations and in compliance with the national

43,301,339.33 38,180,572.87 74,198,840.00

Policy provisions, enjoyment according to determined standards, and the company's

Except for government subsidies that have a lasting impact on profits and losses)

Except for effective hedging related to the company’s normal business operations

In addition to hedging business, non-financial enterprises hold financial assets

698,220,162.88 342,943,640.94 263,013,357.00

and gains and losses from changes in fair value of financial liabilities

and gains and losses arising from the disposal of financial assets and financial liabilities

Reversal of impairment provision for accounts receivable subject to separate impairment test 2,974,934.00 Other non-operating income and expenses other than the above items -14,382,435.77 -13,047,070.48 -10,119,674.00 Other profit and loss items that meet the definition of non-recurring gains and losses 1,377,566.00

Less: Impact on income tax 125,052,599.21 14,872,796.16 13,314,196.00 Impact on minority shareholders’ equity (after tax) 1,792,309.56 359,120.17 1,199,069.00 Total 613,848,669.05 298,211,130.08 295,829,848.00 --

Details of other profit and loss items that meet the definition of non-recurring profits and losses:

Applicable √ Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

Applicable √ Not applicable

The company does not define the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 06

Section 3 and tube

Reasoning

analysis layer

discuss

On

Section 3 Management Discussion and Analysis

Business introduction

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 08

Section 3 Management Discussion and Analysis

1. The main business of the company during the reporting period

The company needs to comply with the disclosure requirements of the "Medical Device Business" in the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 4 - GEM Industry Information Disclosure".

(1) Main business

The company is a comprehensive medical care product supplier based in China, with business covering the world. Since its establishment, the company has always been customer-oriented and committed to providing high-quality medical supplies and services to the global medical industry, industry, service industry and individuals. The company is headquartered in Zibo, Shandong. Its main business covers three major segments: personal protection, rehabilitation care, and other products. Its main products include disposable gloves, wheelchairs, hot and cold compresses, electrode pads and other types of care products. The products are widely used in medical institutions, elderly care institutions, household daily use and other related industries. After years of development, the company has become one of the world's leading suppliers of medical consumables.

Disposable gloves are the company's current core business, with excellent market share in China and around the world. Whether it is innovative automated production facilities, professional technology or advanced production processes, it has a significant leading edge in the industry.

Currently, the company has six domestic production bases in Anhui Huaibei, Anhui Anqing, Jiangxi Jiujiang, Shandong Weifang, Jiangsu Zhenjiang and Shandong Zibo. At the same time, it completed the preliminary construction and commissioning of overseas production capacity during the reporting period.

The company's products are mainly exported to more than 150 countries and regions in the Americas, Europe, Asia, Africa and Oceania, serving more than 15,000 customers worldwide.

Relying on the company's advantages in research and development capabilities, production facilities, production capacity scale, capital strength, supply chain management, marketing network and brand, the company is fully prepared to seize market opportunities, further strengthen its leadership position in the disposable gloves industry, and is determined to become the most competitive company in the global personal protective equipment industry.

(2) Main products

An overview of the company's main products is as follows:

Category Main Products Application Examples

Disposable nitrile gloves are widely used in medical care and examination,

Disposable PVC gloves for food processing, precision electronics and

Personal protection disposable PE gloves

other industries to provide targeted

Isolation suit

Personal protection against hazardous materials.

mask

Electric wheelchairs are mainly used for disabled people or those with

Manual wheelchairs are provided for those in need

Rehabilitation care electric scooter

mobility aid or other means

walker

Meet daily care needs.

Medical bedside table

Ice pack/heat pack for medical, surgical and

Warm patch

Daily care.

hot and cold bags

Other products

ECG electrodes

Label electrode

steam eye mask

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 09

Section 3 Management Discussion and Analysis

1. Personal protection

The company's medical protection products mainly include disposable nitrile gloves, disposable PVC gloves, isolation gowns and other protective equipment, which are widely used in medical care and inspection, and can also be used in many industries such as food processing, precision electronics, retailers and supermarkets. Among them, disposable nitrile gloves and disposable PVC gloves are the company's main products. Masks and caps are also the company's more important personal protection products. The above products are mainly produced by the company independently, and other protective products are mainly purchased from external sources. While focusing on the production of main products, the company further enriches its product portfolio and provides customers with products flexibly and comprehensively.

Disposable nitrile gloves disposable PVC gloves PE gloves masks

(1) Disposable nitrile gloves

Disposable nitrile gloves are a kind of synthetic rubber gloves. They are made of nitrile latex as the main raw material and are vulcanized by the dipping process. They are acid-resistant, alkali-resistant, oil-resistant, odorless, tasteless, non-toxic and safe. They also have good tensile strength, abrasion resistance and puncture resistance. They do not contain proteins in latex that are prone to allergic reactions in the human body. They are widely used in medical examination, chemical industry, electronics and other industries.

The company's main disposable nitrile gloves are disposable medical nitrile examination gloves and disposable nitrile protective gloves. Disposable medical nitrile examination gloves are lightweight, thin and soft, with high elasticity and durability. They have a skin-like touch and can fit snugly on the hands, making them suitable for delicate operations such as medical purposes. The company's disposable medical nitrile examination gloves have also passed US FDA, EU CE and other certifications. They are made of upgraded formulas and have a comfortable feel, high elasticity and strong durability. They fit closely to the hands and can isolate various chemicals and other harmful substances, providing reliable protection.

The disposable nitrile gloves produced by the company meet the test parameters under mainstream quality standards, such as tensile strength, elongation, barrier integrity and protein residues, etc., which all meet the quality standards.

In addition, the company's disposable nitrile gloves are usually available in five sizes from XS to XL, as well as in blue, purple, pink, black and other colors to meet the different needs and preferences of customers.

During the reporting period, the company independently developed and launched disposable Syntex™ gloves. The company's Syntex™ gloves do not contain natural latex protein and are hypoallergenic, highly elastic and have excellent puncture resistance. The cost is controllable, it can resist the price fluctuation of natural latex, and its performance is comparable to latex gloves, with more cost advantages.

Disposable nitrile gloves are widely used in medical examinations, catering services, industrial labor insurance, dental clinics and other fields, as shown below:

Medical examination Catering service Industrial labor insurance Dental clinic

At present, disposable nitrile gloves have replaced disposable latex gloves as the mainstream disposable glove product, and are expected to gain a higher market share in the future. as a pioneer

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 10

Section 3 Management Discussion and Analysis

The company began producing nitrile gloves in 2012 and has now become one of the most experienced manufacturers in the world. It seizes the growth opportunities of nitrile gloves with high quality and promotes the development of new products. The company's technology, resources, capital and marketing network in producing and selling high-end medical-grade nitrile gloves make the company stand out among its peers. In addition, the production centers of disposable nitrile gloves are mainly in Southeast Asia and China. Therefore, the company's production capacity layout can further leverage its location advantages.

(2) Disposable PVC gloves

Disposable PVC gloves are mainly made of PVC paste resin and plasticizer. They are plasticized and molded by a dipping process. They are acid-resistant, alkali-resistant, odorless, tasteless, non-toxic and safe. PVC gloves are not only widely used in medical, electronics and food processing industries, but are also suitable for household cleaning and other daily personal protection.

The company provides disposable PVC glove products for various purposes, mainly including disposable medical PVC examination gloves, disposable PVC protective gloves, and Synmax gloves. Disposable medical PVC examination gloves are medical-grade gloves made of new and improved materials, which are lightweight and soft to the touch; disposable PVC protective gloves are soft, durable, easy to wear, and have a wide range of application scenarios, especially suitable for contact with acid, liquid or alcohol-containing food; the company's Synmax gloves have some of the excellent characteristics of nitrile gloves, and are more durable and lower in cost. They are increasingly popular with customers because of their exquisite appearance and excellent quality. The company's disposable PVC gloves are also available in a variety of sizes and colors to meet the different needs and preferences of customers.

Disposable PVC gloves are widely used in medical examination, planting, catering services, cleaning and disinfection, etc., as shown below:

Medical Examination Implantation Catering Service Cleaning and Disinfection

Most of the world's disposable PVC gloves are produced in China. The company has geographical advantages and can obtain high-quality raw materials, sufficient labor and other resources when producing disposable PVC gloves. The company has accumulated many years of industry experience, and its glove production facilities are equipped with advanced automation technology. Relying on its geographical location and production technology advantages, the company's disposable PVC gloves have been highly recognized by the market.

(3) Other protective products

Relying on the R&D, production experience and global marketing channel advantages accumulated in the disposable glove industry, the company is demand-oriented and continuously expands its product portfolio to provide various types of personal protective equipment to meet customers' one-stop purchasing needs. The company's other protective products mainly include disposable PE gloves, disposable PE aprons, masks, caps, etc., which are widely used in medical examination and nursing, experimental research, precision instrument processing, catering services, and household daily necessities.

Disposable PE gloves and disposable PE aprons are widely used in food processing and other industries to provide basic personal protection. Masks are important personal protective equipment that can keep out bacteria, dust and other harmful substances and are often used in daily activities.

Medical mask PE gloves PE apron strip hat/round hat

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 11

Section 3 Management Discussion and Analysis

In order to meet customers' one-stop purchasing needs, the company purchases some finished products from selected personal protective equipment suppliers, which allows the company to focus on producing its main products while providing flexibility to customers. The company has a strict quality control system for suppliers of personal protective equipment to ensure that their products meet the quality level promised by the company.

The company now has favorable conditions to develop other personal protective products. First, the company has established an excellent international reputation for providing disposable gloves and built a comprehensive marketing network. Secondly, the company has accumulated sufficient funds to lay a solid foundation for future production capacity construction and other work. Finally, the company has accumulated rich experience in technology-intensive manufacturing and has abundant technical resources for the research and development of other personal protective products. The company still has broad room for development in other personal protective product fields in the future.

2. Rehabilitation and nursing care

The company's rehabilitation care products belong to the type of walking-assisted products in the rehabilitation care industry, including electric wheelchairs, manual wheelchairs, walkers, walkers, canes and medical bedside tables. They are transportation tools for physically disabled people, the elderly and people with limited mobility, and are used to assist walking, hospital medical care and daily care for the disabled. The company's main rehabilitation care equipment is wheelchairs, among which electric wheelchairs are high-end products with long battery range, high-quality motors, phone holders and other optional components.

Electric wheelchair Manual wheelchair Electric lift Electric scooter

3. Other products

The company's other products mainly include health care products and examination consumables. Physiotherapy products include ice/heat therapy patch products, such as instant ice/heat patches, physiotherapy bags and ice pads for pets. They are mainly used for medical care, sports care and daily care. They are used to cool down and reduce fever, apply cold compresses to stop bleeding, or generate heat to keep warm. They are relatively easy to use. Inspection consumables include ECG electrode pads, label electrodes (TAB), electrosurgical pens, negative plates, electrode paper, negative plate connecting wires and other related products, which are mainly used for medical examinations.

Warm baby steam goggles diagnostic electrodes wired electrodes

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 12

Section 3 Management Discussion and Analysis

2. Industry conditions of the company during the reporting period

From 2020 to 2021, there was an extreme imbalance in supply and demand in the disposable glove market, and companies in the industry generally expanded production capacity. From 2022 to 2023, market demand gradually returned to a steady state. Downstream customers had too much stock in the early stage and needed a certain period of time to digest the inventory. As a result, short-term procurement demand in the overall market fell sharply, turning from short supply to oversupply. At the same time, competition among original companies and new entrants in the industry is fierce, and price competition has emerged to seize market share. Product sales prices have gradually returned to normal or even lower, which will inevitably lead to a decline in the company's overall sales revenue. Starting from the second half of 2023, the backlog of inventory in the downstream of the industry has entered the final stage of digestion, the effect of clearing high-cost production capacity and old production capacity has appeared, and the concentration of the industry's supply side has increased. In 2024, the overall capacity utilization rate of the industry will generally increase, and the supply and demand relationship will gradually return to balance.

2025 will be a year in which the global economic landscape is reshaped amidst shocks and industry cycles are adjusted to create new opportunities. Faced with the continued escalation of tariff barriers in the U.S. market, the supply and demand pattern of the disposable glove industry is facing in-depth adjustments, and resource allocation is gradually diverging into different regional markets.

As the awareness of medical hygiene and protection continues to increase in various industries around the world, the demand for gloves, as one of the indispensable products in the medical care field, is still driven by stable and sustained market demand. The demand for disposable gloves will increase to a certain extent after 2020 compared with the previous base. Developed countries such as the United States, Europe, and Japan are the main consumer markets for disposable gloves. Employees in the medical care, food, industrial labor insurance and other industries in these countries widely and frequently use disposable gloves in various work and life scenarios based on usage habits and legal requirements. The huge and steadily growing market demand in these countries ensures sustainable growth space for glove consumption.

There are varying degrees of increase in market demand in developing countries and regions. China is the largest developing country in the world and is the main manufacturing base for disposable gloves in the global market. With the improvement of national protection awareness and the improvement of consumption habits, China has become an important consumer market for disposable gloves and has huge growth potential. In the markets of developing countries, with the continuous improvement of economy and living standards, disposable gloves will be more widely used in the future. Therefore, the Chinese market and the markets of developing countries are important sources of growth for the disposable gloves market.

3. Core competitiveness analysis

The company is the world's leading supplier of personal protective equipment with operations all over the world. The company's disposable gloves business has an excellent market share in China and around the world.

In recent years, the company has rapidly expanded production capacity and upgraded production equipment, and has become a global leader in the disposable glove industry. As of the end of the reporting period, the company's annual production capacity of disposable non-latex gloves reached 103 billion pieces, of which the annual production capacity of disposable nitrile gloves was 70 billion pieces and the annual production capacity of disposable PVC gloves was 33 billion pieces. Since the beginning of 2020, the market demand for disposable gloves industry has grown sharply. With the improvement of public health awareness and the increasingly widespread use of disposable gloves, the global disposable gloves market will continue to expand in the future.

At present, the company has achieved a leading position in China and the global market. As the business continues to grow, the company has cultivated strong comprehensive capabilities around R&D, technology, equipment, capital, supply chain, marketing, team management and branding, consolidating the company's core advantages. The company actively seizes the growth and development opportunities in the industry and further consolidates the company's market leadership position in the industry.

(1) Technical advantages

The company has accumulated more than 15 years of production and research and development experience, fully integrating hardware, software, infrastructure, and the company's proprietary technology and expertise. The company's new product research and development projects focus on the core categories of disposable nitrile and PVC gloves, focusing on the launch of clean room gloves, skin care gloves, housework nitrile gloves and other series of products. The above-mentioned new products have achieved breakthroughs in diverse application scenarios such as electronics and chip manufacturing, daily personal care, household cleaning, etc. At the same time, they have completed innovative upgrades in product packaging formats and significantly improved their overall competitiveness.

The company has established a complete production process and can produce medical care products stably and efficiently. At the same time, the company continues to improve the automation of core equipment and fully applies advanced precision distributed control systems (DCS systems) to make process control more precise.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 13

Section 3 Management Discussion and Analysis

(2) Equipment advantages

With technological advancement and equipment upgrading, the glove industry has become a technology-intensive industry. The company has industry-leading disposable glove production equipment, equipped with advanced automation equipment, independently designed production lines and precision DCS systems. The company has reached strategic cooperation with many of the world's leading equipment technology companies, and the technical level of production equipment has been continuously improved.

At present, the company has accumulated rich experience in independent research and development and design of automated production lines, which has greatly reduced labor and energy consumption, and can stably manufacture medical-grade gloves. The company's standard nitrile glove production line is more than 1.6 kilometers long and has about 500 control points to ensure efficient and stable production and low energy consumption. At the same time, the company's precision DCS system has realized automatic temperature control and liquid level control in the production process, significantly improving production efficiency and product quality. According to the temperature and humidity of the production site and the operating status of the production line, the production process can be precisely controlled. During the reporting period, the yield rate of the company's glove products remained above 99%.

(3) Capital advantages

The glove industry is also a capital-intensive industry. For example, the investment in building a nitrile double-hand mold production line developed by a company in China exceeds 25 million yuan. Building a large-scale glove factory requires a large amount of capital investment. The investment scale is usually more than 1 billion yuan, and the production cycle is as long as 12 to 18 months. The company's excellent performance in 2020 and 2021 has accumulated sufficient capital for the company. At the same time, relying on the listed company platform, the company has smooth financing channels and can achieve rapid production capacity expansion in line with market demand. Judging from the current situation of the industry, high investment costs and long construction cycles constitute capital barriers for new entrants, requiring long-term high investments to generate profits, which enables the company to maintain a long-term advantageous position in future competition.

Anhui Huaibei Production Base Anhui Anqing Production Base

Jiangxi Jiujiang Production Base Shandong Qingzhou Production Base

Anhui Kaize New Materials Co., Ltd. Anhui Guoyi Mold Technology Co., Ltd.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 14

Section 3 Management Discussion and Analysis

Jiangsu Zhenjiang Production Base Yingke Medical Intelligent Medical Device R&D Marketing Technology Park

Modern intelligent warehousing and intelligent production line

(4) Supply chain advantages

The company has now established an efficient supply chain that integrates raw materials, energy, production, warehousing and logistics and connects global sales and marketing networks, maintaining the company's continued growth.

In terms of raw materials, China's petrochemical industry is mature and provides sufficient raw materials for the production of disposable gloves. As of the end of the reporting period, the company's two nitrile latex manufacturers, Shandong Haode Plastic Co., Ltd. and Anhui Kaize New Materials Co., Ltd., were in normal production and operation. At the same time, the company also holds shares in two nitrile latex production companies to ensure the supply of nitrile latex raw materials and the improvement of product quality. In addition, the company leverages its in-house R&D capabilities to collaborate with research partners to develop innovative materials. Currently, the company is cooperating with Qingdao University of Science and Technology, one of China's top rubber materials research institutions, to develop innovative materials and new formulas for disposable gloves.

In terms of energy, the company has obtained energy consumption indicators for all operating production bases. The main energy used is clean coal, which has a cost advantage compared to other energy sources. At the same time, during the reporting period, we reduced energy consumption by monitoring energy consumption in the factory, energy-saving renovation of production equipment, and regular inspections of energy-using equipment. We intelligently analyzed the energy consumption data indicators of each workshop, formulated improvement policies for workshops with large unit consumption, and carried out energy-saving renovations on waste heat recovery and utilization, cooling water recovery, air compressor systems, etc. during production operations. Through the improvement and optimization of production equipment, we continued to reduce unit energy consumption.

In terms of production and logistics, the company's production base is located in an area with a large number of skilled workers and convenient transportation facilities, which can meet the needs of expansion and achieve cost-effectiveness. The location is convenient for railway, highway, waterway and air transportation, with obvious location advantages and good transportation conditions. Since most of the company's base construction projects are key government investment projects, it can obtain better preferential policies and conditions.

The company's efficient supply chain makes the company stand out from the industry. With the development of its business, the company believes that it can gain more market share in China and around the world.

(5) Marketing advantages

The company has always adopted a global marketing strategy, established a comprehensive sales and marketing network, and has a professional marketing team of 476 people at home and abroad. As of the end of the reporting period, the company continued to provide high-quality products that meet different local standards to more than 15,000 customers in more than 150 countries and regions, earning the company reputation and the trust of global customers.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 15

Section 3 Management Discussion and Analysis

The company has a broad customer base, which mainly includes large-scale international medical product wholesalers, retailers (such as pharmacies, e-commerce platforms and chain stores), trading companies and enterprises in different industries (such as manufacturing and catering service companies). The company is committed to maintaining and developing long-term cooperative relationships with customers to further promote the company's products around the world.

Based on customers' purchasing needs for the company's products, the company assigns professional marketing teams to provide services to different types of customers around the world. Strategically, the company prioritizes customer base expansion, production capacity improvement and new product research and development, thereby further enhancing the company's marketing network and brand awareness. At the same time, the company also increases brand awareness through cooperation with new media and leading e-commerce platforms (such as Tmall, JD.com, Pinduoduo, etc.).

(6) Team advantages

The company's founder and chairman, Mr. Liu Fangyi, has been engaged in the international trade business of disposable gloves and other protective products, wheelchairs and other care products since the early 1990s, and has more than 30 years of experience in the industry. Mr. Liu Fangyi was engaged in the glove business in the United States before founding the company. He has a precise grasp of the development trends of the glove industry and has achieved remarkable results in marketing to major customers. Its industry expertise, strategic vision and strong execution capabilities have led the company's business growth. In 2020, he won the "2020 Chinese Enterprise Economic Figure of the Year", "2020 Industry Innovative Figure of the Year", and "2020 China's Top Ten Brands of the Year". In 2021, he won the "2021 Outstanding Quality Person Award" and the "Ten Years Outstanding Business Leader Award". In 2022, he won the title of "Top Ten Leading Figures in China's Pharmaceutical Industry". In 2024, he won the "2024 Forbes China Top 30 Overseas Leaders", the "ESG Pioneer 60" Annual ESG Explorer Award, and the "Entrepreneur Leadership Award" at the 7th Annual Investment Conference of China Finance Association. In 2025, he won the title of "Outstanding Contributor to the Pharmaceutical Industry".

Mr. Liu Fangyi leads a dedicated middle and senior management team, most of whom have been with the company for more than 10 years, have rich industry experience, and continuously pursue excellence. The company has established a refined management system within the company and continues to encourage innovation and efficiency improvement, such as innovation and improvement of production processes, equipment and technology. In addition, the company has established a clear career promotion path and an attractive equity incentive plan to provide rewards for outstanding talents who have contributed to the company. From the listing of A shares in 2017 to the reporting period, the company has implemented six rounds of restricted stock incentive plans and granted incentive shares to approximately 2,590 people, covering major senior management personnel and core technology and marketing personnel. The company's equity incentive mechanism enables the company's core team's personal interests to be more closely integrated with the company's interests to support the company's globalization strategy of global marketing, global supply chain, and global manufacturing.

(7) Brand advantages

The company has two private brands: "Intco" and "Basic". Among them, the "Basic" brand originated from Basic International Inc, a trading company established in California in the 1990s by Mr. Liu Fangyi, the actual controller of the company. After having a certain brand foundation, Mr. Liu Fangyi returned to China to start a business in 2003 and established Shanghai Intco, and began to gradually build the "Intco" brand with disposable glove production as its main business. During 2017-2022, the disposable gloves industry maintained a stable compound annual growth rate, industry concentration further increased, and the market share of leading companies achieved rapid growth. The company leverages its R&D, marketing and financial advantages to accelerate its market share, creating a scale effect and a positive brand effect. Moreover, with the improvement of the company's technical level, the high quality of the company's products has established a certain industry reputation for the company's brand. The company's product quality and strong marketing capabilities have greatly enhanced its brand influence and attracted a large number of new customers, many of whom are not brand owners. Some orders have gone directly to European and American hospital terminals, resulting in rapid growth in sales of the company's own brand products.

4. Main business analysis

(1) Overview

Due to the rapid expansion of production capacity in 2020-2021 and the gradual return of demand to a steady state, the market has experienced a period of oversupply in the disposable medical gloves industry. In 2025, the industry clearing effect will be obvious, the overall capacity utilization rate of the industry will increase, and the supply and demand relationship will gradually return to balance. At the same time, the company continues to upgrade production line technology, and through lean improvement and innovative measures such as increasing line speed and reducing energy consumption, it continues to improve profitability, continue to enhance the company's competitive advantages, and consolidate the company's industry position. During the reporting period, the company achieved operating income of 9,925,819,444.72 yuan, an increase of 4.23% over the same period last year; net profit attributable to shareholders of the listed company was 1,010,699,970.94 yuan, a decrease of 31.03% over the same period last year; net cash flow generated from operating activities was 1,885,0 29,379.56 yuan, an increase of 74.69% over the same period of the previous year; the total assets at the end of the reporting period were 40,090,472,559.57 yuan, an increase of 15.77% over the end of the previous year; the net assets attributable to shareholders of listed companies were 18,253,839,363.41 yuan, an increase of 4.88% over the end of the previous year. During the reporting period, the company's operations mainly achieved results in the following aspects:

1. Give full play to the company’s comprehensive competitive advantages and become a global industry leader

In the face of major changes in the disposable glove market, the company has maintained its leading position in the global industry by relying on competitive advantages such as leading production technology and processes, strong marketing and service capabilities, and rapid expansion of production capacity.

In recent years, the company has rapidly expanded production capacity, continuously upgraded production technology and equipment, and continued to increase production line speeds. During the reporting period, as the Anqing base in Anhui Province came into operation, the company's annual production capacity of disposable gloves was 103 billion pieces. Among them, the annual production capacity of disposable nitrile gloves is 70 billion pieces, and the annual production capacity of disposable PVC gloves is 33 billion pieces. At the same time, the company is steadily advancing the construction of overseas projects.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 16

Section 3 Management Discussion and Analysis

During the reporting period, in terms of product categories, personal protection revenue was 8,835,174,990.74 yuan, a year-on-year increase of 2.73%; rehabilitation nursing revenue was 447,870,434.74 yuan, a year-on-year decrease of 2.14%; other product revenue was 642,774,019.24 yuan, a year-on-year increase of 38.08%.

2. Consolidate technological advantages and continuously upgrade production equipment

The company has always attached great importance to the continuous improvement and optimization of production technology and production processes. In terms of disposable glove production, the company has built top disposable glove production facilities equipped with advanced production equipment, independently designed production line processes and precision distributed control systems (DCS systems). Especially with the commissioning of the Anqing base in Anhui Province, the company has built a fourth-generation nitrile double-hand mold fully automatic production line with independent intellectual property rights. The supporting cogeneration project has greatly improved production efficiency while improving energy utilization, making the cost advantage of the company's products more prominent. Not only that, the company also has many advantages or features in production technology. For example, the production yield rate of glove products continues to be maintained at more than 99%; the product formula can be dynamically adjusted according to customer needs; the production process can be accurately controlled based on the temperature and humidity of the production site and the operating status of the production line; the automated batching system that accurately controls the falling weight of ingredients and the thickness of gloves greatly improves the quality consistency and stability of the product; and reduces energy consumption through precise control of the vulcanization process of the raw material dryer. The company continues to upgrade its production equipment, consolidate its technical advantages, optimize production and manufacturing, and improve production efficiency.

In addition, the company has a production base for rehabilitation medical equipment such as wheelchairs, walkers, and scooters in Zhenjiang, producing various specifications and models of wheelchairs, walkers, scooters and other products. Many of the highlight products have attracted attention from all walks of life. While the company continues to make intensive efforts in the wheelchair category, it also strives to develop a series of smart high-end products. In 2025, the company launched a number of new products: E-LITE ultra-light carbon fiber wheelchair, which is extremely lightweight with full carbon fiber, can be folded quickly with one button, can be easily stored in the trunk, and meets aviation shipping standards and can be boarded; Doly manual wheelchair, with an ultra-light aircraft-grade aluminum alloy body, can be quickly folded to save space, and double brakes are safer , suitable for home care and short-distance travel; the Luxe electric scooter can be disassembled and carried with one click, and can be parked and controlled by letting go. It is shock-absorbing and stable without bumps, and is suitable for medium and long-distance transportation in all scenarios; STAR lifting electric wheelchair: multi-dimensional intelligent lifting and posture adjustment, strong power and long battery life, flexible steering in place, suitable for all home and outdoor scenarios. As of 2025, the company has built a strong production system and introduced intelligent production equipment. The self-production rate of products is as high as 90%, which provides guarantee for the high quality requirements of products. In the future, the company will invest in the research and development of lightweight, foldable and intelligent electric products, develop multi-dimensionally in the rehabilitation medical equipment sector, and create a comprehensive blueprint for Inko Medical rehabilitation medical equipment, committed to providing more convenient travel methods for the elderly and people with mobility impairments, and improving the happiness of life. The company has production lines for hot and cold compresses and ECG electrodes in Zhenjiang and Vietnam. Hot and cold compress products are tools used to relieve pain, reduce inflammation or relax muscles, and are widely used in home care, sports rehabilitation and medical fields. ECG electrodes are a critical tool for diagnosing heart disease and monitoring heart health. The company continues to increase the research and development of rehabilitation medical equipment products such as wheelchairs and new hot and cold compress products, and plans to carry out technical transformation of existing production lines, thereby continuously increasing the market share of the company's wheelchairs and hot and cold compress products.

3. Strengthen the construction of a global marketing network and increase investment in online channels

During the reporting period, the company continued to strengthen the construction of the marketing team and attach importance to talent training. The number of marketers at home and abroad was 476, which provided a strong guarantee for the company to quickly seize the market and increase market share. The company attaches great importance to the establishment of marketing channels and actively develops a global marketing network. On the basis of continuing to deepen the traditional marketing channels, it increases the exploration of global retail channels, expands the consumer goods market space of disposable gloves, and provides services to a wider range of customer groups.

In 2025, the company will actively participate in domestic and overseas industry exhibitions, carry out in-depth dialogue and strategic collaboration with international partners, fully demonstrate its industry-leading manufacturing strength and innovation vitality, continue to deepen customer trust, and enhance brand value. During the reporting period, the company traveled to Germany, Dubai, Japan, Guangzhou, Shanghai and other countries and cities and participated in 27 exhibitions, which injected strong impetus into the company's continued growth in the global market. In April 2025, Yingke Medical will appear at the 91st China International Medical Equipment (Spring) Exposition (CMEF). This CMEF has attracted nearly 5,000 companies from more than 30 countries and regions around the world to participate in the event. Yingke Medical has built a "protection + health care" dual ecology with two special exhibition areas. In November 2025, Yingke Medical appeared at the MEDICA 2025 medical exhibition in Germany and the 138th China Import and Export Fair, showing the world the strong strength and unlimited potential of Chinese manufacturing. In 2025, the company will continue to strengthen the exposure of Yingke Medical's medical consumables marketing website, rehabilitation medical equipment marketing website, and physiotherapy care marketing website on Google, Facebook, Linkedin and other platforms, and through large-scale model content optimization and other marketing strategies, the company's information has been widely included and recommended in digital marketing large-scale models. It has realized an iterative upgrade of online promotion, and helped the sales team develop more than 3,000 potential customers throughout 2025, of which more than 130 customers successfully placed orders. Involving more than 150 countries and regions in Europe, the United States, the Middle East, Africa, South America, Oceania, Southeast Asia and other places, it helps companies obtain potential customers around the world and open up a global marketing network.

The company continues to improve its brand promotion channels and enhance its global brand influence. The company pays attention to and strives to strengthen the "Yingke Medical" brand building, using domestic traditional media and new media to carry out brand promotion, seize users' minds, and expand brand influence. On the one hand, the company actively expands e-commerce channels, establishes e-commerce clusters, establishes Tmall official flagship store, JD.com self-operated flagship store, Douyin official flagship store, Pinduoduo official flagship store, etc., and settles on core platforms such as 1688, Maochao, Ali Health Pharmacy, and Meituan to comprehensively improve product coverage, optimize end-user experience, and strengthen C-end customer service capabilities. On the other hand, the company's e-commerce department is also actively strengthening the expansion of new media and new channels, opening up new channels such as Xiaohongshu and Kuaishou, and achieving a total daily exposure of more than 10 million on social e-commerce platforms such as Douyin, Kuaishou and Xiaohongshu, further increasing the brand's online exposure opportunities. The live broadcast business focuses on the Douyin platform, relying on the model of "self-broadcasting + Dabo + short video + mall operation" to enhance fan stickiness through self-optimizing the proportion of natural traffic, deepening user interaction, extending user stay time and other measures, and feeding back the traffic conversion in the live broadcast room. In addition, the company promotes cross-border e-commerce multi-platform layout, builds a matrix of overseas stores such as Amazon, Shopee, Lazada, and Alibaba International Station, builds a global online sales network, consolidates brand promotion channels in all aspects, and establishes a professional and high-quality brand image.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 17

Section 3 Management Discussion and Analysis

4. Strengthen R&D management and continuously improve independent innovation capabilities

The company will continue to strengthen new product development, upgrade existing products and innovate in product applications to meet changing customer needs. During the reporting period, the company's total R&D expenses were RMB 404,381,847.56, and the R&D expense rate was 4.07%. As of the end of this reporting period, the company and its subsidiaries owned a total of 298 patent rights. The company continues to improve its research and development capabilities, providing a steady stream of intellectual drive for corporate development.

(2) Revenue and costs

1. Composition of operating income

Overall operating income Unit: Yuan

2025 2024

Year-on-year increase or decrease

Amount % of operating income Amount % of operating income

Total operating income 9,925,819,444.72 100.00% 9,523,317,123.49 100.00% 4.23%

By industry

Medical device industry 9,925,819,444.72 100.00% 9,523,317,123.49 100.00% 4.23%

by product

Personal protection 8,835,174,990.74 89.01% 8,600,134,455.01 90.31% 2.73%Rehabilitation care 447,870,434.74 4.51% 457,672,620.42 4.80% -2.14%Other products 642,774,019.24 6.48% 465,510,048.06 4.89% 38.08%

by region

Domestic 1,774,268,717.81 17.88% 1,458,475,017.41 15.31% 21.65% Overseas 8,151,550,726.91 82.12% 8,064,842,106.08 84.69% 1.08%

Point sales model

Self-sale 9,925,819,444.72 100.00% 9,523,317,123.49 100.00% 4.23%

2. Industry, products, regions and sales models accounting for more than 10% of the company’s operating revenue or operating profit

√ Applicable Not applicable Unit: Yuan

Operating income Operating costs Gross profit margin Operating income Operating costs Gross profit margin

Increase or decrease compared with the same period last year Increase or decrease compared with the same period last year Increase or decrease compared with the same period last year Increase or decrease by industry

Medical device industry 9,925,819,444.72 7,531,555,720.01 24.12% 4.23% 3.56% 0.48%

by product

Personal protection 8,835,174,990.74 6,690,357,173.81 24.28% 2.73% 2.69% 0.04%

by region

Domestic 1,774,268,717.81 1,521,430,540.69 14.25% 21.65% 28.57% -4.62% Overseas 8,151,550,726.91 6,010,125,179.32 26.27% 1.08% -1.30% 1.77%

Point sales model

Self-sale 9,925,819,444.72 7,531,555,720.01 24.12% 4.23% 3.56% 0.48%

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 18

Section 3 Management Discussion and Analysis

If the statistical caliber of the company's main business data is adjusted during the reporting period, the company's main business data in the most recent year will be adjusted based on the caliber at the end of the reporting period.

Applicable √ Not applicable

3. Whether the company’s physical sales revenue is greater than its labor service revenue

√ Yes No Unit: Yuan

Industry Classification Project Unit 2025 2024 Year-on-year increase or decrease

Sales volume billion pieces 904.04 813.43 11.14% Disposable PVC gloves, nitrile gloves Production volume billion pieces 907.30 836.10 8.52% Inventory volume billion pieces 80.49 80.42 0.09% Sales volume 10,000 units 74.75 80.30 -6.91% Wheelchair products Production volume 10,000 units 75.37 84.00 -10.27% Inventory of 10,000 units 11.43 10.82 5.64% Sales volume of 10,000 pieces 1,863.19 1,520.81 22.51% Hot and cold compress products Production volume of 10,000 pieces 1,843.42 1,568.67 17.51% Inventory of 10,000 pieces 178.77 137.77 29.76% Sales volume 10,000 pieces 23,038.93 12,591.32 82.97% Electrode sheet products Production volume 10,000 pieces 23,235.81 13,071.45 77.76% Inventory 10,000 pieces 1,934.11 1,767.50 9.43%

Explanation of reasons why relevant data changed by more than 30% year-on-year

√ Applicable Not applicable

The output and sales of electrode sheet products increased by more than 30% year-on-year, mainly due to the increase in orders and production lines in this period.

4. Performance of major sales contracts and major purchase contracts signed by the company as of this reporting period

Applicable √ Not applicable

5. Composition of operating costs

Industry Classification Unit: Yuan

2025 2024

Industry classification Items Year-on-year increase or decrease

Amount as a proportion of operating costs Amount as a proportion of operating costs

Medical device industry Direct materials and outsourcing costs 4,651,103,874.53 61.75% 4,587,254,395.97 63.08% 1.39% Medical device industry Processing costs and other expenses 2,880,451,845.48 38.25% 2,685,093,267.50 36.92% 7.28%

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 19

Section 3 Management Discussion and Analysis

6. Whether there are changes in the scope of consolidation during the reporting period

√ Yes No

(1) Increase the scope of merging

Company name Equity acquisition method

Pt Green Environment Management Services Establishment

Shandong Yingcai Printing Technology Co., Ltd. was established

(2) Reduction in merger scope

Company name Equity disposal method

Shanghai Yingke Medical Products Co., Ltd. Log out

Intco Medical Industries Inc. Logout

7. Major changes or adjustments to the company’s business, products or services during the reporting period

Applicable √ Not applicable

8. Major sales customers and major suppliers

The company’s main sales customers

The total sales amount of the top five customers (yuan) 1,207,964,146.60The total sales amount of the top five customers accounts for 12.17% of the total annual sales

Among the top five customer sales, related party sales account for 0.00% of total annual sales.

Information about the company’s top 5 customers

Serial number Customer name Sales (yuan) Proportion of total annual sales

1 Customer One 570,632,238.55 5.75% 2 Customer Two 276,283,551.64 2.78% 3 Customer Three 138,025,278.59 1.39% 4 Customer Four 122,698,613.60 1.24% 5 Customer Five 100,324,464.22 1.01% Total -- 1,207,964,146.60 12.17%

Other descriptions of major customers

Applicable √ Not applicable

The company’s main suppliers

The total purchase amount of the top five suppliers (yuan) 1,604,841,803.32 The total purchase amount of the top five suppliers accounts for 25.24% of the total annual purchase

Purchases from related parties among the top five suppliers account for 0.00% of the total annual purchases.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 20

Section 3 Management Discussion and Analysis

Information about the company’s top 5 suppliers

Serial number Supplier name Purchase amount (yuan) Proportion of total annual purchases

1 Supplier one 584,572,946.15 9.19% 2 Supplier two 425,743,303.19 6.70% 3 Supplier three 237,670,346.36 3.74% 4 Supplier four 220,141,791.04 3.46% 5 Supplier five 136,713,416.58 2.15% Total -- 1,604,841,803.32 25.24%

Other information about major suppliers

Applicable √ Not applicable

During the reporting period, the company’s trading business revenue accounted for more than 10% of its operating revenue.

Applicable √ Not applicable

(3) Fees

2025 2024 Year-on-year increase or decrease Explanation of major changes

Selling expenses 297,730,387.79 288,443,843.68 3.22%

Management expenses 686,464,281.55 518,139,926.38 32.49% Mainly due to the increase in employee compensation, depreciation and amortization during the reporting period. Financial expenses 416,527,898.12 -436,625,362.84 195.40% Mainly due to the decrease in interest income and increase in exchange losses during the reporting period, resulting in R&D expenses. 404,381,847.56 398,344,414.56 1.52%

(4) R&D investment

√ Applicable Not applicable

Name of the main R&D project Project purpose Project progress Goal to be achieved Estimated impact on the company’s future development

To meet the needs of customers, expand sales channels, develop ultra-high elastic nitrile gloves, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers to further enhance the company's competitiveness.

To meet the needs of customers, expand sales channels, develop high-fitting and super-elastic PVC gloves, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers to further enhance the company's competitiveness.

To meet the needs of customers, expand sales channels, develop new cold-resistant PVC gloves, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers to further enhance the company's competitiveness. Highly anti-stick, non-irritating and powdery to meet customer needs and expand sales channels.

Added product functions, accepted and completed, put on the market for sale

The development of PVC gloves has formed its own technical barriers and further enhanced the company's competitiveness.

To meet the needs of customers, expand sales channels, develop two-color medical gloves that are easy to identify, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers to further enhance the company's competitiveness.

To meet the needs of customers, expand sales channels, develop biodegradable nitrile gloves, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers to further enhance the company's competitiveness.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 21

Section 3 Management Discussion and Analysis

Name of main R&D project Project purpose Project progress Goals to be achieved Estimated impact on the company’s future development

To meet the needs of customers, expand sales channels, develop high-strength and puncture-resistant nitrile gloves, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers and further enhance the company's competitiveness. To meet the needs of customers, expand sales channels, develop high-performance active nitrile gloves, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers and further enhance the company's competitiveness. High-quality and stable carboxyl groups for medical gloves. To achieve product diversification, improve economic efficiency, and develop new products. The project is in progress and will be put on the market.

The research and development of nitrile latex enhances market competitiveness.

European standard synthetic latex has a low gram weight to achieve product diversification, improve economic efficiency, and develop new products. Acceptance and completion has been completed and put on the market.

Research on key technologies to enhance market competitiveness.

Large-scale demoulding and mold washing of nitrile gloves to achieve product diversification, improve economic efficiency, and develop new products. The project is in progress and will be put on the market for sale.

The research and development of special supporting materials enhances market competitiveness.

Elongation rate 550 + American standard synthetic latex to achieve product diversification, improve economic efficiency, and develop new products. The project is in progress and will be put on the market for sale.

Research on key super-soft technologies to enhance market competitiveness.

Latex PH value control system and improve product performance, expand economic benefits, and increase product functions have been accepted and completed to improve product performance

The research and development of lye materials enhances market competitiveness and forms its own technical barriers. Realize product diversification, improve economic efficiency, research and development of anti-static nitrile gloves, develop new products, have been accepted and completed, put on the market for sale

Enhance market competitiveness.

To meet the needs of customers, expand sales channels, develop soft housework PVC gloves, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers and further enhance the company's competitiveness. To meet the needs of customers, expand sales channels, develop ultra-long and wear-resistant nitrile gloves, increase product functions, have been accepted and completed, and are now available for sale.

Form its own technical barriers and further enhance the company's competitiveness.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 22

Section 3 Management Discussion and Analysis

Company R&D personnel

2025 2024 Change ratio

Number of R&D personnel (person) 1,141 1,202 -5.07% Number of R&D personnel Proportion 8.82% 10.95% -2.13%

Academic qualifications of R&D personnel

Bachelor's degree 346 292 18.49% Master's degree 49 43 13.95%

Age composition of R&D personnel

Under 30 years old 378 420 -10.00% 30~40 years old 468 476 -1.68%

The company’s R&D investment amount in the past three years and its proportion to operating income

2025 2024 2023

Amount of R&D investment (yuan) 404,381,847.56 398,344,414.56 283,373,145.00 Proportion of R&D investment in operating income 4.07% 4.18% 4.10% Amount of capitalized R&D expenditure (yuan) 0.00 0.00 0.00 Proportion of capitalized R&D expenditure in R&D investment 0.00% 0.00% 0.00% Capitalized R&D expenditure as a proportion of net profit for the current period 0.00% 0.00% 0.00%

The reasons and impacts of major changes in the company's R&D personnel composition

Applicable √ Not applicable

Reasons for the significant change in the proportion of total R&D investment in operating income compared with the previous year

Applicable √ Not applicable

Reasons for significant changes in R&D investment capitalization rates and their rationale

Applicable √ Not applicable

The company needs to comply with the disclosure requirements of "Medical Device Business" in the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 4 - GEM Industry Information Disclosure". Related information on medical device products

Applicable √ Not applicable

(5) Cash flow

Unit: Yuan

Project 2025 2024 Year-on-year increase or decrease

Subtotal cash inflow from operating activities 10,901,873,759.28 10,524,572,432.11 3.58% Subtotal cash outflow from operating activities 9,016,844,379.72 9,445,514,613.85 -4.54% Net cash flow from operating activities 1,885,029,379.56 1,079,057,818.26 74.69% Subtotal of cash inflows from investing activities 19,426,389,940.99 7,277,270,499.28 166.95% Subtotal of cash outflows from investing activities 30,878,069,946.93 11,145,171,558.97 177.05%

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 23

Section 3 Management Discussion and Analysis

Unit: Yuan

Project 2025 2024 Year-on-year increase or decrease

Net cash flow generated from investing activities -11,451,680,005.94 -3,867,901,059.69 -196.07% Subtotal of cash inflows from financing activities 31,517,157,894.05 15,245,577,110.20 106.73% Subtotal of cash outflows from financing activities 23,139,439,988.51 13,820,784,222.67 67.42% Net cash flow generated from financing activities 8,377,717,905.54 1,424,792,887.53 488.00% Net increase in cash and cash equivalents -1,495,345,977.52 -1,304,205,319.28 -14.66%

Explanation of the main factors affecting significant year-on-year changes in relevant data

√ Applicable Not applicable

The net cash flow generated from operating activities during the reporting period increased by 74.69% compared with the same period last year, mainly due to the increase in cash received from selling goods during the reporting period. The net cash flow generated from investing activities during the reporting period decreased by 196.07% compared with the same period last year, mainly due to the increase in cash paid for investments during the reporting period. The net cash flow generated from financing activities during the reporting period increased by 488.00% compared with the same period last year, mainly due to the increase in cash received from bank loans during the reporting period. Explanation of the reasons for the significant difference between the company's net cash flow generated from operating activities during the reporting period and the current year's net profit

Applicable √ Not applicable

5. Non-main business situation

√ Applicable Not applicable Unit: Yuan

Amount Proportion of total profit Explanation of reasons Whether it is sustainable

Investment income 379,720,803.35 30.88% Mainly income from financial management No

Mainly trading financial assets,

Gains and losses from changes in fair value 318,499,359.53 25.90% No

Changes in fair value of other non-current financial assets

Asset impairment 25,115,724.20 2.04% Mainly due to provision for bad debts and inventory depreciation provisions Yes

Non-operating income 22,878,771.51 1.86% Mainly gains from damage and scrapping of non-current assets No

Non-operating expenses 23,309,581.23 1.90% Mainly due to damage and scrapping of non-current assets and donation expenses No

6. Analysis of assets and liabilities

(1) Major changes in asset composition

Unit: Yuan

2025 2024

Increase or decrease in proportion Explanation of major changes

Amount Proportion of total assets Amount Proportion of total assets

Monetary funds 5,948,301,999.22 14.84% 12,014,011,946.78 34.69% -19.85%

Accounts receivable 1,361,320,580.73 3.40% 1,362,747,313.74 3.94% -0.54%

Inventory 1,327,025,777.13 3.31% 1,265,414,044.64 3.65% -0.34%

Investment real estate 522,359,883.86 1.30% 557,007,832.87 1.61% -0.31%

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 24

Section 3 Management Discussion and Analysis

Unit: Yuan

2025 2024

Increase or decrease in proportion Explanation of major changes

Amount Proportion of total assets Amount Proportion of total assets

Fixed assets 10,803,919,811.95 26.95% 8,501,377,706.32 24.55% 2.40%

Construction in progress 803,113,439.04 2.00% 1,287,786,355.90 3.72% -1.72%

Right-of-use assets 66,512.06 0.00% 858,670.46 0.00% 0.00%

Short-term borrowings 16,390,414,942.75 40.88% 12,666,208,536.46 36.57% 4.31%

Contract liabilities 236,995,423.00 0.59% 271,584,036.81 0.78% -0.19%

Long-term borrowings 409,286,523.71 1.02% 165,404,236.66 0.48% 0.54%

The proportion of overseas assets is relatively high

√ Applicable Not applicable

Ensure asset security and income. Overseas assets account for the company. Is there any specific content of heavy assets? Reason for formation. Asset size. Location. Operation model.

Control measures Status Proportion of net assets Large impairment risk

By strengthening management, financial

Hong Kong Yingke Wholly-owned subsidiary 9,178,133,216.10 Hong Kong, China Independent operation Profit 50.28% No

Prevent risks through management and control

PrimeMax Medical has strengthened its management, financial

Wholly owned subsidiary -2,754,928.40 United States Independent operation Loss -0.02% No Industries, Inc. Prevent risks through management and control

By strengthening management, financial

Maxcel LLC wholly-owned subsidiary 48,112,386.72 United States Independent operation Loss 0.26% No control and other means to prevent risks

By strengthening management, financial

German Inco Wholly-owned subsidiary 48,073,718.13 Germany Independent operation Profit 0.26% No Control and other methods to prevent risks

By strengthening management, financial

Singapore Yingke Investment wholly-owned subsidiary 529,300,827.29 Singapore Independent operation Profit 2.90% No management and control to prevent risks

By strengthening management, financial

Vietnam Yingke Wholly-owned subsidiary 127,255,765.98 Vietnam Independent operation Loss 0.70% No Control and other methods to prevent risks

By strengthening management, financial

Highmax LLC Wholly-owned subsidiary 124,048,585.82 United States Independent operation Loss 0.68% No Control and other methods to prevent risks

By strengthening management, financial

Canada Inco Wholly-owned subsidiary 9,563,531.35 Canada Independent operation Profit 0.05% No Control and other means to prevent risks

By strengthening management, financial

Vietnam Technology Wholly-owned subsidiary 44,419,713.36 Vietnam Independent operation Profit 0.24% No Control and other methods to prevent risks

By strengthening management, financial

Vietnam Basic Medical Care Wholly-owned subsidiary 4,107,213.55 Vietnam Independent operation Profit 0.02% No Control and other methods to prevent risks

By strengthening management, financial

Japan Inco Wholly-owned subsidiary 70,481,925.57 Japan Independent operation Profit 0.39% No Control and other methods to prevent risks

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 25

Section 3 Management Discussion and Analysis

Ensure asset security and income. Overseas assets account for the company. Is there any specific content of heavy assets? Reason for formation. Asset size. Location. Operation model.

Control measures Status Proportion of net assets Large impairment risk

By strengthening management, financial

Yingke Medical International Wholly-owned subsidiary 4,187,492,932.21 Independent operation in Hong Kong, China Profit 22.94% No

Prevent risks through management and control

By strengthening management, financial

Singapore Yingke Wholly-owned subsidiary 25,613,196.03 Singapore Independent operation Loss 0.14% No

Prevent risks through management and control

By strengthening management, financial

Malaysia Inco wholly-owned subsidiary -51,257.93 Malaysia Independent operation Slight loss 0.00% No

Prevent risks through management and control

By strengthening management, financial

Realmax LLC Wholly-owned subsidiary 233,000,624.18 United States Independent operation Loss 1.28% No

Prevent risks through management and control

By strengthening management, financial

Realmax GmbH wholly-owned subsidiary 29,866,503.88 Germany Independent operation Slight loss 0.16% No

Prevent risks through management and control

(2) Assets and liabilities measured at fair value

√ Applicable Not applicable Unit: Yuan

Accumulated amounts fairly included in equity in the current period Provisions made in the current period

Item Opening amount Purchase amount in the current period Sales amount in the current period Other changes Ending amount

Gains and losses from changes in value Impairment from changes in fair value

Financial assets

1.Trading financial assets

6,737,459,715.11 -83,172,157.51 15,423,089,384.19 14,695,248,645.21 -139,203,366.00 7,242,924,930.58

(excluding derivative financial assets)

2. Derivative financial assets 17,419,421.54 13,998,987.65 3,420,433.89

3. Other non-current

1,381,882,649.84 274,527,233.03 8,774,073,942.90 108,631,373.35 139,203,366.00 10,461,055,818.42

Financial assets

Subtotal of financial assets 8,136,761,786.49 191,355,075.52 24,197,163,327.09 14,817,879, 006.21 17,707,401,182.89 Others 16,134,087.49 1,434,669,159.26 1,442,562,396.56 8,240,850.19 Total of the above 8,152,895,873.98 191,355,075.52 25,631,832,486.35 16,260,441,402.77 17,715,642,033.08 Financial liabilities 81,655,188.94 55,873,366.11 25,781,822.83 Other changes

Transfer of trading financial assets

Whether there are any significant changes in the measurement attributes of the company's main assets during the reporting period

Yes √ No

(3) Restrictions on asset rights as of the end of the reporting period

1. Asset restrictions at the end of the period

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 26

Section 3 Management Discussion and Analysis

Unit: Yuan Item Ending book balance Ending book value Restriction type Reason for restriction

The pledge is used to issue bank acceptance bills, letters of guarantee, and monetary funds 3,038,469,955.49 3,038,469,955.49 Pledge is used to issue letters of credit, handle forward settlement and sales of foreign exchange, and the pledge is used to

Bank borrowings, litigation-frozen deposits trading financial assets 4,315,472,000.21 4,315,472,000.21 Pledge Pledge is used for bank borrowing Other non-current financial assets 6,518,067,047.88 6,518,067,047.88 Pledge Pledge is used for bank borrowing fixed assets 402,842,458.68 298,009,133.21 Mortgage Mortgage for bank borrowing of intangible assets 31,105,975.35 25,430,669.07 Mortgage Mortgage for bank borrowing of other non-current assets 305,045,555.56 305,045,555.56 Pledge Total pledge of large-denomination certificates of deposit with maturity of more than one year for bank borrowings 14,611,002,993.17 14,500,494,361.42

7. Investment status analysis

(1) Overall situation

Applicable √ Not applicable

(2) Major equity investments obtained during the reporting period

Applicable √ Not applicable

(3) Major non-equity investments ongoing during the reporting period

Applicable √ Not applicable

(4) Financial asset investment

1. Securities investment situation

Applicable √ Not applicable

The company had no securities investments during the reporting period.

2. Derivatives investment situation

√ Applicable Not applicable

(1) Derivative investments for the purpose of hedging during the reporting period

Applicable √ Not applicable

There were no derivative investments for hedging purposes during the reporting period.

(2) Derivative investments for speculative purposes during the reporting period

Applicable √ Not applicable

There were no derivative investments for speculative purposes during the reporting period.

8. Sales of major assets and equity

(1) Sales of major assets

Applicable √ Not applicable

The company did not sell any major assets during the reporting period.

(2) Sale of major equity interests

Applicable √ Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 27

Section 3 Management Discussion and Analysis

9. Analysis of major holding and participating companies

√ Applicable Not applicable

Information on major subsidiaries and joint-stock companies that have an impact of more than 10% on the company’s net profit Unit: Yuan

Company name Company type Main business Registered capital Total assets Net assets Operating income Operating profit Net profit

Medical protection products 2,842,583,350 yuan

Shandong Yingke Subsidiary 6,476,096,527.04 4,528,710,563.40 1,641,837,642.56 57,579,219.60 74,350,970.16 Production and sales RMB

Rehabilitation and nursing

Jiangsu Yingke Subsidiary Production and sales of health care and physical therapy products USD 61.7 million 1,579,731,662.82 807,555,920.33 744,194,114.85 36,370,152.71 32,155,026.61

Medical protection products 2,717,704,000 yuan

Anhui Yingke Subsidiary 8,958,586,546.79 4,267,097,481.20 4,021,380,951.22 209,469,017.23 176,819,305.01 Production and sales RMB

Medical protection products

Jiangxi Yingke Subsidiary USD 177,790,419 3,369,867,991.78 1,853,757,710.41 1,794,443,230.36 219,668,869.14 Production and sales of 174,262,546.34

Medical protection products,

Yingke Medical International Subsidiary Rehabilitation nursing and health care HKD 500,000 24,903,186,836.15 4,187,492,932.21 7,159,745,007.94 534,282,966.44 471,972,906.23 Sales of physical therapy products

Medical protection products 369.4572 million yuan

Anqing Yingke Subsidiary 1,629,317,151.90 446,925,407.71 904,022,667.39 121,023,114.65 100,033,267.82

Production and sales in RMB

Acquisition and disposal of subsidiaries during the reporting period

√ Applicable Not applicable

Company name The impact of the acquisition and disposal of subsidiaries on the overall production, operation and performance during the reporting period

Pt Green Environment

Newly established to improve the company’s business development layout and enhance the company’s market competitiveness

##Management Services

Shandong Yingcai Printing Technology Co., Ltd. was newly established to improve the company's business development layout and enhance the company's market competitiveness.

Shanghai Intco Medical Industries Inc. Logout Optimize the company's resource allocation, focus on core business development, and improve overall operational efficiency Intco Medical Industries Inc. Logout Optimize the company's resource allocation, focus on core business development, and improve overall operational efficiency

10. Structured entities controlled by the company

Applicable √ Not applicable

11. Prospects for the company’s future development

(1) Industry structure and trends

From 2020 to 2021, there was an extreme imbalance in supply and demand in the disposable glove market, and companies in the industry generally expanded production capacity. From 2022 to 2023, market demand gradually returned to a steady state. Downstream customers had too much stock in the early stage and needed a certain period of time to digest the inventory. As a result, short-term procurement demand in the overall market fell sharply, turning from short supply to oversupply. At the same time, competition among original companies and new entrants in the industry is fierce, and price competition has emerged to seize market share. Product sales prices have gradually returned to normal or even lower, which will inevitably lead to a decline in the company's overall sales revenue. Starting from the second half of 2023, the backlog of inventory in the downstream of the industry has entered the final stage of digestion, the effect of clearing high-cost production capacity and old production capacity has appeared, and the concentration of the industry's supply side has increased. In 2024, the overall capacity utilization rate of the industry will generally increase, and the supply and demand relationship will gradually return to balance.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 28

Section 3 Management Discussion and Analysis

2025 will be a year in which the global economic landscape is reshaped amidst shocks and industry cycles are adjusted to create new opportunities. Faced with the continued escalation of tariff barriers in the U.S. market, the supply and demand pattern of the disposable glove industry is facing in-depth adjustments, and resource allocation is gradually diverging into different regional markets.

As the awareness of medical hygiene and protection continues to increase in various industries around the world, the demand for gloves, as one of the indispensable products in the medical care field, is still driven by stable and sustained market demand. The demand for disposable gloves will increase to a certain extent after 2020 compared with the previous base. Developed countries such as the United States, Europe, and Japan are the main consumer markets for disposable gloves. Employees in the medical care, food, industrial labor insurance and other industries in these countries widely and frequently use disposable gloves in various work and life scenarios based on usage habits and legal requirements. The huge and steadily growing market demand in these countries ensures sustainable growth space for glove consumption.

There are varying degrees of increase in market demand in developing countries and regions. China is the largest developing country in the world and is the main manufacturing base for disposable gloves in the global market. With the improvement of national protection awareness and the improvement of consumption habits, China has become an important consumer market for disposable gloves and has huge growth potential. In the markets of developing countries, with the continuous improvement of economy and living standards, disposable gloves will be more widely used in the future. Therefore, the Chinese market and the markets of developing countries are important sources of growth for the disposable gloves market.

1. Industry barriers

(1) Capital investment barriers

Manufacturing nitrile gloves or PVC gloves requires a high initial investment. For example, the investment in building a nitrile double-hand mold production line developed by the company exceeds 25 million yuan. Building a large-scale glove factory requires a large amount of capital investment, and the investment scale is usually more than 1 billion yuan. On this basis, the medical glove production line needs to be matched according to the use and color. Generally, the minimum number of lines is 10, and the production cycle is as long as 12 to 18 months. The high cost and long construction period pose barriers to entry for new entrants, requiring long-term high investment to generate profits.

(2) Technical barriers

Manufacturing disposable gloves is a complex process. The glove production line requires self-design, equipment integration, automation control, supporting facility construction and engineering construction. The above aspects are affected by factors such as environment, temperature, humidity, etc., making it difficult for new entrants to master. For example, the production of nitrile gloves requires more than 30 kinds of raw materials, and the formula needs to be adjusted according to customer needs, the temperature and humidity of the production line, and the operation of the production line. Therefore, only after years of industry exploration and practice can manufacturers obtain mature and systematic formula technology suitable for large-scale production. In the case of medical-grade disposable gloves, the technical barriers are further raised by stricter quality standards than non-medical-grade disposable gloves.

(3) Supply chain management capability barriers

Manufacturers of disposable gloves need strong supply chain management capabilities. The cost of raw materials forms a significant part of the cost structure of glove production, and any disruption or shortage in the supply of raw materials will cause severe constraints on disposable glove production. Manufacturers with experience in the glove industry have an extensive network of suppliers and have bargaining advantages over such suppliers, enjoying the advantage of obtaining sufficient supplies of raw materials at commercially reasonable prices.

(4) Customer network barriers

Disposable gloves are mainly consumed in developed regions such as North America, Europe and Japan. Therefore, it is crucial for disposable glove manufacturers to develop close and long-term relationships with reputable global medical supply distributors, and the establishment of such relationships can take years of effort.

(5) Access licensing barriers in different countries

Glove manufacturers are subject to a variety of regulations, which vary from jurisdiction to jurisdiction. Therefore, glove manufacturers need to invest considerable time and effort in obtaining and maintaining various licenses and complying with regulatory requirements in all countries in which they operate.

2. Industry development trends

(1) Development of new processes and technologies

With the continuous development of the medical industry and electronics industry, more new processes and technologies will be applied to glove production. At the same time, the company has always insisted on improvement and innovation. As technology continues to upgrade, the gap in production efficiency, environmental protection indicators, and product quality between new and old production capacities will widen. Therefore, manufacturers established in recent years that can take advantage of new processes and technologies (such as equipment automation and smart manufacturing technology) will be more competitive.

(2) Supply chain integration

Disposable glove manufacturers mainly rely on economies of scale in terms of cost control capabilities and the ability to provide diversified customized products. To achieve economies of scale, relationships between manufacturers and suppliers are increasingly important. Therefore, disposable glove manufacturers that are able to integrate their supply chains will achieve economies of scale and differentiate themselves from industry competition.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 29

Section 3 Management Discussion and Analysis

(3) The market share of nitrile gloves continues to increase

Nitrile gloves are likely to occupy a higher market share in the future. First of all, nitrile gloves are as comfortable, soft, and elastic as natural latex gloves. They do not contain latex proteins that can cause allergies, and their quality is more stable than natural latex gloves. Second, with the advancement of production technology, the cost of manufacturing nitrile gloves will decrease. Therefore, the cost-effectiveness of nitrile gloves will become more prominent. Third, the supply of natural latex gloves is limited by natural materials, whereas nitrile gloves can be produced on a large scale to meet growing demand.

(2) Company development strategy

1. Implement global strategies to consolidate the company’s industry leading position

The company will closely track global market dynamics, conduct in-depth analysis of industry trends, combine its own advantages and resources, and scientifically adjust its market layout. On the one hand, it accelerates the pace of overseas supply chain construction, optimizes the configuration of each link in the supply chain, ensures stable supply of raw materials, efficient production processes, smooth logistics and distribution, and reduces potential risks caused by trade frictions; on the other hand, it accurately grasps the long-term needs of domestic and overseas markets and flexibly allocates production resources through global production capacity layout to meet market demands in different regions and periods, further increasing the company's market share.

Comprehensively strengthen the construction of the corporate governance system, optimize internal management processes, and improve decision-making efficiency and execution capabilities; at the same time, vigorously strengthen organizational capacity building, recruit talents, and form a world-class team with international vision, professionalism, and innovative spirit to inject strong impetus into the company's development.

2. Continuously improve innovation and strengthen cost moat barriers

In order to continue to consolidate the company's competitive advantages, we will take innovation as the core and strengthen the cost moat barriers in all aspects. The company plans to further deepen the application of automation and intelligent manufacturing technology in production facilities, focusing especially on key areas such as online visual inspection and automated packaging, and improve production efficiency and product quality stability through intelligent and automated upgrades. The company has always attached great importance to technological research and development and innovation, and its research and development expenditures have been expanding year by year.

In the future, we will continue to increase investment in R&D, optimize process flows, and achieve more precise control of the production process, so as to manufacture various types of medical-grade personal protective equipment stably and efficiently. At the same time, the company will continue to strengthen research and development cooperation with well-known domestic and overseas equipment suppliers, continuously improve equipment quality and technical level, and ensure that it always maintains its leading position in technology in the fierce market competition.

3. Expand marketing network and deepen customer stickiness

The company intends to expand its marketing network to cover multiple industries where the company's products are applied. The company has established global marketing service centers in the United States, Canada, Germany, Japan, Malaysia, Singapore, and Hong Kong, China, to further develop overseas markets, maintain existing customers, and better develop potential customers. The company plans to continue to build and develop marketing and service centers in the Middle East, South America, Australia and New Zealand to expand the company's global customer base. Currently, the company has a professional marketing team of 476 people at home and abroad. In the future, it plans to recruit more talents to strengthen the company's global marketing efforts, further penetrate the global disposable glove market, achieve a diversified customer base, and cross-sell other products besides disposable gloves. At the same time, the company will attract new customers and deepen product penetration among existing customers through diversified marketing channels and deepening brand influence.

4. Strengthen new product development, upgrade existing products and innovative product applications

The company continues to deepen new material technology innovation and product matrix layout, and independently developed two core material platforms, Syntex™ synthetic latex glove technology and Synmax™ synthetic glove technology. Among them, Syntex™ does not contain natural latex protein, has both hypoallergenicity and high-elastic skin-fitting properties, and its performance is comparable to natural latex gloves. Its application scenarios cover hospitals, oral care and clean room industries. The professional formula brings products with a feel comparable to latex, which can better reflect its core advantages in professional scenarios; and on the basis of performance that is not inferior to traditional latex, it has a cost advantage. Synmax has upgraded its performance, close to the touch and elasticity of nitrile gloves, and has a significant cost advantage compared with nitrile gloves.

At the same time, the company has successively launched a number of innovative products to form a differentiated and competitive product matrix: Shinyguard™ pearlescent gloves, whose application scenarios cover the fields of household cleaning and beauty and hairdressing. The shiny appearance can not only meet practical needs but also bring people a pleasant experience; Chemtuff ™ chemical-resistant gloves are suitable for laboratories, biopharmaceuticals and other places, and can provide more comprehensive protection for complex working environments; hyaluronic acid gloves have obtained Chinese patent certification and US FDA certification. When used in multiple scenarios, they not only provide basic protection for hands, but also nourish the skin and make hands healthier.

For new materials and new products, the company has established a complete intellectual property protection system: Shinyguard™ pearlescent gloves and hyaluronic acid glove related technologies have obtained Chinese patent authorization; Syntex™, Synmax™ and hyaluronic acid glove technologies are advancing overseas patent layout. The trademarks Syntex™, Synmax™ and Chemtuff™ have been registered in

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 30

Section 3 Management Discussion and Analysis

It has been approved for registration in China, the United States and many other countries and regions, and has built a global intellectual property protection network through patent and trademark collaboration to provide a solid guarantee for the company's technological innovation and international development.

5. Deepen the vertical integration of the industrial value chain through selective strategic investments and acquisitions

The company plans to deepen the vertical integration of the industrial value chain through selective strategic investments and acquisitions. The company will carefully consider relevant merger and acquisition opportunities in the upstream industry, such as suppliers of raw materials, equipment and equipment components. The company believes that the relevant vertical integration will reduce costs, improve bargaining power and consolidate the company's leading position in the industry. At the same time, high-quality resources will be gathered to disperse business risks and ensure the company's three-dimensional development.

(3) Annual business plan for 2026

As the national health protection awareness continues to increase, governments and industry organizations in various countries regulate the use of disposable glove protective equipment, and relevant departments strategic reserves, the demand for disposable gloves industry will continue to maintain steady growth every year.

The company’s main work plans in 2026 are as follows:

1. Continue to promote the construction of overseas production bases.

2. Further improve the automation and intelligence level of production equipment, optimize the process flow, and further improve production efficiency.

3. Increase efforts in new product research and development and comprehensively expand product categories.

4. Strengthen organizational building, promote the company's team development through school recruitment and the introduction of high-end talents, further increase cooperation with well-known universities and scientific research institutes at home and abroad, implement talent training ideas that combine industry, academia, and research, and jointly cultivate professional talents. At the same time, we will strengthen the vocational training of the company's employees, establish a scientific, standardized and systematic human resources training system, and improve the talent introduction and cultivation mechanism, talent incentive and competition mechanism.

5. Continue to improve the company's ESG governance level, closely follow national policies, and strengthen exchanges with international capital.

The company's 2026 business plan and specific work goals are formulated by the company's board of directors based on the current operating conditions and the judgment of the future comprehensive market environment. They do not constitute a commitment to the operating performance in 2026. At the same time, there is a certain degree of uncertainty. Investors are advised to pay attention to investment risks.

The company will strictly abide by national laws and regulations and the provisions of the Articles of Association, continuously improve the corporate governance structure, and form an operating system with clear organizational structures and mutual checks and balances. In accordance with the requirements of the corporate development plan, we will enrich and improve various systems and form a sound corporate management mechanism to improve the company's management level. The company will establish a good information disclosure system, attach importance to corporate social responsibility activities, establish and maintain a good social image of the company, and increase the company's visibility.

(4) Possible risks

1. Impact of international trade frictions

As of the disclosure date of this report, the United States has imposed a total tariff of 110% on China's disposable medical-grade nitrile gloves, a total of 38% tariffs on disposable industrial-grade nitrile gloves, and a 10% tariff on disposable PVC gloves. It will have a certain impact on future export sales and operating performance. The company will pay close attention to changes in tariff policies, actively communicate with customers, and adjust sales strategies. The company will also deploy overseas production capacity and increase marketing in non-U.S. regions to reduce the impact of tariff policies on the company's revenue and profits.

2. Risks of changes in market supply and demand and price fluctuations

From 2020 to 2021, the global demand for protective equipment has surged. Disposable glove products have been in unprecedented supply and demand, and prices have hit historical records. At the same time, more companies in the industry have invested in expanding production, and there are also new manufacturers entering across industries, releasing more new production capacity. After 2021, the demand for disposable gloves has declined compared to the high point. In addition, the industry has built more new production capacity, the supply and demand relationship has changed, and market competition has intensified. The price of disposable nitrile gloves will increase in 2025, but the product selling price will still remain at a relatively low level. The company will adopt phased business strategies based on different market conditions to respond to market fluctuations, and do its best to achieve full production, full sales and full shipments. At the same time, in the face of intensified competition in the industry cycle adjustment stage, the company will strive to further improve its own strength in marketing, production, research and development, supply chain and other aspects, reduce costs and increase efficiency, and strive to increase market share and strengthen customer service.

3. Raw material price fluctuations and supply stability risks

The company's raw material costs account for a high proportion of product costs. The main raw materials of the company's main product, disposable gloves, are nitrile latex, PVC powder and plasticizers. When raw material prices fluctuate, companies usually avoid risks by adjusting product selling prices and other measures. However, if raw material prices fluctuate greatly or even violently and the company cannot pass costs to downstream in a timely manner, the company may face the risk of rising costs and declining profit margins. By understanding the market information in a timely manner, the company can make a rough judgment on the price of raw materials and take corresponding measures such as stocking up. At the same time, we effectively reduce costs and volatility and ensure the stability of the supply chain through self-production of raw materials, bidding and procurement, optimizing process flows, using alternative raw materials and strengthening management.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 31

Section 3 Management Discussion and Analysis

4. Exchange rate fluctuation risk

The company's products are mainly exported abroad, and export business revenue accounts for more than 80% of total revenue. At the same time, some raw materials are settled in US dollars, but overall exports are much higher than imports. If the RMB continues to appreciate in the future, the company's gross profit margin will be reduced and its profits will be reduced. The company has measures to maintain and increase the value of U.S. dollar monetary funds; at the same time, the company will pay close attention to exchange rate changes and rationally use forward foreign exchange and other derivative financial instruments for exchange rate management to reduce the risk of exchange rate fluctuations and ensure the company's steady development.

5. The risk that the construction progress of production bases in various regions will not be as fast as expected

The company plans to build many production bases with large planned production capacity. If it is affected by various factors such as changes in market supply and demand, intensified industry competition, tightened policy approvals, Sino-US trade frictions, etc., it will have a greater impact on the construction of some production bases. If the progress is not as good as expected, future sales revenue may be lower than expected or the construction project will be adjusted due to the impact of market changes. The company will promptly adjust the construction progress or plan according to market changes.

6. Pressures faced by environmental protection

As the country continues to strengthen air pollution control and comprehensively improve pollutant emissions, the company's costs in environmental protection may increase. The company will continue to optimize the production process, lean production links, strengthen environmental protection management, and reduce related costs as much as possible.

12. Registration form for reception of research, communication, interviews and other activities during the reporting period

√ Applicable Not applicable

Reception Reception Reception The main content discussed by the reception The basics of research

Time, place, method, object type, object and information provided, situation index

For details, please see Juchao Information Network’s 2025 Panorama Network “Investor Relations Network Platform. To participate in the 2025 Shandong District Survey, please see Investment (www.cninfo.com.cn) for details.

"Interactive Platform" Others Listed Company Investors Online

May 15th Online Communicator Relations Activity Record Form "300677 Yingke Medical Investor Relations (https://ir.p5w.net) Investor Management Information for Collective Reception Day 20250515"

China Securities Journal·China Securities Network For details, please see Juchao Information Network

Participating companies in 2024

2025 "Roadshow Center" Platform Network Platform Others and the First Quarter of 2025 For details of the survey content, please see Investment (www.cninfo.com.cn)

May 19 (https://www.cs. Online communicator relations activity record sheet "Investors of 300677 Yingke Medical Investor Relations Performance Briefing"

Management information 20250519》

com.cn/roadshow）

13. Formulation and implementation of market value management system and valuation improvement plan

Whether the company has formulated a market value management system.

√ Yes No

Whether the company has disclosed plans to increase its valuation.

Yes √ No

The company held the 27th meeting of the third board of directors on December 30, 2024, and reviewed and approved the "Proposal on Developing the Market Value Management System of Yingke Medical Technology Co., Ltd.". In order to further strengthen the company's market value management work, standardize the company's market value management behavior, and safeguard the legitimate rights and interests of the company and the majority of investors, the "Inco Medical Technology Co., Ltd. Market Value Management System" is formulated in accordance with the "Company Law", the Securities Law, "Listed Company Supervision Guidelines No. 10 - Market Value Management", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operations of GEM Listed Companies" and other relevant laws and regulations.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 32

Section 3 Management Discussion and Analysis

14. Implementation of the “Double Improvement of Quality and Return” action plan

Has the company disclosed an announcement on the “Dual Improvement of Quality and Return” action plan?

√ Yes No

In order to implement the guiding ideology of “activating the capital market and boosting investor confidence” proposed by the Political Bureau of the Central Committee and “vigorously improve the quality and investment value of listed companies, and take more effective measures to stabilize the market and stabilize confidence” proposed by the State Council executive meeting, the company effectively safeguards the interests of investors, based on confidence in the company’s future development prospects and recognition of the company’s stock value. However, an action plan of "double improvement of quality and return" was formulated and disclosed, which specifically covers: giving full play to the company's comprehensive competitive advantages and developing into a global industry leader; strengthening R&D management and continuously improving independent innovation capabilities; actively implementing share buybacks to strengthen long-term development confidence and sharing development results with investors; continuously improving corporate governance levels and strengthening the construction of investor communication bridges and other important aspects.

For details, please refer to the "Progress Announcement on the "Double Improvement of Quality and Return" Action Plan" disclosed by the company on the cninfo.com (www.cninfo.com.cn) on the same day.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 33

Fourth

Jiehe Commune Company Committee Governance︑Environment

Section 4 Corporate Governance, Environment and Society

1. Basic situation of corporate governance

In 2025, in order to fully implement the requirements of new laws and regulations, ensure that corporate governance and regulatory provisions are synchronized, further standardize the company's operating mechanism, and improve the level of corporate governance, in accordance with the requirements of the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and other laws, regulations and normative documents, the company will formulate and revise the company's relevant governance systems based on actual operating conditions. Continuously improve the company's corporate governance structure, improve the internal control system, and further achieve standardized operations. The company's overall operations are standardized, independent, and information disclosure is standardized. The actual situation is basically consistent with the requirements of the China Securities Regulatory Commission's normative documents on the governance of listed companies.

(1) About shareholders and shareholders’ meetings

The company convenes shareholders' meetings in strict accordance with the requirements of relevant laws, regulations and normative documents such as the "Rules for Shareholders' Meetings of Listed Companies", "Company Articles of Association", "Rules of Procedure for Shareholders' Meetings" and other relevant laws, and standardizes the convening, holding and voting procedures of shareholders' meetings. During the reporting period, all shareholders' meetings held by the company were convened by the company's board of directors. The legal consultant hired by the company witnessed the on-site shareholders' meeting and issued a legal opinion. At the shareholders' meeting, we can ensure that every shareholder has a full voice, ensure that all shareholders, especially small and medium-sized shareholders, enjoy equal status and fully exercise their rights. For major matters that need to be reviewed by the shareholders' meeting in accordance with the provisions of the Company Law and the Company's Articles of Association, the company has passed the shareholders' meeting for review. There is no case of bypassing the shareholders' meeting, nor is there any case of implementation first and review later.

(2) About the company and controlling shareholders

The company has independent business operation capabilities and a complete operating system, and is independent from the controlling shareholder in terms of business, personnel, assets and finance. The controlling shareholder and actual controller of the company, Mr. Liu Fangyi, strictly regulates himself in accordance with the "Code of Corporate Governance for Listed Companies", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies", "Articles of Association" and other regulations and requirements. The shareholders exercise their rights and assume obligations in accordance with the law through the shareholders' meeting. There is no behavior that directly or indirectly interferes with the company's decision-making and operating activities beyond the company's shareholders' meeting. It does not harm the interests of the company and other shareholders. There is no phenomenon of the controlling shareholder occupying the company's funds, and there is no situation where the company provides guarantees for the controlling shareholder.

(3) About directors and board of directors

The seventh meeting of the fourth board of directors was held on July 8, 2025, and the fifth extraordinary shareholders' meeting of 2025 was held on July 25, 2025. The "Proposal on Re-formulating the Articles of Association" was reviewed and approved. According to Article 109 of the "Articles of Incorporation of Yingke Medical Technology Co., Ltd." "The company has a board of directors, which is responsible to the shareholders' meeting. The board of directors consists of 9 directors, including 3 independent directors and 2 employee representative directors."

All directors of the company are able to carry out their work in accordance with relevant regulations such as the Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies, the Rules of Procedure for the Board of Directors, and the Working Rules for Independent Directors, attend the board of directors, special committees of the board of directors, special meetings of independent directors and shareholders' meetings, and perform their duties and obligations diligently and responsibly. At the same time, all directors have actively participated in relevant training, become familiar with relevant laws and regulations, and have effectively improved their ability to perform the duties of directors. All directors can attend the board of directors and shareholders' meetings with a serious and responsible attitude, and understand their rights, obligations and responsibilities as directors. In accordance with the requirements of the "Code of Governance for Listed Companies", the company has established four special committees under the board of directors: Strategy and ESG Committee, Nomination Committee, Audit Committee, and Remuneration and Appraisal Committee. The members of the special committees are all composed of directors. Except for the Strategy and ESG Committee, which is convened by the chairman, the other special committees are all convened by independent directors, providing scientific and professional opinions for the board of directors' decision-making. Each committee performs its duties in accordance with the provisions of the Articles of Association and the Working System of Special Committees of the Board of Directors, without interference from any other department or individual in the company.

(4) About supervisors and board of supervisors

The seventh meeting of the fourth board of directors will be held on July 8, 2025, and the seventh meeting will be held on July 25, 2025. 2025 The Fifth Extraordinary General Meeting of Shareholders in 2019 reviewed and approved the "Proposal on Re-formulating the Articles of Association". In accordance with the "Company Law of the People's Republic of China", "Guidelines on the Articles of Association of Listed Companies" and other relevant provisions, and taking into account the actual situation of the company, the company no longer has a board of supervisors. The powers of the board of supervisors stipulated in the "Company Law" are exercised by the audit committee of the board of directors, and the "Rules of Procedure of the Board of Supervisors" are accordingly abolished.

(5) Information disclosure and transparency

The company attaches great importance to information disclosure and investor relations management, and strictly complies with the "Information Disclosure Management Measures for Listed Companies", "Shenzhen Stock Exchange GEM Listed Companies Self-Regulatory Guidelines No. 2 - Announcement Format" and other regulations, as well as the requirements of the "Information Disclosure Management System" and other operational documents formulated by the company, to disclose information in a true, accurate, complete and timely manner. The company designated "Securities Times", "Securities Daily", "China Securities News" and "Shanghai Securities News" as the company's information disclosure newspapers, and Juchao Information Network as the company's information disclosure website. Since its listing, the company has continuously tried to carry out investor relations management in more effective ways, and has established various channels such as interactive channels, dedicated telephone lines, and dedicated mailboxes to communicate with investors.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 35

Section 4 Corporate Governance, Environment and Society

(6) About relevant stakeholders

The company can fully respect and safeguard the legitimate rights and interests of relevant stakeholders, actively cooperate with relevant stakeholders, strengthen communication and exchanges with all parties, and achieve a balance of interests of shareholders, employees, society and other parties, so as to promote the company's sustainable, stable and healthy development.

Whether there are major differences between the actual situation of corporate governance and the laws, administrative regulations and regulations on the governance of listed companies issued by the China Securities Regulatory Commission

□Yes □√ No

There is no significant difference between the actual situation of corporate governance and the laws, administrative regulations and regulations on the governance of listed companies issued by the China Securities Regulatory Commission.

2. The company’s independence from its controlling shareholders and actual controllers in ensuring the company’s assets, personnel, finance, organization, business, etc.

The company operates strictly in accordance with the relevant laws and regulations such as the Company Law and the Securities Law, as well as the relevant provisions of the Articles of Association. During the reporting period, the company was completely separated from existing shareholders in terms of business, personnel, assets, institutions, finance, etc., and was independent of each other. It has independent and complete assets and businesses, and has the ability to operate independently and autonomously in the market.

(1) Business independence

There is no horizontal competition between the company and its controlling shareholder, actual controller and other enterprises controlled by it. The company has independent and complete operating and external business capabilities, has an independent business location, independently signs external contracts, and has no business dependence on the controlling shareholder, actual controller or other related parties.

(2) Personnel independence

1. The company’s general manager, financial director, board secretary and other senior management personnel work full-time in the company and receive remuneration. None of the above personnel holds any position in the controlling shareholder, actual controller or other companies controlled by them, nor does they receive remuneration from the controlling shareholder, actual controller or other companies controlled by them.

2. The company's directors and senior managers are all selected or appointed in accordance with legal procedures, and there is no situation where the controlling shareholder or others interferes with the personnel appointment and removal decisions made by the company's board of directors and shareholders' meeting.

3. The company has established an independent personnel management system, signed labor contracts with employees, and established independent salary management, welfare and social security management. The company has independent labor and employment rights, and there is no interference from the controlling shareholder.

(3) Asset independence

The company legally has independent and complete ownership or use rights of its production and operation sites and trademarks. The asset rights between the company and its shareholders are clearly defined. The production and operation sites are independent. The company's assets and funds are not occupied by shareholders to the detriment of the company's interests.

(4) Financial independence

The company has opened an independent bank account and paid taxes independently in accordance with the law. The company has an independent financial management department and an internal audit department, and is equipped with full-time financial management personnel and internal audit personnel. The company has established an independent accounting system, financial management system and internal audit management system to make independent financial decisions. The company does not have monetary funds or other assets occupied by shareholders or other related parties, nor does it provide guarantees for shareholders, their subordinate units, and other related enterprises.

(5) Institutional independence

The company has a sound management system, and each functional department exercises its respective powers in accordance with the company's internal regulations. The company implements a general manager responsibility system under the leadership of the board of directors. The company's production operations and office structures are completely independent. There is no mixed operation with shareholders. The company's organizational structure is not subject to interference from controlling shareholders and other individuals or units.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 36

Section 4 Corporate Governance, Environment and Society

3. Competition within the industry

Applicable √ Not applicable

4. The company has arrangements for differential voting rights

Applicable √ Not applicable

5. Corporate governance of red-chip structures

Applicable √ Not applicable

6. Directors and senior managers

(1) Basic situation

Position Term Term Beginning of the period Increase in holdings in the current period Decrease in holdings in the current period Others End of the period Increase or decrease in shares

Name Gender Age Position Number of shares held Number of shares Increase or decrease in number of shares Number of shares held

Status Start date End date (share) (share) (share) (share) (share) Reason for change

Liu Fangyi Male 55 Chairman Current April 29, 2015 April 8, 2028 231,703,107 231,703,107

Sun Jing Female 49 Director Current April 1, 2015 April 8, 2028 0 0

1. New directors were appointed through non-transaction transfer, and direct shareholding increased to 657,352 shares Chen Qiong Female 43 Current October 16, 2018 April 8, 2028 413,400 907,352 1,320,752

General Manager 2. 250,000 shares granted under the 2025 restricted stock incentive plan

1. New directors were appointed through non-transaction transfer, and the direct shareholding increased to 79,017 shares in Haisheng Male 49 Current October 16, 2018 April 08, 2028 221,640 199,017 420,657

Deputy General Manager 2. Restricted stock incentives in 2025

Plan to grant 120,000 shares Jia Jianjun Male 53 Independent Director Current April 9, 2025 April 8, 2028 0 0

Wu Xiaohui Male 54 Independent Director Current March 14, 2022 April 8, 2028 0 0

Xiang Jing Female 49 Independent Director Current March 14, 2022 April 8, 2028 0 0

Zhu Lili Female 43 Employee Representative Director Current July 28, 2025 April 8, 2028 59,940 59,940

Employee Representative Director Current July 28, 2025 April 8, 2028

Hua Cuiping Female 40 9,000 9,000

Supervisor Resignation February 13, 2025 July 25, 2025

Financial Director Current October 16, 2018 April 8, 2028 2025 Restricted Stock Incentive Plan Feng Jie Female 40 258,090 100,000 358,090

Secretary of the Board of Directors Current February 27, 2028 Planned grant of 100,000 shares on April 8, 2028 Tang Ye Male 42 Chairman of the Board of Supervisors Resigned April 29, 2015 July 25, 2025 0 300 300 Purchased 300 shares in the secondary market Xu Juan Female 38 Supervisor Resigned March 14, 2022 February 13, 2025 0 0

Zhai Wenning Female 38 Employee Representative Supervisor Resigned March 14, 2022 July 25, 2025 7,290 7,290

Wang Yang Male 46 Independent Director Resigned March 14, 2022 April 9, 2025 0 0

Total -- -- -- -- -- -- 232,672,467 0 0 1,206,669233,879,136 --

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 37

Section 4 Corporate Governance, Environment and Society

Is there any resignation of directors and senior managers during the reporting period?

√ Yes No

Mr. Wang Yang, the independent director of the third board of directors of the company, has expired and will no longer serve as an independent director of the company.

Changes in directors and senior managers of the company

√ Applicable Not applicable

Name Position held Type Date Reason

Wang Yang Independent Director Resigned upon expiration of term April 8, 2025 Reelection

Jia Jianjun, independent director, was elected on April 9, 2025.

Zhu Lili, employee representative director, was elected on July 28, 2025.

Hua Cuiping, employee representative director, was elected on July 28, 2025.

(2) Employment status

The professional background, main work experience and current main responsibilities of the company’s current directors and senior managers in the company

(1) Director

The company's board of directors consists of 9 directors, including 3 independent directors and 2 employee representative directors. The situation of each director is as follows:

1. Liu Fangyi, male, Chinese nationality, born in 1970. He is currently the chairman of the company. After graduating from Shanghai Gezhi Middle School in 1989, he studied at the University of California, Irvine. While studying in the United States in the 1990s, Liu Fangyi began to engage in the trading business of disposable gloves in North America. Later, he returned to China to invest and gradually entered the field of medical device manufacturing. He has more than 30 years of experience in the disposable gloves industry. In 2020, he won the "2020 Chinese Enterprise Economic Figure of the Year", "2020 Industry Innovative Figure of the Year", and "2020 China's Top Ten Brands of the Year". In 2021, he won the "2021 Outstanding Quality Person Award" and the "Ten Years Outstanding Business Leader Award". In 2022, he won the title of "Top Ten Leading Figures in China's Pharmaceutical Industry". In 2024, he won the "2024 Forbes China Top 30 Overseas Leaders", the "ESG Pioneer 60" Annual ESG Explorer Award, and the "Entrepreneur Leadership Award" at the 7th Annual Investment Conference of China Finance Association. In 2025, he won the title of "Outstanding Contributor to the Pharmaceutical Industry". He is currently the chairman of the company.

2. Chen Qiong, female, Chinese nationality, born in 1982, graduated from East China Normal University in June 2004 with a bachelor's degree in business administration. From July 2004 to May 2007, he served as the sales supervisor of Shanghai Greenland Import and Export Co., Ltd.; from May 2007 to August 2009, he served as the manager of the comprehensive product department of Shanghai Greenland Import and Export Co., Ltd.; from August 2009 to December 2014, he served as the general manager of Shanghai Greenland Import and Export Co., Ltd.; from January 2015 to the present, he has worked for Yingke Medical, and is currently the director and general manager of the company. In 2025, she was listed on the "Forbes 100 Outstanding Business Women" and won the title of Outstanding Business Figure.

3. Sun Jing, female, Chinese nationality, born in 1976, graduated from Dalian University of International Studies with a Bachelor of Arts in June 1998, received a Master of Business Administration from the University of Leeds in the United Kingdom in November 2001, and obtained the Global Finance GFD Certificate of Completion from Tsinghua University PBC School of Finance in August 2020. From October 2004 to September 2012, he served as the sales manager of Shanghai Green Forest Import and Export Co., Ltd.; from September 2012 to April 2015, he served as the general manager of the company; from April 2015 to present, he served as the director of the company.

4. Yu Haisheng, male, Chinese nationality, born in 1976, graduated from Tianjin University in June 1997 with a college degree. From August 2003 to May 2007, he served as the business manager of Zibo Hengchang Plastic Products Co., Ltd.; from June 2007 to September 2009, he served as the manager of the import and export department of Zibo Yingke Frame Industry Co., Ltd.; from September 2009, he served as the deputy general manager of Shandong Yingke Medical Supplies Co., Ltd.; from October 2018 to present, he serves as the director and deputy general manager of the company.

5. Wu Xiaohui, male, Chinese nationality, born in 1971, bachelor’s degree, certified public accountant. Obtained a bachelor's degree from the University of Shanghai for Science and Technology in 1993. From April 1994 to January 1999, he served as the audit manager of Deloitte Touche Tohmatsu Certified Public Accountants Co., Ltd.; from February 1999 to December 1999, he served as the financial director of Asia Pacific Wanqi Mold Manufacturing Co., Ltd.; from January 2000 to May 2004, he served as the audit senior manager of Deloitte Touche Tohmatsu Certified Public Accountants LLP (Special General Partnership); from 2004 From June 2021 to July 2021, he served as the audit partner of Deloitte Huayong Certified Public Accountants LLP and the managing partner of Deloitte National A-share market; from August 2021 to the present, he served as the senior partner and national brand market leading partner of Zhonghui Certified Public Accountants LLP (special general partnership); and served as a member of the 10th Listing Committee of the Shenzhen Stock Exchange. From June 2024 to present, he has served as an independent director of Jiangxi Yimai Sunshine Group Co., Ltd.; from October 2025 to present, he has served as an independent director of Shandong Xinhua Medical Devices Co., Ltd.; from March 14, 2022 to present, he has served as an independent director of the company.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 38

Section 4 Corporate Governance, Environment and Society

6. Jia Jianjun, male, Chinese nationality, born in 1972, doctorate degree. Obtained a doctorate in accounting from Fudan University in 2008. From August 1997 to December 2018, he served as an associate professor at Shanghai Lixin University of Accounting and Finance, and from January 2010 to June 2016, he served as the deputy dean of the School of Accountancy, Shanghai University of Finance and Economics; from 2019 to present, he serves as an associate professor at the School of Entrepreneurship and Management, Shanghai University of Science and Technology. He currently serves as an independent director of Shanghai Huide Technology Co., Ltd. and Ningbo Founder Automotive Mold Co., Ltd. From April 9, 2025 to present, he serves as an independent director of the company.

7. Xiang Jing, female, Chinese nationality, born in 1976, doctoral degree, senior economist. Obtained a doctorate degree from Southwest Jiaotong University in 2006. From 1995 to 1997, he successively served as a futures broker and director of the customer department of Guangzhou Huaxin Commodity Futures Company; from 1997 to 2009, he successively served as sales department clerk, investment department manager, general manager office director and board secretary of Guangdong Guangyang High-tech Co., Ltd.; from 2009 to 2010, he served as Boda Hengtong Investment Researcher of Capital Consulting (Shenzhen) Co., Ltd.; from 2010 to 2016, he served as senior investment manager and deputy director of the research department of Shenzhen Hehui Xinda Investment Co., Ltd.; from 2016 to 2017, he served as director and general manager of Shenzhen Hongtiancheng Fund Management Co., Ltd.; from 2017 to 2020, he served as Shenzhen Hua Xinda Investment Co., Ltd. Deputy General Manager and Secretary of the Board of Directors of Weishi Technology Co., Ltd., and concurrently serves as Deputy General Manager and Secretary of the Board of Directors of Shenzhen Zhongdian Intelligent Information Security Technology Co., Ltd.; From 2017 to present, he serves as Executive Director and General Manager of Shenzhen Tuozhi Technology Co., Ltd.; From December 2020 to February 2024, he serves as Shenzhen Haobo Window Control Technology Technology Co., Ltd.; from January 2021 to present, he has been an independent director of Hunan Jiudian Pharmaceutical Co., Ltd.; from February 2021 to October 2022, he has been an independent director of Shenzhen Batian Ecological Engineering Co., Ltd.; from February 2024 to present, he has been an independent director of Shenzhen Grandland Group Co., Ltd. From March 14, 2022 to present, he serves as an independent director of the company.

8. Zhu Lili, female, Chinese nationality, born in 1982, bachelor’s degree. From July 2006 to September 2007, he served as the assistant to the general manager of Shandong Weiming Biopharmaceutical Co., Ltd.; from October 2007 to August 2009, he served as the purchasing specialist of Yingke Renewable Resources Co., Ltd.; from September 2009 to the present, he served as the purchasing manager of the company. From July 28, 2025 to present, he serves as the employee representative director of the company.

9. Hua Cuiping, female, Chinese nationality, born in January 1985, bachelor’s degree. From July 2007 to March 2013, he served as an employee of Zhengyi Energy Technology (Zhenjiang) Co., Ltd.; from March 2013 to January 2017, he served as the accountant of the financial department of Jiangsu Yingke Medical Products Co., Ltd.; from January 2017 to present, he served as the financial manager of Jiangsu Yingke Medical Products Co., Ltd. From February 13, 2025 to July 25, 2025, he served as the non-employee representative supervisor of the company. From July 28, 2025 to present, he serves as the employee representative director of the company.

(2) Senior management personnel

The company's senior management personnel consists of three people. The situation of each senior management personnel is as follows:

1. For the resumes of Chen Qiong and Yu Haisheng, please see the relevant content of "(1) Directors" above.

2. Feng Jie, female, Chinese nationality, born in 1985, graduated from Qingdao University of Science and Technology in July 2008 with a bachelor's degree in financial management. From July 2008 to October 2010, he served as the cost accountant of the finance department of Auston Building Materials (Qingdao) Co., Ltd.; from December 2010 to July 2016, he served as the sales tax accountant of the finance department of the company; from August 2016 to December 2017, he served as the manager of the finance department of Shandong Yingke; from January 2018 to September 2018, he served as the manager of the finance department of the company. From October 2018 to present, he serves as the financial director of the company. From February 2024 to present, he serves as the secretary of the company’s board of directors. In 2025, he won the "Jin Shuguang Outstanding Board Secretary Award", "Gold Medal Innovative Board Secretary of the Year", "Financial Association Elite Board Secretary Award" and "Flush 2025 Most Popular Board Secretary".

The situation where the controlling shareholder and actual controller simultaneously serve as the chairman and general manager of a listed company

Applicable √ Not applicable

Employment status in shareholder units

Applicable √ Not applicable

Employment status in other units

√ Applicable Not applicable

Name of the employee Name of other unit Position held in other unit Start date of term End date of term Whether receiving remuneration and allowances from other units

Liu Fangyi Chairman of Yingke Renewable Resources Co., Ltd. November 26, 2019 Yes

Liu Fangyi Yingke International (Hong Kong) Co., Ltd. Director May 12, 2010 No

Liu Fangyi Director of Intco Recycling Inc. April 18, 2017 No

Intco Industries Vietnam

Liu Fangyi Director July 4, 2019 No

Co., Ltd

Intco Vietnam Compan

Liu Fangyi Chairman November 10, 2020 No

Limited

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 39

Section 4 Corporate Governance, Environment and Society

Name of the employee Name of other unit Position held in other unit Start date of term End date of term Whether receiving remuneration and allowances from other units

Liu Fangyi Chairman of Intco Vietnam Company Limited November 10, 2020 No Liu Fangyi Chairman of Zibo Yazhi Investment Co., Ltd. November 10, 2010 No Liu Fangyi Shanghai Yingjing Enterprise Management Center Investor June 1, 2020 No Sun Jing Zibo Yazhi Investment Co., Ltd. Supervisor November 10, 2010 No

Shanghai Yingxin Enterprise Management Service Center

Sun Jing Executive Partner January 12, 2018 No (Limited Partnership)

Shanghai Yingyi Enterprise Management Center

Sun Jing Executive Partner August 28, 2019 No

(limited partnership)

Sun Jing Hainan Yingsheng Investment Co., Ltd. Executive Director and General Manager June 25, 2021 No Jia Jianjun Associate Professor, School of Entrepreneurship and Management, University of Shanghai Science and Technology January 1, 2019 Yes Jia Jianjun Shanghai Huide Technology Co., Ltd. Independent Director May 19, 2022 Yes Jia Jianjun Ningbo Founder Automobile Mold Co., Ltd. Independent Director September 14, 2019 Yes

Zhonghui Accounting Firm

Wu Xiaohui Senior Partner August 1, 2021 Yes

(Special general partnership)

Wu Xiaohui Jiangxi Yimai Sunshine Group Co., Ltd. Independent director June 7, 2024 Yes Wu Xiaohui Shandong Xinhua Medical Equipment Co., Ltd. Independent director October 28, 2025 Yes Xiangjing Shenzhen Tuozhi Technology Co., Ltd. Executive director and general manager March 1, 2017 No Xiangjing Hunan Jiudian Pharmaceutical Co., Ltd. Independent director January 15, 2021 Yes Xiang Jing Shenzhen Grandland Group Co., Ltd. Independent Director February 5, 2024 Yes

Risk Control Director,

Wang Yang Beijing Zhiming Haojin Investment Management Co., Ltd. January 1, 2018 Yes

Compliance and risk control manager

Wang Yang Zhejiang Xinhecheng Co., Ltd. Independent Director September 19, 2023 Yes

Working in other units

Not applicable

Description of job situation

Penalties imposed by the securities regulatory authorities in the past three years on current and former directors and senior managers of the company during the reporting period

Applicable √ Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 40

Section 4 Corporate Governance, Environment and Society

(3) Remuneration of directors and senior managers

Decision-making procedures, basis for determination, and actual payment status of remuneration of directors and senior managers

Decision-making procedure: The remuneration of the company's directors is determined by the shareholders' meeting, and the remuneration of senior managers is determined by the board of directors; the remuneration of directors and senior managers who hold working positions in the company is paid by the company, and directors are not paid additional allowances. Allowances for independent directors are paid based on resolutions passed by the shareholders' meeting.

Determination basis: Based on relevant national laws, regulations and the relevant provisions of the Articles of Association, combined with the income level of the industry and region and the company's profit level, it is comprehensively determined based on the performance of directors and senior managers' duties and the completion of annual performance.

Actual payment: The remuneration of directors and senior management has been paid in full in accordance with the determined remuneration standards.

Remuneration situation of directors and senior managers of the company during the reporting period

Unit: 10,000 yuan

Name Gender Age Position Position Status Total pre-tax remuneration received from the company Whether remuneration is received from related parties of the company

Liu Fangyi Male 55 Chairman Incumbent 303.87 Yes Sun Jing Female 49 Director Incumbent 277.73 No Chen Qiong Female 43 Director, General Manager Incumbent 411.62 No Yu Haisheng Male 49 Director, Deputy General Manager Incumbent 185.32 No Jia Jianjun Male 53 Independent Director Incumbent 14.56 No Wu Xiaohui Male 54 Independent Director Current 20.00 No Xiangjing Female 49 Independent Director Current 20.00 No Zhu Lili Female 43 Employee Representative Director Current 25.15 No

Employee Representative Director Current

Hua Cuiping Female 40 49.54 No Supervisor Resigned

Financial Director Current

Feng Jie Female 40 91.09 No

Secretary of the Board of Directors Current

Tang Ye Male 42 Chairman of the Board of Supervisors Resigned 24.65 No Xu Juan Female 38 Supervisor Resigned 2.53 No Zhai Wenning Female 38 Employee Representative Supervisor Resigned 19.41 No Wang Yang Male 46 Independent Director Resigned 5.50 No Total -- -- -- -- 1,450.97 --

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 41

Section 4 Corporate Governance, Environment and Society

Assessment basis for the actual remuneration received by all directors and senior managers at the end of the reporting period Remuneration plans related to the company’s directors and senior managers

Completion of assessment of actual remuneration received by all directors and senior managers at the end of the reporting period Completed

Deferred payment arrangement for the actual remuneration received by all directors and senior management at the end of the reporting period Not applicable

Stop payment recourse status of actual remuneration received by all directors and senior managers at the end of the reporting period Not applicable

Other information

Applicable √ Not applicable

7. Directors’ performance of duties during the reporting period

(1) Directors’ attendance at the board of directors and shareholders’ meetings

Directors’ attendance at board of directors and shareholders’ meetings

During this reporting period, participants should attend on-site. Participate by communication. Attend by proxy. Absent directors. Have they not been in person for two consecutive times?

Director’s name Number of shareholders’ meetings attended

Number of times added to the board of directors Number of times added to the board of directors Number of times added to the board of directors Number of times added to the board of directors Number of board meetings Since attending board meetings

Liu Fangyi 15 0 15 0 0 No 0 Sun Jing 15 0 15 0 0 No 5 Chen Qiong 15 1 14 0 0 No 7 Yu Haisheng 15 6 9 0 0 No 3 Wu Xiaohui 15 0 15 0 0 No 7 Xiang Jing 15 0 15 0 0 No 7 Jia Jianjun 13 0 13 0 0 No 5 Zhu Lili 6 1 5 0 0 No 1 Hua Cuiping 6 1 5 0 0 No 1 Wang Yang 2 0 2 0 0 No 2 Explanation for not attending the board of directors in person for two consecutive times

Applicable √ Not applicable

(2) Directors raise objections to company-related matters

Whether directors raise objections to company-related matters

Yes √ No

During the reporting period, the directors raised no objections to relevant matters of the company.

(3) Whether the directors’ suggestions to the company have been adopted

√ Yes No

The director’s explanation of whether the company’s recommendations have been adopted or not.

During the reporting period, all directors of the company strictly complied with relevant laws and regulations such as the Company Law, Securities Law, Shenzhen Stock Exchange GEM Stock Listing Rules, Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operations of GEM Listed Companies, as well as the relevant requirements of the Articles of Association and the Rules of Procedure of the Board of Directors. Really perform their duties, actively attend relevant meetings, conduct in-depth discussions and prudent decisions on various proposals submitted to the board of directors for review, provide suggestions for the company's business development, fully consider the interests and demands of small and medium-sized shareholders when making decisions, effectively enhance the scientific nature of the board of directors' decision-making, and promote the sustainable, stable and healthy development of all aspects of the company's operations.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 42

Section 4 Corporate Governance, Environment and Society

8. The situation of the special committees under the board of directors during the reporting period

Convened. Other important objections to the performance of duties raised. Specific name of the committee. Member status. Meeting. Date of convening. Contents of the meeting.

Times Opinions and Suggestions Responsibility Circumstances (if any)

The Audit Committee carries out its work in accordance with relevant regulations

1. Considered and approved the "Proposal on <Company's Internal Audit Operation, Supervision and Evaluation of Internal Audit Work and 2024 Work Report and 2025 Internal Control on March 24, 2025, No Work Plan> on the basis of detailed review of the content of the proposal". After full communication and discussion, the resolution of this meeting was unanimously adopted.

Wu Xiaohui (Chairman)

The third trial

Wang Yang 2

planning committee

Xiang Jing The Audit Committee carries out its work in accordance with relevant regulations to review, supervise and evaluate external audits

1. Considered and approved the "Proposal on the company's 2024 work, based on a detailed review of the audit plan and implementation of the content of the proposal"

Based on this, make a reasonable evaluation of the work of the audit agency.

The Audit Committee met in strict accordance with the relevant regulations. April 9, 2025 1. Reviewed and approved the "Proposal on the Proposed Appointment of the Company's Financial Director" to carry out the work diligently and responsibly. Based on the actual situation of the company, the Audit Committee put forward relevant opinions and expressed unanimous agreement on the matters under review.

1. Consideration and adoption of the "Annual Report for 2024"

Proposal and its summary"

2. Reviewed and approved the "About 2024 Internal Control

Proposal for Preparing a Self-Evaluation Report>

3. Considered and adopted the "About 2024 Financial Resolution"

Calculation Report>Proposal》

4. Considered and approved the "Profit Sharing Plan for 2024"

Proposal of allocation plan>

5. Considered and approved the "About Submission to the General Meeting of Shareholders for Authorization"

The board of directors decides on the mid-term dividend plan for 2025

motion"

6. Considered and approved the "About 2024 Non-operating

The Audit Committee carries out information on the occupation of industrial funds and other related fund transactions in accordance with relevant regulations.

Proposal to prepare a special report for reviewing the company’s financial information and its disclosure>

April 22, 2025 Disclosure, supervision and evaluation of internal and external audit work None None

7. Reviewed and approved the "About the Development of the Company and its Subsidiaries"

and internal control, after a detailed review of the proposal on foreign exchange derivatives trading business"

Based on the content of the review, make relevant statements on the matters under consideration

8. Reviewed and approved the "Regulations on the Use of the Company and its Subsidiaries"

Regarding opinions.

Discussion on using idle own funds to purchase financial products

case"

The fourth review Wu Xiaohui (Chairman) 9. Reviewed and approved the "About the Company's 2025 Annual Report"

Jia Jianjun 7 Estimated regular related party transactions and daily routine in 2024

planning committee

Proposal on Confirmation of Xiangjingxing Related Transactions"

10. Reviewed and approved the "About the Company's Renewal of Employment in 2025"

Proposal from Accounting Firm

11. Considered and approved the "About Audit Committee of the Board of Directors"

Will review the accounting firm’s performance of duties in 2024

Situation assessment and performance of supervisory responsibilities report>

Bill

The Audit Committee carries out its work in accordance with relevant regulations

1. Considered and approved the "Proposal on the Company's Internal Audit Work, Review of the Company's Financial Information and its Disclosure Report for the First Quarter of 2025 on April 28, 2025, Supervision and Evaluation of Internal and External Audit Work" and internal control, within the detailed review of the proposal

2. Reviewed and approved the relevant opinions on the "Proposal on "Issuing a Comprehensive Report on the Matters Under Review on the Basis of Contents in the First Quarter of 2025"".

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 43

Section 4 Corporate Governance, Environment and Society

Convened. Other important objections to the performance of duties raised. Specific name of the committee. Member status. Meeting. Date of convening. Contents of the meeting.

Times Opinions and Suggestions Responsibility Circumstances (if any)

1. Deliberation and approval of the "Revision of Corporate Governance

System Proposal

1.01 Review and approval of "About Revision of Internal Control"

System>Proposal》

1.02 Review and approval of "About Revision of Raising Funds"

Management System>Proposal》

1.03 Review and approval of "About Revision of Related Transactions"

Management System>Proposal》

1.04 reviewed and approved the "About Revision of Standards and Related

Proposal on the Management System for Fund Transactions between Joint Parties>

1.05 reviewed and passed the "Proposal on Amending the "Foreign Investment Audit Committee Strictly Follows the "Company Management Measures"" Law, the China Securities Regulatory Commission, Shenzhen Stock Exchange and other relevant regulations 1.06 reviewed and adopted the "Proposal on Amending the "Derivatives Investment Decisions" and the "Articles of Association" and the "Board of Directors Special Investment Management System" on July 8, 2025. Diligent and conscientious, after full communication and discussion, the resolution of this meeting was unanimously adopted.

1.08 Review and adoption of "About Revision of Internal Audit"

Management System>Proposal

1.09 Review and approval of "About Revision of Subsidiary Management"

Wu Xiaohui (Chairman) Management System > Proposal"

The Fourth Review 1.10 reviewed and approved the "About Revision of the Financial Report"

Jia Jianjun 7

Proposal of Planning Committee Management System>

Xiang Jing

1.11 Deliberation and approval of "About Revision of Accounting Affairs"

Proposal for Selected Recruitment System>

2. Reviewed and approved the "About the Establishment of Directors, Senior

Proposal on Management System for Resignation of Managers>

1. Review and approve the "2025 Semi-annual Report"

Proposal on the work report and summary of the Audit Committee’s work report in accordance with relevant regulations”

work to review the company’s financial information and its disclosures

2. Reviewed and approved the "About 2025 Semi-annual Profit

Proposal on Disclosure, Supervision and Evaluation of Internal and External Audit Work Profit Distribution Plan> None None August 28, 2025 and internal control, within the detailed review of the proposal

3. Review and approve the "About the Company's Internal Audit"

On the basis of the content, a resolution related to the work report for the second quarter of 2025> was issued on the matters under consideration.

Regarding opinions.

The Audit Committee strictly complies with the Company Law, China Securities Regulatory Commission, Shenzhen Stock Exchange and other relevant regulations.

1. Deliberation and approval of the "Proposal on Participation in the Investment in Warburg" and the "Articles of Association" and the "Working System of the Board of Directors' Special Committee" to carry out work, and there is no transaction. After full communication and discussion, the resolution of this meeting was unanimously adopted.

The Audit Committee carries out its work in accordance with relevant regulations

1. Review and adopt the "About the Third Quarter of 2025"

Supervise and evaluate the internal and external audit work and internal

2. Considered and approved the "About the Company's Internal Audit"

Control, based on a detailed review of the content of the proposal, the third quarter work report of 2025>Proposal》

to express relevant opinions on matters under review.

The Strategy and ESG Committee shall conduct meetings in accordance with relevant regulations

1. Reviewed and approved the "About the Company's Environmental Development Work in 2024" and carefully reviewed the content of the proposal. April 22, 2025 Environmental, Social and Corporate Governance (ESG) Report> After review, all members believe that the "2024 N/A Proposal" Environmental, Social and Corporate Governance (ESG) Report" complies with relevant laws, regulations and the company's Articles of Association.

The Fourth Director Liu Fangyi (Chairman)

Meeting Strategy with Chen Qiong 2

Strategy and ESG Committee ESG Committee in accordance with relevant regulations Wu Xiaohui

Carry out the work and carefully review the contents of the proposal. Members participating in the meeting believed that this association has a total of

1. Review and adoption of the "About Participation in Investment in Warburg"

On October 20, 2025, Pincus Global Growth 15, L.P. and related investments are necessary and reasonable, and there is no proposal to follow open, fair and just pricing of the original transaction.

Therefore, there is no situation that affects the company's independence or is obviously unfair.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 44

Convened. Other important objections to the performance of duties raised. Specific name of the committee. Member status. Meeting. Date of convening. Contents of the meeting.

Times Opinions and Suggestions Responsibility Circumstances (if any)

The Remuneration and Appraisal Committee strictly complies with the "Company

1. Review and adopt the "Regulations on the Company's 2024 Directors' Law", the China Securities Regulatory Commission, the Shenzhen Stock Exchange and other relevant regulations on the performance appraisal of directors, supervisors and senior managers on April 22, 2025, as well as the "Company Articles of Association", "Board of Directors and the Proposal of the 2025 Remuneration Plan" and the Special Committee Working System to carry out work diligently and conscientiously. After full communication and discussion, the resolution of this meeting was unanimously adopted.

The Remuneration and Appraisal Committee strictly complies with the relevant regulations of the Company Law, China Securities Regulatory Commission, Shenzhen Stock Exchange, etc.

1. Considered and approved the "About Adjusting the Company's 2022 Period"

Regulations and the "Articles of Association" and the "Board of Directors' Discussion on the Performance Assessment Indicators of the Institutional Stock Incentive Plan on May 22, 2025 No No Special Committee Work System" to carry out the work plan"

They worked diligently and conscientiously. After full communication and discussion, the resolution of this meeting was unanimously adopted.

1. Review and approve the "About the Company <2025 Restrictions"

The Remuneration and Assessment Committee strictly followed the "Fourth Board of Directors Xiang Jing (Chairman) Case" Law, China Securities Regulatory Commission, Shenzhen Stock Exchange and other relevant committees Liu Fangyi 7 2. Reviewed and approved the "About the Company's 2025 Restriction Regulations and the Company Articles of Association" and the "Board of Directors Assessment Committee Wu Xiaohui May 29, 2025 Implementation Assessment and Management Measures for the Sexual Stock Incentive Plan" The working system of the special committee carries out its work diligently and diligently, and after full communication and discussion

3. The "About Verification of the Company's 2025 Plan" was reviewed and approved, and the resolutions of this meeting were unanimously adopted. Restricted Stock Incentive Plan Grants Incentive Pairs for the First Time

Like List > Motions

The Remuneration and Appraisal Committee strictly complies with the "Company

1. Considered and approved the "Proposal on Adjusting the Restrictive Law of 2025", the China Securities Regulatory Commission, the Shenzhen Stock Exchange and other relevant regulations on matters related to the stock incentive plan on June 20, 2025, as well as the "Articles of Association" and "Special Committee of the Board of Directors" None None

2. Review and adopt the "Proposal on the Working System for the First Grant of Membership to Incentive Objects" to carry out work and diligently fulfill the responsibilities of restricted stocks. After full communication and discussion, the resolution of this meeting was unanimously adopted.

The Remuneration and Appraisal Committee strictly complies with the "Company

1. Consideration and adoption of the "About Adjustment of Restrictions in 2025"

Law", the China Securities Regulatory Commission, the Shenzhen Stock Exchange and other bills on stipulating matters related to stock incentive plans"

October 15, 2025 2. Reviewed and approved the "About Granting to Incentive Objects" and the "Company Articles of Association" and the "Working System of the Special Committee of the Board of Directors" to carry out work and diligently use the reserved shares of the 2025 Restricted Stock Incentive Plan

Responsibility, after full communication and discussion, the resolution was unanimously passed.

Proposal of this meeting.

1. Reviewed and approved the provisions of the "Judiciary on the Removal of Restricted Conditions for the Third Phase of the Public Incentive Plan", the China Securities Regulatory Commission, the Shenzhen Stock Exchange and other relevant regulations on October 20, 2025.

2. Reviewed and approved the "Working System of the Special Committee on Adjusting the Repurchase of Restricted Stocks" to carry out work on industrial purchase prices and the repurchase and cancellation of some restricted stocks. After full communication and discussion, the resolution of this meeting was unanimously adopted.

The Remuneration and Appraisal Committee carried out its work in strict accordance with the "Company Law", the China Securities Regulatory Commission, the Shenzhen Stock Exchange, etc. December 30, 2025 1. Reviewed and approved the "Proposal on the Proposed Purchase of Directors and Senior Provisions, the Articles of Association" and the "Board of Directors Management Personnel Liability Insurance" Special Committee Working System, and worked diligently and conscientiously. After full communication and discussion, the resolution of this meeting was unanimously adopted.

The Nomination Committee carried out its work in strict accordance with the "Law of the Company's Fourth Session of Directors", the China Securities Regulatory Commission, the Shenzhen Stock Exchange and other relevant regulatory committees. Chen Qiong 1 April 9, 2025 1. Reviewed and approved the "Proposal on Nominating the Company's Senior Management Regulations and the Articles of Association, the Proposal of Dedicated Personnel of the Board of Directors" to carry out its work. The committee Xiang Jing

We worked diligently and conscientiously, and after full communication and discussion, the resolution of this meeting was unanimously adopted.

9. Work of the Audit Committee

The audit committee discovered whether there are risks in the company during its supervision activities during the reporting period

Yes √ No

The Audit Committee has no objection to the supervision matters during the reporting period.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 45

Section 4 Corporate Governance, Environment and Society

10. Company employees

(1) Number of employees, professional composition and education level

Number of active employees of the parent company at the end of the reporting period (person) 547

Number of active employees of major subsidiaries at the end of the reporting period (person) 12,395Total number of active employees at the end of the reporting period (person) 12,941Total number of employees receiving salaries during the current period (person) 12,941

The number of retired employees of the parent company and major subsidiaries who need to bear the expenses (person) 347

Professional composition

Professional composition category Professional composition number (people)

Production staff 10,649 Sales staff 476 Technical staff 1,031 Financial staff 76 Administrative staff 709 Total 12,941

education level

Education level category quantity (person)

Master's degree or above 197 Bachelor's degree 1,970 College degree 1,246 Technical secondary school, high school degree or below 9,528 Total 12,941

(2) Remuneration policy

1. The company has signed labor contracts with employees in accordance with relevant national labor laws and provides employees with social security and provident funds;

2. Implement a post-based salary system as a whole and implement the principle of "setting up posts according to the situation and setting salaries according to the posts";

3. Based on the industry and actual operating conditions of the functional positions, employee remuneration is comprehensively assessed based on the job responsibilities, professional skills, work performance, working years and other indicators, and a flexible salary system linked to performance is formulated;

4. Salary distribution for sales positions follows the principle that basic salary is determined by rank and performance-based salary is determined by performance;

5. Some key positions implement equity incentive policies, which effectively improves the company's incentive and restraint mechanism and ensures the stability of the company's core talents; 6) The company actively organizes and carries out various activities to enrich employees' cultural life and enhance employees' sense of belonging and satisfaction.

(3) Training plan

Yingke Medical deeply integrates the international cutting-edge talent training concept and business development needs, combines the characteristics of each functional position under the global layout, iteratively optimizes the "Training Management System", builds a hierarchical classification, full coverage, closed-loop operation training management system, upgrades the digital training platform, and realizes course sharing and progress tracking. We will continue to deepen the implementation of three-level training, create customized courses for each line around leadership, professional skills, and general literacy, strengthen employee academic qualifications and professional qualification certification, and add new certification directions that are suitable for the business, such as intelligent manufacturing and digital intelligent operations. Establish a regular survey and rapid response mechanism for training needs, promote the in-depth integration of training with company development and employee growth, and use high-quality training to build talent competitive advantages and empower corporate development.

(4) Labor outsourcing situation

Applicable √ Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 46

Section 4 Corporate Governance, Environment and Society

11. Company profit distribution and conversion of capital reserve into share capital

The formulation, implementation or adjustment of profit distribution policies, especially cash dividend policies, during the reporting period

√ Applicable Not applicable

During the reporting period, the company implemented the profit distribution plan in strict accordance with the relevant profit distribution policies and review procedures in the Articles of Association. The dividend standards and dividend proportions were clear and clear, and the relevant decision-making procedures and mechanisms were complete.

1. The second (regular) meeting of the fourth board of directors and the second (regular) meeting of the fourth board of supervisors were held on April 23, 2025, and the "Proposal on the Profit Distribution Plan for 2024" was reviewed and approved. The company's profit distribution for 2024 was The allocation plan is as follows: Based on the total share capital on the equity registration date when the company's equity distribution is implemented, minus the shares repurchased in the company's special repurchase account, it is planned to distribute a cash dividend of RMB 1 (tax included) to all shareholders for every 10 shares. No bonus shares will be issued, and no bonus shares will be transferred to increase share capital. If between the disclosure and implementation of the profit distribution plan, the company's total share capital changes due to convertible bonds conversion, share repurchase, etc., the company will adjust the total distribution amount based on the principle that the amount of cash dividends distributed per share remains unchanged.

On May 26, 2025, the company held the 2024 Annual General Meeting of Shareholders to review and approve the "Proposal on the Profit Distribution Plan for 2024". The profit distribution plan reviewed and approved by the company's 2024 Annual General Meeting of Shareholders is: : Based on the total share capital on the equity registration date when the company's equity distribution is implemented, minus the shares repurchased in the company's special repurchase account, a cash dividend of RMB 1 (tax included) will be distributed to all shareholders for every 10 shares. No bonus shares will be issued, and no bonus shares will be transferred to share capital. If between the disclosure and implementation of the profit distribution plan, the company's total share capital changes due to convertible bonds conversion, share repurchase, etc., the company will adjust the total distribution amount based on the principle that the amount of cash dividends distributed per share remains unchanged.

2. The eighth (regular) meeting of the fourth board of directors was held on August 28, 2025, and the "Proposal on the 2025 Semi-annual Profit Distribution Plan" was unanimously reviewed and approved. According to the authorization of the 2024 Annual General Meeting of Shareholders, this interim dividend plan does not need to be submitted to the shareholders' meeting for review. The company's 2025 semi-annual profit distribution plan is as follows: Based on the total share capital on the equity registration date when the company's equity distribution is implemented, minus the shares repurchased in the company's repurchase account, it is planned to distribute a cash dividend of RMB 0.5 (tax included) to all shareholders for every 10 shares. No bonus shares will be given, and no bonus shares will be converted into share capital.

Special explanation of cash dividend policy

Whether it complies with the provisions of the company's articles of association or the requirements of the resolution of the shareholders' meeting: Yes

Are the dividend standards and proportions clear and clear: Yes

Are the relevant decision-making procedures and mechanisms complete: Yes

Whether the independent directors have performed their duties and played their due role: Yes

If the company does not distribute cash dividends, it should disclose the specific reasons and the next steps it plans to take to enhance investor returns: Not applicable

Whether small and medium-sized shareholders have the opportunity to fully express their opinions and demands, and whether their legitimate rights and interests are fully protected: Yes

If the cash dividend policy is adjusted or changed, whether the conditions and procedures are compliant and transparent: Not applicable

The company's profit distribution plan for the reporting period and capital reserve conversion plan are consistent with the relevant provisions of the company's articles of association and dividend management measures.

√ Yes No Not applicable

The company's profit distribution plan for the reporting period and capital reserve conversion plan are in compliance with the relevant provisions of the company's articles of association and other provisions.

Profit distribution and capitalization of capital reserve this year

Number of bonus shares for every 10 shares (shares) 0

Dividend amount per 10 shares (yuan) (tax included) 1.00

Number of shares converted per 10 shares (shares) 0

The share capital base of the distribution plan (shares) 651,447,083

Amount of cash dividends (yuan) (tax included) 65,144,708.30

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 47

Section 4 Corporate Governance, Environment and Society

Amount of cash dividends distributed in other ways (such as share repurchase) (yuan) 100,015,581.00

Total cash dividends (including other methods) (yuan) 165,160,289.30

The ratio of total cash dividends (including other methods) to total profit distribution 100.00%

Cash dividend distribution this time

Others

Details of profit distribution or capital reserve conversion plan Detailed description of profit distribution or capital reserve conversion plan

According to the China Securities Regulatory Commission's "Guidelines for the Supervision of Listed Companies No. 3 - Cash Dividends by Listed Companies", listed companies are encouraged to distribute cash dividends and provide investors with guidance on stable and reasonable returns. On the premise of complying with the principle of profit distribution and ensuring the company's normal operations and long-term development, the company 202 The profit distribution plan for 5 years is as follows: Based on the total share capital on the equity registration date when the company's equity distribution is implemented, minus the shares repurchased in the company's repurchase account, it is planned to distribute a cash dividend of RMB 1.00 (tax included) to all shareholders for every 10 shares. No bonus shares will be given, and no bonus shares will be transferred to share capital. If the company's total share capital or the number of repurchased shares changes between the disclosure and implementation of the profit distribution plan, the company will adjust the total distribution amount based on the principle that the amount of cash dividends distributed per share remains unchanged.

The company made profits during the reporting period and the parent company’s profits available for distribution to shareholders were positive but no cash dividend distribution plan was proposed

Applicable √ Not applicable

12. Implementation of the company’s equity incentive plan, employee stock ownership plan or other employee incentive measures

√ Applicable Not applicable

(1) Equity incentives

1. On May 29, 2025, the company held the fifth meeting of the fourth board of directors and the fifth meeting of the fourth board of supervisors, and reviewed and approved the "Proposal on the Company's "2025 Restricted Stock Incentive Plan (Draft)" and its Summary, and the "Proposal on the Company's "2025 Restricted Stock Incentive Plan Implementation Assessment and Management Measures" and other proposals. For specific details, please refer to the relevant announcements disclosed by the company on the Juchao Information Network (www.cninfo.com.cn), announcement numbers: 2025-073, 2025-074.

2. On June 17, 2025, the company held the fourth extraordinary general meeting of shareholders in 2025, which reviewed and approved the "Proposal on the Company's 2025 Restricted Stock Incentive Plan (Draft)" and its Summary and "On the Implementation Assessment of the Company's 2025 Restricted Stock Incentive Plan" "Management Measures" "Proposal on Proposing to the General Meeting of Shareholders to Authorize the Board of Directors to Handle Matters Related to Equity Incentives". For details, please refer to the relevant announcements disclosed by the company on the Juchao Information Network (www.cninfo.com.cn), announcement number: 2025-087.

3. On June 20, 2025, the company held the sixth meeting of the fourth board of directors and the sixth meeting of the fourth board of supervisors, and reviewed and approved the "Proposal on Adjusting Matters Related to the 2025 Restricted Stock Incentive Plan" and "Proposal on the First Grant of Restricted Stocks to Incentive Objects". For details, please refer to the relevant announcements disclosed by the company on the cninfo.com (www.cninfo.com.cn), announcement numbers: 2025-088, 2025-089, 2025-090, 2025-091.

4. According to the China Securities Regulatory Commission's "Equity Incentive Management Measures for Listed Companies", the relevant regulations of the Shenzhen Stock Exchange and the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd., the company has completed the grant registration of the restricted stocks first awarded under the 2025 Restricted Stock Incentive Plan. The listing date of the restricted stocks granted this time is: July 22, 2025. For details, please refer to the relevant announcement disclosed by the company on the cninfo.com (www.cninfo.com.cn), announcement number: 2025-105.

5. On October 15, 2025, the company held the 10th meeting of the fourth board of directors, and reviewed and approved the "Proposal on Adjusting Matters Related to the 2025 Restricted Stock Incentive Plan" and adjusted the reserved grant price from 11.30 yuan/share to 11.25 yuan/share. For details, please refer to the company's relevant announcements disclosed on the Cninfo Network (www.cninfo.com.cn), announcement numbers: 2025-135, 2025-136.

6. On October 15, 2025, the company held the 10th meeting of the fourth session of the Board of Directors, which reviewed and approved the "Proposal on Granting Reserved Shares of the 2025 Restricted Stock Incentive Plan to Incentive Objects", and determined October 15, 2025 as the reserved grant date, and granted 370,000 reserved restricted shares to 2 incentive objects at a grant price of 11.25 yuan/share. For details, please refer to the relevant announcements disclosed by the company on the Juchao Information Network (www.cninfo.com.cn), announcement numbers: 2025-135, 2025-137.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 48

Section 4 Corporate Governance, Environment and Society

7. According to the "Measures for the Administration of Equity Incentives for Listed Companies" of the China Securities Regulatory Commission, the relevant regulations of the Shenzhen Stock Exchange and the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd., the company has completed the grant registration of the restricted shares reserved for the 2025 restricted stock incentive plan. The listing date of the restricted shares granted this time is: November 26, 2025. For details, please refer to the relevant announcement disclosed by the company on the cninfo.com (www.cninfo.com.cn), announcement number: 2025-157.

8. On October 20, 2025, the company held the 11th meeting of the fourth session of the Board of Directors, and reviewed and approved the "Proposal on the Achievements of Lifting the Restriction Conditions for the Third Phase of the Company's 2022 Restricted Stock Incentive Plan". A total of 540 incentive targets met the conditions for lifting the sales restrictions this time, and the actual number of shares that were lifted from the sales restrictions was 1,052,520 shares, accounting for 0.1607% of the company's current total share capital. The date for the restricted stocks to be released this time, that is, the date of listing and circulation, is October 29, 2025. For specific content, please refer to the relevant announcements disclosed by the company on the Juchao Information Network (www.cninfo.com.cn), announcement numbers: 2025-138, 2025-140, 2025-145.

Equity incentives received by directors and senior managers

√ Applicable Not applicable Unit: shares

Held at the beginning of the reporting period Reporting period During the reporting period Held at the end of the reporting period Reporting period Held at the beginning of the period Reporting period Restrictive Held at the end of the period

There are stocks. Newly granted. Exercised shares. Restricted. Unlocked. Newly granted stocks. Restricted. Name. Position. Available within the period. Executed within the period. Stocks available. Last market price.

Option Stock Period Number of Exercise Price Sexual Stock Shares Restricted Grant Price Number of Sexual Stock Rights Number of Rights Shares Number of Option (Yuan/share)

Quantity Quantity of rights (Yuan/share) Quantity Quantity Number of shares (Yuan/share) Quantity

Chen Qiong Director and General Manager 30,000.00 15,000.00 250,000.00 11.2500 265,000.00 Yu Haisheng Director and Deputy General Manager 24,000.00 12,000.00 120,000.00 11.2500 132,000.00

financial director,

Feng Jie 24,000.00 12,000.00 100,000.00 11.3000 112,000.00

Secretary of the Board of Directors

Zhu Lili, employee representative director 24,000.00 12,000.00 30,000.00 11.3000 42,000.00 Hua Cuiping, employee representative director 9,000.00 4,500.00 0.00 -- 4,500.00Total -- 0 0 0 0 -- 0 -- 111,000.00 55,500.00 500,000.00 -- 555,500.00

Evaluation mechanism and incentives for senior managers

The company's senior managers are appointed by the board of directors and are accountable to the board of directors. The Company's Board of Directors has a Remuneration and Appraisal Committee, which is responsible for conducting year-end evaluations of senior management personnel's abilities, performance of duties, and completion of responsibility goals.

During the reporting period, the company's senior managers performed their duties in strict accordance with the Company Law, Articles of Association and relevant laws and regulations, actively implemented relevant resolutions of the company's shareholders' meeting and the board of directors, and completed the operating tasks for the year.

(2) Implementation of employee stock ownership plan

Applicable √ Not applicable

(2) Other employee incentives

Applicable √ Not applicable

13. Construction and implementation of internal control system during the reporting period

(1) Construction and implementation of internal control

During the reporting period, the company organized and carried out internal control evaluation work in accordance with the "Basic Standards for Enterprise Internal Control" and its supporting guidelines and other internal control regulatory requirements.

According to the identification of major deficiencies in the company's internal control, the company did not have any major deficiencies in the internal control of financial reporting in 2025, and no major deficiencies in the internal control of non-financial reporting were found. Through the operation, analysis and evaluation of the internal control system, the company effectively prevents risks in operation and management and promotes the realization of internal control objectives.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 49

Section 4 Corporate Governance, Environment and Society

(2) Details of major internal control deficiencies discovered during the reporting period

Yes √ No

14. The company’s management and control of subsidiaries during the reporting period

Company name Integration plan Integration progress Problems encountered during integration Resolution measures taken Resolution progress Follow-up resolution plan Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable

Abnormalities in management control of subsidiaries

Yes √ No

15. Internal control evaluation report and internal control audit report

(1) Internal control evaluation report

Date of disclosure of the full text of the internal control evaluation report: April 24, 2026

On April 24, 2026, it was disclosed on the cninfo.com (http://www.cninfo.com.cn)

Full text disclosure of internal control evaluation report

"Inco Medical Technology Co., Ltd. 2025 Internal Control Evaluation Report" on

The total assets of the units included in the evaluation scope account for

100.00%

Proportion of total assets in the company’s consolidated financial statements

The operating income of units included in the evaluation scope accounts for

100.00%

Proportion of operating income in the company’s consolidated financial statements

Defect identification standards

Category Financial Reporting Non-Financial Reporting

If a defect or a combination of defects results in the inability to prevent or discover and correct, for example, a major defect refers to one or more actions/events under control defects, or the defect or combination of defects can directly lead to the following combination of actions/events, which may cause the company to seriously deviate from the control actions/events, the defect or combination of defects is determined to be a major defect: Objectives.

(1) Fraud by directors and senior managers;

(2) The company corrects the published financial report; an important defect refers to one or more control defects

(3) The certified public accountant discovers that there is a material misstatement in the current financial report, and the combination of internal controls has a lower severity and economic consequences than if the misstatement had not been discovered during the operation of the system; there are major deficiencies, but they may still cause the enterprise to deviate from the control.

(4) The corporate audit committee and internal audit institution are ineffective in supervising internal controls. target.

If a defect or combination of defects results in the inability to prevent or detect and correct e.g.

Qualitative criteria

The defect or combination of defects can directly lead to the following behavior/event, or the defect or combination of defects can directly lead to the following behavior: General defects refer to defects other than the occurrence of major defects and important defects/events. The defect or combination of defects is identified as an important defect: Defects.

(1) Failure to select and apply accounting policies in accordance with generally accepted accounting principles;

(2) Failure to establish anti-fraud procedures and control measures;

(3) No corresponding controls have been established for the accounting processing of non-routine or special transactions

Mechanisms may not be implemented and there are no corresponding compensating controls;

(4) There are one or more deficiencies in the control of the period-end financial reporting process and the

Can reasonably ensure that the financial statements prepared achieve true and accurate objectives.

General defects refer to other controls other than the above-mentioned major defects and important defects.

defects.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 50

Section 4 Corporate Governance, Environment and Society

Defect identification standards

Category Financial Reporting Non-Financial Reporting

Internal control deficiencies that may cause the misstatement of financial statements to be less than 0.5% of the company's total assets or may cause direct property losses to be less than 1% of the company's total pre-tax profits are deemed to be general deficiencies; internal control deficiencies that may cause 0.5% of the company's total pre-tax profits to cause financial statement misstatements to be greater than or equal to 0.5% of the company's total assets, but less than the deficiencies, are deemed to be general deficiencies; for possible quantitative standards of 3%, or the amount of financial statement misstatements is greater than or equal to the total pre-tax profits Internal control deficiencies with a direct economic loss greater than or equal to 1% but less than 5% of pre-tax profits are deemed important deficiencies; internal control deficiencies with a direct economic loss of 0.5% but less than 3% of the total profit that may result in financial statement misstatements greater than or equal to 3% of the company's total assets are deemed important deficiencies; deficiencies that may result in 5% of the total pre-tax profits are deemed major deficiencies. The direct economic loss is greater than or equal to the pre-tax profit

Defects exceeding 3% of the total amount are considered major defects.

Number of major defects in financial reports (number) 0

Number of major deficiencies in non-financial reports (number) 0

Number of important flaws in financial reports (number) 0

Number of important defects in non-financial reports (number) 0

(2) Internal control audit report

√ Applicable Not applicable

Review opinion paragraph in internal control audit report

We believe that Yingke Medical Company maintained effective internal control over financial reporting in all material aspects in accordance with the "Basic Standards for Corporate Internal Control" and relevant regulations on December 31, 2025.

Disclosure of internal control audit report Disclosure

Date of disclosure of the full text of the internal control audit report: April 24, 2026

Disclosure index for the full text of the internal control audit report. For details, please refer to the "Internal Control Audit Report" disclosed by the company on April 24, 2026 on the cninfo.com (www.cninfo.com.cn). Type of internal control audit report opinion: Standard unqualified opinion

Are there any major deficiencies in the non-financial report? No

Whether the accounting firm issues an internal control audit report with non-standard opinions

Yes √ No

Whether the internal control audit report issued by the accounting firm is consistent with the self-evaluation report of the board of directors

√ Yes No

Whether a non-standard audit opinion on internal control was issued during the reporting period or the previous year

Yes √ No

16. Rectification of self-examination issues under special action on governance of listed companies

Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 51

Section 4 Corporate Governance, Environment and Society

17. Environmental information disclosure

Whether listed companies and their major subsidiaries are included in the list of companies that disclose environmental information in accordance with the law

√ Yes No

Number of companies included in the list of companies disclosing environmental information in accordance with the law (household) 7 serial number Company name Query index of environmental information disclosure reports in accordance with the law

1 Yingke Medical Technology Co., Ltd. Corporate Environmental Information Disclosure System (Shandong) (http://221.214.62.226:8090/EnvironmentDisclosure/)

2 Shandong Yingke Medical Products Co., Ltd. Corporate Environmental Information Disclosure System (Shandong) (http://221.214.62.226:8090/EnvironmentDisclosure/)

3 Anhui Yingke Medical Products Co., Ltd. Corporate Environmental Information Disclosure System (Anhui) (https://39.145.37.16:8081/zhhb/yfplpub_html/#/companyList) 4 Jiangxi Yingke Medical Co., Ltd. Corporate Environmental Information Disclosure System Management Platform (Jiangxi Province) (http://111.75.227.203:15001/)

5 Anhui Kaize New Materials Co., Ltd. Corporate Environmental Information Disclosure System (Anhui) (https://39.145.37.16:8081/zhhb/yfplpub_html/#/companyList) 6 Anqing Yingke Medical Co., Ltd. Corporate Environmental Information Disclosure System (Anhui) (https://39.145.37.16:8081/zhhb/yfplpub_html/#/companyList) 7 Anhui Yingyi Thermal Power Co., Ltd. Corporate Environmental Information Disclosure System (Anhui) (https://39.145.37.16:8081/zhhb/yfplpub_html/#/companyList)

18. Social Responsibility

For specific content, please refer to the "2025 Environmental, Social and Corporate Governance (ESG) Report" released by the company on April 24, 2026 on the website of the Shenzhen Stock Exchange and information disclosure media that meet the conditions specified by the China Securities Regulatory Commission.

19. Consolidate and expand the results of poverty alleviation and rural revitalization

For specific content, please refer to the "2025 Environmental, Social and Corporate Governance (ESG) Report" released by the company on April 24, 2026 on the website of the Shenzhen Stock Exchange and information disclosure media that meet the conditions specified by the China Securities Regulatory Commission.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 52

heavy

The fifth important thing is to keep things safe

item

Section 5 Important Matters

1. Fulfillment of commitments

(1) Commitments made by the company’s actual controller, shareholders, related parties, acquirers, the company and other relevant parties that have been fulfilled during the reporting period and have not yet been fulfilled by the end of the reporting period

□√ Applicable □ Not applicable

Reason for commitment Commitment party Commitment type Commitment content Commitment time Commitment period Performance status

Other commitments: I will not interfere with the company's operations beyond my authority. April 17, 2016. No time limit. Management activities are being performed normally and I will not infringe on the company's interests.

1. If I plan to sell any other assets, business or interests related to the production and operation of the company, the company has the right of first refusal; I will try my best to make the price of the relevant transaction fair and reasonable, and the transaction price will be determined based on the transaction price of normal commercial transactions with independent third parties. 2. I currently do not directly or indirectly develop, operate or assist in operating or participate in any activities that compete with the company's business anywhere in China or outside China, nor do I have any interests (whether directly or indirectly) in any company or enterprise that directly or indirectly competes with the company's business. 3. I guarantee and promise that I will not directly or indirectly develop, operate or assist in the operation or participate in or engage in any activities that compete with the company's horizontal competition or the company's business, unless with the written consent of the company. 4. Ben

issue or

Liu Fangyi Related transactions and funds Persons will comply with laws, regulations and the company's rules April 17, 2016 No time limit When refinancing is being performed normally, commitments regarding occupation will be disclosed to the company and relevant institutions or departments in a timely manner that may compete with or compete with the company's business.

commitments made

Details of any businesses or interests that may compete until I am no longer the actual controller of the company. 5. I will not use my status as the actual controller of the company to conduct business activities that harm the interests of the company and other shareholders. 6. If during the actual implementation process, I violate the commitments I made during the initial public offering, I will take the following measures: (1) Promptly and fully disclose the reasons why the commitment has not been implemented, cannot be implemented, or cannot be implemented as scheduled; (2) Propose supplementary or alternative commitments to Inko Medical and its investors to protect Inko Medical (3) Submit the above supplementary commitments or alternative commitments to the general meeting of shareholders for review; (4) If direct losses are caused to investors, the losses shall be compensated in accordance with the law; (5) If there are illegal gains, they shall be dealt with in accordance with relevant laws and regulations; (6) Other measures that may be taken according to the regulations at that time.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 54

Section 5 Important Matters

Reason for commitment Commitment party Commitment type Commitment content Commitment time Commitment period Performance status

(1) Principle of profit distribution The company implements a positive, continuous and stable profit distribution policy. The company's profit distribution should pay attention to the reasonable investment return to investors and take into account the company's actual operating conditions and sustainable development for the year; the company's board of directors, board of supervisors and shareholders' meeting should fully consider the opinions of independent directors, supervisors and shareholders in their decision-making and demonstration of the profit distribution policy. (2) Form of profit distribution 1. Form of profit distribution: The company may distribute dividends in the form of cash, stocks, a combination of cash and stocks, or other methods permitted by law, and will give priority to distributing profits in cash. The company may make mid-term cash dividends based on its profitability and capital needs. 2. Stock dividend distribution: If stock dividends are used for profit distribution, real and reasonable factors such as the company's growth potential and the dilution of net assets per share should be taken into consideration. If the company's operating income and net profit grow rapidly, and the board of directors believes that the company's share capital size and equity structure are reasonable, it can propose and implement a stock dividend distribution plan.

first public

case. 3. Cash dividend distribution: On the premise of cash flow issuance or to meet the company's normal operations and long-term development, the company should refinance in cash. The company's dividend commitment is to distribute dividends. The company distributes cash every year on July 21, 2017 without a deadline. The profits distributed during normal performance shall not be less than the amount realized in the current year.

commitments made

Distribute 10% of profits. The company's board of directors should comprehensively consider factors such as the characteristics of the industry, development stage, its own business model, profitability, and whether there are major capital expenditure arrangements, distinguish the following situations, and propose differentiated cash dividend policies in accordance with the procedures stipulated in these articles of association: (1) If the company's development stage is a mature stage and there are no major capital expenditure arrangements, when making profit distribution, the proportion of cash dividends in this profit distribution should be at least 80%; (2) Corporate If the company's development stage is in a mature stage and there are major capital expenditure arrangements, when making profit distribution, the proportion of cash dividends in this profit distribution should be at least 40%; (3) If the company's development stage is in the growth stage and there are major capital expenditure arrangements, when making profit distribution, the proportion of cash dividends in this profit distribution should be at least 20%; if the company's development stage is not easy to distinguish but there are major capital expenditure arrangements, it can be handled in accordance with the provisions of the preceding paragraph.

4. Interval of profit distribution: In principle, the company distributes cash dividends once a year. The company’s board of directors may propose the company to conduct mid-term cash dividends based on the company’s profitability and capital needs. (3) Profit distribution procedures 1. When the company formulates a specific plan for cash dividends, the board of directors should carefully study

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 55

Section 5 Important Matters

Reason for commitment Commitment party Commitment type Commitment content Commitment time Commitment period Performance status

Independent directors should express clear opinions on matters such as the timing, conditions and minimum proportion of the company's cash dividends, conditions for adjustments and requirements for decision-making procedures, etc. 2. The company's annual profit distribution plan shall be proposed and drafted by the company's board of directors based on the provisions of these Articles of Association and the company's financial operating conditions, and shall be submitted to the shareholders' meeting for approval after being approved by a majority vote of all directors. Independent directors should express clear independent opinions on the profit distribution plan. 3. Before the general meeting of shareholders deliberates on the specific cash dividend plan, it should proactively communicate with shareholders, especially small and medium-sized shareholders, through multiple channels, fully listen to the opinions and demands of small and medium-sized shareholders, and respond to issues of concern to small and medium-sized shareholders in a timely manner. 4. If the company’s board of directors fails to make a cash profit distribution plan, the board of directors shall disclose the reasons and the independent directors shall issue a

first public

express independent opinions. 5. If the company needs to adjust its profit distribution policy based on production, issuance or operating conditions, investment plans, long-term development company dividend commitments or due to the external operating environment, its own operating conditions, there are major changes in the company's operating conditions, and it is necessary to adjust the profit distribution policy, the board of directors should use shares

commitments made

The profit distribution adjustment policy was formulated based on the protection of East China's rights and interests. Modifications to the company's profit distribution policy are proposed by the company's board of directors to the company's general meeting of shareholders and approved by more than 2/3 of the voting rights held by shareholders attending the general meeting. Independent directors should express their opinions on modifications to the profit distribution policy. The adjusted profit distribution policy shall not violate the relevant regulations of the China Securities Regulatory Commission and the stock exchange. 6. The board of supervisors shall supervise the implementation and decision-making procedures of the board of directors and management of the company's profit distribution policy and shareholder return plan. The board of supervisors shall review modifications to the profit distribution plan and profit distribution policy. 7. If a shareholder illegally appropriates company funds, the company shall deduct the cash dividends distributed by the shareholder to repay the funds occupied.

Is the commitment

Yes

Fulfill on time

If the promise is overdue

Not yet completed

Yes, should

Detailed description

outstanding performance

Specific reasons for Not applicable

and next step

work plan

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 56

Section 5 Important Matters

(2) If there is a profit forecast for the company's assets or projects, and the reporting period is still in the profit forecast period, the company will explain why the assets or projects have reached the original profit forecast and the reasons why.

□Applicable □√ Not applicable

(3) The company’s performance commitments

□Applicable □√ Not applicable

2. Non-operating capital occupation of listed companies by controlling shareholders and other related parties

□Applicable □√ Not applicable

During the company's reporting period, there was no non-operational occupation of funds by the controlling shareholder or other related parties of the listed company.

3. Illegal external guarantees

□Applicable □√Not applicable

The company had no illegal external guarantees during the reporting period.

4. The Board of Directors’ explanation of the latest “non-standard audit report”

□Applicable □√ Not applicable

5. Explanation of the "non-standard audit report" of the accounting firm for this reporting period by the board of directors, audit committee and independent directors (if any)

□Applicable □√ Not applicable

6. Explanation of the Board of Directors on changes in accounting policies, accounting estimates or correction of major accounting errors during the reporting period

□Applicable □√Not applicable

7. Explanation of changes in the scope of consolidated statements compared with the previous year’s financial report

□√ Applicable □ Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 57

Section 5 Important Matters

Company name Equity acquisition method

PT Green Environment Management Services Established Shandong Yingcai Printing Technology Co., Ltd. Established Shanghai Intco Medical Supplies Co., Ltd. Canceled Intco Medical Industries Inc. Canceled

8. Appointment and dismissal of accounting firms

Currently employed accounting firm

Name of domestic accounting firm Tianjian Accounting Firm (Special General Partnership)

Domestic accounting firm remuneration (10,000 yuan) 125

Continuous years of audit services provided by domestic accounting firms 2

Name of the CPA of the domestic accounting firm Fei Fanghua, Li Jingcheng Number of consecutive years of auditing service provided by the CPA of the domestic accounting firm Fei Fanghua 1 year and Li Jingcheng 1 year Whether to hire a new accounting firm

□Yes □√ No

Recruitment of internal control audit accounting firms, financial consultants or sponsors

□√ Applicable □ Not applicable

This year, the company hired Tianjian Accounting Firm (Special General Partnership) as the company's internal control audit agency and paid an additional RMB 150,000 in internal control audit fees.

9. Facing delisting after the annual report is disclosed

□Applicable □√Not applicable

10. Matters related to bankruptcy and reorganization

□Applicable □√Not applicable

The company had no bankruptcy or reorganization related matters during the reporting period.

11. Major litigation and arbitration matters

□√ Applicable □ Not applicable

Litigation (arbitration) Amount involved Whether to form a lawsuit (arbitration) Litigation (arbitration) trial Litigation (arbitration) judgment Disclosure date Basic information on disclosure index (10,000 yuan) Estimated liabilities Progress Results and impact Implementation status

Other litigation 310 Not applicable All have been judged, the case has been settled through mediation, and performance has been completed. Not applicable Not applicable Summary of inapplicable matters No significant impact on the company's operations

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 58

Section 5 Important Matters

12. Punishment and rectification

□Applicable □√Not applicable

There were no penalties or rectifications during the company's reporting period.

13. Integrity status of the company, its controlling shareholders and actual controllers

□Applicable □√Not applicable

14. Major related transactions

(1) Related transactions related to daily operations

□√ Applicable □ Not applicable

Related Transactions Related Transactions Related Transactions Related Transactions Related Transactions Related Transactions Related Transactions Percentage of Approved Related Transactions Approved Exceeds Related Transactions Obtainable Disclosure Date Disclosure of Requesting Party Transaction Type Transaction Content Transaction Pricing Transaction Price Transaction Amount Transaction Price Transaction Amount Approved Transaction Settlement Period Citations

Principle (10,000 Yuan) Ratio of Amount (10,000 Yuan) Quota Method Trading Market

Example (yuan) price

2025 Juchao Ziyingke Re Tongshoushi Purchaser Purchaser Reference market Market price 398.4 0.06% 1,062.8 No Cash Not applicable

April 2 News Network, market prices of production and internationally controlled products and receiving products

Announcement on the 4th that the company is under human control and subject to labor

No.: 202

5-049 2025 Juchao Ziyingke Re Tongshoushi Seller Sale Warm Reference Market Market Price 54.11 0.01% 175 No Cash Not Applicable

April 2 News Network, production and international control of product, gas and shopping mall prices

Announcement on the 4th that the company’s personnel control the supply of labor services, etc.

No.: 202

5-049 2025 Juchao Capital Shanghai Ying Subsidiary Seller Seller Reference market Market price 6.7 0.00% 15 No Cash Not applicable

On April 2, News Network, Ke Public Welfare, Shanghai British products, imported products and other market prices

Announcement on the 4th of the Foundation’s Enzuo Service

No.: 202 main original

Donate starting from 5-049

people

In 2025, Juchao Capital Shanghai Ying Tongshoushi Company leased factory Reference market market price 16 1.16% 16 No Cash Not applicable

On April 2, Xunwang, Congji controlled the rental market price.

4th Announcement Editor Control

No.: 202

5-049 In 2025, Juchao Ziyingke Re-Tongshoushi Company leased factory Reference market market price 40.18 2.91% 43 No Cash Not applicable

April 2 News Network, production and international control, rental market price

Announcement on the 4th that the company is under personal control

No.: 202

5-049

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 59

Section 5 Important Matters

Yingke Re Tongshou Real Estate Company Rental Factory Reference Market Price 150.22 3.15% 200 No Cash Not Applicable 2025 Juchao Zisheng and its International Control Rental Housing Market Price April 2 Xunwang, subsidiary controlled by person on April 4th Announcement No.: 202

5-049 total -- -- 665.61 -- 1,511.8 -- -- -- -- --

Details of large sales returns Not applicable

Daily correlations that will occur in this period by category Not applicable

The total amount of transactions carried out is estimated and reported in

Actual performance during the period (if any)

The difference between the transaction price and the market reference price is not applicable

Big reason (if applicable)

(2) Related transactions arising from asset or equity acquisition and sale

□Applicable □√Not applicable

The company had no related transactions involving acquisition or sale of assets or equity during the reporting period.

(3) Related transactions related to joint external investment

□Applicable □√Not applicable

The company had no related transactions involving joint external investments during the reporting period.

(4) Related credit and debt transactions

□Applicable □√Not applicable

The company had no related creditor's rights or debts during the reporting period.

(5) Dealings with related financial companies

□Applicable □√Not applicable

There are no deposits, loans, credit or other financial business between the company and its related financial companies and related parties.

(6) Dealings between financial companies controlled by the company and related parties

□Applicable □√Not applicable

There are no deposits, loans, credit or other financial business between the financial companies controlled by the company and related parties.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 60

Section 5 Important Matters

(7) Other major related transactions

□√Applicable □Not applicable

On October 20, 2025, the company held the second meeting of the Strategy and ESG Committee of the fourth board of directors, the second special meeting of the independent directors of the fourth board of directors, and the sixth meeting of the Audit Committee of the fourth board of directors, and reviewed and approved the "Proposal on Participating in Investment in Warburg Pincus Global Growth 15, L.P. and Related Transactions", in which the wholly-owned subsidiary Inko Medical International (Hong Kong) Co., Ltd. will subscribe as a limited partner (LP) of the partnership to contribute US$70 million. Since Yingke Environmental Protection International (Hong Kong) Co., Ltd., a subsidiary of the company's related party Inko Recycling, also participated in the investment in the partnership and became one of the limited partners of the partnership, according to the "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 7 - Transactions and Related Transactions" and other laws and regulations, as well as the "Articles of Association" and other relevant regulations, this investment constitutes a related transaction (related joint investment).

As of the end of this reporting period, the investment has not yet been funded.

Inquiries related to the temporary report disclosure website of major related party transactions

Temporary announcement name Temporary announcement disclosure date Temporary announcement disclosure website name

"Announcement on Participating in Investment in Warburg Pincus Global Growth 15, L.P. and Related Transactions" October 21, 2025 Juchao Information Network www.cninfo.com.cn

15. Major contracts and their performance

(1) Custody, contracting and leasing matters

1. Custody situation

□Applicable □√Not applicable

There was no custody situation during the company's reporting period.

2. Contracting situation

□Applicable □√Not applicable

There was no contracting situation during the reporting period of the company.

3. Leasing situation

□Applicable □√Not applicable

There was no leasing situation during the company's reporting period.

(2) Major guarantees

□√ Applicable □ Not applicable

Unit: 10,000 yuan

External guarantees provided by the company and its subsidiaries (excluding guarantees to subsidiaries)

Guarantee pair Guarantee amount Guarantee amount Actual guarantee Type of guarantee Collateral Counter guarantee Guarantee period Whether it has been fulfilled Whether it is an object Degree of relevance Date of birth Amount of guarantee Type (if any) Situation Completed Announcement and disclosure of related parties

(if any) Warranty disclosure date

External guarantees provided by the company and its subsidiaries

Guarantee pair Guarantee amount Guarantee amount Actual guarantee Guarantee type Collateral Counter guarantee Guarantee period Whether it has been fulfilled Whether it is an object Degree of relevance Date of birth Insurance amount Type (if any) Situation (Complete announcement of related parties)

If any) Warranty disclosure date

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 61

Section 5 Important Matters

Anhui Ying 2024 12,651.84 2024 10,698.05 Joint and several liability None None 5 years No Fuke Medical April 23 August 09 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2025 5,000 2025 5,000 Joint and several liability None None 1 year No Fuke Medical April 24 June 13 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2023 11,000 2023 1,003.2 Joint and several liability None None 3 years No Fuke Medical April 27 July 24 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2025 38,500 2025 26,092.37 Joint and several liability None None 2 years No Fuke Medical April 24 December 05 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2023 11,000 2023 10,000 Joint and several liability None None 3 years No Fuke Medical April 27 October 11 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2024 10,000 2025 8,000 Joint and several liability None None 3 years No Fuke Medical April 23 April 17 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2023 15,000 2023 15,000 Joint and several liability None None 3 years No Fuke Medical April 27 December 18 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2022 61,150.56 2022 21,547.99 Joint and several liability None None 3 years No Fuke Medical April 28 September 22 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2021 12,930.2 2022 12,930.2 Joint and several liability None None 5 years No Fuke Medical March 15 March 09 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2021 47,000 2021 36,980 Joint and several liability None None 6 years No Fuke Medical March 15 April 02 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2025 5,000 2025 5,000 Joint and several liability None None 3 years No Fuke Medical April 24 June 19 Liability guarantee

Supplies include day day

Ltd.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 62

Section 5 Important Matters

Anhui Ying 2025 25,000 2025 0 Joint and several liability None None 3 years No Fuke Medical April 24 December 22 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2025 4,000 2025 4,000 Joint and several liability None None 1 year No Fuke Medical April 24 August 29 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2024 15,000 2025 15,000 Joint and several liability None None 2 years No Fuke Medical April 23 February 26 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2025 13,000 2025 13,000 Joint and several liability None None 3 years No Fuke Medical April 24 June 20 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2024 15,000 2024 15,000 Joint and several liability None None 3 years No Fuke Medical April 23 June 17 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2024 33,000 2024 30,000 Joint and several liability None None 5 years No Fuke Medical April 23 November 22 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2024 10,000 2025 10,000 Joint and several liability None None 1 year No Fuke Medical April 23 February 19 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2024 15,000 2025 15,000 Joint and several liability None None 2 years No Fuke Medical April 23 April 10 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2025 20,000 2025 20,000 Joint and several liability None None 1 year No Fuke Medical April 24 October 13 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2025 1,000 2025 1,000 Joint and several liability None None 1 year No Fuke Medical April 24 September 22 Liability guarantee

Supplies include day day

Ltd.

Anhui Ying 2025 9,000 2025 0 Joint and several liability None None 1 year No Fuke Medical April 24 November 14 Liability guarantee

Supplies include day day

Ltd.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 63

Section 5 Important Matters

Anhui Ying 2025 1,000 2025 990 Joint and several liability None None 1 year No Color printing April 24 December 08 Liability guarantee

Technology has

Ltd.

Anhui Ying 2024 1,000 2025 1,000 Joint and several liability None None 3 years No Color printing April 23 April 17 Liability guarantee

Technology has

Ltd.

Anhui Ying 2025 1,000 2025 999 Joint and several liability None None 2 years No Color printing April 24 June 18 Liability guarantee

Technology has

Ltd.

Anhui Ying 2025 1,100 2025 0 Joint and several liability None None 2 years No Color printing April 24 December 05 Liability guarantee

Technology has

Ltd.

An Qingying 2024 40,000 2025 20,000 Joint and several liability None None 3 years No Fuke Medical April 23 February 24 Liability guarantee

limited company day day

Division

An Qingying 2025 20,000 2025 10,000 Joint and several liability None None 3 years No Fuke Medical April 24 April 28 Liability guarantee

limited company day day

Division

An Qingying 2025 5,000 2025 5,000 Joint and several liability None None 3 years No Fuke Medical April 24 September 04 Liability guarantee

limited company day day

Division

An Qingying 2025 22,000 2025 13,000 Joint and several liability None None 4 years No Fuke Medical April 24 October 23 Liability guarantee

limited company day day

Division

An Qingying 2025 5,000 2025 0 Joint and several liability None None 3 years No Fuke Medical April 24 December 29 Liability guarantee

limited company day day

Division

Anhui Ying 2024 15,000 2024 15,000 Joint and several liability None None 3 years No Fuyi Thermal Power April 23 July 30 Liability guarantee

limited company day day

Division

Anhui Ying 2025 1,100 2025 0 Joint and several liability None None 3 years No Fuyi Thermal Power April 24 October 23 Liability guarantee

limited company day day

Division

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 64

Section 5 Important Matters

Shandong Ying 2023 29,700 2023 8,889.33 Joint and several liability None None 3 years No Fuke Medical April 27 April 17 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2024 10,000 2024 4,700 Joint and several liability None None 1 year No Fuke Medical April 23 August 22 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2024 10,000 2024 10,000 Joint and several liability None None 1 year Yes Fuke Medical April 23 December 10 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2023 10,000 2024 9,999.65 Joint and several liability None None 2 years No Fuke Medical April 27 March 10 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2024 5,000 2025 5,000 Joint and several liability None None 1 year No Fuke Medical April 23 March 28 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2025 10,000 2025 6,064.97 Joint and several liability None None 1 year No Fuke Medical April 24 April 28 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2025 6,000 2025 4,000 Joint and several liability None None 1 year No Fuke Medical April 24 June 16 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2025 5,000 2025 4,500 Joint and several liability None None 1 year No Fuke Medical April 24 August 26 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2025 12,000 2025 10,000 Joint and several liability None None 1 year No Fuke Medical April 24 September 10 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2025 10,000 2025 5,000 Joint and several liability None None 1 year No Fuke Medical April 24 November 17 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2025 12,000 2025 4,000 Joint and several liability None None 0.5 years No Fuke Medical April 24 December 15 Liability guarantee

Products include Day Day

Ltd.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 65

Section 5 Important Matters

Shandong Ying 2025 15,000 2025 9,000 Joint and several liability None None 1 year No Fuke Medical April 24 December 19 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2025 15,000 2025 9,391.68 Joint and several liability None None 1 year No Fuke Medical April 24 June 06 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2024 20,000 2024 5,000 Joint and several liability None None 1 year Yes Fuke Medical April 23 November 01 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2022 42,172.8 2022 16,837.73 Joint and several liability None None 3 years No Fuke Medical April 28 September 22 Liability guarantee

Products include Day Day

Ltd.

Shandong Ying 2021 9,350 2022 9,328.59 Joint and several liability None None Long-term No Fuke Medical March 15 March 09 Liability guarantee

Products include Day Day

Ltd.

Jiangxi Ying 2024 1,000 2025 319 Joint and several liability None None 3 years No Fucai Technology April 23 January 20 Liability guarantee

limited company day day

Division

Jiangxi Ying 2024 1,000 2025 1,000 Joint and several liability None None 3 years No Fucai Technology April 23 March 26 Liability guarantee

limited company day day

Division

Jiangxi Ying 2024 1,000 2025 1,000 Joint and several liability None None 3 years No Fucai Technology April 23 August 25 Liability guarantee

limited company day day

Division

Jiangxi Ying 2025 4,000 2025 334.8 Joint and several liability None None 3 years No Fucai Technology April 24 August 25 Liability guarantee

limited company day day

Division

Jiangxi Ying 2025 1,000 2025 0 Joint and several liability None None 3 years No Fucai Technology April 24 December 22 Liability guarantee

limited company day day

Division

Jiangxi Ying 2022 28,115.2 2022 14,543.09 Joint and several liability None None 3 years No Fucai Technology April 28 September 22 Liability guarantee

limited company day day

Division

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 66 Jiangxi Ying 2021 5,166.5 2022 5,166.5 Joint and several liability None None 5 years No Yingke Medical March 15 March 09 Liability guarantee

limited company day day

Division

Jiangxi Ying 2021 50,000 2021 1,977.67 Joint and several liability None None 4 years Yes Fuke Medical March 15 August 02 Liability guarantee

limited company day day

Division

Jiangxi Ying 2023 11,000 2023 0 Joint and several liability None None 3 years No Fuke Medical April 27 June 15 Liability guarantee

limited company day day

Division

Jiangxi Ying 2024 30,000 2024 20,000 Joint and several liability None None 3 years No Fuke Medical April 23 December 12 Liability guarantee

limited company day day

Division

Jiangxi Ying 2024 10,000 2024 10,000 Joint and several liability None None 3 years No Fuke Medical April 23 December 16 Liability guarantee

limited company day day

Division

Jiangxi Ying 2024 10,000 2025 5,000 Joint and several liability None None 3 years No Fuke Medical April 23 February 19 Liability guarantee

limited company day day

Division

Jiangxi Ying 2024 10,000 2025 7,756.98 Joint and several liability None None 3 years No Fuke Medical April 23 March 12 Liability guarantee

limited company day day

Division

Jiangxi Ying 2024 10,000 2025 2,000 Joint and several liability None None 3 years No Fuke Medical April 23 March 25 Liability guarantee

limited company day day

Division

Jiangxi Ying 2024 10,000 2025 8,200 Joint and several liability None None 3 years No Fuke Medical April 23 April 17 Liability guarantee

limited company day day

Division

Jiangxi Ying 2025 19,000 2025 14,000 Joint and several liability None None 3 years No Fuke Medical April 24 June 09 Liability guarantee

limited company day day

Division

Jiangxi Ying 2025 10,000 2025 7,348.24 Joint and several liability None None 3 years No Fuke Medical April 24 August 25 Liability guarantee

limited company day day

Division

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 67

Section 5 Important Matters

Jiangxi Ying 2025 30,000 2025 30,000 Joint and several liability Yes No 3 years No Fuke Medical April 24 August 28 Liability guarantee,

Limited Company Day Day Mortgage

Division

Jiangxi Ying 2025 15,000 2025 9,471.5 Joint and several liability None None 3 years No Fuke Medical April 24 October 22 Liability guarantee

limited company day day

Division

Jiangxi Ying 2025 10,000 2025 10,000 Joint and several liability None None 3 years No Fuke Medical April 24 October 22 Liability guarantee

limited company day day

Division

Jiangxi Ying 2025 10,000 2025 0 Joint and several liability None None 3 years No Fuke Medical April 24 December 30 Liability guarantee

limited company day day

Division

Jiangsu Ying 2023 8,100 2023 5,000 Joint and several liability None None 3 years No Fuke Medical April 27 July 21 Liability guarantee

Products include Day Day

Ltd.

Jiangsu Ying 2023 10,000 2023 4,000 Joint and several liability None None 5 years No Fuke Medical April 27 June 15 Liability guarantee

Products include Day Day

Ltd.

Jiangsu Ying 2024 5,000 2024 0 Joint and several liability None None 3 years No Fuke Medical April 23 December 20 Liability guarantee

Products include Day Day

Ltd.

Jiangsu Ying 2025 8,000 2025 1,785.87 Joint and several liability None None 1 year No Fuke Medical April 24 June 19 Liability guarantee

Products include Day Day

Ltd.

Jiangsu Ying 2025 9,000 2025 6,000 Joint and several liability None None 1 year No Fuke Medical April 24 November 06 Liability guarantee

Products include Day Day

Ltd.

Jiangsu Ying 2025 20,000 2025 18,740 Joint and several liability Yes No 1 year No Fuke Medical April 24 November 06 Liability guarantee,

Products have day day mortgage

Ltd.

Jiangsu Ying 2025 3,600 2025 3,000 Joint and several liability None None 3 years No Fuke Medical April 24 November 06 Liability guarantee

Products include Day Day

Ltd.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 68

Section 5 Important Matters

Jiangsu Ying 2025 8,000 2025 0 Joint and several liability None None 3 years No Fuke Medical April 24 November 17 Liability guarantee

Products include Day Day

Ltd.

Jiangsu Ying 2025 4,500 2025 4,000 Joint and several liability None None 3 years No Fuke Medical April 24 November 17 Liability guarantee

Products include Day Day

Ltd.

Anhui Kai 2024 20,000 2024 8,000 Joint and several liability None None 1 year No Fuze New Materials April 23 August 23 Liability guarantee

Materials are limited day by day

company

Anhui Kai 2024 28,840 2025 28,000 Joint and several liability None None 5 years No Fuze New Materials April 23 February 11 Liability guarantee

Materials are limited day by day

company

Anhui Kai 2024 5,500 2024 5,000 Joint and several liability None None 3 years No Fuze New Materials April 23 October 12 Responsibility guarantee

Materials are limited day by day

company

Anhui Kai 2024 3,000 2024 3,000 Joint and several liability None None 1 year No Fuze New Materials April 23 December 30 Liability guarantee

Materials are limited day by day

company

Anhui Kai 2024 3,000 2024 3,000 Joint and several liability None None 1 year No Fuze New Materials April 23 October 31 Liability guarantee

Materials are limited day by day

company

Anhui Kai 2024 5,000 2025 5,000 Joint and several liability None None 3 years No Fuze New Materials April 23 May 14 Liability guarantee

Materials are limited day by day

company

Anhui Kai 2024 10,000 2025 0 Joint and several liability None None 2 years No Fuze New Materials April 23 April 10 Ren Guarantee

Materials are limited day by day

company

Anhui Kai 2025 2,000 2025 2,000 Joint and several liability None None 3 years No Fuze New Materials April 24 December 16 Liability guarantee

Materials are limited day by day

company

Anhui Kai 2024 10,000 2024 9,350 Joint and several liability None None 3 years No Fuze New Materials April 23 June 21 Liability guarantee

Materials are limited day by day

company

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 69

Section 5 Important Matters

Shanghai Ying 2025 7,000 2025 0 Joint and several liability None None 3 years No Feien International April 24 August 28 Liability guarantee

Trade has days

Ltd.

Shandong Ying 2025 10,000 2025 10,000 Joint and several liability None None 1 year No Fuke Medical April 24 March 25 Liability guarantee

Technology has

Ltd.

Shandong Ying 2025 1,000 2025 1,000 Joint and several liability None None 1 year No Fuke Medical April 24 July 29 Liability guarantee

Technology has

Ltd.

Shandong Ying 2025 1,000 2025 1,000 Joint and several liability None None 1 year No Fuke Medical April 24 July 29 Liability guarantee

Technology has

Ltd.

Shandong Ying 2025 1,000 2025 1,000 Joint and several liability None None 1 year No No Ke Health April 24 May 28 Liability guarantee

Supplies include day day

Ltd.

Approval for subsidiaries during the reporting period 3,600,000 Approval for subsidiaries during the reporting period 407,994.41

Total guarantee amount (B1) Total actual guarantee amount (B2)

Approved pairs at the end of the reporting period 3,600,000 Actual payments to subsidiaries at the end of the reporting period 518,260.11

Total company guarantee limit (B3) Total guarantee balance (B4)

Guarantees provided by subsidiaries to subsidiaries

Guarantee pair Guarantee amount Guarantee amount Actual issuance Actual guarantee Guarantee type Collateral Counter guarantee Guarantee period Whether it has been fulfilled Whether it is an object Degree of relevance Date of birth Amount of guarantee Type (if any) Circumstances (Complete announcement of related parties If any) Guarantee

exposure date

Anhui Ying 2024 74,200 2025 50,000 Joint and several liability None None 1 year No Fuke Medical April 23 February 11 Liability guarantee

Supplies include day day

Ltd.

An Qingying 2025 4,500 2025 4,500 Joint and several liability None None 3 years No Fuke Medical April 24 July 14 Liability guarantee

limited company day day

Division

Shandong Ying 2025 15,000 2025 14,997.96 Joint and several liability None None 1.5 years No Fuke Medical April 24 October 28 Liability guarantee

Products include Day Day

Ltd.

Jiangxi Ying 2024 47,700 2025 14,494.33 Joint and several liability None None 1.5 years No Fuke Medical April 23 January 21 Responsibility guarantee

limited company day day

Division

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 70

Section 5 Important Matters

Approval for subsidiaries during the reporting period 0 Approval for subsidiaries during the reporting period 83,992.29

Total guarantee amount (C1) Total actual guarantee amount (C2)

Approved transactions at the end of the reporting period 0 Actual transactions with subsidiaries at the end of the reporting period 81,992.29

Total guarantee limit of subsidiaries (C3) Total guarantee balance (C4)

The total amount of company guarantees (i.e. the total of the first three major items)

Guarantees approved during the reporting period 3,600,000 Guarantees actually incurred during the reporting period 491,986.7

Total amount (A1+B1+C1) Total amount (A2+B2+C2)

Guarantees approved at the end of the reporting period

3,600,000 Actual guarantee balance at the end of the reporting period 600,252.4

Total quota (A3+B3+C3)

Total (A4+B4+C4)

The total guarantee balance (i.e. A4+B4+C4) accounts for 32.88% of the company’s net assets, of which:

The balance of guarantees provided to shareholders, actual controllers and their related parties (D) 0 Directly or indirectly provided to guaranteed objects whose asset-liability ratio exceeds 70%

57,883.02

Debt guarantee balance of ## (E)

The amount of the total guarantee exceeding 50% of the net assets (F) 0

The total amount of the above three guarantees (D+E+F) 57,883.02Details of the use of composite guarantees

(3) Entrusting others to manage cash assets

1. Entrusted financial management situation

□√ Applicable □ Not applicable

Overview of entrusted financial management during the reporting period

Unit: 10,000 yuan

Product category Risk characteristics Balance of entrusted financial management during the reporting period Overdue amount that has not been recovered

Bank wealth management products have higher security and better liquidity 1,420,890.91 0 Brokerage wealth management products have higher safety and better liquidity 136,549.64 0 The company, as a single client, entrusts financial institutions to carry out asset management, or invests in high-risk entrusted wealth management products with lower security and poor liquidity. Specific conditions

□Applicable □√Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 71

Section 5 Important Matters

2. Entrusted loans

□Applicable □√Not applicable

The company had no entrusted loans during the reporting period.

(4) Other major contracts

□Applicable □√Not applicable

The company had no other major contracts during the reporting period.

16. Usage of raised funds

□Applicable □√Not applicable

The company has no use of raised funds during the reporting period.

17. Description of other major matters

□√ Applicable □ Not applicable

1. The company held the 28th meeting of the third board of directors and the 25th meeting of the third board of supervisors on January 26, 2025, respectively, and held the first extraordinary shareholders meeting of 2025 on February 13, 2025, and reviewed and approved the "Proposal on the Proposed Purchase of Liability Insurance for Directors, Supervisors and Senior Management". Agree to purchase liability insurance for the company and all directors, supervisors and senior managers, with the compensation limit not exceeding RMB 80 million per year, the premium expenditure not exceeding RMB 350,000 per year, and the insurance period being 12 months (the insurance can be renewed or re-insured every year). For details, please refer to the relevant announcements disclosed on the cninfo.com.cn, January 27, 2025: 2025-007, 2025-008, 2025-009; February 13, 2025: 2025-016.

2 The company held the third meeting of the fourth board of directors and the third meeting of the fourth board of supervisors on April 28, 2025, and held the third extraordinary shareholders' meeting of 2025 on May 16, 2025. It reviewed and approved the "Proposal on Changing the Use of Repurchased Shares and Cancellation" and agreed to the fifteenth meeting of the third board of directors held on July 13, 2023. The purpose of the repurchased shares (hereinafter referred to as the "2023 repurchase") in the "Proposal on the Company's Share Repurchase Plan" reviewed and approved by the 14th meeting of the third Board of Supervisors was changed from "used to implement employee stock ownership plans and/or equity incentives" to "reduce the company's registered capital", and all shares repurchased in 2023, a total of 4,504,300 shares, will be cancelled. The cancellation of the company's share repurchase was completed on July 10, 2025. For details, please refer to the relevant announcements disclosed on the cninfo.com.cn, April 29, 2025: 2025-054, 2025-055, 2025-058, 2025- 059, 2025-060; May 13, 2025: 2025-063; May 16, 2025: 2025-067, 2025-068; July 11, 2025: 2025-097.

3. On June 16, 2025, Mr. Liu Fangyi, the company’s controlling shareholder, went through the procedures to unpledge the 1,000,000 shares he held. After the unpledge, the cumulative number of pledged shares was 6,650,000 shares, accounting for 2.87% of the shares held by him and 1.03% of the company’s total share capital. For details, please refer to the relevant announcement disclosed on the Juchao Information Network www.cninfo.com.cn, June 17, 2025: 2025-085.

4. The company held the 25th meeting of the third board of directors and the 23rd meeting of the third board of supervisors on September 19, 2024, and reviewed and approved the "Proposal on the Company's Share Repurchase Plan" and agreed to use its own funds to repurchase some of the company's shares (RMB ordinary shares (A shares)) through centralized bidding transactions for the implementation of employee stock ownership plans and/or equity incentives. The total amount of the repurchase shall not be less than RMB 80 million (including the principal amount) and shall not exceed RMB 120 million (including the principal amount). The repurchase price shall not exceed RMB 26.66 per share (including the principal amount). The number and amount of shares repurchased shall be based on the actual number and amount of shares repurchased when the repurchase period expires.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 72

Section 5 Important Matters

The amount shall prevail. The implementation period of the share repurchase shall not exceed 12 months from the date when the 25th meeting of the company's third board of directors considers and approves the share repurchase plan. On October 31, 2024, the company's 2024 semi-annual equity distribution was completed. In accordance with the relevant regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange, and based on the principle that the total repurchase fund range remains unchanged, the repurchase price upper limit was adjusted accordingly. The repurchase price upper limit was adjusted to 26.61 yuan/share (including the principal amount). The adjusted repurchase price upper limit will take effect from October 31, 2024 (ex-rights and ex-dividend date). On June 13, 2025, the company's 2024 equity distribution was completed. In accordance with the relevant regulations of the China Securities Regulatory Commission and the Shenzhen Stock Exchange, and based on the principle that the total repurchase fund range remains unchanged, the repurchase price upper limit was adjusted accordingly. The repurchase price upper limit was adjusted to 26.51 yuan/share (including the principal amount). The adjusted repurchase price upper limit will take effect from June 13, 2025 (ex-rights and ex-dividend date). As of On September 18, 2025, the company's share repurchase period expired, and the share repurchase plan has been completed. The company has repurchased a total of 3,306,180 shares of the company through centralized bidding transactions through a special securities account for share repurchase, accounting for 0.5049% of the company's current total share capital ( Based on the calculation based on the total share capital of 654,793,743 shares on September 18, 2025), the highest transaction price was 36.83 yuan/share, the lowest transaction price was 20.06 yuan/share, and the total transaction amount was RMB 80,000,705.08 (excluding transaction fees). For details, please refer to the relevant announcements disclosed on the Juchao Information Network www.cninfo.com.cn, September 19, 2024: 2024-091, 2024-092, 2024-093; 20 September 20, 2024: 2024-094; October 31, 2024: 2024-115; June 13, 2025: 2025-084; September 19, 2025: 2025-131.

5. The company signed the "Haining Qingchuan Venture Capital Partnership (Limited Partnership) Partnership Agreement" with Shanghai Rongxi Venture Capital Management Co., Ltd. to invest in Haining Qingchuan Venture Capital Partnership (Limited Partnership) with its own funds (hereinafter referred to as the "Partnership" or "Fund"). The total subscribed capital contribution of the partnership shall not exceed 220 million yuan (the currency is RMB, the same below), of which the company, as the limited partner (LP) of the partnership, subscribes 30 million yuan. Due to the transfer and withdrawal of some projects of the fund, the total subscribed capital contribution of the partnership was changed from 220 million yuan to 211 million yuan, and the company's subscribed share of the fund was correspondingly changed from 30 million yuan to 28.7727 million yuan. For details, please refer to the relevant announcements disclosed on the cninfo.com.cn, October 27, 2021: 2021-132; September 3, 2025: 2025-124.

18. Major events of the company’s subsidiaries

□√ Applicable □ Not applicable

The company's wholly-owned subsidiary Inko Medical International (Hong Kong) Co., Ltd. (hereinafter referred to as "Inko Medical International") plans to sign a subscription agreement "WARBURG PINCUS GLOBAL GROWTH 15, L.P. SUBSCRIPTION AGREEMENT" with Warburg Pincus Global Growth 15 GP, L.P., and use its own funds to participate in the investment in Warburg Pincus Global Growth 15, L.P. (hereinafter referred to as the "Partnership"). The target fundraising scale of the partnership is US$1.7 billion, of which Inco Medical International will contribute US$70 million as a limited partner (LP) of the partnership. For details, please refer to the relevant announcements disclosed on the cninfo.com.cn, October 21, 2025: 2025-138, 2025-139.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 73

Section 6 and Shares

shares

east change

Emotional

situation

Section 6 Changes in Shares and Shareholders

1. Changes in shares

(1) Changes in shares

Before this change, this change increased or decreased (+, -) After this change

Quantity Proportion Issuance of new shares Bonus shares Conversion of provident funds Others Subtotal Quantity Proportion

1. Shares subject to sales restrictions 177,152,329 27.41% 13,172,100 -757,140 12,414,960 189,567,289 28.93%

2. State shareholding 0 0.00% 0 0 0.00%

3. Shareholdings held by state-owned legal persons 0 0.00% 0 0 0.00% 3. Shareholdings held by other domestic investors 177,152,329 27.41% 13,172,100 -174,534,470 -161,362,370 15,789,959 2.41% Among them: shares held by domestic legal persons 0 0.00% 0 0 0.00% Shareholdings held by domestic natural persons 177,152,329 27.41% 13,172,100 -174,534,470 -161,362,370 15,789,959 2.41%

4. Foreign shareholding 0 0.00% 173,777,330 173,777,330 173,777,330 26.52% of which: shareholding by overseas legal persons 0 0.00% 0 0 0.00% shareholding by foreign natural persons 0 0.00% 173,777,330 173,777,330 173,777,330 26.52%

5. Shares without selling restrictions 469,041,167 72.59% 302,447 -3,747,160 -3,444,713 465,596,454 71.07%

6. RMB ordinary shares 469,041,167 72.59% 302,447 -3,747,160 -3,444,713 465,596,454 71.07%

7. Domestic listed foreign shares 0 0.00% 0 0 0.00%

8. Foreign shares listed overseas 0 0.00% 0 0 0.00%

9. Others 0 0.00% 0 0 0.00%

10. Total number of shares 646,193,496 100.00% 13,474,547 -4,504,300 8,970,247 655,163,743 100.00%

Reasons for share changes

□√Applicable □Not applicable

(1) Cancellation of shares

On July 10, 2025, the company completed the cancellation procedures for the repurchased public shares at the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd., totaling 4,504,300 shares.

(2) Convertible bonds into shares

In 2025, a total of 302,447 convertible bonds issued by the company were converted into shares.

(3) Grant and release of restricted stocks

On July 22, 2025, the grant registration for the restricted shares initially granted under the 2025 Restricted Stock Incentive Plan was completed, with 12,802,100 shares granted; on November 26, 2025, the grant registration for the reserved portion of restricted stocks under the 2025 Restricted Stock Incentive Plan was completed, with 370,000 shares granted; a total of 13,172,100 shares were granted.

On October 29, 2025, 1,052,520 equity incentive restricted shares that met the unlocking conditions in the third phase of the company's 2022 restricted stock incentive plan were released and listed for circulation, and the equity incentive restricted shares were reduced by 1,052,520 shares.

(4) Executive lock-in

Changes in executive locked shares are mainly due to the relevant provisions of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 10 - Management of Share Changes". On the first trading day of each year, the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. The shares of the company registered under the names of senior managers on the last trading day of the previous year are used as the basis, and the legal limit of their transferable shares for the year is calculated at 25%; at the same time, the unrestricted tradable shares held by the personnel within the limit of transferable shares for the year are unlocked.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 75

Section 6 Changes in Shares and Shareholders

Ms. Chen Qiong, the company’s director and general manager, Mr. Yu Haisheng, the director and deputy general manager, Ms. Zhu Lili and Ms. Hua Cuiping, employee representative directors, Ms. Feng Jie, secretary of the board of directors and financial director, and Mr. Tang Ye and Ms. Zhai Wenning (retired) as supervisors. This year, an additional 576,855 shares of executive locked shares were locked.

Since Mr. Li Bin, deputy general manager and secretary of the board of directors, resigned on February 27, 2024, all the shares he held were locked in accordance with the relevant provisions of the "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 10 - Management of Share Changes"; on September 15, 2025, the 281,475 shares he held were unlocked.

Approval status of share changes

□√ Applicable □ Not applicable

(1) Cancellation of shares

The company held the third meeting of the fourth board of directors and the third meeting of the fourth board of supervisors on April 28, 2025, respectively. On May 16, 2025, the company held the third extraordinary shareholders' meeting of 2025 to review and adopt the "Proposal on Changing the Use of Repurchased Shares and Cancellation", and agreed to the fifteenth meeting of the third board of directors and the third meeting of the third board of directors held on July 13, 2023. The purpose of the repurchased shares (hereinafter referred to as the "2023 repurchase") in the "Proposal on the Company's Share Repurchase Plan" reviewed and approved by the 14th meeting of the Supervisory Board was changed from "used to implement employee stock ownership plans and/or equity incentives" to "reduce the company's registered capital", and all shares repurchased in 2023, a total of 4,504,300 shares, will be cancelled.

(2) Convertible bonds into shares

As approved by the China Securities Regulatory Commission's "Zhengjian Xu [2019] No. 1183" document, the company publicly issued 4.7 million convertible corporate bonds on August 16, 2019, with a face value of 100 yuan each, and a total issuance of 470 million yuan. With the approval of the Shenzhen Stock Exchange's "Shenzhen Zhengshang [2019] No. 525" document, the company's 470 million yuan convertible corporate bonds were listed for trading on the Shenzhen Stock Exchange on September 10, 2019. The bond's abbreviation is "Yingke Convertible Bonds" and the bond code is "123029". According to relevant regulations such as the "Shenzhen Stock Exchange GEM Stock Listing Rules" and the relevant provisions of the "Prospectus for the Public Issuance of Convertible Corporate Bonds on the GEM of Shandong Yingke Medical Supplies Co., Ltd.", the "Yingke Convertible Bonds" can be converted into company shares starting from February 24, 2020.

(3) Restricted stock grant

1. On May 29, 2025, the company held the fifth meeting of the fourth board of directors and the fifth meeting of the fourth board of supervisors, and reviewed and approved the "Proposal on the Company's "2025 Restricted Stock Incentive Plan (Draft)" and its Summary, and the "Proposal on the Company's "2025 Restricted Stock Incentive Plan Implementation Assessment and Management Measures" and other proposals. Relevant matters have been reviewed and approved at the third meeting of the Remuneration and Appraisal Committee of the fourth session of the Board of Directors of the company.

2. From May 30, 2025 to June 8, 2025, the company publicized the names and positions of the incentive objects to be awarded for the first time under this incentive plan within the company. As of the expiration of the publicity period, the company’s Board of Supervisors has not received any objections to the incentive objects to be awarded for the first time under this incentive plan. On June 9, 2025, the company disclosed the "Explanation and Verification Opinions of the Board of Supervisors of Yingke Medical on the Announcement and Verification Opinions of the First List of Incentive Objects Granted to the 2025 Restricted Stock Incentive Plan".

3. On June 17, 2025, the company held the fourth extraordinary general meeting of shareholders in 2025, which reviewed and approved the "Proposal on the Company's "2025 Restricted Stock Incentive Plan (Draft)" and its Summary, "The Proposal on the Company's "2025 Restricted Stock Incentive Plan Implementation Assessment and Management Measures", and "The Proposal on Requesting the General Meeting of Shareholders to Authorize the Board of Directors to Handle Equity Incentive-related Matters."

4. On June 20, 2025, the company held the sixth meeting of the fourth board of directors and the sixth meeting of the fourth board of supervisors, and reviewed and approved the "Proposal on Adjusting Matters Related to the 2025 Restricted Stock Incentive Plan" and the "Proposal on the First Grant of Restricted Stocks to Incentive Objects". Relevant matters have been reviewed and approved at the fourth meeting of the Remuneration and Appraisal Committee of the fourth board of directors of the company. The company's Board of Supervisors verified the list of incentive targets granted for the first time under this incentive plan and issued verification opinions.

5. On October 15, 2025, the company held the 10th meeting of the fourth board of directors, and reviewed and approved the "Proposal on Adjusting Matters Related to the 2025 Restricted Stock Incentive Plan" and "The Proposal on Granting Reserved Shares for the 2025 Restricted Stock Incentive Plan to Incentive Objects". Relevant matters have been reviewed and approved at the fifth meeting of the Remuneration and Appraisal Committee of the fourth session of the Board of Directors of the company. The Remuneration and Assessment Committee of the Company's Board of Directors verified the list of incentive targets reserved for this incentive plan and issued verification opinions.

(4) Unlocking restricted sales of restricted stocks

On October 20, 2025, the company held the fourth meeting of the fourth board of directors and the fourth meeting of the fourth board of supervisors and reviewed and approved the "Proposal on the Achievements of Unlocking the Conditions for the Third Phase of the Company's 2022 Restricted Stock Incentive Plan", which means that the equity incentive objects that meet the conditions for unlocking the restrictions will be lifted. A total of 1,052,520 shares of this part of the stock will be listed and circulated on October 29, 2025.

Transfer status of changes in shares

□√ Applicable □ Not applicable

The company has all completed the corresponding procedures at the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 76

Section 6 Changes in Shares and Shareholders

The impact of share changes on financial indicators such as basic earnings per share and diluted earnings per share in the most recent year and period, net assets per share attributable to the company's common shareholders. □√ Applicable □ Not applicable

During the reporting period, the total number of shares and shareholder structure of the company changed. Relevant data can be found in the "V. Main Accounting Data and Financial Indicators" section of "Section 2 Company Profile and Main Financial Indicators" of this report.

Other content that the company deems necessary or required to be disclosed by securities regulatory authorities

□Applicable □√ Not applicable

(2) Changes in restricted shares

□√ Applicable □ Not applicable

Unit: Share

Name of shareholder Number of restricted shares at the beginning of the period Number of restricted shares increased during the current period Number of shares released from restricted sales during the current period Number of restricted shares at the end of the period Reason for selling restrictions Release date of selling restrictions

According to executive locked shares Executive locked shares 174,684,529 576,855 281,475 174,979,909 Executive locked shares

The rules will lift the sales restrictions in 2022 and 2025. Equity incentives are based on equity incentives.

2,467,800 13,172,100 1,052,520 14,587,380

Total equity incentive restricted shares Restricted shares Planned repurchase and cancellation 177,152,329 13,748,955 1,333,995 189,567,289

2. Securities issuance and listing

(1) Securities issuance (excluding preference shares) during the reporting period

□Applicable □√ Not applicable

(2) Description of changes in the company’s total number of shares and shareholder structure, and changes in the company’s asset and liability structure

□√ Applicable □ Not applicable

During the reporting period, the total number of shares and shareholder structure of the company changed. For changes in the total number of shares and shareholder structure, please see "1. Changes in Shares" in this section. Please refer to "Section 8, Financial Report" of this report for details of changes in the company's asset and liability structure.

(3) Existing internal employee shares

□Applicable □√ Not applicable

3. Shareholders and actual controllers

(1) Number of shareholders and shareholding status of the company

Unit: Share

Voting rights at the end of the reporting period before the annual report disclosure date

End of reporting period Annual report disclosure Holding special voting rights

The voting rights of the restored preferred shares were restored at the end of the previous month.

Ordinary shares 42,723 The end of the previous month 38,118 0 0 Total number of shareholders of shares 0

Total number of shareholders (if any) Total number of preference shareholders

Total number of shareholders Total number of ordinary shareholders (if any) (see Note 9) (See Note 9) Number (if any) (See Note 9)

Shareholding status of shareholders holding more than 5% of the shares or the top 10 shareholders (excluding shares lent through refinancing)

During the reporting period, limited holdings, unlimited holdings

At the end of the reporting period, pledge, mark or freeze status. Name of shareholder. Nature of shareholder. Shareholding ratio. Increase or decrease. Conditions for sale. Conditions for sale.

Number of shares held Share status Quantity

Situation Number of shares Number of shares

Liu Fangyi Overseas natural person 35.37% 231,703,107 0 173,777,330 57,925,777 Pledge 28,560,000

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 77

Section 6 Changes in Shares and Shareholders

Bank of China shares

Co., Ltd. - Hua

Baozhongzheng Medical Exchange

Others 2.15% 14,065,509 -693,100 0 14,065,509 Not applicable 0 Easy open-end index

Digital securities investment fund

gold

Industrial and Commercial Bank of China

Co., Ltd.

－E Fund Entrepreneurship

Others 1.23% 8,047,399 -3,715,221 0 8,047,399 Not applicable 0 board trading type open

index securities investment

capital fund

Industrial and Commercial Bank of China

Co., Ltd.

• China Europe Healthcare Others 1.09% 7,139,692 6,899,192 0 7,139,692 Not applicable 0 Kang Hybrid Securities

investment fund

Agricultural Bank of China

Co., Ltd.

• CSI 500 payment

Others 1.03% 6,735,563 410,400 0 6,735,563 Not applicable 0 Easy open-end index

Digital securities investment fund

gold

Hong Kong Securities Clearing Company

Overseas legal person 0.83% 5,430,322 -9,066,842 0 5,430,322 Not applicable 0 Co., Ltd.

Taikang Life Insurance

limited liability company

Others 0.81% 5,327,481 2,998,581 0 5,327,481 Not applicable 0 - Investment-linked - Innovation

motivation

China CITIC Bank

Co., Ltd. - Delivery

Silver Schroeder Freshman

Others 0.70% 4,555,596 4,555,596 0 4,555,596 Not applicable 0 Vitality Flexible configuration

Hybrid securities investment

capital fund

Industrial and Commercial Bank of China

Co., Ltd.

-BoCom Schroders

Others 0.68% 4,431,711 4,431,711 0 4,431,711 Not applicable 0 Trend priority mixing

securities investment fund

gold

China Construction Bank

Co., Ltd.

-Nord Value Advantage Others 0.65% 4,273,574 4,273,574 0 4,273,574 Not applicable 0 potential hybrid securities

investment fund

Strategic investors or general legal persons become the top 10 shareholders due to the placement of new shares. Inapplicable circumstances (if any)

The above-mentioned shareholders are related or consistent

Description of actions not applicable

Explanation of non-applicability of the above-mentioned shareholders involving entrusted/entrusted voting rights and abstention from voting rights

Among the top 10 shareholders, there are buyback specialties

Special instructions not suitable for users (if any)

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 78

Section 6 Changes in Shares and Shareholders

Shareholdings of the top 10 shareholders without sales restrictions (excluding shares lent through refinancing and shares locked by executives)

Share type

Name of shareholder Number of shares without selling restrictions held at the end of the reporting period

Share Type Quantity

Liu Fangyi 57,925,777 RMB ordinary shares 57,925,777 Bank of China Co., Ltd.

• Huabao CSI Medical Trading Type 14,065,509 RMB ordinary shares 14,065,509 Open-end Index Securities Investment Fund

Industrial and Commercial Bank of China Co., Ltd.

Company-E Fund GEM trading type 8,047,399 RMB ordinary shares 8,047,399 Open-end index securities investment fund

Industrial and Commercial Bank of China Co., Ltd.

Company - Sino-European Medical and Health Hybrid 7,139,692 RMB ordinary shares 7,139,692 Securities Investment Fund

Agricultural Bank of China Co., Ltd.

Company - CSI 500 Trading Open 6,735,563 RMB ordinary shares 6,735,563 Index Securities Investment Fund

Hong Kong Securities Clearing Company Limited 5,430,322 RMB ordinary shares 5,430,322 Taikang Life Insurance Co., Ltd.

5,327,481 RMB ordinary shares 5,327,481 Company - Investment-linked - Innovation power

China CITIC Bank Co., Ltd.-

Bank of Communications Schroders New Vitality and Flexibility 4,555,596 RMB ordinary shares 4,555,596 Allocation of hybrid securities investment funds

Industrial and Commercial Bank of China Co., Ltd.

Company - Bank of Communications Schroders Trend Priority 4,431,711 RMB ordinary shares 4,431,711 Hybrid securities investment funds

China Construction Bank Co., Ltd.

Company-Nord Value Advantage Hybrid 4,273,574 RMB ordinary shares 4,273,574 Securities investment funds

Top 10 shareholders of unrestricted tradable shares

between, and unlimited sales for the first 10

Shareholders of tradable shares and top 10 shareholders Not applicable

relationship or concerted action

description

Information about shareholders participating in margin trading and securities lending business

Not applicable

Description of the situation (if any)

The situation of shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders of unrestricted tradable shares participating in the refinancing business and lending shares

□Applicable □√ Not applicable

The top 10 shareholders and the top 10 shareholders of unrestricted tradable shares have changed from the previous period due to refinancing lending/returning.

□Applicable □√ Not applicable

Whether the company has differential voting rights arrangements

□Applicable □√Not applicable

Whether the company's top 10 ordinary shareholders and the top 10 unrestricted ordinary shareholders conducted agreed repurchase transactions during the reporting period

□Yes □√No

The company's top 10 common shareholders and the top 10 common shareholders without selling restrictions did not conduct agreed repurchase transactions during the reporting period.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 79

Section 6 Changes in Shares and Shareholders

(2) Controlling shareholders of the company

Nature of controlling shareholder: Natural person holding

Controlling shareholder type: natural person

Name of controlling shareholder Nationality Whether he has obtained the right of residence in other countries or regions

Liu Fangyi, Hong Kong, China, is the main occupation and position. Mr. Liu Fangyi serves as the chairman of Yingke Medical (300677)

Controlling and equity participation during the reporting period

Yingke Recycling (688087) controlled by Mr. Liu Fangyi was listed on the Shanghai Stock Exchange Science and Technology Innovation Board on July 9, 2021

Equity information of other domestic and overseas listed companies

Changes in controlling shareholders during the reporting period

□Applicable □√Not applicable

The company’s controlling shareholder did not change during the reporting period

(3) The actual controller of the company and its persons acting in concert

Nature of actual controller: Overseas natural person

Type of actual controller: natural person

Name of the actual controller Relationship with the actual controller Nationality Whether the person has obtained the right of residence in other countries or regions

Liu Fangyi I am Hong Kong, China. His main occupation and position are Mr. Liu Fangyi, chairman of Yingke Medical (300677)

Domestic and foreign holdings held in the past 10 years

Yingke Recycling (688087) controlled by Mr. Liu Fangyi was listed on the Shanghai Stock Exchange Science and Technology Innovation Board on July 9, 2021

Listed company situation

Changes in actual controller during the reporting period

□Applicable □√Not applicable

The actual controller of the company did not change during the reporting period

Block diagram of the property rights and control relationship between the company and the actual controller

35.37%

Liu Fangyi Yingke Medical Technology Co., Ltd.

The actual controller controls the company through trust or other asset management methods

□Applicable □√Not applicable

(4) The ratio of the cumulative number of pledged shares by the company’s controlling shareholder or largest shareholder and its persons acting in concert to the number of company shares held by them

Cases reached 80%

□Applicable □√Not applicable

(5) Other legal person shareholders holding more than 10% of the shares

□Applicable □√Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 80

Section 6 Changes in Shares and Shareholders

(6) Shareholding restrictions and reductions of controlling shareholders, actual controllers, reorganizers and other commitment entities

□Applicable □√Not applicable

4. Specific implementation of share repurchases during the reporting period

Implementation progress of share buybacks

□√Applicable □Not applicable

Plan disclosure time Number of shares to be repurchased Proportion of total equity Amount to be repurchased Period to be repurchased Purpose of repurchase Number of shares repurchased Number of shares repurchased (shares) (RMB 10,000) (shares) Involved in the incentive plan

Proportion of underlying stock (if any)

2024 3,000,751 shares - 0.46% - 0.69% Not less than the People's Bank of China Review and Implementation Employees 3,306,180 N/A September 19 4,501,125 shares (repurchased (according to the upper limit of the repurchase amount RMB 80 million) The repurchase shareholding plan was approved

The upper limit of the purchase price is 26.66 yuan/share, (inclusive) and shall not exceed the share plan and/or equity

Yuan/share calculation) Accounting for the repurchase report is public RMB 12,000 from the day to the repurchase incentive

The company's total share capital at the time of reporting was RMB 10,000 (inclusive). The plan was implemented

ratio)

Implementation progress of reducing and repurchasing shares using centralized bidding transactions

□Applicable □√Not applicable

5. Relevant information on preference shares

□Applicable □√Not applicable

The company did not have preferred shares during the reporting period

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 81

debt

The Seventh Voucher Festival

close

Love

situation

Section 7 Bond-Related Information

□√Applicable □Not applicable

1. Corporate bonds

□Applicable □√Not applicable

The company did not have corporate bonds during the reporting period.

2. Corporate bonds

□Applicable □√Not applicable

The company did not have corporate bonds during the reporting period.

3. Non-financial corporate debt financing tools

□Applicable □√Not applicable

During the reporting period, the company had no non-financial corporate debt financing instruments.

4. Convertible corporate bonds

□√Applicable □Not applicable

(1) Issuance of convertible bonds

As approved by the China Securities Regulatory Commission's "Zhengjian Xu [2019] No. 1183" document, the company publicly issued 4.7 million convertible bonds on August 16, 2019, with a face value of 100 yuan each, and a total issuance of 470 million yuan.

With the approval of the Shenzhen Stock Exchange's "Shenzhen Zhengshang [2019] No. 525" document, the company's 470 million yuan convertible bonds were listed for trading on the Shenzhen Stock Exchange on September 10, 2019. The bond's abbreviation is "Yingke Convertible Bonds" and the bond code is "123029".

(2) Convertible bond guarantors and top ten holders during the reporting period

Convertible corporate bond name Yingke Convertible Bond 1

Number of convertible bond holders at the end of the period 0 Guarantors of the company’s convertible bonds Not applicable Significant changes in the guarantor’s profitability, asset status and credit status Not applicable Note 1: The company has fully redeemed the "Yingke Convertible Bonds" registered with the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. as of the market close on the redemption registration date (August 15, 2025). The total face value of the "Yingke Convertible Bonds" redeemed by the company this time is 178,800.00 yuan. After this redemption is completed, the "Yingke Convertible Bonds" have been delisted from the Shenzhen Stock Exchange on August 18, 2025.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 83

Section 7 Bond-Related Information

(3) Changes in convertible bonds during the reporting period

□√Applicable □Not applicable

Unit: Yuan

This change increases or decreases (+, -)

Convertible corporate bond name Before this change After this change

Share conversion, redemption, sale back

Yingke Convertible Bonds 1,191,000.00 1,012,200.00 178,800.00 0.00

(4) Accumulated share transfers

□√Applicable □Not applicable

Convertible company Issuance Issuance Cumulative shares converted Cumulative number of shares converted % of shares converted Not yet converted % of the amount not converted

Start and end date of stock conversion Name of the total amount of bonds issued by the company before the start date Total amount (pieces) Total amount (yuan) Amount (yuan) Number of shares converted (shares) Proportion of the total amount of shares issued Amount (yuan) Proportion

February 24, 2020

Yingke Convertible Bonds 4,700,000 470,000,000.00 469,821,200.00 37,194,870.00 12.50% 0.00 0.00%

Until August 15, 2025

(5) Previous adjustments and revisions to the stock conversion price

After adjustment Convertible companies as of this report Conversion Latest conversion price adjustment date at the end of the period Disclosure time Description of conversion price adjustment

Price Conversion price Bond name

(Yuan) (Yuan)

On December 31, 2019, the company held the 18th meeting of the second board of directors and the 16th meeting of the second board of supervisors to review

The "Proposal on Granting Restricted Stocks to Incentive Objects" was passed and the 2019 restricted stocks were completed on February 21, 2020.

February 26, 2020 16.17 February 24, 2020

The grant registration of the stock incentive plan and the registration and listing date of the equity incentive restricted shares are February 26, 2020. The total number of company shares is

198,299,014 shares were changed to 200,280,014 shares.

June 5, 2020 16.02 May 29, 2020 The company plans to implement the 2019 equity distribution plan, based on the company’s existing total share capital of 220,033,105 shares, to all shareholders for every 10

Stock distribution of RMB 1.50 in cash (tax included)

On June 2, 2020, the company held the 28th meeting of the second board of directors and the 26th meeting of the second board of supervisors.

The "Proposal on Granting Restricted Stocks to Incentive Objects" was reviewed and approved, and the 2020 restrictions were completed on July 20, 2020

July 22, 2020 16.11 July 20, 2020

The grant registration of the stock incentive plan, the registration and listing date of equity incentive restricted shares is July 22, 2020, and the total number of company shares

Changed from 220,192,808 shares to 221,692,408 shares

October 12, 2020 10.41 September 25, 2020 The company plans to implement the 2020 semi-annual equity distribution plan, based on the total share capital on the equity registration date for dividend distribution, to all shareholders

Dong Dong distributed a cash dividend of RMB 5.00 (tax included) for every 10 shares, and transferred 5 shares to all shareholders for every 10 shares from the capital reserve.

According to the China Securities Regulatory Commission's "About Approval of Yingke Medical Technology Co., Ltd.'s Registration of Issuance of Stocks to Specific Objects"

"Approval" (China Securities Regulatory Commission Permit [2020] No. 2809) approved the registration, and the company issued shares to Liu

Mr. Fang Yi issued 17,415,534 RMB ordinary shares, and the relevant shares have been transferred to the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd.

December 17, 2020 11.32 December 14, 2020 The company completed the registration procedures for newly issued shares. The newly added shares will be listed on the Shenzhen Stock Exchange on December 17, 2020.

The current price is 28.71 yuan/share. According to the information issued by China Securities Depository and Clearing Co., Ltd. Shenzhen Branch on December 1, 2020

"Capital Structure Table (Including Shares in Transit)", after this issuance, the company's total share capital increased from 334,388,357 shares to

351,803,891 shares.

April 20, 2021 8.32 April 13, 2021 The company plans to implement the 2020 annual equity distribution plan, based on the total share capital on the equity registration date for dividend distribution, to all shareholders

Cash dividend of RMB 30.00 per 10 shares (tax included)

September 30, 2021 5.55 September 24, 2021 The company plans to implement the 2021 semi-annual equity distribution plan. It plans to use the total share capital on the equity registration date for dividend distribution as the base, and capital

The provident fund will be transferred to all shareholders for 5 shares for every 10 shares, and no cash dividends will be distributed.

Yingke Convertible Bonds June 13, 2022 4.00 June 3, 2022 The company implemented the 2021 annual equity distribution plan. It plans to use the total share capital on the record date of dividend payment as the base, use the capital reserve of 3.42 to convert 2 shares for every 10 shares to all shareholders, and distribute a cash dividend of RMB 7.5 for every 10 shares.

June 7, 2023 3.90 May 31, 2023 The company plans to implement the equity distribution plan for 2022. It plans to distribute dividends to all shareholders based on the total share capital on the equity registration date.

A cash dividend of RMB 1.0 (tax included) will be distributed for every 10 shares, and no bonus shares will be issued or converted into share capital.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 84

Section 7 Bond-Related Information

The company completed the repurchase and cancellation procedures at the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. on November 16, 2023. The number of incentive objects involved in the company's repurchase and cancellation was 801, and the seventh section of the restricted stocks repurchased and canceled was 2,933,262 shares, accounting for 0.4452% of the company's total share capital before the repurchase and cancellation at that time (based on the China Securities Regulatory Commission as of September 28, 2023 November 17, 2023 3.87 November 17, 2023

Calculated based on the data stated by the Shenzhen Branch of Clearing Co., Ltd.), the total funds used for the repurchase were 28,810,991.87 yuan (including the bank time deposit interest borne during the same period). After the cancellation, the company's total share capital changed from 658,922,826 shares to 655,989,564 shares.

The company completed the repurchase and cancellation procedures at the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. on March 5, 2024. March 06, 2024 3.64 March 06, 2024 The number of shares canceled by the company this time is 8,116,107 shares, accounting for 1.2372% of the company’s total share capital of 656,009,601 shares before the repurchase and cancellation. After the cancellation, the company's total share capital changed from 656,009,601 shares to 647,893,494 shares.

The company plans to implement the equity distribution plan for 2023. It plans to distribute a cash dividend of RMB 0.8 (tax included) to all shareholders for every 10 shares based on the total share capital on the equity registration date when the company's equity distribution is implemented, deducting the company's total share capital after repurchasing the shares in the special repurchase account on May 31, 2024 3.56 May 24, 2024, to all shareholders. No bonus shares will be issued, and no bonus shares will be transferred to increase share capital.

The company completed the repurchase and cancellation procedures at the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. on October 17, 2024. The number of incentive objects involved in the company's repurchase and cancellation is 709, and the number of restricted stocks repurchased and canceled is 1,724,400 shares, accounting for 0.2661% of the company's total share capital before the repurchase and cancellation (based on the China Securities Registration Ending as of October 9, 2024 October 18, 2024 3.54 October 18, 2024

Calculated based on the data stated by the Shenzhen Branch of Shenzhen Accounting Co., Ltd.), the total funds used for the repurchase were 19,773,878.81 yuan (including the bank time deposit interest borne during the same period). After the cancellation, the company's total share capital changed from 647,909,319 shares to 646,184,919 shares.

The company plans to implement the 2024 semi-annual equity distribution plan. It plans to use the total share capital on the equity registration date when the company's equity distribution is implemented minus the total share capital after repurchasing the shares in the company's repurchase account on October 24, 2024.

The company plans to implement the equity distribution plan for 2024. It plans to distribute a cash dividend of RMB 1 yuan for every 10 shares to all shareholders (including June 13, 2025 3.39 June 6, 2025, based on the total share capital on the equity registration date when the company's equity distribution is implemented minus the repurchased shares in the company's repurchase account).

tax), no bonus shares will be given, and no bonus shares will be transferred to increase share capital.

The company completed the repurchase cancellation procedure at the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. on July 10, 2025. July 11, 2025 3.26 July 11, 2025 Continued. The number of shares canceled by the company this time is 4,504,300 shares, accounting for 0.6969% of the company's total share capital of 646,326,180 shares before the repurchase and cancellation. After the cancellation, the company's total share capital changed from 646,326,180 shares to 641,821,880 shares.

The company has completed registration for the grant of restricted stocks at the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd., and the relevant restricted stocks will be listed on July 22, 2025. The registered number of restricted stocks granted this time is 12.8021 million shares, accounting for 3.42 July 22, 2025 July 19, 2025

1.9946% of the company’s total share capital of 641,832,807 shares before share registration and on July 14, 2025. After this registration is completed, the company's total share capital will increase from 641,832,807 shares to 654,634,907 shares.

(6) The company’s liabilities, credit changes at the end of the reporting period, and cash arrangements for debt repayment in future years

1. For details of the company's liabilities at the end of the reporting period, please refer to the specific content of "8. The company's main accounting data and financial indicators in the past two years as of the end of the reporting period" in this section.

2. During the reporting period, the company's public issuance of convertible corporate bonds was credit rated by Shanghai New Century Credit Rating and Investment Services Co., Ltd., and the "Yingke Medical Technology Co., Ltd. Yingke Convertible Bonds Periodic Tracking Rating Report" was issued. The credit rating result of this credit rating is that the company's main credit rating is "AA", and the credit rating of this convertible corporate bond is "AA". The rating outlook is stable, and the rating time is On June 23, 2025, for the above credit rating report, please refer to the relevant information disclosed by the company on June 27, 2025 on the cninfo website (www.cninfo.com.cn).

3. As of the end of this reporting period, the company has fully redeemed the "Yingke Convertible Bonds" registered with the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. after the market closed on the redemption registration date (August 15, 2025). The total face value of the "convertible bonds" is 178,800.00 yuan, accounting for 0.04% of the total issuance. It will not have a major impact on the company's financial status, operating results and cash flow, nor will it affect the normal use of the funds raised by this convertible bond. After the completion of this redemption, "Yingke Convertible Bonds" were delisted from the Shenzhen Stock Exchange on August 18, 2025.

5. The loss in the consolidated statement scope during the reporting period exceeds 10% of the net assets at the end of the previous year

□Applicable □√Not applicable

6. Overdue interest-bearing debts other than bonds at the end of the reporting period

□Applicable □√Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 85

Section 7 Bond-Related Information

7. Whether there were any violations of rules and regulations during the reporting period

□Yes □√ No

8. The company’s main accounting data and financial indicators in the past two years as of the end of the reporting period

Unit: 10,000 yuan

Items The end of the reporting period The end of the previous year The increase or decrease at the end of the reporting period compared with the end of the previous year

Current ratio 0.85 1.50 -43.33% Asset-liability ratio 53.68% 48.94% 4.74% Quick ratio 0.76 1.38 -44.93%

This reporting period The same period last year This reporting period Increases or decreases compared with the same period last year

Net profit after deducting non-recurring gains and losses 39,685.13 116,726.51 -66.00% EBITDA total debt ratio 12.16% 16.41% -4.25% Interest coverage ratio 3.89 6.22 -37.46% Cash interest coverage ratio 6.80 6.06 12.21% EBITDA interest coverage ratio 6.15 9.03 -31.89%Loan repayment rate 100.00% 100.00% 0.00%Interest repayment rate 100.00% 100.00% 0.00%

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 86

Section 8 Finance

service

newspaper

sue

Section 8 Financial Report

1. Audit report

Type of audit opinion Standard unqualified opinion

Audit report signing date April 23, 2026

Name of the audit institution: Tianjian Certified Public Accountants (Special General Partnership)

Audit report number Tianjian Shen [2026] No. 9292

Name of CPA: Fei Fanghua, Li Jingcheng

Audit report text

(1) Audit opinions

We have audited the financial statements of Yingke Medical Technology Co., Ltd. (hereinafter referred to as Yingke Medical Corporation), including the consolidated and parent company balance sheets on December 31, 2025, the consolidated and parent company income statements, consolidated and parent company cash flow statements, consolidated and parent company owner's equity changes statements, and relevant financial statement notes for 2025.

We believe that the attached financial statements are prepared in accordance with the provisions of the Accounting Standards for Business Enterprises in all material respects and fairly reflect the consolidated and parent company's financial status of Inko Medical on December 31, 2025, as well as the consolidated and parent company's operating results and cash flows in 2025.

(2) The basis for forming audit opinions

We performed the audit work in accordance with the Chinese Certified Public Accountants Auditing Standards. Our responsibilities under these standards are further described in the "CPA's Responsibilities for the Audit of Financial Statements" section of the auditor's report. In accordance with the "Independence Standards for Chinese Certified Public Accountants No. 1 - Requirements for Independence in Financial Statement Auditing and Review Engagements" and the Chinese Code of Professional Ethics for Certified Public Accountants, we are independent from Yingke Medical Company and have fulfilled other responsibilities in terms of professional ethics. In our audit, we followed the independence requirements for audits of public interest entities. We believe that the audit evidence we obtained is sufficient and appropriate and provides a basis for issuing an audit opinion.

(3) Key audit matters

Key audit matters are matters that we, based on our professional judgment, consider to be most important in the audit of the current period's financial statements. The response to these matters is based on the audit of the financial statements as a whole and the formation of audit opinions. We do not express opinions on these matters individually.

1. Revenue recognition

(1) Description of the matter

For relevant information disclosure, please refer to the notes to the financial statements.

Yingke Medical's operating income mainly comes from the sales of personal protective products and rehabilitation care products. In 2025, Yingke Medical's operating income was RMB 9.926 billion. Since operating income is one of Inko Medical's key performance indicators, there may be an inherent risk that Inko Medical's management (hereinafter referred to as the management) may use inappropriate revenue recognition to achieve specific goals or expectations, so we identified revenue recognition as a key audit matter.

(2) Audit response

For revenue recognition, the audit procedures we implement mainly include:

1. Understand the key internal controls related to revenue recognition, evaluate the design of these controls, determine whether they are implemented, and test the operating effectiveness of relevant internal controls;

2. Check the sales contract, understand the main contract terms or conditions, and evaluate whether the accounting policy for main business income recognition complies with the relevant accounting standards;

3. Implement analysis procedures on operating income and gross profit margin by month, product, customer, etc. to identify whether there are major or abnormal fluctuations and find out the reasons;

4. For domestic sales revenue, select relevant supporting documents for project inspection, including sales contracts, orders, sales invoices, outbound orders, delivery notes, customer receipt notes, etc.; for export revenue, obtain electronic port information and check it with accounting records, and select relevant supporting documents for project inspection, including sales contracts, export declarations, freight bills of lading, sales invoices, customer receipt notes, etc.;

5. Combined with the confirmation of accounts receivable, select projects to confirm the current sales volume to major customers;

6. Obtain the sales return records after the balance sheet date and check whether there are any situations where the revenue recognition conditions are not met on the balance sheet date;

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 88

Section 8 Financial Report

7. Implement cut-off testing to check whether revenue is recognized during the appropriate period;

8. Check whether information related to operating income has been appropriately presented in the financial statements.

2. The existence and integrity of monetary funds, trading financial assets, other non-current financial assets and other non-current assets (certificates of deposit with a maturity of more than one year)

(1) Description of the matter

For relevant information disclosure, please refer to the notes to the financial statements.

As of December 31, 2025, Yingke Medical's monetary funds, trading financial assets, other non-current financial assets and other non-current assets (large-denomination certificates of deposit maturing for more than one year) were RMB 23.957 billion, accounting for 59.76% of total assets, and are the main assets of Yingke Medical. Due to their significant amount, their existence and completeness will have a significant impact on the financial statements, so we identified the existence and completeness of monetary funds, trading financial assets, other non-current financial assets and other non-current assets (large-denomination certificates of deposit maturing for more than one year) as key audit matters.

(2) Audit response

Regarding the existence and completeness of monetary funds, trading financial assets, other non-current financial assets and other non-current assets (certificates of deposit maturing for more than one year), the audit procedures we implement mainly include:

1. Understand the key internal controls related to monetary funds and financial asset investment business, evaluate the design of these controls, determine whether they are implemented, and test the operational effectiveness of relevant internal controls;

2. Obtain product agreements related to time deposits, certificates of deposit, trading financial assets, and other non-current financial assets, understand the main product terms and investment purposes, and evaluate whether the accounting of time deposits, certificates of deposit, trading financial assets, and other non-current financial assets complies with the relevant provisions of the Accounting Standards for Business Enterprises;

3. Supervise the cash inventory of important companies;

4. Obtain and check bank statements and details of trading financial assets, and implement confirmation procedures for bank accounts and trading financial assets;

5. Combined with the confirmation procedures for monetary funds, trading financial assets, other non-current financial assets and other non-current assets (large-denomination certificates of deposit due for more than one year), check whether there are mortgages, pledges or freezes on monetary funds, trading financial assets, other non-current financial assets and other non-current assets (large-denomination certificates of deposit due for more than one year);

6. Conduct two-way capital flow tests on important bank accounts to check large-amount payment transactions;

7. Implement cut-off testing for monetary funds;

8. Review the interest income and investment income, and check whether the interest income, investment income and monetary funds and financial asset investment scale match;

9. Check whether information related to monetary funds, trading financial assets, other non-current financial assets and other non-current assets (certificates of deposits with maturities of more than one year) have been appropriately presented in the financial statements.

(4) Other information

Management is responsible for other information. Other information includes information covered in the annual report but does not include the financial statements and our auditor's report.

Our audit opinion on the financial statements does not cover other information, nor do we express any form of assurance conclusion on other information.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the audit or otherwise appears to be materially misstated.

If we determine, based on the work we have performed, that other information is materially misstated, we should report that fact. We have nothing to report in this regard.

(5) Responsibility of management and those charged with governance for financial statements

The management is responsible for preparing financial statements in accordance with the provisions of the Accounting Standards for Business Enterprises to achieve fair reflection, and to design, implement and maintain necessary internal controls so that the financial statements are free of material misstatements due to fraud or errors.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 89

Section 8 Financial Report

In preparing financial statements, management is responsible for evaluating Inko Medical's ability to continue as a going concern, disclosing matters related to going concern (if applicable), and applying the going concern assumption unless it plans to liquidate, terminate operations, or has no other realistic alternative.

Those charged with corporate governance of Inko Medical (hereinafter referred to as those charged with governance) are responsible for overseeing Inko Medical's financial reporting process.

(6) Responsibilities of certified public accountants for the audit of financial statements

Our objective is to obtain reasonable assurance as to whether the financial statements as a whole are free of material misstatements due to fraud or error, and to issue an audit report containing an audit opinion. Reasonable assurance is a high level of assurance, but it does not guarantee that an audit performed in accordance with auditing standards will always detect a material misstatement when it exists. Misstatements may be due to fraud or error and are generally considered material if they are reasonably expected individually or in aggregate to affect the economic decisions made by users of financial statements based on the financial statements.

In the process of performing audit work in accordance with the auditing standards, we use professional judgment and maintain professional skepticism. At the same time, we also perform the following tasks:

(1) Identify and assess the risks of material misstatement of financial statements due to fraud or error, design and implement audit procedures to respond to these risks, and obtain sufficient and appropriate audit evidence as a basis for issuing an audit opinion. Because fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal controls, the risk of failing to detect a material misstatement resulting from fraud is higher than the risk of failing to detect a material misstatement resulting from error.

(2) Understand audit-related internal controls to design appropriate audit procedures.

(3) Evaluate the appropriateness of management’s selection of accounting policies and the reasonableness of accounting estimates and related disclosures.

and (4) draw conclusions about the appropriateness of management's use of the going concern assumption. At the same time, based on the audit evidence obtained, a conclusion is drawn as to whether there is a material uncertainty about events or conditions that may cast significant doubt on Inco Medical's ability to continue as a going concern. If we conclude that significant uncertainty exists, auditing standards require us to draw the attention of users to the relevant disclosures in the financial statements in our audit report; if the disclosures are insufficient, we should issue a qualified opinion. Our conclusions are based on information available as of the date of the auditor's report. However, future events or conditions may cause Inco Medical to cease to continue as a going concern.

(5) Evaluate the overall presentation, structure and content of the financial statements and evaluate whether the financial statements fairly reflect the underlying transactions and events.

(6) Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within Inco Medical to express an audit opinion on the financial statements. We are responsible for directing, supervising and performing group audits and take full responsibility for our audit opinions.

We communicate with those charged with governance regarding, among other matters, the planned audit scope, timing and significant audit findings, including communication of significant internal control deficiencies identified during our audit.

We also provide statements to those charged with governance that we have complied with ethical requirements related to independence and communicate with those charged with governance all relationships and other matters that may reasonably be considered to affect our independence, and related safeguards, if applicable.

From the matters communicated with those charged with governance, we determine which matters are most significant to the audit of the current period's financial statements and therefore constitute key audit matters. We describe these matters in our auditor's report unless laws or regulations prohibit public disclosure of the matter or, in rare circumstances, we determine that the matter should not be communicated in our auditor's report if the adverse consequences of communicating the matter in the auditor's report are reasonably expected to outweigh the benefits in the public interest.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 90

Section 8 Financial Report

2. Financial statements

The unit of statements in the financial notes is: Yuan

(1) Consolidated balance sheet

Prepared by: Yingke Medical Technology Co., Ltd.

December 31, 2025

Unit: Yuan

Item Closing balance Opening balance Current assets:

Monetary funds 5,948,301,999.22 12,014,011,946.78 Settlement reserves

Loan funds

Trading financial assets 7,242,924,930.58 6,737,459,715.11 Derivative financial assets 3,420,433.89 17,419,421.54 Notes receivable 1,132,639.73 50,345.10 Accounts receivable 1,361,320,580.73 1,362,747,313.74 Receivables financing 8,240,850.19 16,134,087.49 Prepayments 181,221,258.10 204,297,475.65 Premiums receivable

Reinsurance accounts receivable

Receivable reinsurance contract reserves

Other receivables 46,081,202.74 78,326,027.38 Including: interest receivable

Dividends receivable

Buy financial assets under resale agreements

Inventory 1,327,025,777.13 1,265,414,044.64 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 179,343,823.09 258,907,139.11 Total current assets 16,299,013,495.40 21,954,767,516.54

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 91

Section 8 Financial Report

Non-current assets:

Grant loans and advances

debt investment

Other debt investments

long-term receivables

long term equity investment

Other equity instrument investments

Other non-current financial assets 10,461,055,818.42 1,381,882,649.84 Investment real estate 522,359,883.86 557,007,832.87 Fixed assets 10,803,919,811.95 8,501,377,706.32 Construction in progress 803,113,439.04 1,287,786,355.90 Productive biological assets

oil and gas assets

Right-of-use assets 66,512.06 858,670.46 Intangible assets 729,104,872.88 767,025,854.81 Including: data resources

development expenditure

Among them: data resources

goodwill

Long-term deferred expenses 4,917,088.93 5,221,036.45 Deferred income tax assets 51,607,926.25 80,347,074.89 Other non-current assets 415,313,710.78 94,621,714.36 Total non-current assets 23,791,459,064.17 12,676,128,895.90 Total assets 40,090,472,559.57 34,630,896,412.44

Current liabilities:

Short-term borrowings 16,390,414,942.75 12,666,208,536.46 Borrowings from the central bank

borrowing funds

Trading financial liabilities

Derivative financial liabilities 25,781,822.83 81,655,188.94 Notes payable 19,866,511.82 79,765,311.40 Accounts payable 1,236,654,739.07 765,617,912.37 Advance receipts

Contract liabilities 236,995,423.00 271,584,036.81 Financial assets sold and repurchased

Taking deposits and placing deposits with other banks

Agent for buying and selling securities

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 92

Section 8 Financial Report

Employee benefits payable 141,412,194.22 126,518,625.98 Taxes payable 146,491,376.50 91,147,361.58 Other payables 278,471,838.63 162,334,409.88 Including: interest payable

Dividends payable

Handling fees and commissions payable

Reinsurance accounts payable

Liabilities held for sale

Non-current liabilities due within one year 697,547,643.53 436,372,644.95 Other current liabilities 4,524,200.52 1,314,247.65 Total current liabilities 19,178,160,692.87 14,682,518,276.02

Non-current liabilities:

insurance contract reserves

Long-term borrowings 409,286,523.71 165,404,236.66 Bonds payable 1,393,228.34 Including: preference shares

perpetual bond

Lease liability

long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 211,988,473.38 155,840,533.57 Deferred income tax liabilities 1,719,141,366.53 1,944,059,099.90 Other non-current liabilities

Total non-current liabilities 2,340,416,363.62 2,266,697,098.47 Total liabilities 21,518,577,056.49 16,949,215,374.49

Owner’s Equity:

Equity 654,753,263.00 646,193,496.00 Other equity instruments 104,170.09 Including: preference shares

perpetual bond

Capital reserve 1,182,764,415.95 1,113,947,030.65 Less: treasury shares 239,118,428.08 133,466,706.00 Other comprehensive income -50,044,700.51 -8,367,027.53Special reserves 13,362,981.50 7,881,389.45 Surplus reserve 252,258,282.05 249,302,977.00 General risk reserve

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 93

Section 8 Financial Report

Undistributed profits 16,439,863,549.50 15,528,484,819.86 Total owners’ equity attributable to the parent company 18,253,839,363.41 17,404,080,149.52 Minority shareholders’ equity 318,056,139.67 277,600,888.43 Total owners’ equity 18,571,895,503.08 17,681,681,037.95 Total liabilities and owners’ equity 40,090,472,559.57 34,630,896,412.44

Legal representative: Liu Fangyi Person in charge of accounting work: Feng Jie Head of accounting department: Jiao Yufa

(2) Balance sheet of parent company

Unit: Yuan

Item Closing balance Opening balance Current assets:

Monetary funds 42,800,819.42 26,459,738.69 Trading financial assets

Derivative financial assets

Notes receivable

Accounts receivable 367,900,839.22 262,468,398.46 Accounts receivable financing 490,204.84 413,098.88 Prepayments 245,216,974.52 206,215,363.97 Other receivables 646,681,147.02 552,632,129.72 of which: interest receivable

Dividends receivable 300,000,000.00 Inventory 34,301,821.85 38,094,700.53 Including: data resources

contract assets

Assets held for sale

Non-current assets due within one year

Other current assets 6,637,414.04 9,954,451.52 Total current assets 1,344,029,220.91 1,096,237,881.77

Non-current assets:

debt investment

Other debt investments

long-term receivables

Long-term equity investment 4,625,491,370.13 4,480,715,401.50 Other equity instrument investments

Other non-current financial assets 564,240,368.71 499,928,273.41

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 94

Section 8 Financial Report

investment real estate

Fixed assets 57,653,844.59 64,723,943.03 Construction in progress

productive biological assets

oil and gas assets

right-of-use assets

Intangible assets 5,694,137.41 5,942,064.02 Including: data resources

development expenditure

Among them: data resources

goodwill

Long-term deferred expenses 314,734.23 364,173.63 Deferred income tax assets 36,757,871.51 47,838,124.51 Other non-current assets 722,626.60 5,230,034.46 Total non-current assets 5,290,874,953.18 5,104,742,014.56 Total assets 6,634,904,174.09 6,200,979,896.33

Current liabilities:

Short-term borrowings 275,268,712.43 791,578,954.07 Trading financial liabilities

Derivative financial liabilities

Notes payable

Accounts payable 24,073,500.79 32,131,588.40 Advance payments

Contract liabilities 294,383,841.00 341,580,594.17 Employee benefits payable 6,907,740.01 6,003,663.79 Taxes payable 775,368.55 1,183,540.39 Other payables 3,689,774,689.93 2,739,314,630.36 of which: interest payable

Dividends payable

Liabilities held for sale

Non-current liabilities due within one year 149,019,007.78

Other current liabilities 7,027,896.38 9,776,460.59 Total current liabilities 4,447,230,756.87 3,921,569,431.77

Non-current liabilities:

Long-term borrowings 900,000.00

Bonds payable 1,393,228.34

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 95

Section 8 Financial Report

Among them: preferred shares

perpetual bond

Lease liability

long-term payables

Long-term employee benefits payable

Estimated liabilities

Deferred income 3,613,750.00

Deferred income tax liability

Other non-current liabilities

Total non-current liabilities 4,513,750.00 1,393,228.34 Total liabilities 4,451,744,506.87 3,922,962,660.11

Owner’s Equity:

Equity 654,753,263.00 646,193,496.00 Other equity instruments 104,170.09 Including: preference shares

perpetual bond

Capital reserve 1,152,442,503.26 1,083,291,061.30 Less: treasury shares 239,118,428.08 133,466,706.00 Other comprehensive income

special reserve

Surplus reserve 251,063,357.05 248,108,052.00 Undistributed profits 364,018,971.99 433,787,162.83 Total owners’ equity 2,183,159,667.22 2,278,017,236.22 Total liabilities and owners’ equity 6,634,904,174.09 6,200,979,896.33

(3) Consolidated income statement

Unit: Yuan

Project 2025 2024

1. Total operating income 9925,819,444.72 9,523,317,123.49 Including: operating income 9,925,819,444.72 9,523,317,123.49 Interest income

Premiums earned

Fee and commission income

2. Total operating costs 9,433,955,186.70 8,106,201,641.65 Including: operating costs 7,531,555,720.01 7,272,347,663.47

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 96

Section 8 Financial Report

interest expense

Handling fees and commission expenses

surrender deposit

Net compensation expenses

Net withdrawal of insurance liability contract reserves

policy dividend payout

Reinsurance cost

Taxes and surcharges 97,295,051.67 65,551,156.40 Sales expenses 297,730,387.79 288,443,843.68 Management expenses 686,464,281.55 518,139,926.38 Research and development expenses 404,381,847.56 398,344,414.56Financial expenses 416,527,898.12 -436,625,362.84Including: Interest expenses 369,151,102.52 308,037,023.74Interest income 367,932,996.49 533,356,405.99Plus: other income 65.599,372.30 58,372,443.32 Investment income (losses are listed with "-") 379,720,803.35 63,176,605.34 Including: investment income from associates and joint ventures

Gains from derecognition of financial assets measured at amortized cost

Exchange gains (losses are listed with "-")

Net exposure hedging income (losses are listed with "-")

Gains from changes in fair value (losses are listed with "-") 318,499,359.53 279,767,035.60 Credit impairment losses (losses are listed with "-") 6,306,257.36 -32,779,876.77 Asset impairment losses (losses are listed with "-") -31,421,981.56 -109,052,505.20 Asset disposal income (losses are listed with "-") -397,114.67 224,360.40

3. Operating profit (losses are listed with "-") 1,230,170,954.33 1,676,823,544.53 Plus: non-operating income 22,878,771.51 2,541,261.33 Less: non-operating expenses 23,309,581.23 70,446,789.13

4. Total profits (total losses are listed with "-") 1,229,740,144.61 1,608,918,016.73 Less: income tax expenses 182,552,677.66 117,228,963.13

5. Net profit (net loss is listed with "-") 1,047,187,466.95 1,491,689,053.60

(1) Classification by business continuity

1. Net profit from continuing operations (net losses are listed with "-") 1,047,187,466.95 1,491,689,053.60 2. Net profit from discontinued operations (net losses are listed with "-")

(2) Classification according to ownership ownership

1. Net profit attributable to shareholders of the parent company 1,010,699,970.94 1,465,476,194.01 2. Profit and loss of minority shareholders 36,487,496.01 26,212,859.59

2. Net after-tax amount of other comprehensive income -41,766,121.34 -5,904,455.53

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 97

Section 8 Financial Report

Net after-tax other comprehensive income attributable to owners of the parent company -41,677,672.98 -5,904,455.53

(1) Other comprehensive income that cannot be reclassified into profit or loss

1. Remeasure the changes in defined benefit plan

2. Other comprehensive income that cannot be transferred to profit or loss under the equity method

3. Changes in fair value of other equity instrument investments

4. Changes in the fair value of the company’s own credit risk

5.Others

(2) Other comprehensive income that will be reclassified into profit and loss -41,677,672.98 -5,904,455.53 1. Other comprehensive income that can be converted into profit and loss under the equity method

2. Changes in fair value of other debt investments

3. The amount of financial assets reclassified and included in other comprehensive income

4. Credit impairment provisions for other debt investments

5. Cash flow hedging reserve

6. Translation differences of foreign currency financial statements -41,677,672.98 -5,904,455.53 7. Others

Net after-tax other comprehensive income attributable to minority shareholders -88,448.36

7. Total comprehensive income 1,005,421,345.61 1,485,784,598.07 Total comprehensive income attributable to owners of the parent company 969,022,297.96 1,459,571,738.48 Total comprehensive income attributable to minority shareholders 36,399,047.65 26,212,859.59

8. Earnings per share:

(1) Basic earnings per share 1.58 2.26

(2) Diluted earnings per share 1.57 2.26 Legal representative: Liu Fangyi Person in charge of accounting: Feng Jie Head of accounting department: Jiao Yufa

(4) Income statement of the parent company

Unit: Yuan

Project 2025 2024

1. Operating income 440,567,478.06 388,948,579.64 Less: Operating costs 381,202,440.00 313,819,174.81 Taxes and surcharges 2,600,512.14 1,355,665.03 Sales expenses 18,538,530.74 22,227,561.05 Administrative expenses 30,888,135.79 42,904,862.91 Research and development expenses 14,467,296.57 13,484,945.17 Financial expenses 11,191,602.22 28,904,980.82 Including: interest expenses 11,078,219.08 27,480,466.75 Interest income 945,216.48 771,037.49 Plus: other income 3,604,976.82 1,955,017.46

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 98

Section 8 Financial Report

Investment income (losses are listed with "-") 9,098,687.71 300,000,000.00 Including: investment income from associates and joint ventures

Income from derecognition of financial assets measured at amortized cost (losses are listed with a “-” sign)

Net exposure hedging income (losses are listed with "-")

Gains from changes in fair value (losses are listed with "-") 50,106,070.30 12,978,737.21 Credit impairment losses (losses are listed with "-") 6,457,205.04 7,665,435.35 Asset impairment losses (losses are listed with "-") -5,879,623.67 -2,406,313.93 Asset disposal income (losses are listed with "-") -5,066.36 -201,291.18

2. Operating profit (losses are listed with "-") 45,061,210.44 286,242,974.76 Plus: non-operating income 50,503.77 66,970.44 Less: non-operating expenses 1,639,964.67 281,962.03

3. Total profits (total losses are listed with "-") 43,471,749.54 286,027,983.17 Less: income tax expenses 13,918,699.08 4,043,133.19

4. Net profit (net loss is listed with "-") 29,553,050.46 281,984,849.98

(1) Net profit from continuing operations (net loss is listed with "-") 29,553,050.46 281,984,849.98

(2) Net profit from discontinued operations (net loss is listed with "-")

5. Net amount of other comprehensive income after tax

(1) Other comprehensive income that cannot be reclassified into profit or loss

1. Remeasure the changes in defined benefit plan

2. Other comprehensive income that cannot be transferred to profit or loss under the equity method

3. Changes in fair value of other equity instrument investments

4. Changes in the fair value of the company’s own credit risk

5.Others

(2) Other comprehensive income that will be reclassified into profit and loss

1. Other comprehensive income that can be converted to profit or loss under the equity method

2. Changes in fair value of other debt investments

3. The amount of financial assets reclassified and included in other comprehensive income

4. Credit impairment provisions for other debt investments

5. Cash flow hedging reserve

6. Translation differences of foreign currency financial statements

7.Others

6. Total comprehensive income 29,553,050.46 281,984,849.98

7. Earnings per share:

(1) Basic earnings per share

(2) Diluted earnings per share

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 99

Section 8 Financial Report

(5) Consolidated cash flow statement

Unit: Yuan

Project 2025 2024

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 10,034,175,920.78 9,503,696,970.97 Net increase in customer deposits and deposits from banks

Net increase in borrowing from the central bank

Net increase in borrowing funds from other financial institutions

Cash received from premiums from the original insurance contract

Net cash received from reinsurance business

Net increase in policyholders’ savings and investment funds

Cash collected from interest, fees and commissions

Net increase in borrowing funds

Net increase in repurchase business funds

Net cash received from buying and selling securities on behalf of agents

Tax refunds received 612,110,809.49 610,133,427.68 Other cash received related to operating activities 255,587,029.01 410,742,033.46 Subtotal of cash inflows from operating activities 10,901,873,759.28 10,524,572,432.11 Cash paid for purchasing goods and receiving services 6,574,998,299.51 7,219,858,769.71 Net increase in customer loans and advances

Net increase in deposits with central banks and inter-banks

Cash used to pay compensation from the original insurance contract

Net increase in lending funds

Cash payments for interest, fees and commissions

Cash payment for policy dividends

Cash paid to and for employees 1,304,724,247.70 1,093,896,867.58 Various taxes and fees paid 454,143,066.30 169,777,870.12 Cash paid for other operating activities 682,978,766.21 961,981,106.44 Subtotal cash outflow from operating activities 9,016,844,379.72 9,445,514,613.85 Net cash flow generated from operating activities 1,885,029,379.56 1,079,057,818.26

2. Cash flow generated from investing activities:

Cash received from investment recovery 18,749,358,055.52 6,996,601,298.10 Cash received from investment income 407,416,015.36 278,126,744.21 Net cash received from disposal of fixed assets, intangible assets and other long-term assets 112,529,555.18 2,542,456.97 Net cash received from disposal of subsidiaries and other business units

Other cash received related to investing activities 157,086,314.93

Subtotal of cash inflows from investing activities 19,426,389,940.99 7,277,270,499.28

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 100

Section 8 Financial Report

Cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets 2,574,752,568.94 1,789,427,190.45 Cash paid for investment 28,129,231,063.06 9,332,744,368.52 Net increase in pledged loans

Net cash received from subsidiaries and other business units

Payment of other cash related to investing activities 174,086,314.93 23,000,000.00 Subtotal cash outflow from investing activities 30,878,069,946.93 11,145,171,558.97 Net cash flow generated from investing activities -11,451,680,005,94 -3,867,901,059.69

3. Cash flow generated from financing activities:

Cash received from investment 148,826,230.00

Including: Cash received by subsidiaries from minority shareholders’ investments

Cash received from borrowings 21,095,914,588.65 14,059,865,517.73 Cash received from other financing activities 10,272,417,075.40 1,185,711,592.47 Subtotal of cash inflows from financing activities 31,517,157,894.05 15,245,577,110.20 Cash paid to repay debts 16,959,794,382.28 8,014,287,699.33 Cash paid to distribute dividends, profits or pay interest 422,168,603.78 338,282,212.48 Including: dividends and profits paid by subsidiaries to minority shareholders

Cash payments related to other financing activities 5,757,477,002.45 5,468,214,310.86 Subtotal cash outflows from financing activities 23,139,439,988.51 13,820,784,222.67 Net cash flow generated from financing activities 8,377,717,905.54 1,424,792,887.53

4. Impact of exchange rate changes on cash and cash equivalents -306,413,256.68 59,845,034.62

5. Net increase in cash and cash equivalents -1,495,345,977.52 -1,304,205,319.28 plus: opening balance of cash and cash equivalents 3,297,869,898.72 4,602,075,218.00

6. Balance of cash and cash equivalents at the end of the period 1,802,523,921.20 3,297,869,898.72

(6) Cash flow statement of the parent company

Unit: Yuan

Project 2025 2024

1. Cash flow generated from operating activities:

Cash received from selling goods and providing services 322,006,474.80 229,374,801.14 Tax refunds received 12,323,634.65 14,404,553.72 Cash received from other operating activities 74,383,471.59 37,597,537.48 Subtotal of cash inflows from operating activities 408,713,581.04 281,376,892.34 Cash paid for purchasing goods and receiving services 421,797,648.32 208,848,386.21 Cash paid to and for employees 63,234,245.12 57,900,471.48 Various taxes and fees paid 5,704,593.81 76,018,643.41 Other cash payments related to operating activities 79,811,939.70 87,964,726.11 Subtotal of cash outflows from operating activities 570,548,426.95 430,732,227.21

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 101

Section 8 Financial Report

Net cash flow from operating activities -161,834,845.91 -149,355,334.87

2. Cash flow generated from investing activities:

Cash received from investment recovery 152,793,975.00 19,037,045.80 Cash received from investment income 310,081,306.24 300,000,000.00 Net cash received from disposal of fixed assets, intangible assets and other long-term assets 86,540.00 16,939,566.44 Net cash received from disposal of subsidiaries and other business units 1,751,559.47

Other cash received related to investing activities 100,705,795.26 871,923,902.76 Subtotal of cash inflows from investing activities 565,419,175.97 1,207,900,515.00 Cash paid for the purchase and construction of fixed assets, intangible assets and other long-term assets 2,561,411.72 17,216,565.09 Cash paid for investment 286,419,490.00 135,086,121.68 Net cash paid to acquire subsidiaries and other business units

Other cash payments related to investing activities 512,213,379.47 1,716,995,597.42 Subtotal cash outflow from investing activities 801,194,281.19 1,869,298,284.19 Net cash flow generated from investing activities -235,775,105.22 -661,397,769.19

3. Cash flow generated from financing activities:

Cash received from investment 148,826,230.00

Cash received from borrowings 425,000,000.00 1,018,255,000.00 Cash received from other financing activities 2,789,914,643.48 694,373,857.50 Subtotal of cash inflows from financing activities 3,363,740,873.48 1,712,628,857.50 Cash paid to repay debts 790,242,902.89 456,365,000.00 Cash paid to distribute dividends, profits or pay interest 108,295,623.74 109,769,737.29 Cash paid to other financing activities 2,050,107,499.05 390,586,319.33 Subtotal of cash outflows from financing activities 2,948,646,025.68 956,721,056.62 Net cash flow generated from financing activities 415,094,847.80 755,907,800.88

4. Impact of exchange rate changes on cash and cash equivalents -1,143,815.94 -4,254,105.13

5. Net increase in cash and cash equivalents 16,341,080.73 -59,099,408.31 plus: opening balance of cash and cash equivalents 26,459,738.69 85,559,147.00

6. Balance of cash and cash equivalents at the end of the period 42,800,819.42 26,459,738.69

(7) Consolidated statement of changes in owners’ equity

Amount of current period

Unit: Yuan

2025

Owner's equity attributable to parent company

Items Minority shares Owners' other equity instruments General shareholders' equity Equity combined capital Preferred Perpetual Other capital Public capital reduction Treasury: Deposited shares Other combined income Special reserves Profit reserve Risk reserve Undistributed profit distribution Other subtotal

stocks bonds

1. Closing balance of the previous year 646,193,496.00 104,170.09 1,113,947,030.65 133,466,706.00 -8,367,027.53 7,881,389.45 249,302,977.00 15,528,484,819.86 17,404,080,149.52 277,600,888.43 17,681,681,037.95

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 102

Section 8 Financial Report

Add: Changes in accounting policies

Early error correction

Others

2. Balance at the beginning of the year 646,193,496.00 104,170.09 1,113,947,030.65 133,466,706.00 -8,367,027.53 7,881,389.45 249,302,977.00 15,528,484,819.86 17,404,080,149.52 277,600,888.43 17,681,681,037.95

3. Increases and decreases in this period

Amount (decreased by "-" 8,559,767.00 -104,170.09 68,817,385.30 105,651,722.08 -41,677,672.98 5,481,592.05 2,955,305.05 911,378,729.64 849,759,213.89 40,455,251.24 (Fill in No. 890,214,465.13)

(1) Total comprehensive income -41,677,672.98 1,010,699,970.94 969,022,297.96 36,399,047.65 1,005,421,345.61 (minus two less) Capital owners’ investment and 13,474,547.00 168,887,467.16 132,134,247.00 50,227,767.16 50,227,767.16 1 Common stock invested by all shareholders 13,172,100.00 135,654,130.00 148,826,230.00

2. Other equity instruments held

Someone invests capital

3 The payment amount of the equity interest of the owner shall be credited to the institution 31,997,687.05 31,997,687.05 31,997,687.05

4. Others 302,447.00 1,235,650.11 -16,691,983.00 18,230,080.11 18,230,080.11

(3) Profit distribution 2,955,305.05 -99,321,241.30 -96,365,936.25 -96,365,936.25

1. Withdrawal from surplus reserve 2,955,305.05 -2,955,305.05

2. Extract general risks

Prepare

3 shares. To all shareholders of ()

4. Others

(4) Owner’s equity

internal carry forward

1. Conversion of capital reserve to increase

capital (or equity)

2. Conversion of surplus reserve to increase

capital (or equity)

3. Replenishment of surplus reserve

Loss

4. Set up a benefit plan

Changes carried forward and retained

income

5 Other comprehensive income

Carry forward retained earnings

6. Others

(5) Special reserves 5,481,592.05 5,481,592.05 3,722,146.93 9,203,738.98

1. Withdrawal in this period 7,781,956.62 7,781,956.62 4,989,979.21 12,771,935.83

2. Use in this period -2,300,364.57 -2,300,364.57 -1,267,832.28 -3,568,196.85

(6) Others -4,914,780.00 -104,170.09 -100,070,081.86 -26,482,524.92 -78,606,507.03 334,056.66 -78,272,450.37

4. Ending balance of the current period 654,753,263.00 1,182,764,415.95 239,118,428.08 -50,044,700.51 13,362,981.50 252,258,282.05 16,439,863,549.50 18,253,839,363.41 318,056,139.67 18,571,895,503.08

Amount of last period

Unit: Yuan

2024

Owner's equity attributable to parent company

Items Minority shares Owners' other equity instruments General shareholders' equity Equity combined capital Preferred Perpetual Other capital Public capital reduction Treasury: Deposited shares Other combined income Special reserves Profit reserve Risk reserve Undistributed profit distribution Other subtotal

stocks bonds

1. Closing balance of the previous year 656,004,151.00 113,590.00 1,286,962,029.00 320,552,982.00 -2,462,572.00 12,982,167.00 221,104,492.00 14,174,436,942.00 16,028,587,817.00 265,993,000.00 16,294,580,817.00 plus: changes in accounting policies

Early error correction

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 103

Section 8 Financial Report

Others

2. Balance at the beginning of the year 656,004,151.00 113,590.00 1,286,962,029.00 320,552,982.00 -2,462,572.00 12,982,167.00 221,104,492.00 14,174,436,942.00 16,028,587,817.00 265,993,000.00 16,294,580,817.00

3. Increases and decreases in this period

Amount (decreased by "-" -9,810,655.00 -9,419.91 -173,014,998.35 -187,086,276.00 -5,904,455.53 -5,100,777.55 28,198,485.00 1,354,047,877.86 1,375,492,332.52 11,607,888.43 (Fill in No. 1,387,100,220.95)

(1) Total comprehensive income -5,904,455.53 1,465,476,194.01 1,459,571,738.48 26,212,859.59 1,485,784,598.07 (minus two less) Capital owner’s investment and 29,852.00 -9,419.91 9,403,461.30 9,423,893.39 9,423,893.39

1. The general investment of the owner

common stock

2 Other equity instruments held

Someone invests capital

3 The payment amount of the owner’s equity shares is credited to the institution 9,302,013.00 9,302,013.00 9,302,013.00

4. Others 29,852.00 -9,419.91 101,448.30 121,880.39 121,880.39

(3) Profit distribution -458,766.00 28,198,485.00 -111,428,316.15 -82,771,065.15 -21,805,000.00 -104,576,065.15

1. Withdrawal from surplus reserve 28,198,485.00 -28,198,485.00

2. Extract general risks

Prepare

3 shares. To all shareholders of ()

4. Others -458,766.00 458,766.00 458,766.00

(4) Owner’s equity

internal carry forward

1. Conversion of capital reserve to increase

capital (or equity)

2. Conversion of surplus reserve to increase

capital (or equity)

3. Replenishment of surplus reserve

Loss

4. Set up a defined benefit plan

Changes carried forward and retained

income

5. Other comprehensive income

Carry forward retained earnings

6. Others

(5) Special reserves -5,100,777.55 -5,100,777.55 6,877,150.80 1,776,373.25

1. Withdrawal in this period 6,515,727.41 6,515,727.41 10,080,236.31 16,595,963.72

2. Use in this period -11,616,504.96 -11,616,504.96 -3,203,085.51 -14,819,590.47

(6) Others -9,840,507.00 -182,418,459.65 -186,627,510.00 -5,631,456.65 322,878.04 -5,308,578.61

4. Ending balance of the current period 646,193,496.00 104,170.09 1,113,947,030.65 133,466,706.00 -8,367,027.53 7,881,389.45 249,302,977.00 15,528,484,819.86 17,404,080,149.52 277,600,888.43 17,681,681,037.95

(8) Statement of changes in owner’s equity of the parent company

Amount of current period

Unit: Yuan

2025

Project Other Equity Instruments

Other Comprehensive Ownership Equity Capital Reserves Less: Treasury Stocks Special Reserves Surplus Reserves Undistributed Profits Others

Profit total

Preferred shares Perpetual bonds Others

1. Closing balance of the previous year 646,193,496.00 104,170.09 1,083,291,061.30 133,466,706.00 248,108,052.00 433,787,162.83 2,278,017,236.22 plus: Changes in accounting policies

Early error correction

Others

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 104

Section 8 Financial Report

2. Opening balance of the year 646,193,496.00 104,170.09 1,083,291,061.30 133,466,706.00 248,108,052.00 433,787,162.83 2,278,017,236.22

3. Increase or decrease of change funds in this period

Amount (decrease is indicated by "-") 8,559,767.00 -104,170.09 69,151,441.96 105,651,722.08 2,955,305.05 -69,768,190.84 -94,857,569.00

(1) Total comprehensive income 29,553,050.46 29,553,050.46

(2) Owner’s investment and

13,474,547.00 168,887,467.16 132,134,247.00 50,227,767.16 Capital reduction

1． Owner's investment

13,172,100.00 135,654,130.00 148,826,230.00

common stock

2. Other equity instruments

holders invest capital

3． Share-based payment included

Amount of owners’ equity 31,997,687.05 31,997,687.05 4. Others 302,447.00 1,235,650.11 -16,691,983.00 18,230,080.11

(3) Profit distribution 2,955,305.05 -99,321,241.30 -96,365,936.25 1. Withdrawal from surplus reserve 2,955,305.05 -2,955,305.05

2. to the owner (or

Distribution to shareholders) -96,365,936.25 -96,365,936.25 3. Others

(4) Owner’s equity

internal carry forward

1． Capital reserve transfer to increase

capital (or equity)

2. Transfer of surplus reserve to increase

capital (or equity)

3． Make up surplus reserve

Loss

4． Defined benefit plan changes

Moving amount carried forward to retained earnings

5. other comprehensive income

Carry forward retained earnings

6． Others

(5) Special reserves

1． Extract this period

2. Used in this issue

(6) Others -4,914,780.00 -104,170.09 -99,736,025.20 -26,482,524.92 -78,272,450.37

4. Closing balance of the current period 654,753,263.00 1,152,442,503.26 239,118,428.08 251,063,357.05 364,018,971.99 2,183,159,667.22

Amount of last period

Unit: Yuan

2024

Project Other Equity Instruments

Other Comprehensive Ownership Equity Capital Reserves Less: Treasury Stocks Special Reserves Surplus Reserves Undistributed Profits Others

Profit total

Preferred shares, perpetual bonds, others

1. Closing balance of the previous year 656,004,151.00 113,590.00 1,257,142,252.00 320,552,982.00 219,909,567.00 263,230,629.00 2,075,847,207.00 plus: Changes in accounting policies

Early error correction

Others

2. Opening balance of the year 656,004,151.00 113,590.00 1,257,142,252.00 320,552,982.00 219,909,567.00 263,230,629.00 2,075,847,207.00

3. Increase or decrease of change funds in this period

Amount (decreases are listed with "-") -9,810,655.00 -9,419.91 -173,851,190.70 -187,086,276.00 28,198,485.00 170,556,533.83 202,170,029.22

(1) Total comprehensive income 281,984,849.98 281,984,849.98

(2) Owner’s investment and

29,852.00 -9,419.91 9,403,461.30 9,423,893.39 Capital reduction

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 105

Section 8 Financial Report

1. The general investment of the owner

common stock

2. Other equity instruments

holders invest capital

3. Share-based payment included

Amount of owners’ equity 9,302,013.00 9,302,013.00

4. Others 29,852.00 -9,419.91 101,448.30 121,880.39

(3) Profit distribution -458,766.00 28,198,485.00 -111,428,316.15 -82,771,065.15

1. Withdrawal from surplus reserve 28,198,485.00 -28,198,485.00

2. To the owner (or

Distribution from shareholders) -83,229,831.15 -83,229,831.15

3. Others -458,766.00 458,766.00

(4) Owner’s equity

internal carry forward

1. Conversion of capital reserve to increase

capital (or equity)

2. Conversion of surplus reserve to increase

capital (or equity)

3. Replenishment of surplus reserve

Loss

4. Changes to defined benefit plans

Moving amount carried forward to retained earnings

5. Other comprehensive income

Carry forward retained earnings

6. Others

(5) Special reserves

1. Extraction in this period

2. Use in this issue

(6) Others -9,840,507.00 -183,254,652.00 -186,627,510.00 -6,467,649.00

4. Ending balance of the current period 646,193,496.00 104,170.09 1,083,291,061.30 133,466,706.00 248,108,052.00 433,787,162.83 2,278,017,236.22

3. Basic situation of the company

Yingke Medical Technology Co., Ltd. (hereinafter referred to as the company or the company) is a joint-stock company established on April 28, 2015 by natural persons Liu Fangyi, Feng Zicheng, Shenzhen Innovation Investment Group Co., Ltd., Suzhou Kangbo Riverside Venture Capital Center (Limited Partnership), Zibo Jinzhao Investment Co., Ltd. and Zibo Innovation Capital Venture Capital Co., Ltd. It is headquartered in Zibo City, Shandong Province. The company currently holds a business license with the unified social credit code 9137030068946500X7. As of December 31, 2025, the company's registered capital was 654,753,263 yuan and the total number of shares was 654,753,263 shares. Among them, there are 189,156,809 A shares with trading restrictions and 465,596,454 A shares without selling conditions. The company's shares were listed for trading on the Shenzhen Stock Exchange on July 21, 2017.

The company belongs to the medical device industry. The main business activities are the research and development, production and sales of personal protection and rehabilitation care products.

This financial statement has been approved by the company at the 14th meeting of the fourth session of the Board of Directors on April 23, 2026.

4. Basis for preparation of financial statements

(1) Basis for preparation

The company's financial statements are prepared on a going concern basis.

(2) Continued operations

The Company has no events or circumstances that would cause significant doubts about its ability to continue operating within 12 months from the end of the reporting period.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 106

Section 8 Financial Report

5. Important accounting policies and accounting estimates

Specific accounting policies and accounting estimation tips:

The Company has formulated specific accounting policies and accounting estimates based on the actual production and operation characteristics for transactions or matters such as impairment of financial instruments, inventories, depreciation of fixed assets, construction in progress, intangible assets, and revenue recognition.

(1) Statement on compliance with accounting standards for enterprises

The financial statements prepared by the company comply with the requirements of the Accounting Standards for Business Enterprises and truly and completely reflect the company's financial status, operating results, cash flow and other relevant information.

(2) Accounting period

The fiscal year begins on January 1 and ends on December 31 of the Gregorian calendar.

(3) Business cycle

The company's operating business has a short operating cycle, and 12 months is used as the liquidity classification standard for assets and liabilities.

(4) Accounting standard currency

The Company and its domestic subsidiaries use RMB as their accounting standard currency. Overseas subsidiaries engaged in overseas operations choose the currency in the main economic environment in which they operate as their accounting standard currency.

(5) Determination method and selection basis of materiality standards

□√ Applicable □ Not applicable

Project Materiality Criteria

Important accounts receivable for which single amount of bad debt provision is made. Important accounts receivable with single amount exceeding 0.5% of total assets. Important accounts receivable with bad debt provision recovered or reversed. Important accounts receivable with single amount exceeding 0.5% of total assets. Important single account receivables with single amount of impairment provision exceeding 0.5% of total assets. Financing of receivables with single amount exceeding 0.5% of total assets. Important single amount of impairment provision for accounts receivable is recovered or reversed. Financing of important write-off receivables with a single amount exceeding 0.5% of total assets. Important other receivables with provision for bad debts with a single amount exceeding 0.5% of total assets. Important other receivables with a single amount exceeding 0.5% of total assets. Bad debt provisions are recovered or reversed. Significant write-off of other receivables with a single amount exceeding 0.5% of total assets. Important overdue interest receivables with a single amount exceeding 0.5% of total assets. An important advance payment with an individual amount exceeding 0.5% of total assets, an important prepayment with an aging of more than 1 year, an important debt instrument investment with an individual amount exceeding 0.5% of the total assets, an important construction project in progress with an individual amount exceeding 0.5% of the net assets, an important overdue loan with an individual amount exceeding 0.5% of the total assets, an important overdue interest payable with an individual amount exceeding 0.5% of the total assets, an important account payable with an age exceeding 1 year, with an individual amount exceeding 0.5% of the total assets. The individual amount exceeds 0.5% of total assets. Important other payables aged more than 1 year. The individual amount exceeds 0.5% of total assets. Important advance receipts aged more than 1 year or overdue. The individual amount exceeds 0.5% of total assets. Important contract liabilities aged more than 1 year. The individual amount exceeds 0.5% of total assets.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 107

Section 8 Financial Report

There is a significant change in the book value of contract liabilities, and the amount of change exceeds 0.5% of total assets.

Important cash flow from investing activities: The amount of a single item exceeds 10% of total assets

Important subsidiaries and non-wholly owned subsidiaries whose total assets exceed 15% of the group's total assets

The book value of a single long-term equity investment exceeds 15% of the group's net assets/important joint ventures and associates

Important commitments where the investment income calculated using the equity method alone exceeds 15% of the group's total profits. The amount of a single commitment exceeds 0.5% of the net assets.

(6) Accounting treatment methods for business combinations under the same control and those not under the same control

1. Accounting treatment for business combinations under common control

The assets and liabilities acquired by the company in a business merger are measured according to the book value of the merged party in the consolidated financial statements of the ultimate controlling party on the merger date. The company adjusts the capital reserve based on the difference between the book value share of the owner's equity of the merged party in the final controlling party's consolidated financial statements and the book value of the merger consideration paid or the total face value of the shares issued; if the capital reserve is insufficient for offset, the company adjusts the retained earnings.

2. Accounting treatment for business combinations not under common control

On the acquisition date, the company recognizes the difference between the merger cost and the fair value share of the acquiree's identifiable net assets acquired in the merger as goodwill; if the merger cost is less than the fair value share of the acquiree's identifiable net assets acquired in the merger, the difference is first recognized as goodwill. The fair value of the acquiree's identifiable assets, liabilities and contingent liabilities and the measurement of merger costs are reviewed. After review, if the merger cost is still less than the fair value share of the acquiree's identifiable net assets obtained in the merger, the difference is included in the current profit and loss.

(7) Judgment standards for control and preparation methods of consolidated financial statements

1. Judgment of control

If it has rights over the investee, enjoys variable returns by participating in the relevant activities of the investee, and has the ability to use its power over the investee to affect the amount of its variable returns, it is deemed to be control.

2. Preparation method of consolidated financial statements

The parent company includes all subsidiaries it controls in the consolidated financial statements. The consolidated financial statements are based on the financial statements of the parent company and its subsidiaries, and based on other relevant information, are prepared by the parent company in accordance with the "Accounting Standards for Business Enterprises No. 33 - Consolidated Financial Statements".

(8) Classification of joint arrangements and accounting treatment of joint operations

1. Joint arrangements are divided into joint operations and joint ventures.

2. When the company is a joint venture party, the following items related to the interest share in the joint operation are recognized:

(1) Recognize assets held individually, and recognize assets held jointly based on holding shares;

(2) Recognize liabilities borne individually and liabilities borne jointly based on holding shares;

(3) Recognize the income generated from the sale of the company’s share of joint operating output;

(4) The income generated by the joint operation from the sale of assets is recognized based on the company’s share;

(5) Recognize the expenses incurred individually, and recognize the expenses incurred by joint operations based on the company’s holding share.

(9) Determination standards for cash and cash equivalents

The cash shown in the cash flow statement refers to cash on hand and deposits that can be used for payment at any time. Cash equivalents refer to short-term, highly liquid, and

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 108

Section 8 Financial Report

An investment that is easily convertible into a known amount of cash and which risks little risk of change in value.

(10) Foreign currency business and foreign currency statement conversion

1. Foreign currency business conversion

When foreign currency transactions are initially recognized, they are converted into RMB amounts using the approximate exchange rate of the spot exchange rate on the date of the transaction. On the balance sheet date, foreign currency monetary items are translated using the spot exchange rate on the balance sheet date. The exchange differences arising from different exchange rates, except for the exchange differences on the principal and interest of special foreign currency borrowings related to the acquisition and construction of assets that qualify for capitalization, are included in the current profit and loss; calculated at historical cost. Non-monetary items in foreign currencies are still translated at the approximate exchange rate of the spot exchange rate on the date of the transaction, without changing their RMB amounts; non-monetary items in foreign currencies measured at fair value are translated at the spot exchange rate on the date when the fair value is determined, and the difference is included in the current profit or loss or other comprehensive income.

2. Translation of foreign currency financial statements

Assets and liability items in the balance sheet are translated using the spot exchange rate on the balance sheet date; owners' equity items, except for "undistributed profits" items, are translated using the spot exchange rate on the date of the transaction; income and expense items in the income statement are translated using the approximate exchange rate of the spot exchange rate on the date of the transaction. The translation difference of foreign currency financial statements arising from the above translation shall be included in other comprehensive income.

(11) Financial instruments

1. Classification of financial assets and financial liabilities

Financial assets are divided into the following three categories upon initial recognition: (1) Financial assets measured at amortized cost; (2) Financial assets measured at fair value with changes included in other comprehensive income; (3) Financial assets measured at fair value with changes included in current profits and losses.

Financial liabilities are divided into the following four categories upon initial recognition: (1) Financial liabilities measured at fair value and whose changes are included in current profits and losses; (2) Financial liabilities formed when the transfer of financial assets does not meet the conditions for derecognition or continued involvement in the transferred financial assets; (3) Financial guarantee contracts that do not belong to the above (1) or (2), and loan commitments that do not belong to the above (1) and provide loans at lower than market interest rates; (4) Financial liabilities measured at amortized cost.

2. Recognition basis, measurement method and derecognition conditions of financial assets and financial liabilities

(1) Recognition basis and initial measurement method of financial assets and financial liabilities

When a company becomes a party to a financial instrument contract, it recognizes a financial asset or financial liability. When financial assets or financial liabilities are initially recognized, they are measured at fair value; for financial assets and financial liabilities measured at fair value and whose changes are included in current profits and losses, relevant transaction costs are directly included in current profits and losses; for other types of financial assets or financial liabilities, relevant transaction costs are included in the initial recognition amount. However, if the company's initial recognition of accounts receivable does not contain a significant financing component or the company does not consider the financing component of a contract that does not exceed one year, the initial measurement shall be based on the transaction price defined in "Accounting Standards for Business Enterprises No. 14 - Revenue".

(2) Subsequent measurement method of financial assets

1. Financial assets measured at amortized cost

The actual interest rate method is adopted and subsequent measurement is carried out based on amortized cost. Gains or losses arising from financial assets that are measured at amortized cost and are not part of any hedging relationship are included in the current profit and loss when derecognized, reclassified, amortized according to the effective interest method, or impairment is recognized.

2. Debt instrument investments measured at fair value and changes included in other comprehensive income

Fair value is used for subsequent measurement. Interest, impairment losses or gains and exchange gains and losses calculated using the effective interest rate method are included in the current profit and loss, and other gains or losses are included in other comprehensive income. When derecognition is terminated, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in the current profit and loss.

3. Equity instrument investments measured at fair value and changes included in other comprehensive income

Fair value is used for subsequent measurement. Dividends received (except for the recovery part of investment costs) are included in the current profits and losses, and other gains or losses are included in other comprehensive income. Upon derecognition, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in retained earnings.

4. Financial assets measured at fair value and changes included in current profits and losses

Fair value is used for subsequent measurement, and the resulting gains or losses (including interest and dividend income) are included in the current profit or loss, unless the financial asset is part of a hedging relationship.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 109

Section 8 Financial Report

(3) Subsequent measurement method of financial liabilities

1. Financial liabilities measured at fair value and changes included in current profits and losses

Such financial liabilities include trading financial liabilities (including derivatives that are financial liabilities) and financial liabilities designated as measured at fair value with changes included in current profits and losses. Such financial liabilities are subsequently measured at fair value. The amount of changes in the fair value of financial liabilities designated as at fair value through profit or loss due to changes in the company's own credit risk is included in other comprehensive income, unless such treatment would cause or expand accounting mismatches in profit or loss. Other gains or losses arising from such financial liabilities (including interest expenses, excluding changes in fair value caused by changes in the company's own credit risk) are included in the current profits and losses, unless the financial liabilities are part of a hedging relationship. Upon derecognition, the accumulated gains or losses previously included in other comprehensive income will be transferred out of other comprehensive income and included in retained earnings.

2. Financial liabilities arising from the transfer of financial assets that do not meet the conditions for derecognition or continued involvement in the transferred financial assets

Measurement shall be carried out in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets".

3. Financial guarantee contracts that do not fall under 1) or 2) above, and loan commitments that do not fall under 1) above and provide loans at lower than market interest rates

After initial recognition, subsequent measurement shall be carried out according to the higher of the following two amounts: ① The amount of loss provision determined in accordance with the impairment regulations of financial instruments; ② The balance after the initial recognition amount deducts the accumulated amortization amount determined in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 14 - Revenue".

4. Financial liabilities measured at amortized cost

Measured at amortized cost using the effective interest method. Gains or losses arising from financial liabilities that are measured at amortized cost and are not part of any hedging relationship are included in the current profit and loss when they are derecognized and amortized according to the effective interest method.

(4) Derecognition of financial assets and financial liabilities

1. Financial assets are derecognised when one of the following conditions is met:

① The contractual right to receive cash flows from financial assets has terminated;

② The financial assets have been transferred, and the transfer meets the provisions of "Accounting Standards for Business Enterprises No. 23 - Transfer of Financial Assets" regarding the derecognition of financial assets.

2. When the current obligation of a financial liability (or part thereof) has been discharged, the financial liability (or part thereof) shall be derecognised accordingly.

3. Recognition basis and measurement method of financial asset transfer

If the company transfers almost all the risks and rewards of the ownership of the financial asset, it shall terminate the recognition of the financial asset, and separately recognize the rights and obligations arising or retained in the transfer as assets or liabilities; if it retains almost all the risks and rewards of the ownership of the financial asset, it shall continue to recognize the transferred financial asset. If the company neither transfers nor retains substantially all the risks and rewards of ownership of a financial asset, the following situations will apply: (1) If it does not retain control over the financial asset, the financial asset will be derecognised, and the rights and obligations arising or retained in the transfer will be separately recognized as assets or liabilities; (2) If it retains control over the financial asset, the relevant financial assets will be recognized to the extent of its continued involvement in the transferred financial assets, and the relevant liabilities will be recognized accordingly.

If the overall transfer of a financial asset meets the conditions for derecognition, the difference between the following two amounts will be included in the current profit and loss: (1) The book value of the transferred financial asset on the date of derecognition; (2) The sum of the consideration received for the transfer of the financial asset and the amount corresponding to the derecognition part of the cumulative amount of changes in fair value that was originally directly included in other comprehensive income (the financial assets involved are debt instrument investments measured at fair value and their changes are included in other comprehensive income). If a part of a financial asset is transferred, and the transferred part as a whole meets the conditions for derecognition, the entire book value of the financial asset before transfer will be apportioned between the derecognized part and the continued recognition part according to their respective relative fair values on the date of transfer, and the difference between the following two amounts shall be included in the current profit and loss: (1) The book value of the derecognized part; (2) The consideration for the derecognition part is the sum of the amount corresponding to the derecognition part of the cumulative amount of changes in fair value that was originally directly included in other comprehensive income (the financial assets involved in the transfer are debt instrument investments that are measured at fair value and their changes are included in other comprehensive income).

4. Determination method of fair value of financial assets and financial liabilities

The company determines the fair value of relevant financial assets and financial liabilities using valuation techniques that are applicable under the current circumstances and supported by sufficient available data and other information. The company divides the input values used in the valuation technology into the following levels and uses them in sequence:

(1) The first level input value is the unadjusted quoted price in an active market for the same asset or liability that can be obtained on the measurement date;

(2) The second level input value is the directly or indirectly observable input value of the relevant assets or liabilities in addition to the first level input value, including: quotations of similar assets or liabilities in active markets; quotations of the same or similar assets or liabilities in inactive markets; other observable input values other than quotations, such as interest rates and yield curves that are observable during normal quotation intervals; market verification input values, etc.;

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 110

Section 8 Financial Report

(3) The third level input value is the unobservable input value of the relevant assets or liabilities, including interest rates that cannot be directly observed or cannot be verified by observable market data, stock volatility, future cash flows of abandonment obligations assumed in business combinations, financial forecasts made using its own data, etc.

5. Impairment of financial instruments

Based on expected credit losses, the company calculates financial assets measured at amortized cost, debt instrument investments measured at fair value with changes included in other comprehensive income, contract assets, lease receivables, and financial liabilities classified as measured at fair value with changes included in current profits and losses. Other than loan commitments, financial liabilities that are not measured at fair value through profit or loss, or financial guarantee contracts that are not financial liabilities arising from the transfer of financial assets that do not meet the conditions for derecognition or that continue to be involved in the transferred financial assets are subject to impairment treatment and loss provisions are recognized.

Expected credit losses refer to the weighted average of the credit losses of financial instruments with the risk of default as the weight. Credit loss refers to the difference between all contractual cash flows receivable under the contract and all cash flows expected to be received by the company, discounted at the original effective interest rate, that is, the present value of all cash shortfalls. Among them, credit-impaired financial assets purchased or originated by the company are discounted according to the credit-adjusted actual interest rate of the financial assets.

For purchased or originated financial assets that have suffered credit impairment, the company will only recognize the cumulative change in expected credit losses during the entire duration since initial recognition as loss provisions on the balance sheet date.

For lease receivables, receivables and contract assets formed by transactions regulated by "Accounting Standards for Business Enterprises No. 14 - Revenue", the company uses simplified measurement methods and measures loss provisions based on an amount equivalent to the expected credit losses during the entire duration.

For financial assets other than the above measurement methods, the company evaluates at each balance sheet date whether its credit risk has increased significantly since initial recognition. If the credit risk has increased significantly since the initial recognition, the company will measure the loss provision based on the amount of expected credit losses during the entire duration; if the credit risk has not increased significantly since the initial recognition, the company will measure the loss provisions based on the amount of expected credit losses of the financial instrument in the next 12 months.

The Company uses reasonable and evidence-based information available, including forward-looking information, to determine whether the credit risk of a financial instrument has increased significantly since initial recognition by comparing the risk of default on the financial instrument on the balance sheet date with the risk of default on the initial recognition date.

On the balance sheet date, if the company determines that a financial instrument has only low credit risk, it is assumed that the credit risk of the financial instrument has not increased significantly since initial recognition.

The company assesses expected credit risk and measures expected credit losses on the basis of a single financial instrument or a combination of financial instruments. When based on a portfolio of financial instruments, the company divides financial instruments into different portfolios based on common risk characteristics.

The company remeasures expected credit losses on each balance sheet date, and the resulting increase or reversal of loss provisions is included in the current profit and loss as impairment losses or gains. For financial assets measured at amortized cost, the loss provision is deducted from the book value of the financial asset listed in the balance sheet; for debt investments measured at fair value with changes included in other comprehensive income, the company recognizes its loss provision in other comprehensive income and does not deduct the book value of the financial asset.

6. Offset of financial assets and financial liabilities

Financial assets and financial liabilities are presented separately in the balance sheet and do not offset each other. However, if the following conditions are met at the same time, the company will present the net amount after offsetting each other in the balance sheet: (1) The company has the legal right to offset the recognized amount, and the legal right is currently enforceable; (2) The company plans to settle on a net basis, or realize the financial assets and pay off the financial liabilities at the same time.

For transfers of financial assets that do not meet the conditions for derecognition, the company will not offset the transferred financial assets and related liabilities.

(12) Accounts receivable

1. Accounts receivable with expected credit losses based on combination of credit risk characteristics

Portfolio category Basis for determining portfolio Method for measuring expected credit losses

Referring to historical credit loss experience, combined with current conditions and predictions of future economic conditions, bank/commercial acceptance bills receivable through default risk Note types

Exposure and lifetime expected credit loss rate, calculate expected credit losses

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 111

Section 8 Financial Report

With reference to historical credit loss experience, combined with current conditions and predictions of future economic conditions, prepare accounts receivable - aging portfolio Aging

Comparison table of aging and expected credit loss rate to calculate expected credit losses

Accounts receivable - receivable from the Company. With reference to historical credit loss experience, combined with current conditions and predictions of future economic conditions, expected credit losses are calculated through the nature of accounts, exposure, and the expected credit loss rate within the next 12 months or the entire duration of the related party portfolio within the default risk department's consolidated scope.

With reference to historical credit loss experience, combined with current conditions and predictions of future economic conditions, prepare a comparison table of other receivables and expected credit loss rates to calculate expected credit losses.

Other receivables - receivables from the Company refer to historical credit loss experience, combined with current conditions and predictions of future economic conditions, through default risk

Nature of payment

Calculate the expected credit losses based on the exposure of the related party portfolio within the scope of the company's consolidation and the expected credit loss rate in the next 12 months or the entire duration.

2. Comparison table of aging portfolio and expected credit loss rate

Aging Accounts receivable Expected credit loss rate (%) Other receivables Expected credit loss rate (%)

Within 1 year (inclusive, the same below) 5.00 5.00 1-2 years 7.00 7.00 2-3 years 15.00 15.00 3-4 years 30.00 30.00 4-5 years 50.00 50.00 More than 5 years 100.00 100.00 The aging of accounts receivable and other receivables is calculated from the initial confirmation date.

3. Recognition standards for accounts receivable for which expected credit losses are accrued individually

For receivables whose credit risk is significantly different from the combined credit risk, the company accrues expected credit losses on an individual basis.

(13) Contract assets

Companies present contract assets or contract liabilities on their balance sheets based on the relationship between the fulfillment of performance obligations and payments from customers. The company will present the net amount after offsetting contract assets and contract liabilities under the same contract.

The Company presents the right to receive consideration from customers that is unconditional (i.e., dependent only on the passage of time) as receivables and the right to receive consideration for goods transferred to the customer (that right is dependent on factors other than the passage of time) as a contract asset.

(14) Inventory

1. Classification of inventory

Inventories include finished products or commodities held for sale in daily activities, work-in-progress in the production process, materials and supplies consumed in the production process or in the process of providing services, etc.

2. Valuation method for issued inventory

Inventories are issued using the weighted average method at the end of the month.

3. Inventory inventory system

The inventory system of inventories is the perpetual inventory system.

4. Amortization method for low-value consumables and packaging materials

(1) Low value consumables

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 1112

Section 8 Financial Report

Amortization is carried out using the one-time write-off method.

(2) Packaging

Amortization is carried out using the one-time write-off method.

5. Provision for inventory decline

On the balance sheet date, inventories are measured at the lower of cost and net realizable value, and inventory depreciation provisions are made based on the difference between cost and net realizable value. For inventories that are directly used for sale, the net realizable value is determined by the estimated selling price of the inventory minus the estimated sales expenses and related taxes in the normal production and operation process; for inventories that need to be processed, the estimated selling price of the finished products produced during the normal production and operation process is deducted by the estimated costs to be incurred upon completion. The amount after the estimated sales expenses and related taxes is determined to determine its net realizable value; on the balance sheet date, if part of the same inventory has a contract price and other parts do not have a contract price, its net realizable value is determined separately and compared with its corresponding cost to determine the amount of provision or reversal of inventory depreciation provisions.

(15) Long-term equity investment

1. Judgment of joint control and significant influence

If there is shared control over an arrangement in accordance with relevant agreements, and the relevant activities of the arrangement must be decided with the unanimous consent of the parties sharing control rights, it is deemed to be joint control. Having the power to participate in decision-making on the financial and operating policies of the investee, but not being able to control or jointly control the formulation of these policies with other parties, is deemed to have significant influence.

2. Determination of investment cost

(1) Formed through a merger of enterprises under common control, if the merging party pays cash, transfers non-cash assets, assumes debts or issues equity securities as the merger consideration, the initial investment cost shall be the share of the book value of the owner's equity of the merged party in the consolidated financial statements of the ultimate controlling party on the date of merger. The difference between the initial investment cost of the long-term equity investment and the book value of the merger consideration paid or the total face value of the shares issued is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

The company realizes the long-term equity investment formed by the merger of enterprises under the same control step by step through multiple transactions to determine whether it is a "package transaction". If it belongs to a "package transaction", each transaction shall be accounted for as a transaction that obtains control. If it does not belong to a "package deal", on the merger date, the initial investment cost will be determined based on the share of the book value of the combined party's net assets in the ultimate controlling party's consolidated financial statements that should be enjoyed after the merger. The difference between the initial investment cost of the long-term equity investment on the merger date and the book value of the long-term equity investment before the merger plus the book value of the new payment for further shares acquired on the merger date is adjusted to the capital reserve; if the capital reserve is insufficient for offset, the retained earnings are adjusted.

(2) If it is formed by a business combination not under the same control, the fair value of the merger consideration paid on the purchase date shall be regarded as its initial investment cost.

The company realizes the long-term equity investment formed by the merger of enterprises not under common control step by step through multiple transactions, and distinguishes individual financial statements and consolidated financial statements for relevant accounting treatment:

1. In individual financial statements, the sum of the book value of the original equity investment plus the new investment cost is regarded as the initial investment cost that is calculated according to the cost method.

2. In the consolidated financial statements, determine whether it is a "package deal". If it belongs to a "package transaction", each transaction shall be accounted for as a transaction that obtains control. If it does not belong to a "package transaction", the equity of the purchased party held before the purchase date will be remeasured according to the fair value of the equity on the purchase date, and the difference between the fair value and its book value will be included in the investment income of the current period; if the equity of the purchased party held before the purchase date involves other comprehensive income under equity method accounting, the other comprehensive income related to it will be converted into the current period income on the purchase date. However, other comprehensive income arising from changes in the net liabilities or net assets of the defined benefit plan due to the remeasurement of the investee is excluded.

(3) Except for business mergers: if it is obtained by paying cash, the actual purchase price paid will be used as its initial investment cost; if it is obtained by issuing equity securities, its initial investment cost will be based on the fair value of the equity securities issued; if it is obtained by debt restructuring, its initial investment cost will be determined according to "Accounting Standards for Business Enterprises No. 12 - Debt Reorganization"; if it is obtained by exchanging non-monetary assets, its initial investment cost will be determined according to "Accounting Standards for Business Enterprises No. 7 - Exchange of Non-monetary Assets".

3. Subsequent measurement and profit and loss recognition methods

Long-term equity investments that control the invested unit are accounted for using the cost method; long-term equity investments in associates and joint ventures are accounted for using the equity method.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 113

Section 8 Financial Report

4. Methods for disposing of investment in subsidiaries step by step through multiple transactions until loss of control

(1) Principles for judging whether it belongs to a “package deal”

If the equity investment in a subsidiary is disposed of in stages through multiple transactions until it loses control, the company shall determine whether the step-by-step transaction is a "package transaction" based on the transaction agreement terms of each step of the step-by-step transaction, the disposal consideration obtained respectively, the object of the equity sale, the disposal method, the time of disposal, and other information. If the terms, conditions and economic impact of each transaction meet one or more of the following conditions, it usually indicates that multiple transactions are a "package deal":

1. These transactions are entered into at the same time or with consideration of mutual effects;

2. These transactions as a whole can achieve a complete business result;

3. The occurrence of one transaction depends on the occurrence of at least one other transaction;

4. A transaction is uneconomical on its own but is economical when considered together with other transactions.

(2) Accounting treatment that does not belong to “package transaction”

1. Individual financial statements

For the equity disposed of, the difference between its book value and the actual price obtained shall be included in the current profit and loss. For the remaining equity, if it still has a significant influence on the invested unit or exercises joint control with other parties, it will be converted to equity method accounting; if it can no longer exercise control, joint control or significant influence on the invested unit, it will be accounted for in accordance with the relevant provisions of "Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments".

2. Consolidated financial statements

Before the loss of control, the difference between the disposal price and the share of the subsidiary's net assets corresponding to the disposal of the long-term equity investment continuously calculated from the date of purchase or merger will be adjusted to the capital reserve (capital premium). If the capital premium is insufficient to offset, the retained earnings will be offset.

When control over the atomic company is lost, the remaining equity will be remeasured according to its fair value on the date of loss of control. The difference between the sum of the consideration obtained for disposing of the equity and the fair value of the remaining equity, minus the share of the original subsidiary's net assets calculated continuously from the date of purchase or merger based on the original shareholding ratio, shall be included in the investment income for the period when control is lost, and goodwill shall be offset at the same time. Other comprehensive income related to the equity investment in the original subsidiary shall be converted into investment income for the current period when control is lost.

(3) Accounting treatment for “package transactions”

1. Individual financial statements

Each transaction is accounted for as a transaction in which a subsidiary is disposed of and control is lost. However, the difference between the price of each disposal before the loss of control and the book value of the long-term equity investment corresponding to the disposal investment is recognized as other comprehensive income in individual financial statements, and is transferred to the profit and loss of the current period when control is lost.

2. Consolidated financial statements

Each transaction is accounted for as a transaction in which a subsidiary is disposed of and control is lost. However, before the loss of control, the difference between the price of each disposal and the share of the subsidiary's net assets corresponding to the disposal investment is recognized as other comprehensive income in the consolidated financial statements, and is transferred to the profits and losses of the current period when the control is lost.

(16) Investment real estate

Investment real estate measurement model

Cost method measurement

Depreciation or amortization method

1. Investment real estate includes leased land use rights, land use rights held and prepared to be transferred after appreciation, and leased buildings.

2. Investment real estate is initially measured according to cost, and subsequently measured using the cost model, and depreciation or amortization is calculated using the same methods as fixed assets and intangible assets.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 114

Section 8 Financial Report

(17) Fixed assets

1. Confirm conditions

Fixed assets refer to tangible assets held for the production of goods, provision of labor services, leasing or operation and management, and with a useful life of more than one accounting year. Fixed assets are recognized when it is likely that economic benefits will flow in and the cost can be measured reliably.

2. Depreciation method

Category Depreciation method Depreciation life Residual value rate Annual depreciation rate

Houses and buildings Average age method 20-50 0-10.00 1.80-5.00 General equipment Average age method 3-10 5.00-10.00 9.00-31.67 Special equipment Average age method 3-10 5.00-10.00 9.00-31.67 Transportation Mean age method 3-10 5.00-10.00 9.00-31.67 Land Others Unlimited —— ——

(18) Projects under construction

1. Construction in progress is recognized when it is likely that economic benefits will flow in and the cost can be measured reliably. Construction in progress is measured based on the actual costs incurred before the asset reaches its intended usable condition.

2. When the project under construction reaches the intended usable state, it will be transferred to fixed assets according to the actual cost of the project. If the asset has reached the intended usable state but has not yet completed the final settlement, the estimated value will be transferred to fixed assets first. After the final settlement is completed, the original temporary estimated value will be adjusted according to the actual cost, but the originally accrued depreciation will not be adjusted.

Category Standards and timing for transferring construction in progress to fixed assets

The main construction project and supporting projects of houses and buildings have been substantially completed, met the predetermined design requirements, and the machinery and equipment have been inspected and accepted. After installation and commissioning, they have reached the design requirements or the standards stipulated in the contract.

(19) Borrowing costs

1. Recognition principles for capitalization of borrowing costs

If the borrowing costs incurred by the company can be directly attributed to the purchase, construction or production of assets that meet the capitalization conditions, they shall be capitalized and included in the cost of the relevant assets; other borrowing costs shall be recognized as expenses when incurred and included in the current profits and losses.

2. Capitalization period of borrowing costs

(1) Capitalization begins when borrowing costs meet the following conditions at the same time: 1) Asset expenditures have occurred; 2) Borrowing costs have been incurred; 3) The purchase, construction or production activities necessary to bring the asset to its intended usable or salable state have begun.

(2) If an asset that meets the capitalization conditions is abnormally interrupted during the acquisition, construction or production process, and the interruption lasts for more than 3 months, the capitalization of borrowing costs is suspended; the borrowing costs incurred during the interruption are recognized as current expenses until the acquisition, construction or production activities of the asset are restarted.

(3) When the assets purchased, constructed or produced that meet the capitalization conditions reach the intended usable or salable state, the capitalization of borrowing costs ceases.

3. Capitalization rate and capitalization amount of borrowing costs

If a special loan is borrowed for the purpose of purchasing, constructing or producing assets that meet the capitalization conditions, the interest expenses actually incurred on the special loan in the current period (including those determined according to the actual interest rate method)

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 115

Section 8 Financial Report

The amount of interest that should be capitalized is determined by deducting the interest income from depositing the unused borrowed funds in the bank or the investment income from temporary investment. If general borrowings are occupied for the purchase, construction or production of assets that meet the capitalization conditions, the amount of interest that should be capitalized on general borrowings is calculated and determined based on the weighted average of the accumulated asset expenditures exceeding the special borrowing multiplied by the capitalization rate of the general borrowings.

(20) Intangible assets

1. Useful life and its determination basis, estimation, amortization method or review procedure

(1) Intangible assets include land use rights, office software, patent rights, non-patented technology and coal use rights, etc., which are initially measured at cost.

(2) Intangible assets with limited service life shall be amortized systematically and reasonably within the service life according to the expected realization method of the economic benefits related to the intangible asset. If the expected realization method cannot be reliably determined, the straight-line method shall be used for amortization. The details are as follows:

Item Useful life and basis for determination Amortization method

Land use rights have a service life of 50 years based on the property rights registration period. Straight-line method office software has a service life of 3-10 years based on the expected benefit period. Straight-line method patent rights are amortized evenly based on the legal validity period and the expected useful life of 10 years. Straight-line method coal use rights are amortized evenly based on the expected useful life of 10 years. Straight-line method

2. Scope of aggregation of R&D expenditures and related accounting treatment methods

(1) Scope of collection of R&D expenditures

1. Personnel labor costs

Personnel labor expenses include the wages and salaries of the company's R&D personnel, basic pension insurance premiums, basic medical insurance premiums, unemployment insurance premiums, work-related injury insurance premiums, maternity insurance premiums and housing provident funds, as well as labor costs for external R&D personnel.

If R&D personnel serve multiple R&D projects at the same time, labor costs will be recognized based on the working hours records of R&D personnel for each R&D project provided by the company's management department, and will be allocated proportionally among different R&D projects.

For those who are directly engaged in R&D activities or external R&D personnel who are also engaged in non-R&D activities, the company will allocate the actual labor costs incurred by the R&D personnel between R&D expenses and production and operating expenses based on reasonable methods such as the proportion of actual working hours based on the R&D personnel’s working time records in different positions.

2. Direct investment costs

Direct investment expenses refer to the actual expenditures incurred by the company to implement research and development activities. Including: ① direct consumption of materials, fuel and power costs; ② mold, process equipment development and manufacturing costs for intermediate testing and product trial production, purchase costs for samples, prototypes and general testing means that do not constitute fixed assets, and inspection fees for trial products; ③ operation and maintenance, adjustment, inspection, detection, repair and other costs of instruments and equipment used for research and development activities.

3. Depreciation expenses and long-term prepaid expenses

Depreciation expenses refer to the depreciation expenses of instruments, equipment and buildings in use used for research and development activities.

If instruments, equipment, and buildings in use are used for R&D activities and are also used for non-R&D activities, necessary records shall be made of the use of such instruments, equipment, and buildings in use, and the actual depreciation expenses incurred shall be allocated between R&D expenses and production and operating expenses in a reasonable manner based on factors such as actual working hours and usage area.

Long-term deferred expenses refer to the long-term deferred expenses incurred during the reconstruction, modification, decoration and repair of R&D facilities. They are collected based on actual expenditures and amortized evenly in installments within the specified period.

4. Amortization expense of intangible assets

Amortization expenses of intangible assets refer to the amortization expenses of software, intellectual property, non-patented technology (proprietary technology, licenses, design and calculation methods, etc.) used in research and development activities.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 116

Section 8 Financial Report

5. Design fee

Design expenses refer to the expenses incurred in conceiving, developing and manufacturing new products and new processes, and designing processes, technical specifications, procedures, operating characteristics, etc., including expenses related to creative design activities to obtain innovative, creative, and breakthrough products.

6. Equipment debugging and testing costs

Equipment debugging costs refer to the costs incurred in research and development activities during tooling preparation, including costs incurred in developing special and dedicated production machines, changing production and quality control procedures, or formulating new methods and standards.

Expenses incurred for routine tooling preparation and industrial engineering for large-scale batch and commercial production are not included in the scope of the collection.

7. Commissioned external research and development expenses

Entrusted external research and development expenses refer to the expenses incurred by the company entrusting other institutions or individuals at home and abroad to conduct research and development activities (the results of research and development activities are owned by the company and are closely related to the company's main business).

8. Other expenses

Other expenses refer to other expenses directly related to research and development activities in addition to the above expenses, including technical book materials fees, data translation fees, expert consultation fees, high-tech R&D insurance fees, retrieval, demonstration, review, identification, and acceptance fees for R&D results, application fees, registration fees, agency fees for intellectual property rights, conference fees, travel expenses, communication fees, etc.

(2) Expenditures in the research phase of internal research and development projects shall be included in the current profits and losses when incurred.

Expenditures in the development phase of internal research and development projects are recognized as intangible assets if they meet the following conditions: (1) It is technically feasible to complete the intangible asset so that it can be used or sold; (2) There is the intention to complete the intangible asset and use or sell it; (3) The way in which the intangible asset generates economic benefits includes being able to prove that there is a market for the products produced using the intangible asset or that the intangible asset itself has a market. If the intangible asset will be used internally, its usefulness can be proven; (4) It has sufficient technical, financial and other resource support to complete the development of the intangible asset and has the ability to use or sell the intangible asset; (5) Expenditures attributable to the development stage of the intangible asset can be measured reliably.

(21) Impairment of long-term assets

For long-term equity investments, investment properties measured using the cost model, fixed assets, projects under construction, right-of-use assets, intangible assets with limited useful lives and other long-term assets, if there are signs of impairment on the balance sheet date, the recoverable amount is estimated. Goodwill and intangible assets with indefinite useful lives formed due to business combinations are subject to impairment testing every year regardless of whether there are signs of impairment. Goodwill is tested for impairment in combination with its related asset groups or combinations of asset groups.

If the recoverable amount of the above-mentioned long-term assets is lower than its book value, the asset impairment provision shall be recognized based on the difference and included in the current profit and loss.

(22) Long-term deferred expenses

Long-term deferred expenses are calculated as expenses that have been spent and have an amortization period of more than 1 year (excluding 1 year). Long-term deferred expenses are recorded according to the actual amount incurred, and are amortized evenly over the benefit period or a specified period. If a long-term deferred expense item cannot benefit future accounting periods, all the amortized value of the item that has not been amortized will be transferred to the current profit and loss.

(23) Contract liabilities

Companies present contract assets or contract liabilities on their balance sheets based on the relationship between the fulfillment of performance obligations and payments from customers. The company will present the net amount after offsetting contract assets and contract liabilities under the same contract.

The Company presents obligations to transfer goods to customers for consideration received or receivable from customers as contract liabilities.

(24) Employee compensation

1. Accounting treatment of short-term compensation

During the accounting period when employees provide services to the company, the actual short-term compensation is recognized as a liability and included in the current profit and loss or related asset costs.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 117

Section 8 Financial Report

2. Accounting treatment of post-employment benefits

Post-employment benefits are divided into defined contribution plans and defined benefit plans.

(1) During the accounting period when employees provide services to the company, the deposit amount payable calculated according to the defined contribution plan is recognized as a liability and included in the current profit and loss or related asset costs.

(2) The accounting treatment of defined benefit plans usually includes the following steps:

1. Based on the expected cumulative benefit unit method, use unbiased and mutually consistent actuarial assumptions to estimate relevant demographic variables and financial variables, measure the obligations arising from the defined benefit plan, and determine the period to which the relevant obligations belong. At the same time, the obligations arising from the defined benefit plan are discounted to determine the present value of the defined benefit plan obligations and the current service cost;

2. If there are assets in the defined benefit plan, the deficit or surplus formed by deducting the present value of the defined benefit plan obligations from the fair value of the defined benefit plan assets is recognized as a net liability or net asset of the defined benefit plan. If a defined benefit plan has a surplus, the net assets of the defined benefit plan shall be measured at the lower of the surplus of the defined benefit plan and the asset upper limit;

3. At the end of the period, the employee compensation costs generated by the defined benefit plan are recognized as service costs, net interest on the net liabilities or net assets of the defined benefit plan, and changes caused by remeasurement of the net liabilities or net assets of the defined benefit plan. Among them, service costs and net liabilities or net assets of the defined benefit plan are The net interest is included in the current profit and loss or related asset costs, and the changes resulting from the remeasurement of the net liabilities or net assets of the defined benefit plan are included in other comprehensive income, and are not allowed to be transferred back to profit or loss in subsequent accounting periods, but these amounts recognized in other comprehensive income can be transferred within the scope of equity.

3. Accounting treatment of dismissal benefits

For dismissal benefits provided to employees, the employee compensation liabilities arising from the dismissal benefits are recognized and included in the current profit and loss at the earliest of the following two situations: (1) when the company cannot unilaterally withdraw the dismissal benefits provided due to the termination of labor relations plan or layoff proposal; (2) when the company recognizes costs or expenses related to the restructuring involving the payment of dismissal benefits.

4. Accounting treatment methods for other long-term employee benefits

Other long-term benefits provided to employees that meet the conditions of the defined contribution plan shall be accounted for in accordance with the relevant provisions of the defined contribution plan; other long-term benefits shall be accounted for in accordance with the relevant provisions of the defined benefit plan. In order to simplify the relevant accounting treatment, the employee compensation costs incurred are recognized as service costs, net interest on other long-term employee benefit net liabilities or net assets, and the total net amount of the changes resulting from the remeasurement of other long-term employee benefit net liabilities or net assets shall be included in the current profit and loss or related asset costs.

(25) Estimated liabilities

1. Obligations resulting from contingencies such as external guarantees, litigation matters, product quality guarantees, loss-making contracts, etc., become current obligations borne by the company. When the performance of the obligation is likely to cause economic benefits to flow out of the company, and the amount of the obligation can be reliably measured, the company will recognize the obligation as an estimated liability.

2. The company initially measures estimated liabilities based on the best estimate of the expenditure required to fulfill relevant current obligations, and reviews the book value of estimated liabilities on the balance sheet date.

(26) Share-based payment

(1) Types of share-based payment

Including equity-settled share-based payments and cash-settled share-based payments.

(2) Accounting treatments related to the implementation, modification, and termination of share-based payment plans

1. Equity-settled share-based payment

Equity-settled share-based payments that become exercisable immediately after grant in exchange for employee services will be included in relevant costs or expenses based on the fair value of the equity instrument on the date of grant, and the capital reserve will be adjusted accordingly. For equity-settled share-based payments in exchange for employee services that are vested upon completion of services within the waiting period or upon meeting specified performance conditions, on each balance sheet date during the waiting period, based on the best estimate of the number of exercisable equity instruments and the fair value on the date of grant of the equity instrument, the services obtained in the current period are included in the relevant costs or expenses, and the capital reserve is adjusted accordingly.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 118

Section 8 Financial Report

For equity-settled share-based payments in exchange for services from other parties, if the fair value of the other party's services can be reliably measured, it will be measured based on the fair value of the other party's services on the date of acquisition; if the fair value of the other party's services cannot be reliably measured, but the fair value of the equity instrument can be measured reliably, it will be measured based on the fair value of the equity instrument on the date of service acquisition, and the relevant costs or expenses will be included, and the owner's equity will be increased accordingly.

(2) Cash-settled share-based payment

Cash-settled share-based payments that are exercisable immediately after grant in exchange for employee services will be included in relevant costs or expenses based on the fair value of the company's liabilities on the date of grant, with corresponding increases in liabilities. For cash-settled share-based payments in exchange for employee services that are vested upon completion of services within the waiting period or upon meeting specified performance conditions, on each balance sheet date during the waiting period, based on the best estimate of the vesting situation and the fair value of the liabilities borne by the company, the services obtained in the current period are included in the relevant costs or expenses and corresponding liabilities.

(3) Modification and termination of share-based payment plan

If the modification increases the fair value of the equity instruments granted, the company will recognize the increase in the services obtained according to the increase in the fair value of the equity instruments; if the modification increases the number of equity instruments granted, the company will recognize the increased fair value of the equity instruments as an increase in the services obtained accordingly; if the company modifies the vesting conditions in a way that is beneficial to employees, the company will consider the modified vesting conditions when processing the vesting conditions.

If the modification reduces the fair value of the equity instruments granted, the company will continue to recognize the amount of services obtained based on the fair value of the equity instruments on the date of grant, regardless of the decrease in the fair value of the equity instruments; if the modification reduces the number of equity instruments granted, the company will treat the reduction as the cancellation of the equity instruments granted; if the vesting conditions are modified in a way that is unfavorable to employees, the modified vesting conditions will not be considered when processing the vesting conditions.

If the company cancels the granted equity instruments or settles the granted equity instruments during the waiting period (except for cancellation due to failure to meet vesting conditions), the cancellation or settlement will be treated as accelerated vesting, and the amount originally recognized during the remaining waiting period will be immediately recognized.

(27) Income

Disclose accounting policies adopted for revenue recognition and measurement by business type

(1) Revenue recognition principle

On the contract commencement date, the company evaluates the contract, identifies each individual performance obligation contained in the contract, and determines whether each individual performance obligation is to be performed within a certain period of time or at a certain point in time.

When one of the following conditions is met, the performance obligation is fulfilled within a certain period of time; otherwise, the performance obligation is fulfilled at a certain point in time: 1) The customer obtains and consumes the economic benefits brought by the company's performance while the company performs the contract; 2) The customer is able to control the goods under construction during the company's performance; 3) The goods produced during the company's performance have irreplaceable uses, and the company has the right to collect payment for the cumulative performance part that has been completed during the entire contract period.

For performance obligations performed within a certain period of time, the company recognizes revenue based on the performance progress within that period of time. When the progress of contract performance cannot be reasonably determined, if the costs incurred are expected to be compensated, revenue shall be recognized based on the amount of costs incurred until the progress of contract performance can be reasonably determined. For performance obligations fulfilled at a certain point in time, revenue is recognized at the point when the customer obtains control of the relevant goods or services. When judging whether the customer has obtained control of the goods, the company considers the following signs: 1) The company has a current right to receive payment for the goods, that is, the customer has a current payment obligation for the goods; 2) The company has transferred the legal ownership of the goods to the customer, that is, the customer has legal ownership of the goods; 3) The company has physically transferred the goods to the customer, that is, the customer has physical possession of the goods; 4) The company has transferred the main risks and rewards of ownership of the commodity to the customer, that is, the customer has obtained the main risks and rewards of ownership of the commodity; 5) the customer has accepted the commodity; 6) other indications that the customer has obtained control of the commodity.

(2) Income measurement principle

1. The company measures revenue based on the transaction price allocated to each individual performance obligation. The transaction price is the amount of consideration that the company expects to be entitled to receive for the transfer of goods or services to the customer, excluding amounts collected on behalf of third parties and amounts expected to be returned to the customer.

2. If there is variable consideration in the contract, the company determines the best estimate of the variable consideration based on the expected value or the most likely amount, but the transaction price including the variable consideration shall not exceed the amount at which a significant reversal of the accumulated recognized revenue is unlikely to occur when the relevant uncertainty is eliminated.

3. If there is a significant financing component in the contract, the company determines the transaction price based on the amount payable in cash when the customer obtains control of the goods or services. The difference between the transaction price and the contract consideration is amortized using the effective interest method during the contract period. On the contract start date, if the company expects that the interval between the customer's obtaining control of the goods or services and the customer's payment of the price will not exceed one year, it will not consider the significant financing component in the contract.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 119

Section 8 Financial Report

4. If the contract contains two or more performance obligations, the company will allocate the transaction price to each individual performance obligation based on the relative proportion of the standalone selling price of the goods promised by each individual performance obligation on the contract commencement date.

(3) Specific method of revenue recognition

When the company obtains control of the relevant goods or services, the company recognizes revenue based on the amount of consideration that it is expected to be entitled to receive.

1. Selling goods

The company sells personal protection products, rehabilitation care products and other products to buyers. When the buyer obtains control of the products, revenue is recognized based on the consideration amount that it is expected to be entitled to receive. Among them:

Domestic sales: The sales contract signed between the company and local customers usually stipulates that the time point for the transfer of control of the product is when the goods arrive and are signed for, or the customer completes door-to-door pickup. The company recognizes sales revenue at the point when the product arrives at the domestic customer or the customer completes door-to-door pickup and sign for delivery.

Overseas sales: The sales contracts signed between the company and most of its export customers usually stipulate that the time point for the transfer of control of the product is delivery on board the ship at the shipping port. Therefore, the company recognizes overseas sales revenue based on the time point when the product is shipped. The sales contracts signed between the Company and a small number of export customers stipulate that the time point for the transfer of control of the products is delivery after tax payment at the designated destination. For this part of the sales, the Company will recognize sales revenue after the products arrive at the destination and the signature is completed.

The credit period granted to customers by the Company usually does not exceed 180 days, which is consistent with industry practice and does not contain a major financing component.

2. Providing labor services

The company provides product transportation services to customers and recognizes revenue over a period of time based on the progress of completed services. The progress of completed services is determined based on the proportion of costs incurred to the estimated total costs. On the balance sheet date, the Company re-estimates the progress of completed services so that it can reflect changes in contract performance. If the contract price received or receivable by the company exceeds the labor services completed, the excess will be recognized as contract liabilities.

(28) Contract costs

The incremental costs incurred by the company to obtain the contract are expected to be recovered and are recognized as an asset as the contract acquisition cost. If the amortization period of the contract acquisition cost does not exceed one year, it will be directly included in the current profit and loss when incurred.

If the costs incurred by the company to fulfill the contract do not apply to the scope of relevant standards such as inventory, fixed assets or intangible assets and meet the following conditions at the same time, they will be recognized as an asset as the cost of contract performance:

1. The cost is directly related to a current or expected contract, including direct labor, direct materials, manufacturing overhead (or similar expenses), costs expressly borne by the customer, and other costs incurred solely because of the contract;

2. This cost increases the company’s future resources for fulfilling performance obligations;

3. The cost is expected to be recovered.

The company amortizes assets related to contract costs on the same basis as the revenue recognition of goods or services related to the assets, and includes them in the current profits and losses.

If the book value of an asset related to the contract cost is higher than the remaining consideration expected to be obtained from the transfer of the goods or services related to the asset minus the estimated costs to be incurred, the company will make an impairment provision for the excess and recognize it as an asset impairment loss. If the factors of impairment in the previous period subsequently change, so that the remaining consideration expected to be obtained from the transfer of the goods or services related to the asset minus the estimated costs to be incurred is higher than the book value of the asset, the asset impairment provision that has been originally accrued will be reversed and included in the current profit and loss, but the book value of the asset after the reversion shall not exceed the book value of the asset on the date of reversal if no impairment provision is made.

(29) Government subsidies

1. Government subsidies are recognized when the following conditions are met at the same time: (1) the company can meet the conditions attached to the government subsidy; (2) the company can receive the government subsidy. If the government subsidy is a monetary asset, it shall be measured according to the amount received or receivable. If the government subsidy is a non-monetary asset, it shall be measured at fair value; if the fair value cannot be obtained reliably, it shall be measured at the nominal amount.

2. Judgment basis and accounting treatment method for government subsidies related to assets

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 120

Section 8 Financial Report

Government documents stipulate that government subsidies used to purchase, construct or otherwise form long-term assets are classified as asset-related government subsidies. If the government documents are unclear, the judgment will be based on the basic conditions that must be met to obtain the subsidy. If the basic condition is the acquisition, construction or other means of forming long-term assets, it will be regarded as an asset-related government subsidy. Government subsidies related to assets are offset against the book value of the relevant assets or recognized as deferred income. If government subsidies related to assets are recognized as deferred income, they shall be included in profits and losses in installments according to a reasonable and systematic method within the useful life of the relevant assets. Government subsidies measured according to the nominal amount are directly included in the current profit and loss. If the relevant assets are sold, transferred, scrapped or damaged before the end of their useful life, the undistributed balance of relevant deferred income will be transferred to the profit and loss of the current period of asset disposal.

3. Judgment basis and accounting treatment method for government subsidies related to income

Government subsidies other than asset-related government subsidies are classified as income-related government subsidies. For government subsidies that contain both asset-related parts and income-related parts, it is difficult to distinguish whether they are asset-related or income-related, and are generally classified as income-related government subsidies. If government subsidies related to income are used to compensate for relevant costs, expenses or losses in the future period, they are recognized as deferred income. During the period when the relevant costs, expenses or losses are recognized, they are included in the current profits and losses or offset the relevant costs; if they are used to compensate for the relevant costs, expenses or losses that have already occurred, they are directly included in the current profits and losses or offset the relevant costs.

4. Government subsidies related to the company's daily operating activities shall be included in other income or offset related costs and expenses according to the economic business essence. Government subsidies that are not related to the company's daily activities are included in non-operating income and expenses.

5. Accounting treatment method for policy preferential loan interest discounts

If the finance department directly allocates interest discount funds to the company, the corresponding interest discount will be used to offset related borrowing costs.

(30) Deferred income tax assets/deferred income tax liabilities

1. Based on the difference between the book value of assets and liabilities and their tax basis (if the tax basis of items not recognized as assets and liabilities can be determined in accordance with tax laws, the difference between the tax basis and their book amount), deferred income tax assets or deferred income tax liabilities are calculated and recognized according to the applicable tax rate during the period when the asset is expected to be recovered or the liability is settled.

2. Deferred income tax assets are recognized to the extent that it is probable that the taxable income will be available to offset the deductible temporary differences. On the balance sheet date, if there is conclusive evidence that sufficient taxable income is likely to be obtained in the future period to offset the deductible temporary differences, deferred income tax assets that have not been recognized in previous accounting periods will be recognized.

3. On the balance sheet date, the book value of the deferred tax assets is reviewed. If it is likely that sufficient taxable income will not be available in the future period to offset the benefits of the deferred tax assets, the book value of the deferred tax assets will be written down. The amount of the write-down is reversed when it is probable that sufficient taxable income will be obtained.

4. The company's current income tax and deferred income tax are included in the current profit and loss as income tax expenses or income, but do not include income tax arising from the following situations: (1) business merger;

(2) Transactions or events directly recognized in owners’ equity.

5. When the following conditions are met at the same time, the company will present the deferred income tax assets and deferred income tax liabilities as the net amount after offsetting: (1) It has the legal right to settle the current income tax assets and current income tax liabilities on a net basis; (2) Deferred income tax assets and deferred income tax liabilities are related to the income tax levied by the same tax collection and administration department on the same taxable entity or to different taxable entities. However, in each future period when important deferred income tax assets and deferred income tax liabilities are reversed, the taxable entity involved intends to settle the current income tax assets and current income tax liabilities with a net amount or to obtain assets and pay off debts at the same time.

(31) Leasing

1. Accounting treatment of lease as lessee

On the start date of the lease period, the company identifies leases with a lease period of no more than 12 months and that do not include a purchase option as short-term leases; leases with a low value when a single leased asset is a new asset are identified as low-value asset leases. If a company subleases or anticipates subletting a leased asset, the original lease will not be deemed a low-value asset lease.

For all short-term leases and low-value asset leases, the company includes the lease payments into the relevant asset cost or current profit and loss on a straight-line basis throughout the lease term.

In addition to the above-mentioned short-term leases and low-value asset leases that adopt simplified treatment, the company recognizes right-of-use assets and lease liabilities for leases on the start date of the lease period.

(1) Right-of-use assets

The right-of-use assets are initially measured at cost, which includes: 1) the initial measurement amount of the lease liability; 2) the lease payment amount paid on or before the start date of the lease period, and if there is a lease incentive, the amount related to the lease incentive that has been enjoyed is deducted; 3) the initial direct costs incurred by the lessee; 4) the costs expected to be incurred by the lessee to dismantle and remove the leased asset, restore the site where the leased asset is located, or restore the leased asset to the state agreed upon in the lease terms.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 121

Section 8 Financial Report

The company depreciates right-of-use assets on a straight-line basis. If it is reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the company will accrue depreciation over the remaining useful life of the leased asset. If it is not reasonably certain that the ownership of the leased asset will be obtained at the expiration of the lease term, the company will accrue depreciation during the shorter of the lease term and the remaining useful life of the leased asset.

(2) Lease liabilities

At the beginning of the lease period, the company recognizes the present value of the unpaid lease payments as lease liabilities. When calculating the present value of lease payments, the interest rate implicit in the lease is used as the discount rate. If the interest rate implicit in the lease cannot be determined, the company's incremental borrowing rate is used as the discount rate. The difference between the lease payment and its present value is regarded as an unrecognized financing expense, and interest expenses are recognized at the discount rate used to confirm the present value of the lease payment during each period of the lease term, and included in the current profit and loss. Variable lease payments that are not included in the measurement of lease liabilities are included in the current profit and loss when they actually occur.

After the start date of the lease period, when the actual fixed payment amount changes, the estimated amount payable of the guaranteed residual value changes, the index or ratio used to determine the lease payment amount changes, the evaluation results or actual exercise of the purchase option, lease renewal option or termination option change, When a change occurs, the company remeasures the lease liability based on the present value of the changed lease payment, and adjusts the book value of the right-of-use asset accordingly. If the book value of the right-of-use asset has been reduced to zero, but the lease liability still needs to be further reduced, the remaining amount will be included in the current profit and loss.

2. Accounting treatment of lease as lessor

On the lease commencement date, the Company classifies leases that substantially transfer almost all risks and rewards related to the ownership of the leased assets as finance leases, and other leases as operating leases.

(1) Operating lease

The company recognizes the lease receipts as rental income according to the straight-line method in each period during the lease term. The initial direct expenses incurred are capitalized and amortized on the same basis as the rental income recognition, and included in the current profit and loss in installments. Variable lease payments obtained by the company related to operating leases that are not included in the lease receipts are included in the current profit and loss when they actually occur.

(2) Financial leasing

On the start date of the lease period, the company recognizes the financial lease receivable based on the net lease investment (the sum of the unguaranteed residual value and the present value of the lease payments not yet received on the start date of the lease discounted at the interest rate implicit in the lease), and terminates the recognition of financial lease assets. During each period of the lease term, the company calculates and recognizes interest income based on the interest rate implicit in the lease.

Variable lease payments obtained by the company that are not included in the measurement of net lease investment are included in the current profit and loss when actually incurred.

(32) Changes in important accounting policies and accounting estimates

1. Changes in important accounting policies

□Applicable □√ Not applicable

2. Changes in important accounting estimates

□Applicable □√ Not applicable

3. Adjustments to relevant items in the financial statements at the beginning of the year when the new accounting standards are implemented for the first time in 2025.

□Applicable □√ Not applicable

6. Taxes

(1) Main tax types and tax rates

Tax Type Tax Calculation Basis Tax Rate

Calculate output tax based on income from sales of goods and taxable services calculated in accordance with tax laws.

Value-added tax 10%, 13%, 19%, after deducting the input tax allowed to be deducted in the current period, the difference is the value-added tax payable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 122

Section 8 Financial Report

Urban maintenance and construction tax Actual turnover tax paid 1%, 5%, 7%

15%, 16.5%, 17%, 20%, 22%, 25%, corporate income tax taxable income

26.5%, 29.84%, 30%, 33.58%

If the tax is assessed on an ad valorem basis, it will be calculated based on 1.2% of the remaining value after deducting 30% of the original value of the property;

Property tax 1.2%, 12%

If the tax is based on rent, it is calculated and paid at 12% of the rental income.

Education fee surcharge Actual turnover tax paid 3% local education surcharge Actual turnover tax paid 2% Land use tax Actual land use area 1-14 yuan/square meter/year

If there are taxpayers with different corporate income tax rates, a description of the disclosure

Taxpayer name Income tax rate

Shandong Yingke Medical Products Co., Ltd. 15%

Anhui Yingke Medical Supplies Co., Ltd. 15%

Jiangxi Yingke Medical Co., Ltd. 15%

Jiangsu Yingke Medical Products Co., Ltd. 15%

Hainan Yingke Medical Technology Co., Ltd. 15%

Anhui Kaize New Materials Co., Ltd. 15%

Anhui Guoyi Mold Technology Co., Ltd. 15%

Shandong Haode Plastic Co., Ltd. 15%

Shanghai Yingmai International Trade Co., Ltd. 20%

Anhui Yinghai Smart Energy Co., Ltd. 20%

Intco Medical Industries Inc. 29.84%

Basic Medical Technology Inc 29.84%

PrimeMax Medical Industries, Inc. 29.84%

Maxcel LLC, Highmax LLC, Realmax LLC According to the U.S. Internal Revenue Code, Maxcel LLC, Highmax LLC, and Realmax LLC are non-independent entities and do not need to declare and pay corporate income tax. The tax liability entity is Intco Medical Industries, Inc.

According to the Inland Revenue Ordinance of Hong Kong, for enterprises registered or operating business in Hong Kong, the profits generated in Hong Kong by Liyingke Medical Products (Hong Kong) Co., Ltd. are applicable, and the income tax rate is 16.5%. The profits generated or obtained outside Hong Kong are exempt from Hong Kong profits tax. According to Pillar 2 of the BEPS 2.0 scheme Inco Medical International (Hong Kong) Limited, annual consolidated revenue has reached €750 million in at least two of the four years immediately preceding the current financial year

A global minimum tax of 15% is levied on multinational enterprise groups worth RMB 10,000 or more ("Covered Multinational Enterprise Groups") Realmax Gmbh 30%

Intco Medical Vietnam Co., Ltd. 20%

Intco Medical Technology Vietnam Company Limited 20%

Basic Medical Vietnam Co., Ltd. 20%

Intco Europe Gmbh 30%

Intco Medical Investment Singapore Pte. Ltd. 17%

Intco Medical Singapore Pte. Ltd. 17%

Intco Canada Inc. 26.50%

Intco Medical Japan Co.,Limited 33.58%

PT Basic International Sumatera 22%

PT Green Environment Management Services 22%

Other tax entities other than the above 25%

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 123

Section 8 Financial Report

(2) Tax incentives

1. Corporate income tax

(1) The subsidiary Shandong Yingke Medical Products Co., Ltd. is recognized as a high-tech enterprise from 2024 to 2026, and the applicable corporate income tax rate in 2025 is 15%; the subsidiary Anhui Yingke Medical Products Co., Ltd. is recognized as a high-tech enterprise from 2024 to 2026. It is designated as a high-tech enterprise, and the applicable corporate income tax rate in 2025 is 15%; the subsidiary Jiangxi Yingke Medical Co., Ltd. is recognized as a high-tech enterprise from 2025 to 2027, and the applicable corporate income tax rate in 2025 is 15%; The subsidiary Jiangsu Yingke Medical Products Co., Ltd. is recognized as a high-tech enterprise from 2025 to 2027, and the applicable corporate income tax rate in 2025 is 15%; the subsidiary Anhui Guoyi Mold Technology Co., Ltd. is recognized as a high-tech enterprise from 2024 to 2026 It is designated as a high-tech enterprise, and the applicable corporate income tax rate in 2025 is 15%; the subsidiary Anhui Kaizer New Materials Co., Ltd. is recognized as a high-tech enterprise from 2023 to 2025, and the applicable corporate income tax rate in 2025 is 15%. The subsidiary Shandong Haode Plastic Co., Ltd. is recognized as a high-tech enterprise from 2023 to 2025, and the applicable corporate income tax rate in 2025 is 15%.

(2) The subsidiaries Shanghai Yingmai International Trade Co., Ltd. and Anhui Yinghai Smart Energy Co., Ltd. are recognized as small and micro enterprises. According to the Ministry of Finance and the State Administration of Taxation’s “Announcement on Tax Policies to Further Support the Development of Small and Micro Enterprises and Individual Industrial and Commercial Households” (State Administration of Taxation Announcement [2023] No. 12), small and low-profit enterprises are subject to a 25% reduction in the calculation of taxable income and a corporate income tax policy of 20%, which will continue to be implemented until December 31, 2027.

(3) According to the "Notice on Preferential Corporate Income Tax Policies for Hainan Free Trade Port" (Caishui [2020] No. 31) promulgated by the Ministry of Finance and the State Administration of Taxation, from January 1, 2020 to December 31, 2027, enterprises in encouraged industries registered and substantively operating in Hainan Free Trade Port will be levied a corporate income tax at a reduced rate of 15%. The subsidiary Hainan Yingke Medical Technology Co., Ltd. applies to this preferential policy, and the applicable corporate income tax rate in 2025 is 15%.

2. Value Added Tax

According to the "Announcement on the Additional Deduction Policy for Value-Added Tax for Advanced Manufacturing Enterprises" (Announcement No. 43 of the Ministry of Finance and the State Administration of Taxation in 2023), from January 1, 2023 to December 31, 2027, advanced manufacturing enterprises are allowed to deduct an additional 5% of the deductible input tax for the current period to deduct the value-added tax payable. The subsidiaries Anhui Kaize New Materials Co., Ltd., Shandong Haode Plastic Co., Ltd., and Anhui Guoyi Mold Technology Co., Ltd. enjoy the super deduction policy.

7. Notes on Consolidated Financial Statement Items

(1) Monetary funds

Unit: Yuan

Item Ending balance Beginning balance

Cash on hand 1,452,056.40 1,485,401.54 Bank deposits 5,683,706,555.69 10,477,007,707.92 Other monetary funds 263,143,387.13 1,535,518,837.32 Total 5,948,301,999.22 12,014,011,946.78 Including: Total amount deposited abroad 2,635,743,084.69 8,077,782,803.40

(2) Trading financial assets

Unit: Yuan

Item Ending balance Beginning balance

Financial assets at fair value through profit or loss 7,242,924,930.58 6,737,459,715.11 Among them:

Financial products 7,242,924,930.58 6,737,459,715.11 of which:

Total 7,242,924,930.58 6,737,459,715.11

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 124

Section 8 Financial Report

(3) Derivative financial assets

Unit: Yuan

Item Ending balance Beginning balance

Foreign exchange derivatives 3,420,433.89 17,419,421.54 Total 3,420,433.89 17,419,421.54

(4) Notes receivable

1. Classified presentation of notes receivable

Unit: Yuan

Item Ending balance Beginning balance

Bank acceptance notes 1,132,639.73 50,345.10 Total 1,132,639.73 50,345.10

(5) Accounts receivable

1. Disclosure by age

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 1,422,231,229.71 1,426,959,420.78 1 to 2 years 5,117,937.10 7,127,205.63 2 to 3 years 6,306,710.53 572,371.41 More than 3 years 14,830,231.42 15,070,612.36 3 to 4 years 93,576.91 15,070,612.36 4 to 5 years 14,736,654.51

Total 1,448,486,108.76 1,449,729,610.18

2. Disclosure by classification according to bad debt accrual method

Unit: Yuan

Ending balance Beginning balance

Category Book balance Bad debt provision Book balance Bad debt provision

book value book value

Amount Proportion Amount Provision proportion Amount Proportion Amount Provision proportion

Accounts receivable with bad debt provisions made individually 14,706,608.18 1.02% 14,706,608.18 100.00% 15,040,544.94 1.04% 15,040,544.94 100.00%

Among them

Accounts receivable with provision for bad debts on a combined basis 1,433,779,500.58 98.98% 72,458,919.85 5.05% 1,361,320,580.73 1,434,689,065.24 98.96% 71,941,751.50 5.01% 1,362,747,313.74 of which

Total 1,448,486,108.76 100.00% 87,165,528.03 6.02% 1,361,320,580.73 1,449,729,610.18 100.00% 86,982,296.44 6.00% 1,362,747,313.74

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 125

Section 8 Financial Report

Provision for bad debts on an individual basis: 14,706,608.18

Unit: Yuan

Beginning balance Closing balance

Name

Book balance Bad debt provision Book balance Bad debt provision Ratio of provision Reason for provision

Individual provision for bad debts 15,040,544.94 15,040,544.94 14,706,608.18 14,706,608.18 100.00% Total expected to be unrecoverable 15,040,544.94 15,040,544.94 14,706,608.18 14,706,608.18

Provision for bad debts on a group basis: 72,458,919.85

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Provision for bad debts by combination 1,433,779,500.58 72,458,919.85 5.05% Total 1,433,779,500.58 72,458,919.85

Description of what this combination is based on:

Closing amount

Project

Book balance Bad debt provision Provision ratio (%)

Within 1 year 1,422,231,229.71 71,111,561.48 5.00 1-2 years 5,117,937.10 358,255.59 7.00 2-3 years 6,306,710.53 946,006.56 15.00 3-4 years 93,576.91 28,073.06 30.00 4-5 years 30,046.33 15,023.16 50.00 Subtotal 1,433,779,500.58 72,458,919.85 5.05

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

□Applicable □√Not applicable

3. Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan

Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off Others

Individual provision for bad debts 15,040,544.94 -333,936.76 14,706,608.18 Provision for collective bad debts 71,941,751.50 1,045,569.45 528,401.10 72,458,919.85Total 86,982,296.44 1,045,569.45 528,401.10 -333,936.76 87,165,528.03

4. Accounts receivable actually written off in this period

Unit: Yuan

Project write-off amount

Accounts receivable actually written off 528,401.10

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 126

Section 8 Financial Report

5. Accounts receivable and contract assets of the top five ending balances by debtors

Unit: Yuan

Accounts receivable and combined accounts receivable and bad debt allowance

Accounts receivable and contracts

Unit name Closing balance of accounts receivable Closing balance of contract assets Closing balance of same assets Provisions and contract assets minus closing balance of assets

Proportion of Total Value Preparation Closing Balance

Customer One 91,686,157.74 91,686,157.74 6.33% 4,588,464.00 Customer Two 43,775,408.58 43,775,408.58 3.02% 2,188,770.43 Customer Three 37,908,413.89 37,908,413.89 2.62% 1,895,420.70Customer four 33,096,081.80 33,096,081.80 2.28% 1,654,804.09Customer five 28,313,211.20 28,313,211.20 1.95% 1,415,660.56 Total 234,779,273.21 234,779,273.21 16.20% 11,743,119.78

(6) Accounts receivable financing

1. Classified presentation of financing receivables

Unit: Yuan

Item Ending balance Beginning balance

Bank acceptance bill 8,240,850.19 16,134,087.49 Total 8,240,850.19 16,134,087.49

2. Financing of receivables that have been endorsed or discounted by the company at the end of the period and have not yet matured on the balance sheet date

Unit: Yuan

Item Amount derecognized at the end of the period Amount not derecognized at the end of the period

Bank acceptance bill 31,401,385.29

Total 31,401,385.29

(7) Other receivables

Unit: Yuan

Item Ending balance Beginning balance

Other receivables 46,081,202.74 78,326,027.38 Total 46,081,202.74 78,326,027.38

1. Other receivables

(1) Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Deposit and security deposit 33,314,456.06 53,111,409.21 Temporary payment receivable 26,567,690.26 44,429,467.53 Reserve fund 378,556.74 507,642.66 Others 5,302,531.54 6,896,991.01Total 65,563,234.60 104,945,510.41

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 127

Section 8 Financial Report

(2) Disclosure based on aging

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 13,402,230.66 59,359,867.64 1 to 2 years 19,361,441.89 4,058,166.48 2 to 3 years 1,629,306.30 25,138,564.93 More than 3 years 31,170,255.75 16,388,911.36 3 to 4 years 25,946,984.21 5,149,486.36 4 to 5 years 4,793,271.54 3,100,000.00 More than 5 years 430,000.00 8,139,425.00 Total 65,563,234.60 104,945,510.41

(3) Classified disclosure according to bad debt accrual method

□√Applicable □Not applicable

Unit: Yuan

Ending balance Beginning balance

Category Book balance Bad debt provision Book balance Bad debt provision

book value book value

Amount Proportion Amount Provision proportion Amount Proportion Amount Provision proportion

Provision for bad debts made individually 10,549,873.41 16.09% 10,549,873.41 100.00% 10,549,873.41 10.05% 10,549,873.41 100.00%

Among them

Provision for bad debts by combination 55,013,361.19 83.91% 8,932,158.45 16.24% 46,081,202.74 94,395,637.00 89.95% 16,069,609.62 17.02% 78,326,027.38 of which

Total 65,563,234.60 100.00% 19,482,031.86 29.71% 46,081,202.74 104,945,510.41 100.00% 26,619,483.03 25.37% 78,326,027.38

Provision for bad debts on an individual basis: 10,549,873.41

Unit: Yuan

Beginning balance Closing balance

Name

Book balance Bad debt provision Book balance Bad debt provision Ratio of provision Reason for provision

Individual provision for bad debts 10,549,873.41 10,549,873.41 10,549,873.41 10,549,873.41 100.00% Total expected to be unrecoverable 10,549,873.41 10,549,873.41 10,549,873.41 10,549,873.41

Provision for bad debts on a group basis: 8,932,158.45

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Provision for bad debts by combination 55,013,361.19 8,932,158.45 16.24% Total 55,013,361.19 8,932,158.45

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 128

Section 8 Financial Report

Description of what this combination is based on:

Closing amount

Combination name

Book balance Bad debt provision Provision ratio (%)

Aging combination 55,013,361.19 8,932,158.45 16.24 Of which: within 1 year 13,402,230.66 670,111.56 5.00 1-2 years 19,361,441.89 1,355,300.93 7.00 2-3 years 553,432.89 83,014.93 15.00 3-4 years 20,946,984.21 6,284,095.26 30.00 4-5 years 419,271.54 209,635.77 50.00

More than 5 years 330,000.00 330,000.00 100.00 Subtotal 55,013,361.19 8,932,158.45 16.24

Provision for bad debts is made based on the general expected credit loss model:

Unit: Yuan

The first stage The second stage The third stage

Bad debt provision Forecast for the next 12 months Expected credit for the entire duration Expected credit for the entire duration Total

Period credit loss Loss (no credit impairment occurred) Loss (credit impairment occurred)

Balance on January 1, 2025 2,967,993.44 208,760.52 23,442,729.07 26,619,483.03 Balance on January 1, 2025 in the current period

——Transfer to the second stage -968,072.09 968,072.09

——Transfer to the third stage -38,740.30 38,740.30

Provisions for the current period -1,544,185.43 217,208.62 -6,024,850.00 -7,351,826.81 Other changes 214,375.64 214,375.64 Balance on December 31, 2025 670,111.56 1,355,300.93 17,456,619.37 19,482,031.86

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

□Applicable □√Not applicable

(4) Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan

Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off or write-off Others

Provision for bad debts individually 10,549,873.41 10,549,873.41 Provision for bad debts based on combination 16,069,609.62 -7,351,826.81 214,375.64 8,932,158.45 Total 26,619,483.03 -7,351,826.81 214,375.64 19,482,031.86

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 129

Section 8 Financial Report

(5) Other receivables with top five closing balances based on debtors

Unit: Yuan

Accounting for other receivables at the end of the period

Unit name Nature of payment Closing balance Account age Closing balance of bad debt provision

Proportion of total balance

Unit 1 Deposit and security deposit 16,000,000.00 1-2 years 24.40% 1,120,000.00 Unit 2 Temporary payment receivable 9,650,000.00 3-4 years 14.72% 2,895,000.00 Unit 3 Deposit and security deposit 5,818,850.00 3-4 years 8.88% 1,745,655.00 Unit 4 Deposit and security deposit 5,084,395.25 3-4 years 7.75% 1,525,318.58 Unit 5 Temporary payment receivable 5,000,000.00 3-4 years 7.63% 5,000,000.00 Total 41,553,245.25 63.38% 12,285,973.58

(8) Advance payments

1. Prepayments are listed based on aging

Unit: Yuan

Ending balance Beginning balance

Aging

Amount Ratio Amount Ratio

Within 1 year 159,564,710.24 87.30% 186,494,371.53 91.29% 1 to 2 years 23,210,927.86 12.70% 17,803,104.12 8.71% Total 182,775,638.10 204,297,475.65

2. Prepayments of the top five ending balances by prepayment objects

Unit name Book balance (yuan) Proportion of prepayment balance (%)

供应商一 48,586,498.83 26.58%供应商二 30,371,808.63 16.62%供应商三 14,120,599.14 7.73%供应商四 13,244,321.59 7.25%供应商五 8,420,105.07 4.61% Subtotal 114,743,333.26 62.79%

(9) Inventory

Whether the company needs to comply with the real estate industry’s disclosure requirements

No

1. Inventory classification

Unit: Yuan

Ending balance Beginning balance

Name Inventory impairment provision or contract Inventory impairment provision or contract

Book balance Book value Book balance Book value

Provision for impairment of performance costs Provision for impairment of performance costs

Raw materials 547,447,617.29 3,435,528.62 544,012,088.67 452,763,077.12 1,086,765.79 451,676,311.33

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 130

Section 8 Financial Report

Work in progress 61,180,214.07 61,180,214.07 70,244,959.75 70,244,959.75 Goods in stock 587,368,961.07 62,547,793.62 524,821,167.45 681,180,488.34 75,342,946.57 605,837,541.77Goods shipped 196,648,046.51 196,648,046.51 137,114,620.85 137,114,620.85Others 364,260.43 364,260.43 540,610.94 540,610.94Total 1,393,009,099.37 65,983,322.24 1,327,025,777.13 1,341,843,757.00 76,429,712.36 1,265,414,044.64

2. Provision for inventory depreciation and provision for impairment of contract performance costs

Unit: Yuan

Increase amount in this period Decrease amount in this period

Item Beginning Balance Ending Balance

Provision Others Reversal or write-off Others

Raw materials 1,086,765.79 3,435,528.62 1,086,765.79 3,435,528.62 Inventory goods 75,342,946.57 17,212,072.94 -7,652.96 29,999,572.93 62,547,793.62 Total 76,429,712.36 20,647,601.56 -7,652.96 31,086,338.72 65,983,322.24

Item Specific basis for determining net realizable value Reasons for reversing inventory depreciation provisions Reasons for writing off inventory depreciation provisions

The estimated selling price of the relevant finished goods is reduced to the estimated completion price

In this period, the cost of raw materials for which inventory depreciation provisions have been made, the estimated sales expenses and the related -

Inventory consumed/sold

The amount after duties and taxes determines the net realizable value

The estimated selling price minus the estimated selling expenses and the corresponding inventory goods for which inventory depreciation provisions will have been made in the current period -

The amount after duties and taxes determines the net realizable value Inventory consumed/sold

(10) Other current assets

Unit: Yuan

Item Ending balance Beginning balance

留抵增值税 164,397,159.58 204,530,131.68预缴企业所得税 2,630,769.44 29,835,088.19待摊费用 12,315,894.07 24,541,919.24合计 179,343,823.09 258,907,139.11

(11) Other non-current financial assets

Unit: Yuan

Item Ending balance Beginning balance

Financial products 8,331,480,619.46

Investment in debt instruments 2,099,575,198.96 1,348,382,649.84 Investment in equity instruments 30,000,000.00 33,500,000.00 Total 10,461,055,818.42 1,381,882,649.84

Other notes:

Important debt instrument investment details

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 131

Section 8 Financial Report

Ending amount Beginning amount

Investee

Cost at the end of the period Cumulative changes in fair value Cost at the beginning of the period Cumulative changes in fair value

Warburg Pincus 566,741,000.00 124,775,763.96 384,454,400.00 88,748,411.43 (Warburg Pincus Global Growth 14.l.p.)

Wuxi Shangxian Lake Boshang Investment Partnership (Limited Partnership) 119,118,616.00 7,129,525.74 119,118,616.00 7,868,218.89 Golub Capital Private Income Fund I 141,518,000.00 -942,000.00

KKR K-INFRA iCapital Offshore Access 141,734,000.00 -1,283,485.10

Fund SPC

Suzhou Jifeng No. 3 Equity Investment Partnership 94,674,633.02 31,668,164.69 101,000,000.00 22,125,347.41 (limited partnership)

Qilu Qianhai (Qingdao) Venture Capital Fund Partnership 80,000,000.00 45,570,171.38 80,000,000.00 16,229,799.27 Enterprise (Limited Partnership)

Others 678,449,676.14 70,421,133.13 522,500,421.18 6,337,435.66 Total 1,822,235,925.16 277,339,273.80 1,207,073,437.18 141,309,212.66 Note 1: This type of partnership invested by the Company has a set operating period, and the Company has no significant influence on this type of partnership. Therefore, the Company determines that this type of investment is a non-trading debt instrument investment, classifies it as a financial asset measured at fair value and its changes are included in profit and loss, and lists it as other non-current financial assets. Note 2: Others include Ningbo Shunze Rubber Co., Ltd. (hereinafter referred to as Ningbo Shunze, the investment cost at the end of the period is 50,000,000.00 yuan, and the cumulative fair value change is 37,800,000.00 yuan) and Zhejiang Tianchen Glue Industry Co., Ltd. (hereinafter referred to as Zhejiang Tianchen, the closing investment cost is 52,500,000.00 yuan, the cumulative fair value change is -14,823,077.00 yuan), according to the company’s relationship with Ningbo Shunze and Zhejiang In the investment agreement signed by Tianchen (hereinafter collectively referred to as the "invested company"), although the company has appointed directors to Ningbo Shunze and Zhejiang Tianchen, considering that the company has special rights such as the right to sell back the above two investments, the risks and rewards that the company bears are substantially different from those of ordinary shareholders. Therefore, the two investments are accounted as financial instruments as a whole, classified as financial assets at fair value through profit and loss, and listed as other non-current financial assets.

Equity instrument investment details

Ending amount Beginning amount

Investee

Cost at the end of the period Cumulative changes in fair value Cost at the beginning of the period Cumulative changes in fair value

Beijing Zhongshui Shuangyun Finance and Taxation Technology Co., Ltd. 30,000,000.00 30,000,000.00

United Medical Technology (Beijing) Co., Ltd. 3,500,000.00 -3,500,000.00 3,500,000.00

Total 33,500,000.00 -3,500,000.00 33,500,000.00

(12) Investment real estate

1. Investment real estate using cost measurement model

□√ Applicable □ Not applicable Unit: Yuan

Projects Houses and buildings Land use rights Construction in progress Total

1. Original book value

1. Balance at the beginning of the period 614,176,186.93 614,176,186.93 2. Increase in the current period -13,636,208.25 -13,636,208.25 (1) Outsourcing

(2) Transfer of inventories\fixed assets\projects under construction

(3) Increase in business mergers

(4) Impact of exchange rate changes -13,636,208.25 -13,636,208.25 3. Decrease amount in the current period

(1) Disposal

(2) Other transfer-out

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 132

Section 8 Financial Report

4. Ending balance 600,539,978.68 600,539,978.68

2. Accumulated depreciation and accumulated amortization

1. Opening balance 57,168,354.06 57,168,354.06 2. Increase in current period 21,011,740.76 21,011,740.76 (1) Provision or amortization 22,631,968.69 22,631,968.69 (2) Impact of exchange rate changes -1,620,227.93 -1,620,227.93 3. Decrease amount in this period

(1) Disposal

(2) Other transfer-out

4. Closing balance 78,180,094.82 78,180,094.82

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

(2) Other transfer-out

4. Ending balance

4. Book value

1. Book value at the end of the period 522,359,883.86 522,359,883.86 2. Book value at the beginning of the period 557,007,832.87 557,007,832.87

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□Applicable □√Not applicable

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable □√Not applicable

2. Investment real estate using fair value measurement model

□Applicable □√Not applicable

(13) Fixed assets

Unit: Yuan

Item Ending balance Beginning balance

Fixed assets 10,803,919,811.95 8,501,377,706.32 Total 10,803,919,811.95 8,501,377,706.32

1. Fixed assets

Unit: Yuan

Projects Houses and buildings General equipment Special equipment Transportation Land Total

1. Original book value:

1. Opening balance 4,556,780,771.58 260,862,008.33 6,203,575,280.23 186,286,535.23 11,718,194.00 11,219,222,789.37

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 133

Section 8 Financial Report

2. Increase in the current period 1,366,339,492.93 48,718,605.21 1,869,810,108.82 20,421,050.83 3,305,289,257.79 (1) Purchase 21,867,122.03 10,783,892.28 103,860,991.62 14,426,831.95 150,938,837.88 (2) Transfer of construction in progress 1,394,916,101.27 38,963,881.94 1,819,997,039.97 6,666,704.04 3,260,543,727.22 (3) Increase in business mergers

(4) Impact of exchange rate changes -50,443,730.37 -1,029,169.01 -54,047,922.77 -672,485.16 -106,193,307.31 3. Decrease amount in the current period 36,467,526.82 7,705,296.67 81,336,877.20 3,761,122.34 129,270,823.03 (1) Disposal or scrapping 36,467,526.82 7,705,296.67 81,336,877.20 3,761,122.34 129,270,823.03 4. Closing balance 5,886,652,737.69 301,875,316.87 7,992,048,511.85 202,946,463.72 11,718,194.00 14,395,241,224.13

2. Accumulated depreciation

1. Opening balance 634,015,954.31 104,544,260.18 1,854,163,421.44 98,818,880.16 2,691,542,516.09 2. Increase in the current period 222,253,306.03 31,244,270.72 631,480,816.81 27,855,148.80 912,833,542.36 (1) Provision 224,784,813.63 31,539,645.91 632,400,081.59 27,987,992.89 916,712,534.02 (2) Impact of exchange rate changes -2,531,507.60 -295,375.19 -919,264.78 -132,844.09 -3,878,991.66 3. Decrease amount in the current period 18,138,394.08 6,957,411.25 11,868,419.08 2,392,988.82 39,357,213.23 (1) Disposal or scrapping 18,138,394.08 6,957,411.25 11,868,419.08 2,392,988.82 39,357,213.23 4. Closing balance 838,130,866.26 128,831,119.65 2,473,775,819.17 124,281,040.14 3,565,018,845.22

3. Impairment provision

1. Opening balance 157,658.18 26,090,879.83 54,028.95 26,302,566.96 2. Increase in the current period

(1) Provision

3. Reduction amount in this period

(1) Disposal or scrapping

4. Ending balance 157,658.18 26,090,879.83 54,028.95 26,302,566.96

4. Book value

1. Book value at the end of the period 5,048,521,871.43 172,886,539.04 5,492,181,812.85 78,611,394.63 11,718,194.00 10,803,919,811.95 2. Book value at the beginning of the period 3,922,764,817.27 156,160,089.97 4,323,320,978.96 87,413,626.12 11,718,194.00 8,501,377,706.32

2. Fixed assets leased through operating leases

Unit: Yuan

Item Closing book value

Houses and buildings 144,998,263.75

3. Fixed assets whose property rights certificates have not been obtained

Unit: Yuan

Item Book Value Reason for Not Obtaining Certificate of Property Rights

Houses and buildings 1,589,268,337.13 The information required to apply for the warrant has not been collected yet

4. Impairment testing of fixed assets

□Applicable □√Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 134

Section 8 Financial Report

(14) Projects under construction

Unit: Yuan

Item Ending balance Beginning balance

Construction in progress 803,113,439.04 1,287,786,355.90 Total 803,113,439.04 1,287,786,355.90

1. Projects under construction

Unit: Yuan

Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value

Anqing Yingke Company has an annual output of 40 billion pieces 174,070,315.97 174,070,315.97 350,216,088.58 350,216,088.58 (40 million boxes) high-end medical gloves project

Annual output of 8.82 billion pieces (8.82 million boxes) high-end 133,310,554.02 133,310,554.02

Medical gloves and other medical consumable items

Shandong Technology Company Intelligent Medical Device Research 98,212,770.88 26,348,653.13 71,864,117.75 164,287,485.22 26,348,653.13 137,938,832.09 Marketing Technology Park Project

High-end disposable protective gloves production and distribution

92,905,093.09 92,905,093.09

set of construction projects

Shandong Yingke Company has an annual output of 50 billion pieces 81,644,390.32 81,644,390.32 412,819,604.51 412,819,604.51 high-end medical gloves project

Comprehensive first phase project of sewage treatment plant 72,168,696.31 72,168,696.31

Shandong Yingke Company No. 1 Nitrile Workshop 63,308,990.95 63,308,990.95

construction project

Anhui Kaize Company has an annual output of 500,000 tons 44,914,238.63 44,914,238.63 2,247,425.60 2,247,425.60 Carboxylic nitrile latex project

Anhui Yingke Company Protective Products 28,739,563.93 28,739,563.93 54,111,404.78 54,111,404.78 Industrial Park Project

Jiangxi Yingke Company has an annual output of 27.168 billion pieces 21,402,386.70 21,402,386.70 101,032,132.99 101,032,132.99 (27.44 million boxes) high-end medical gloves project

Anhui Yingke Company has an annual output of 10.736 billion pieces 7,422,128.29 2,936,775.84 4,485,352.45 20,354,527.64 7,593,735.58 12,760,792.06 (10.736 million boxes) high-end medical gloves project

Vietnam Technology Company Guangning Small Daily Chemical Project 6,844,544.95 6,844,544.95 6,979,250.61 6,979,250.61 Jiangxi Yingcai Company Box Printing Factory Project 1,301,976.01 1,301,976.01 312,212.39 312,212.39 Shandong Yingke Company production line renovation project 1,215,033.32 1,215,033.32 2,881,714.89 2,881,714.89 Anhui Yingke Company has an annual output of 11.08 billion pieces 428,318.58 428,318.58 1,938,729.20 1,938,729.20 High-end glove production line renovation project

Anhui Guoyi Company has an annual output of 10 million pieces 151,612.56 151,612.56 226,986.98 226,986.98 Ceramic hand mold project

Anhui Yingke Company 11.2MW self-generated distributed wind power project

Jiangsu Yingke Company has an annual output of 200 million hot and cold tablets

29,199,657.86 29,199,657.86 pieces of isolation gowns, 130 million bottles of disinfectant hand sanitizer, and 570 million heart electrode projects

Anhui Yingyi Company Huaining Economic Development 2,741,354.84 2,741,354.84 District Cogeneration Project

Other sporadic projects 4,358,253.50 4,358,253.50 139,887,342.73 139,887,342.73 Total 832,398,868.01 29,285,428.97 803,113,439.04 1,321,728,744.61 33,942,388.711,287,786,355.90

2. Changes in important construction projects during this period

Accumulated interest capital transferred to the project during this period, including: capital

Project name Budget number Beginning balance Principal period increase Fixed fixed amount assets Capital decrease period Other capital amount Ending balance Investment included Proportion of project progress Accumulated amount Capital period Principal capital interest interest rate Capital capital period Principal interest interest rate Fund source

High-end disposable anti-

Production of protective gloves and 5,865,200,000.00 1,512,393,260.04 1,411,415,178.95 8,072,988.00 92,905,093.09 25.84% 25.00 Supporting construction projects with self-owned funds

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 135

Section 8 Financial Report

Anqing Yingke Company

Annual output: 40 billion pieces

(40 million boxes) High 4,000,000,000.00 350,216,088.58 188,873,678.71 365,019,451.32 174,070,315.97 26.70% 25.00 Medical gloves item with own funds

Head

Shandong Yingke Company

Annual output of 50 billion pieces 3,951,870,000.00 412,819,604.51 33,154,135.64 364,329,349.83 81,644,390.32 29.91% 30.00 Own funds High-end medical gloves

Project

Jiangxi Yingke Company

Annual output 27.168 billion

Only (27.44 million boxes) 2,563,661,500.00 101,032,132.99 34,546,038.79 114,175,785.08 21,402,386.70 92.47% 90.00 Own funds High-end medical gloves

Project

Anhui Yingke Company

Protective equipment industry 1,967,735,900.00 54,111,404.78 39,585,857.68 61,524,070.21 3,433,628.32 28,739,563.93 94.19% 94.00 Own capital park project

Annual output: 8.82 billion pieces

(8.82 million boxes) high-end

Medical gloves and other medical supplies 1,232,363,200.00 845,683,390.39 709,172,797.87 3,200,038.50 133,310,554.02 68.53% 68.00 Own funds and other medical consumables

Head

Shandong Technology Company

Intelligent medical devices 1,065,000,000.00 164,287,485.22 25,774,508.28 91,849,222.62 98,212,770.88 46.64% 46.00 Own funds to research and develop marketing technology

garden project

Anhui Yingyi Company

Huaining Economic Development

997,072,727.00 2,741,354.84 10,066,419.16 12,807,774.00 80.10% 80.00 Self-owned capital area cogeneration project

Head

Anhui Kaiser Company

Annual output of 500,000 tons of carboxylic acid 700,000,000.00 2,247,425.60 44,424,911.67 1,758,098.64 44,914,238.63 95.92% 96.00 Own capital-based nitrile latex project

Head

Anhui Yingke Company

Annual output: 10.736 billion pieces 500,000,000.00 20,354,527.64 3,904,994.48 13,422,433.28 3,414,960.55 7,422,128.29 128.35% 100.00 Own funds (10.736 million boxes) are high

End medical gloves project

Shandong Yingke Company

Construction of 1# nitrile workshop 250,000,000.00 63,308,990.95 63,308,990.95 27.60% 27.00 Self-owned fund construction project

Total 23,092,903,327.00 1,107,810,024.16 2,801,716,185.79 3,145,474,161.80 18,121,615.37 745,930,432.78

3. Provision for impairment of projects under construction in the current period

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance Reason for provision

Anhui Yingke Company has an annual output of 10.736 billion pieces

7,593,735.58 4,656,959.74 2,936,775.84 (10.736 million boxes) high-end medical gloves project

Shandong Technology Company Intelligent Medical Device Research

26,348,653.13 26,348,653.13 Marketing Technology Park Project

Total 33,942,388.71 4,656,959.74 29,285,428.97

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 136

Section 8 Financial Report

4. Impairment testing of projects under construction

□√Applicable □Not applicable

The recoverable amount is determined as the net amount after fair value minus disposal costs.

□√Applicable □Not applicable

Unit: Yuan

fair value and

Items of key parameters Book value Recoverable amount Impairment amount Key parameters of disposal costs

Determine the basis for determining the method

Replacement cost of machinery and equipment: composed of equipment purchase cost minus dismantling costs; comprehensive newness rate: combined with the age method and the current fair value of Anhui Yingke Company’s annual output of 10.736 billion (10.736 million boxes) high-end medical 4,485,352.45 4,485,352.45. The disposal costs of the glove project include: including legal fees related to the disposal of assets, related taxes, handling fees and direct costs incurred in bringing the assets to a salable state, etc.

Replacement cost of machinery and equipment: consists of equipment purchase cost minus dismantling costs; comprehensive newness rate: combined with the age method and current fair value, the field survey method is used to determine the replacement cost method and newness rate of Shandong Technology Company's intelligent medical devices 71,864,117.75 71,864,117.75. Disposal expenses for the Machinery R&D and Marketing Science and Technology Park Project include expenses related to the disposal of assets, including legal fees, related taxes, handling fees, and direct expenses incurred in bringing the assets to a salable state, etc.

Total 76,349,470.20 76,349,470.20

The recoverable amount is determined based on the present value of expected future cash flows.

□Applicable □√Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 137

Section 8 Financial Report

(15) Right-of-use assets

1. Right-of-use assets

Unit: Yuan

Project Houses and Buildings Total

1. Original book value

1. Opening balance 931,168.58 931,168.58

2. Increase amount in this period

3. Reduction amount in this period

4. Closing balance 931,168.58 931,168.58

2. Accumulated depreciation

1. Balance at the beginning of the period 72,498.12 72,498.12 2. Increase in the current period 792,158.40 792,158.40

(1) Provision 792,158.40 792,158.40

3. Reduction amount in this period

(1) Disposal

4. Ending balance 864,656.52 864,656.52

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

4. Ending balance

4. Book value

1. Book value at the end of the period 66,512.06 66,512.06 2. Book value at the beginning of the period 858,670.46 858,670.46

(16) Intangible assets

1. Intangible assets

Unit: Yuan

Project Land use rights Patent rights Non-patented technology Office software Coal use rights Total

1. Original book value

1. Opening balance 782,711,017.33 24,264,430.00 34,038,040.06 15,000,000.00 856,013,487.39 2. Increase in the current period -11,587,120.96 4,040,937.50 -7,546,183.46

(1) Purchase 8,554,599.51 4,089,577.57 12,644,177.08

(2) Internal R&D

(3) Increase in business mergers

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 138

Section 8 Financial Report

Unit: Yuan

Project Land use rights Patent rights Non-patented technology Office software Coal use rights Total

1. Original book value

(4) Impact of exchange rate changes -20,141,720.47 -48,640.07 -20,190,360.54 3. Decrease amount in the current period 3,921,414.74 3,921,414.74

(1) Disposal 3,921,414.74 3,921,414.74 4. Closing balance 767,202,481.63 24,264,430.00 38,078,977.56 15,000,000.00 844,545,889.19

2. Accumulated amortization

1. Opening balance 58,186,963.12 5,200,889.94 19,224,779.52 6,375,000.00 88,987,632.58 2. Increase in the current period 17,680,434.35 4,465,339.64 3,160,537.00 1,500,000.00 26,806,310.99

(1) Provision 18,590,981.23 4,465,339.64 3,171,089.17 1,500,000.00 27,727,410.04

(2) Impact of exchange rate changes -910,546.88 -10,552.17 -921,099.05 3. Decrease amount in the current period 352,927.26 352,927.26

(1) Disposal 352,927.26 352,927.26 4. Closing balance 75,514,470.21 9,666,229.58 22,385,316.52 7,875,000.00 115,441,016.31

3. Impairment provision

1. Opening balance

2. Increase amount in this period

(1) Provision

3. Reduction amount in this period

(1) Disposal

4. Ending balance

4. Book value

1. Book value at the end of the period 691,688,011.42 14,598,200.42 15,693,661.04 7,125,000.00 729,104,872.88 2. Book value at the beginning of the period 724,524,054.21 19,063,540.06 14,813,260.54 8,625,000.00 767,025,854.81 The intangible assets formed through the company’s internal research and development at the end of the period accounted for 0.00% of the balance of intangible assets.

2. Land use rights for which property rights certificates have not been obtained

Unit: Yuan

Item Book Value Reason for Not Obtaining Certificate of Property Rights

Land 196,165,260.36 The information required to apply for the warrant has not been collected yet

(17) Long-term deferred expenses

Unit: Yuan

Item Opening balance Increase in the current period Amortization amount in the current period Other decreases Ending balance

Thermal oil 364,173.63 49,439.40 314,734.23 Decoration costs 4,856,862.82 254,508.12 4,602,354.70 Total 5,221,036.45 303,947.52 4,917,088.93

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 139

Section 8 Financial Report

(18) Deferred income tax assets/deferred income tax liabilities

1. Deferred income tax assets without offset

Unit: Yuan

Ending balance Beginning balance

Project

Deductible temporary differences Deferred income tax assets Deductible temporary differences Deferred income tax assets

Asset impairment provision 146,071,640.48 29,104,671.09 165,239,458.05 31,868,984.25 Unrealized profits from internal transactions 21,848,687.80 3,745,068.18 60,394,472.93 9,059,170.94 Deductible losses 739,670,674.58 148,620,314.48 1,049,800,630.65 187,182,341.68 Withheld expenses 14,121,912.76 2,604,853.63 14,732,155.76 2,757,414.38 Deferred income 28,938,329.92 6,923,592.98 2,437,298.32 365,594.75 Changes in fair value 11,587,052.36 1,738,057.85

Total 962,238,297.90 192,736,558.21 1,292,604,015.71 231,233,506.00

2. Deferred income tax liabilities without offset

Unit: Yuan

Ending balance Beginning balance

Project

Taxable temporary differences Deferred income tax liabilities Taxable temporary differences Deferred income tax liabilities

Undistributed profits of overseas subsidiaries 9,083,045,301.00 1,362,456,795.15 10,630,490,740.40 1,594,573,611.06 Accelerated depreciation of fixed assets 2,794,821,250.95 466,997,920.59 2,989,482,468.44 478,000,794.63 Changes in fair value 142,564,886.51 30,815,282.75 116,806,707.16 22,371,125.32 Total 12,020,431,438.46 1,860,269,998.49 13,736,779,916.00 2,094,945,531.01

3. Deferred income tax assets or liabilities presented on a net basis after offsetting

Unit: Yuan

Deferred income tax assets and deferred income tax items after offset Deferred income tax assets and deferred income tax items after offset

The offset amount of liabilities at the end of the period. The closing balance of assets or liabilities. The offset amount of liabilities at the beginning of the period. The opening balance of assets or liabilities.

Deferred income tax assets 141,128,631.96 51,607,926.25 150,886,431.11 80,347,074.89 Deferred income tax liabilities 141,128,631.96 1,719,141,366.53 150,886,431.11 1,944,059,099.90

4. Details of deferred income tax assets not recognized

Unit: Yuan

Item Ending balance Beginning balance

Deductible temporary differences 205,984,056.61 2,167,971.31 Deductible losses 504,834,954.70 499,256,924.37 Total 710,819,011.31 501,424,895.68

5. The deductible losses of unrecognized deferred income tax assets will expire in the following years Unit: Year Yu Ending amount Beginning amount Remarks

2025 4,329,979.64

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 140

Section 8 Financial Report

2026 10,481,369.60 16,921,788.93

2027 157,065,203.19 167,641,036.00

2028 107,772,117.26 113,349,730.71

2029 88,136,379.41 197,014,389.09

2030 141,379,885.24

Total 504,834,954.70 499,256,924.37

(19) Other non-current assets

Unit: Yuan

Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value

Prepayment for house purchase 25,505,077.00 25,505,077.00 25,505,077.00 25,505,077.00 Prepayment for construction equipment 77,441,256.60 9,220,000.00 68,221,256.60 64,032,242.11 64,032,242.11 Prepaid land payment 16,541,821.62 16,541,821.62 5,084,395.25 5,084,395.25

Large amount due for more than one year

305,045,555.56 305,045,555.56

##’s certificate of deposit and interest receivable

Total 424,533,710.78 9,220,000.00 415,313,710.78 94,621,714.36 94,621,714.36

(20) Assets whose ownership or use rights are restricted

Unit: Yuan

End of period Beginning of period

Project

Book balance Book value Restriction type Restriction situation Book balance Book value Restriction type Restriction situation

Pledge is used to issue silver

Pledge is used to issue

bank acceptance bill, guarantee

Monetary funds 3,038,469,955.49 3,038,469,955.49 Pledge letter, letter of credit, application 8,716,142,048.06 8,716,142,048.06 Pledge Bank acceptance bill handling forward settlement and sale of foreign exchange, deposit, pledge Pledge is used for bank borrowings and litigation frozen deposits

mortgage for

Fixed assets 402,842,458.68 298,009,133.21 Mortgage

bank borrowing

Mortgage for intangible assets 31,105,975.35 25,430,669.07 Mortgage 7,935,008.38 7,935,008.38 Mortgage

Bank borrowings Bank borrowings for trading Pledge for Pledge for

4,315,472,000.21 4,315,472,000.21 Pledge 445,803,326.63 445,803,326.63 Pledge

Financial assets Bank borrowings Bank loan guarantees Other non-current Pledge used

6,518,067,047.88 6,518,067,047.88 Pledge

Financial assets Bank borrowings

Due in more than one year

Other non-

305,045,555.56 305,045,555.56 Pledge of large amount of deposit certificate

Current assets

pledged for bank borrowing

Total 14,611,002,993.17 14,500,494,361.42 9,169,880,383.07 9,169,880,383.07

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 141

Section 8 Financial Report

(21) Short-term borrowings

1. Classification of short-term loans

Unit: Yuan

Item Ending balance Beginning balance

Pledged loans 10,615,426,944.50 7,111,070,637.40 Guaranteed loans 3,073,933,310.14 2,400,223,510.73 Credit loans 150,000,000.00 852,766,984.95 Pledged and guaranteed loans 556,013,428.88 Mortgage and guaranteed loans 310,000,000.00

Internally issued commercial bill discount financing 2,134,953,975.81 1,746,133,974.50 Provision of undue interest payable 106,100,712.30

Total 16,390,414,942.75 12,666,208,536.46

(22) Derivative financial liabilities

Unit: Yuan

Item Ending balance Beginning balance

Foreign exchange derivatives 21,885,311.37 81,655,188.94 Interest rate derivatives 3,896,511.46

Total 25,781,822.83 81,655,188.94

(23) Notes payable

Unit: Yuan

Category Ending balance Beginning balance

Bank acceptance bill 19,866,511.82 29,220,704.00 Letter of credit 50,544,607.40 Total 19,866,511.82 79,765,311.40 The total amount of bills payable that has expired and not been paid at the end of this period is RMB 0.00.

(24) Accounts payable

1. Presentation of accounts payable

Unit: Yuan

Item Ending balance Beginning balance

Payables for materials and others 590,493,531.84 452,615,055.61 Payables for engineering equipment 646,161,207.23 313,002,856.76 Total 1,236,654,739.07 765,617,912.37

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 142

Section 8 Financial Report

2. Are there any overdue payments to small and medium-sized enterprises?

Is it a large enterprise?

Yes √ No

(25) Other payables

Unit: Yuan

Item Ending balance Beginning balance

Other payables 278,471,838.63 162,334,409.88 Total 278,471,838.63 162,334,409.88

1. Other payables

(1) Other payables are presented according to the nature of the payment Unit: Yuan

Item Ending balance Beginning balance

Restricted stock repurchase obligation 159,117,723.00 26,983,474.85 Expenses payable 66,332,150.34 66,057,921.73 Deposit payable 7,078,196.36 16,494,748.41 Land payment payable 1,572,487.13 Others 45,943,768.93 51,225,777.76 Total 278,471,838.63 162,334,409.88

(26) Contract liabilities

Unit: Yuan

Item Ending balance Beginning balance

Advance payment 236,995,423.00 271,584,036.81 Total 236,995,423.00 271,584,036.81

(27) Employee compensation payable

1. Presentation of employee benefits payable

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Short-term compensation 116,134,751.03 1,248,811,371.34 1,229,978,620.94 134,967,501.43

2. Post-employment benefits - defined contribution plan 10,383,874.95 71,235,176.52 75,174,358.68 6,444,692.79 Total 126,518,625.98 1,320,046,547.86 1,305,152,979.62 141,412,194.22

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 143

Section 8 Financial Report

2. Presentation of short-term compensation

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Salaries, bonuses, allowances and subsidies 110,790,001.27 1,147,380,159.33 1,128,322,089.19 129,848,071.41

2. Employee welfare fees 31,291,271.46 31,291,271.46

3. Social insurance premiums 2,246,832.16 43,659,514.39 43,889,702.16 2,016,644.39 Including: medical insurance premiums 2,115,711.00 39,046,901.36 39,279,483.26 1,883,129.10 Work injury insurance premium 131,121.16 4,347,464.55 4,345,070.42 133,515.29 Maternity insurance premium 265,148.48 265,148.48

4. Housing provident fund 3,097,917.60 16,953,774.62 16,967,127.57 3,084,564.65

5. Union funds and employee education funds 9,526,651.54 9,508,430.56 18,220.98 Total 116,134,751.03 1,248,811,371.34 1,229,978,620.94 134,967,501.43

3. Set the contribution plan display

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

1. Basic pension insurance 10,383,874.95 68,356,149.58 72,295,395.78 6,444,628.75

2. Unemployment insurance premium 2,879,026.94 2,878,962.90 64.04Total 10,383,874.95 71,235,176.52 75,174,358.68 6,444,692.79

(28) Taxes payable

Unit: Yuan

Item Ending balance Beginning balance

Value-added tax 6,110,090.90 5,839,920.80 Corporate income tax 116,411,356.99 65,177,661.13 Personal income tax 3,352,940.05 3,163,621.39 Urban maintenance and construction tax 3,310,124.74 2,278,996.86 Real estate tax 7,012,026.35 6,792,410.26 Land use tax 2,623,731.24 3,050,185.49 Education surcharge 1,970,611.36 1,190,776.83 Local education surcharge 1,297,707.55 777,817.88 Stamp duty 2,109,241.85 1,928,560.96 Others 2,293,545.47 947,409.98 Total 146,491,376.50 91,147,361.58

(29) Non-current liabilities due within one year

Unit: Yuan

Item Ending balance Beginning balance

Long-term borrowings due within one year 697,547,643.53 436,372,644.95 Total 697,547,643.53 436,372,644.95

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 144

Section 8 Financial Report

(30) Other current liabilities

Unit: Yuan

Item Ending balance Beginning balance

Output tax to be transferred 4,012,349.44 1,314,247.65 Bank acceptance bills endorsed but not expired and not derecognized 511,851.08

Total 4,524,200.52 1,314,247.65

(31) Long-term loans

1. Classification of long-term loans

Unit: Yuan

Item Ending balance Beginning balance

Guaranteed loans 249,029,757.05 165,404,236.66 Credit loans 160,256,766.66

Total 409,286,523.71 165,404,236.66

(32) Bonds payable

1. Bonds payable

Unit: Yuan

Item Ending balance Beginning balance

Yingke convertible bonds 1,393,228.34 Total 1,393,228.34

2. Increases and decreases in bonds payable (excluding preference shares, perpetual bonds and other financial instruments classified as financial liabilities)

Unit: Yuan

Bond Par Issue Bond Issuance Beginning of Period Current Period Based on Par Value Premium and Discount Current Period End of Period Whether

face value

Name Interest Rate Date Term Amount Balance Issuance Interest Accrual Amortization Repayment Balance Default

first year

is 0.5%

second year

is 0.8%

third year

is 2.6%

Yingke

470,000,000.0 Fourth year 2019/8/16 6 years 470,000,000.00 1,393,228.34 1,217,489.40 41,757.91 11,367.15 228,864.00 0.00 No convertible bonds 3.3%

fifth year

is 3.5%

sixth year

is 4.0%

Total —— 470,000,000.00 1,393,228.34 1,217,489.40 41,757.91 11,367.15 228,864.00 0.00 ——

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 145

Section 8 Financial Report

3. Description of convertible corporate bonds

As approved by the China Securities Regulatory Commission's Zhengjian Ke [2019] No. 1183, the company publicly issued 4.70 million convertible corporate bonds on August 16, 2019, with a face value of 100.00 yuan each, with a total issuance of 470 million yuan, and a term of 6 years. The company's convertible corporate bonds have been listed for trading on the Shenzhen Stock Exchange since September 10, 2019, and the bonds are referred to as "Yingke Convertible Bonds".

On June 21, 2021, the circulating face value balance of "Yingke Convertible Bonds" was 29.7337 million yuan, which was less than 30 million yuan. According to the relevant provisions of the "Implementation Rules of the Shenzhen Stock Exchange Convertible Corporate Bond Business" and "Business Handling Guidelines for GEM Listed Companies No. 8 - Issuance of Convertible Corporate Bonds to Unspecified Objects", trading of "Yingke Convertible Bonds" will cease on June 29, 2021, and all bondholders can still apply for stock conversion.

This year, a total of 10,122.00 convertible corporate bonds were converted into shares. The conversion increased the share capital by RMB 302,447.00, increased the capital reserve (equity premium) by RMB 1,235,650.04, and decreased other equity instruments by RMB 104,170.09.

"Yingke Convertible Bonds" entered the conversion period on February 24, 2020. As of August 15, 2025 (expiration date), a total of 4,698,212 bonds have been converted into company stocks, and the cumulative number of shares converted is 37,194,870 shares. The remaining number of "Yingke Convertible Bonds" that have not been converted into shares at maturity is 1,788. The company will redeem all the convertible corporate bonds that have not been converted into shares from investors at a price of 128% of the face value of the convertible bonds (including the last period of interest). The maturity payment amount is 228,864 yuan (including the last period of interest), which has been fully redeemed on August 18, 2025.

(33) Deferred income

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance Reason for formation

Government subsidies 155,840,533.57 74,015,000.00 17,867,060.19 211,988,473.38 Related to assets

Total 155,840,533.57 74,015,000.00 17,867,060.19 211,988,473.38

(34) Share capital

Unit: Yuan

This change increases or decreases (+, -)

Beginning balance Closing balance

Issuance of new shares Bonus shares Conversion of provident funds Others Subtotal

Total number of shares 646,193,496.00 13,172,100.00 -4,612,333.00 8,559,767.00 654,753,263.00

Other notes:

1. In 2025, the company actually received a total of RMB 148,826,230.00 in currency contributions from equity incentive recipients, of which RMB 13,172,100.00 was included in share capital and RMB 135,654,130.00 was included in capital reserves (share premium). The restricted stocks issued by the company to employees completed the registration and other capital increase procedures, and at the same time confirmed the repurchase obligation, increasing treasury shares and other payables by RMB 148,826,230.00.

2. In 2025, the convertible corporate bonds will be converted into shares to increase the share capital by RMB 302,447.00.

3. In 2025, the company repurchased and canceled 410,480 restricted shares of equity incentive objects that did not meet the unlocking conditions, reducing share capital by RMB 410,480.00 and reducing capital reserve (capital premium) by RMB 4,224,744.20.

4. In 2025, the company will cancel the remaining 4,504,300 unused shares repurchased in 2023, reducing the share capital by RMB 4,504,300.00 and the capital reserve (share premium) by RMB 95,511,281.00.

(35) Other equity instruments

1. Basic information on preferred stocks, perpetual bonds and other financial instruments outstanding at the end of the period

As approved by the China Securities Regulatory Commission, Zhengjian Keke [2019] No. 1183, the company publicly issued 4.7 million convertible corporate bonds on August 16, 2019.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 146

Section 8 Financial Report

The face value is 100 yuan, the total issuance amount is 470 million yuan, and the term is 6 years. The company's convertible corporate bonds have been listed for trading on the Shenzhen Stock Exchange since September 10, 2019. The bonds are referred to as "Yingke Convertible Bonds". The convertible corporate bonds have been fully redeemed on August 18, 2025.

2. Table of changes in outstanding preferred stocks, perpetual bonds and other financial instruments at the end of the period Unit: Yuan Outstanding Beginning of the period Increase in this period Decrease in this period End of period

Financial Instrument Quantity Book Value Quantity Book Value Quantity Book Value Quantity Book Value

Yingke Convertible Bonds 11,910.00 104,170.09 11,910.00 104,170.09

Total 11,910.00 104,170.09 11,910.00 104,170.09

(36) Capital reserve

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Capital premium (equity premium) 1,089,365,072.30 150,516,514.95 99,736,025.20 1,140,145,562.05 Other capital reserves 24,581,958.35 31,663,630.39 13,626,734.84 42,618,,853.90 Total 1,113,947,030.65 182,180,145.34 113,362,760.04 1,182,764,415.95

Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

1. In 2025, restricted stocks will be issued for equity incentives, increasing capital reserve (capital premium) by RMB 135,654,130.00. For details, please see the explanation in Note 7 (34) of this financial report.

2. In 2025, the convertible corporate bonds issued by the company were converted into 302,447 shares, increasing the capital reserve (equity premium) by RMB 1,235,650.11. For details, please see the explanation in Note 7 (32) of this financial report.

3. Repurchase and cancel the restricted stocks that do not meet the unlocking conditions, reducing the capital reserve (equity premium) by RMB 4,224,744.20. For details, please see the explanation in Note 7 (34) of this financial report.

4. In 2025, the company will cancel the remaining 4,504,300 unused shares repurchased in 2023, reducing the capital reserve (equity premium) by RMB 95,511,281.00. For details, please see the explanation in Note 7 (34) of this financial report.

5. In 2025, the company implemented the equity incentive plan and recognized relevant equity incentive expenses of RMB 31,997,687.05, of which: RMB 31,663,630.39 was included in the capital reserve and RMB 334,056.66 was included in the minority shareholders' equity of non-wholly owned subsidiaries.

6. In 2025, the conditions for lifting the sales restrictions of the third phase of the company's 2022 restricted stock incentive plan were achieved. The actual number of shares that were unlocked was 1,052,520 shares, reducing the capital reserve (other capital reserve) by 13,626,734.84 yuan, and increasing the capital reserve (equity premium) by 13,626,734.84 yuan.

(37) Treasury stocks

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Equity incentives 26,983,476.00 148,826,230.00 16,691,983.00 159,117,723.00 Stock repurchase 106,483,230.00 73,533,056.08 100,015,581.00 80,000,705.08 Total 133,466,706.00 222,359,286.08 116,707,564.00 239,118,428.08

Other explanations, including changes in increases and decreases in the current period and explanations of reasons for changes:

1. In 2025, due to the implementation of the restricted stock equity incentive plan, the repurchase obligation was confirmed to increase by 148,826,230.00 yuan in treasury shares.

2. In 2025, according to the resolutions of the second session of the company’s fourth session of the Board of Directors and the 2024 Annual General Meeting of Shareholders, the company will distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares, with a total of 246,780.00 yuan distributed to restricted stock holders, correspondingly reducing treasury shares by 246,780.00 yuan.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 147

Section 8 Financial Report

3. In 2025, according to the resolution of the eighth meeting of the fourth session of the board of directors of the company, the company will distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares, with a total of 763,495.00 yuan distributed to restricted stock holders, correspondingly reducing treasury shares by 763,495.00 yuan.

4. In 2025, according to the "Proposal on the Company's Share Repurchase Plan" reviewed and approved by the 25th meeting of the 3rd Board of Directors and the 23rd meeting of the 3rd Board of Supervisors, the company will repurchase a total of 3,002,880 shares in 2025, increasing treasury shares by RMB 73,533,056.08.

5. In 2025, the company will repurchase and cancel the restricted stocks of equity incentive targets who have resigned or whose personal performance does not meet the standards, reducing treasury shares by RMB 4,198,714.80.

6. According to the resolution of the 11th meeting of the fourth session of the board of directors of the company, the third batch of share-based payment in 2022 has partially met the unlocking conditions, and a total of 1,052,520.00 shares have been released from sale restrictions. The obligation to repurchase restricted shares has been accordingly reduced, and treasury shares have been reduced by 11,482,993.20 yuan.

7. In 2025, the company will cancel the remaining 4,504,300 unused shares repurchased in 2023, reducing treasury shares by RMB 100,015,581.00.

(38) Other comprehensive income

Unit: Yuan

Amount incurred this period

Less for the current period: included in the previous period Less: included in the previous period Return after tax Return after tax

Less: income

Item Opening balance Closing balance before tax Other comprehensive income Other comprehensive income Belonging to parent Belonging to minority

tax expenses

Amount incurred is transferred to profit and loss in the current period Transferred to retained earnings in the current period Company Several shareholders

2. Will be heavy

Classification entry loss

-8,367,027.53 -41,766,121.34 -41,677,672.98 -88,448.36 -50,044,700.51

Others of benefit

Comprehensive income

Foreign currency financial statements

-8,367,027.53 -41,766,121.34 -41,677,672.98 -88,448.36 -50,044,700.51

Table conversion difference

Other comprehensive

-8,367,027.53 -41,766,121.34 -41,677,672.98 -88,448.36 -50,044,700.51

Total income

(39) Special reserves

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Safety production expenses 7,881,389.45 7,781,956.62 2,300,364.57 13,362,981.50 Total 7,881,389.45 7,781,956.62 2,300,364.57 13,362,981.50

(40) Surplus reserve

Unit: Yuan

Item Opening balance Increase in the current period Decrease in the current period Ending balance

Statutory surplus reserve 249,302,977.00 2,955,305.05 252,258,282.05 Total 249,302,977.00 2,955,305.05 252,258,282.05

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 148

Section 8 Financial Report

(41) Undistributed profits

Unit: Yuan

Project Current issue Previous issue

Undistributed profit at the end of the previous period before adjustment 15,528,484,819.86 14,174,436,942.00 Undistributed profit at the beginning of the period after adjustment 15,528,484,819.86 14,174,436,942.00 Plus: Net profit attributable to the owners of the parent company for the current period 1,010,699,970.94 1,465,476,194.01 Less: Withdrawal of statutory surplus reserve 2,955,305.05 28,198,485.00 Common stock dividends payable 96,492,053.65 83,540,223.43 Repurchase and cancellation of restricted stocks Cancellation of dividends from previous years -126,117.40 -310,392.28 Undistributed profits at the end of the period 16,439,863,549.50 15,528,484,819.86 Details of adjustments to undistributed profits at the beginning of the period:

1. Due to the retrospective adjustment of the Accounting Standards for Business Enterprises and its related new regulations, the undistributed profit at the beginning of the period was affected by RMB 0.00.

2. Due to changes in accounting policies, the undistributed profit at the beginning of the period was affected by RMB 0.00.

3. Due to the correction of major accounting errors, the undistributed profit at the beginning of the period was affected by RMB 0.00.

4. Changes in the scope of consolidation due to the same control affect the undistributed profit at the beginning of the period by RMB 0.00.

5. The total impact of other adjustments on the undistributed profit at the beginning of the period is 0.00 yuan.

Detailed explanation of the use of capital reserves to cover losses:

1. According to the resolution of the second session of the company’s fourth session of the Board of Directors and the 2024 Annual General Meeting of Shareholders: Based on the share capital on the equity registration date when the company’s equity distribution is implemented (deducting the repurchased shares in the company’s special repurchase account), a cash dividend of RMB 1.00 (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of RMB 63,917,675.50.

2. According to the resolution of the eighth meeting of the fourth session of the board of directors of the company: based on the share capital on the equity registration date when the company's equity distribution is implemented (excluding the repurchased shares in the company's special repurchase account), a cash dividend of RMB 0.5 (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of RMB 32,574,378.15.

3. Due to the company's repurchase and cancellation of restricted stocks, the previous year's dividend of RMB 126,117.40 was cancelled.

(42) Operating income and operating costs

Unit: Yuan

Amount for the current period Amount for the previous period

Project

revenue cost revenue cost

Main business 9,859,560,514.37 7,484,171,781.70 9,435,985,963.85 7,190,255,357.78 Other businesses 66,258,930.35 47,383,938.31 87,331,159.64 82,092,305.69 Total 9,925,819,444.72 7,531,555,720.01 9,523,317,123.49 7,272,347,663.47 The company’s total audited profit, net profit, and net profit after deducting non-recurring gains and losses during the reporting period, whichever is lower, is negative.

Yes √ No

Breakdown information of operating income and operating costs:

Unit: Yuan

Segment 1 Total

Contract classification

Operating income Operating cost Operating income Operating cost Business type

Among them:

Personal protection 8,835,174,990.74 6,690,357,173.81 8,835,174,990.74 6,690,357,173.81 Rehabilitation care 447,870,434.74 353,155,253.87 447,870,434.74 353,155,253.87

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 149

Section 8 Financial Report

Other products 642,774,019.24 488,043,292.33 642,774,019.24 488,043,292.33Total 9,925,819,444.72 7,531,555,720.01 9,925,819,444.72 7,531,555,720.01

Information related to the transaction price allocated to the remaining performance obligations:

At the end of the reporting period, the amount of revenue corresponding to the performance obligations that have been signed but have not been performed or have not been completed is 236,995,423.00 yuan, of which 236,995,423.00 yuan is expected to be recognized in 2026.

(43) Taxes and surcharges

Unit: Yuan

Item Amount of current period Amount of previous period

Urban maintenance and construction tax 21,811,792.14 7,676,383.43 Education fee surcharge 11,662,546.96 3,965,248.31 Resource tax 2,245,241.94 2,391,843.66 Property tax 30,391,324.73 26,466,196.97Land use tax 10,620,164.87 12,107,058.09Stamp tax 8,171,849.50 7,273,861.79Environmental protection tax 1,650,292.00 1,500,223.39Local education surcharge 7,775,531.26 2,632,772.17 Others 2,966,308.27 1,537,568.59 Total 97,295,051.67 65,551,156.40

(44) Management expenses

Unit: Yuan

Item Amount of current period Amount of previous period

Employee compensation 271,606,274.35 199,865,312.68 Depreciation and amortization 187,505,331.36 152,070,075.66 Office expenses and repair expenses 82,240,832.09 52,627,936.68 Intermediary agency expenses 38,712,941.25 21,516,576.98 Travel expenses and car expenses 32,781,648.73 25,315,404.61 Raw materials and low-value consumables consumed 14,434,446.26 9,025,459.62 Business entertainment expenses 13,466,026.50 8,335,209.78 Share-based payment expenses 14,917,973.25 9,302,013.00 Insurance premium 7,350,028.81 5,854,690.47 Others 23,448,778.95 34,227,246.90 Total 686,464,281.55 518,139,926.38

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 150

Section 8 Financial Report

(45) Sales expenses

Unit: Yuan

Item Amount of current period Amount of previous period

Employee compensation 153,640,693.45 135,514,565.11 Depreciation and amortization expenses 31,102,329.92 51,229,852.15 Office expenses 33,343,000.68 36,126,605.10 Business development expenses 11,889,829.91 15,629,852.92 Travel expenses 20,606,494.31 18,406,303.61 Share-based payment 7,609,744.83

Advertising expenses 18,773,924.66 18,924,667.78 Business entertainment expenses 3,111,418.56 2,343,065.27 Others 17,652,951.47 10,268,931.74 Total 297,730,387.79 288,443,843.68

(46) Research and development expenses

Unit: Yuan

Item Amount of current period Amount of previous period

Material input 217,996,305.75 231,877,018.05 Employee compensation 127,323,150.06 119,701,342.07 Depreciation and amortization 37,056,867.09 28,176,576.85 Water, electricity, coal and heating expenses 16,869,185.52 17,160,010.91 Share-based payment 1,875,837.68

Others 3,260,501.46 1,429,466.68 Total 404,381,847.56 398,344,414.56

(47) Financial expenses

Unit: Yuan

Item Amount of current period Amount of previous period

Borrowing interest expenses 369,151,102.52 308,032,971.36 Interest income 367,932,996.49 533,356,405.99 Exchange gains and losses 401,175,649.88 -225,485,081.39 Lease liability interest expenses 4,052.38 Others 14,134,142.21 14,179,100.80 Total 416,527,898.12 -436,625,362.84

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 151

Section 8 Financial Report

(48) Other income

Unit: Yuan

Sources of other income Amount for the current period Amount for the previous period

Government subsidies related to assets 17,867,060.19 7,814,007.31 Government subsidies related to income 34,917,689.69 35,594,872.87 Refund of personal income tax withholding fees 400,506.76 710,345.38 Value-added tax additional deduction 12,414,115.66 14,253,217.76 Total 65,599,372.30 58,372,443.32

(49) Gains from changes in fair value

Unit: Yuan

Sources of income from changes in fair value Amount incurred in the current period Amount incurred in the previous period

Financial products 137,637,504.89 255,477,129.38 Debt and equity instrument investments 203,223,243.58 88,525,673.62 Foreign exchange derivatives -22,361,388.94 -64,235,767.40 Total 318,499,359.53 279,767,035.60

(50) Investment income

Unit: Yuan

Item Amount of current period Amount of previous period

Investment income from trading financial assets during the holding period 223,984,025.00 50,337,113.16 Investment income from other non-current financial assets during the holding period 13,177,114.39 Investment income from the disposal of derivative financial instruments 159,472,311.27

Losses on financing discount of accounts receivable -337,622.21 Financial asset transaction costs -3,735,532.92

Total 379,720,803.35 63,176,605.34

(51) Credit impairment losses

Unit: Yuan

Item Amount of current period Amount of previous period

Bad debt losses on accounts receivable -1,045,569.45 -23,824,941.74 Bad debt losses on other receivables 7,351,826.81 -8,954,935.03Total 6,306,257.36 -32,779,876.77

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 152

Section 8 Financial Report

(52) Asset impairment losses

Unit: Yuan

Item Amount of current period Amount of previous period

1. Inventory depreciation losses and contract performance cost impairment losses -20,647,601.56 -75,110,116.49

2. Impairment losses on projects under construction -33,942,388.71

3. Others -10,774,380.00

Total -31,421,981.56 -109,052,505.20

(53) Income from asset disposal

Unit: Yuan

Source of asset disposal income Amount incurred in the current period Amount incurred in the previous period

Income from disposal of fixed assets -776,056.55 224,360.40 Income from disposal of intangible assets 378,941.88

Total -397,114.67 224,360.40

(54) Non-operating income

Unit: Yuan

Item Amount incurred in the current period Amount incurred in the previous period Amount included in non-recurring gains and losses for the current period

Gains from damage and scrapping of non-current assets 20,268,462.21 65,010.30 20,268,462.21 Penalty and confiscation income 636,862.52 503,828.45 636,862.52 Unable to pay 224,516.45 12,184.41 224,516.45 Others 1,748,930.33 1,960,238.17 1,748,930.33 Total 22,878,771.51 2,541,261.33 22,878,771.51

(55) Non-operating expenses

Unit: Yuan

Item Amount incurred in the current period Amount incurred in the previous period Amount included in non-recurring gains and losses for the current period

External donations 8,884,665.94 6,520,229.45 8,884,665.94 Loss from damage and scrapping of non-current assets 6,316,836.16 54,923,467.62 6,316,836.16 Others 8,108,079.13 9,003,092.06 8,108,079.13 Total 23,309,581.23 70,446,789.13 23,309,581.23

(56) Income tax expenses

1. Income tax expense schedule

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 153

Section 8 Financial Report

Unit: Yuan

Item Amount of current period Amount of previous period

Current income tax expense 378,731,262.39 154,907,711.12 Deferred income tax expense -196,178,584.73 -37,678,747.99 Total 182,552,677.66 117,228,963.13

2. Adjustment process of accounting profits and income tax expenses

Unit: Yuan

Item Amount incurred in this period

Total profit 1,229,740,144.61 Income tax expenses calculated according to statutory/applicable tax rates 307,435,036.15 The impact of different tax rates applicable to subsidiaries -117,846,334.11 The impact of adjusting income taxes in previous periods 8,131,403.48 The impact of non-taxable income -20,202,466.33 The impact of non-deductible costs, expenses and losses 12,813,123.01 The impact of using deductible temporary differences or deductible losses of unrecognized deferred income tax assets in the previous period -10,101,023.88 The impact of deductible temporary differences or deductible losses of unrecognized deferred income tax assets in the current period 57,832,804.81 The impact of technology development fees, additional salary deductions for disabled people and environmental protection equipment tax credits -55,509,865.47 Income tax expenses 182,552,677.66

(57) Other comprehensive income

See Note (38) for details

(58) Cash flow statement items

1. Cash related to operating activities

Other cash received related to operating activities Unit: Yuan

Item Amount of current period Amount of previous period

Interest income 54,580,132.46 236,208,271.44 Government subsidies 116,841,716.69 75,800,463.99 Collection of bank acceptance bills and guarantee deposits 4,638,926.13 33,141,452.75 Others 79,526,253.73 65,591,845.28 Total 255,587,029.01 410,742,033.46

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 154

Section 8 Financial Report

Other cash paid related to operating activities

Unit: Yuan

Item Amount of current period Amount of previous period

Cash payment 610,203,504.64 562,772,462.83 Bank acceptance bill, letter of credit and guarantee deposit 24,142,724.94 333,519,300.21 Handling fee 14,134,142.21 14,179,100.80 External donation 8,884,665.94 5,950,305.89 Others 25,613,728.48 45,559,936.71 Total 682,978,766.21 961,981,106.44

2. Cash related to investing activities

Other cash received related to investing activities Unit: Yuan

Item Amount of current period Amount of previous period

Recovery of deposit for forward foreign exchange settlement and sales 157,086,314.93

Total 157,086,314.93

Important cash received related to investing activities Unit: Yuan

Item Amount of current period Amount of previous period

Recovery of financial products 14,695,248,645.21 3,273,373,873.72 Recovery of time deposit certificates 3,969,444,482.70 3,704,125,486.99 Recovery of investments in external debt instruments and equity instruments 84,664,927.61 19,101,937.39 Total 18,749,358,055.52 6,996,601,298.10

Other cash paid related to investment activities Unit: Yuan

Item Amount of current period Amount of previous period

Payment of deposit for forward foreign exchange settlement and sales 174,086,314.93 23,000,000.00 Total 174,086,314.93 23,000,000.00

Significant cash payments related to investing activities

Item Amount of current period Amount of previous period

Purchase of financial products 23,548,226,547.11 5,171,507,093.57 Deposit certificates of deposit 3,928,332,203.05 4,021,860,534.34 New investment in debt instruments and equity instruments 652,672,312.90 139,376,740.61 Total 28,129,231,063.06 9,332,744,368.52

3. Cash related to financing activities

Other cash received related to financing activities

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 155

Section 8 Financial Report

Unit: Yuan

Item Amount of current period Amount of previous period

Received loan deposit 10,272,417,075.40 1,083,796,050.47 Received discounted bills 98,657,500.00 Received bill deposit 3,258,042.00 Total 10,272,417,075.40 1,185,711,592.47

Other cash paid related to financing activities Unit: Yuan

Item Amount of current period Amount of previous period

Payment of loan deposit 5,679,308,722.17 5,440,319,054.64 Payment of restricted stock repurchase 78,168,280.28 25,834,515.00 Payment of lease liabilities 2,060,741.22 Total 5,757,477,002.45 5,468,214,310.86

Changes in various liabilities arising from financing activities

√ Applicable Not applicable Unit: Yuan

Increase in this period Decrease in this period

Item Beginning Balance Ending Balance

Cash changes Non-cash changes Cash changes Non-cash changes

Short-term borrowings 12,666,208,536.46 19,911,452,816.81 390,815,113.58 16,578,061,524.10 16,390,414,942.75 Other payables—dividends payable 96,492,053.65 96,492,053.65

Other payables—restrictive

26,983,476.00 148,826,230.00 4,198,714.80 12,493,268.20 159,117,723.00

Stock repurchase obligation

Long-term loan

601,776,881.61 1,184,461,771.84 27,776,058.10 707,180,544.31 1,106,834 single, 16 digits 7.24: Yuan

(Including long-term loans due within one year)

Bonds Payable

1,393,228.34 40,698.68 228,864.00 1,205,063.02

(Including bonds payable due within one year)

Total 13,296,362,122.41 21,244,740,818.65 515,123,924.01 17,386,161,700.86 13,698,331.22 17,656,366,832.99

(59) Supplementary information for cash flow statement

1. Supplementary information for cash flow statement Unit: Yuan

Supplementary information Amount for the current period Amount for the previous period 1. Adjust net profit to cash flow from operating activities

Net profit 1,047,187,466.95 1,491,689,053.60 plus: asset impairment provision 25,115,724.20 141,832,381.97 Depreciation of fixed assets, depreciation of oil and gas assets, depreciation of productive biological assets 939,344,502.71 838,340,895.32

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 156

Section 8 Financial Report

Unit: Yuan

Supplementary information Amount for the current period Amount for the previous period 1. Adjust net profit to cash flow from operating activities

Depreciation of right-of-use assets 792,158.40 2,732,417.19 Amortization of intangible assets 27,727,410.04 21,401,258.19 Amortization of long-term prepaid expenses 303,947.52 2,071,462.97 Losses on disposal of fixed assets, intangible assets and other long-term assets (income is listed with "-") 397,114.67 -224,360.40 Loss from scrapping of fixed assets (income is listed with "-") -13,951,626.05 54,858,457.32 Loss from changes in fair value (income is listed with "-") -314,855,762.45 -279,767,035.60 Financial expenses (income is listed with "-") 464,882,915.37 -194,278,721.74 Investment losses (income is listed with "-") -383,364,400.43 -63,514,227.55 Decrease in deferred income tax assets (increase is listed with "-") 28,739,148.64 -16,259,854.89 Increase in deferred income tax liabilities (decreases are indicated by "-") -224,917,733.37 -21,418,893.10 Decrease in inventories (increases are indicated by "-") -82,251,681.09 -190,524,676.13 Decrease in operating receivables (increases are indicated by "-") 107,530,704.96 -1,102,876,669.36 Increase in operating payables (decreases are indicated by "-") 224,870,210.39 385,365,217.74 Others 37,479,279.10 9,631,112.73 Net cash flow from operating activities 1,885,029,379.56 1,079,057,818.26

2. Major investment and financing activities that do not involve cash receipts and payments

Convert Debt to Capital

Convertible corporate bonds due within one year

Financing lease of fixed assets

3. Net changes in cash and cash equivalents:

Closing balance of cash 1,802,523,921.20 3,297,869,898.72 Less: Opening balance of cash 3,297,869,898.72 4,601,053,537.00

Add: Ending balance of cash equivalents

Less: Opening balance of cash equivalents 1,021,681.00 Net increase in cash and cash equivalents -1,495,345,977.52 -1,304,205,319.28

2. Composition of cash and cash equivalents Unit: Yuan

Item Ending balance Beginning balance

1. Cash 1,802,523,921.20 3,297,869,898.72 Including: Cash on hand 1,452,056.40 1,485,401.54 Bank deposits that can be used for payment at any time 1,770,029,368.70 3,217,558,154.51 Other monetary funds that can be used for payment at any time 31,042,496.10 78,826,342.67

2. Balance of cash and cash equivalents at the end of the period 1,802,523,921.20 3,297,869,898.72

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 157

Section 8 Financial Report

3. Monetary funds other than cash and cash equivalents

Unit: Yuan

Item Amount of the current period Reasons why amount of the previous period does not belong to cash and cash equivalents

Bank deposits 1,107,308,122.53 Bank deposits of time deposit certificates that management plans to hold until maturity 2,806,369,064.46 7,559,499,396.16 Pledged time deposit certificates

Other monetary funds 232,100,891.03 1,156,642,651.90 Total restricted deposits such as bank acceptance bill deposits 4,145,778,078.02 8,716,142,048.06

(60) Foreign currency monetary items

1. Foreign currency monetary items

Unit: Yuan

Items Foreign currency balance at the end of the period Conversion exchange rate RMB conversion balance at the end of the period

Monetary funds 4,774,323,416.70 Including: US dollars 605,922,972.31 7.0288 4,258,911,387.77 Euros 354,485.80 8.2355 2,919,367.81 Hong Kong dollars 290,461,532.70 0.9032 262,350,665.57 Japanese yen 4,870,150,992.00 0.0448 218,168,153.99 Canadian dollars 587,819.65 5.1142 3,006,227.25 Singapore dollars 498,727.23 5.4586 2,722,352.46 Vietnamese dong 35,542,626,741.00 0.0003 9,944,747.42 British pounds 4.65 9.4346 43.87 Indonesian rupiah 39,065,623,704.17 0.0004 16,272,800.39 Malaysian ringgit 15,796.99 1.7319 27,359.31 AED 163.00 1.9071 310.86 Accounts receivable 1,233,637,591.34 Including: USD 175,175,983.05 7.0288 1,231,281,060.26 EUR 264,653.28 8.2355 2,179,552.09 Hong Kong dollars 24,220.00 0.9032 21,875.50 Singapore dollars 24,043.18 5.4586 131,242.09 Malaysian ringgit 377.80 1.7319 654.31 British pounds 2,444.00 9.4346 23,058.16 VND 557,883.67 0.0003 148.93

Long-term loan

Where: USD

Euro

Hong Kong Dollar

Other receivables 10,689,834.82 including: USD 235,706.60 7.0288 1,656,734.55

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 158

Section 8 Financial Report

Unit: Yuan

Items Foreign currency balance at the end of the period Conversion exchange rate RMB conversion balance at the end of the period

Euro 106,032.66 8.2355 873,231.97 Indonesian rupiah 7,747,152,828.00 0.0004 3,227,079.45 Vietnamese dong 15,398,600,096.99 0.0003 4,308,493.85 Canadian dollars 10,000.00 5.1142 51,142.00 Singapore dollars 105,000.00 5.4586 573,153.00Accounts payable 262,584,226.53 Including: US dollars 15,159,071.25 7.0288 106,550,079.97 Hong Kong dollars 21,642.66 0.9032 19,548.08 Indonesian rupiah 195,832,949,196.74 0.0004 81,574,289.34 Vietnamese dong 264,441,435,256.69 0.0003 73,990,121.81 Canadian dollars 88,026.93 5.1142 450,187.33 Short-term borrowings 2,121,095,223.29 Including: US dollars 178,850,000.00 7.0288 1,257,100,880.00 Singapore dollars 51,110,000.00 5.4586 HKD 278,989,046.00 647,688,600.00 0.9032 585,005,297.29 Other payables 49,107,062.69 Including: HKD 50,488.37 0.9032 USD 45,602.11 6,417,129.89 7.0288 45,104,722.57 Euro 2,901.91 8.2355 23,898.68 Japanese yen 24,123,377.60 0.0448 1,080,654.95 Indonesian rupiah 1,621,917,579.31 0.0004 675,610.38 Vietnamese Dong 7,779,097,231.33 0.0003 2,176,574.00

2. Description of overseas operating entities, including important overseas operating entities, should disclose their main overseas business location, accounting standard currency and the basis for selection. If the accounting standard currency changes, the reasons should also be disclosed.

√ Applicable Not applicable

The company's accounting standard currency is RMB. The Company's subsidiaries determine their accounting functional currencies based on the main economic environment in which they operate. These financial statements are presented in RMB.

(61) Leasing

1. The company serves as the lessee

√ Applicable Not applicable

Variable lease payments not included in the measurement of lease liabilities

Applicable √ Not applicable

Simplified treatment of short-term leases or lease payments for low-value assets

√ Applicable Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 159

Section 8 Financial Report

1. For detailed information on right-of-use assets, please refer to Note (15) of this financial statement.

2. For details of the company’s accounting policies on short-term leases and low-value asset leases, please refer to Note (31) of this financial statement.

2. Our company serves as the lessor

Operating lease as lessor

√ Applicable Not applicable

Unit: Yuan

Item Lease income Including: income related to variable lease payments not included in lease receipts

Lease income 49,385,293.04 49,385,293.04 Total 49,385,293.04 49,385,293.04

Finance lease as lessor

Applicable √ Not applicable

Undiscounted lease payments for each of the next five years

√ Applicable Not applicable

Unit: Yuan

Annual undiscounted lease payments

Project

Ending amount Beginning amount

First year 31,239,202.93 26,532,305.33 Second year 10,562,015.58 10,687,274.63 Third year 6,964,665.15 9,637,768.23 Fourth year 921,431.27 6,425,178.82 Fifth year 217,478.99

Total undiscounted lease payments after five years 49,904,793.92 53,282,527.01

8. R&D expenditures

Unit: Yuan

Item Amount of current period Amount of previous period

Direct investment 217,996,305.75 231,877,018.05 Personnel labor 127,323,150.06 119,701,342.07 Depreciation and amortization 37,056,867.09 28,176,576.85 Water, electricity, coal and heating expenses 16,869,185.52 17,160,010.91 Others 3,260,501.46 1,429,466.68 Share-based payment 1,875,837.68

Total 404,381,847.56 398,344,414.56 Including: Expenditure R&D expenditure 404,381,847.56 398,344,414.56

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 160

Section 8 Financial Report

9. Changes in consolidation scope

(1) Changes in the scope of consolidation due to other reasons

Explain the changes in the scope of consolidation caused by other reasons (such as the establishment of new subsidiaries, liquidation of subsidiaries, etc.) and their related circumstances:

Company name Equity acquisition method

PT Green Environment Management Services Establishment

Shandong Yingcai Printing Technology Co., Ltd. was established

Company name Equity disposal method

Shanghai Yingke Medical Products Co., Ltd. Log out

Intco Medical Industries Inc. Logout

10. Interests in other entities

(1) Equity in subsidiaries

1. Structure of enterprise group

Unit: Yuan

Shareholding ratio

Name of subsidiary company Registered capital Main place of business Place of registration Nature of business How to obtain

direct indirect

Highmax LLC 250,352,239.00 City of Ontario, U.S.A. City of Ontario, U.S.A. Commercial 100.00% Establishment of Maxcel LLC 18,541,358.00 City of Ontario, U.S.A. City of Ontario, U.S.A. Commercial 100.00% Business combination under common control Realmax LLC 265,648,195.00 City of Ontario, U.S.A. City of Ontario, U.S.A. Commercial 100.00% Establishment of Shanghai Yingke Medical Supplies Co., Ltd. 5,646,640.59 Fengxian District, Shanghai Fengxian District, Shanghai Manufacturing 17.66% 82.34% Merger of enterprises under the same control Shanghai Yingyan Enterprise Management Co., Ltd. 21,004,205.00 Fengxian District, Shanghai Fengxian District, Shanghai Commercial 100.00% Merger of enterprises under the same control Shanghai Yingen International Trade Co., Ltd. 2,000,000.00 Shanghai Free Trade Zone Shanghai Free Trade Zone Commercial 100.00% Establishment of Anhui Inco Medical Products Co., Ltd. 2,717,704,000.00 Huaibei City, Anhui Province Huaibei City, Anhui Province Manufacturing 81.13% 18.87% Establishment of Intco Europe Gmbh 37,004,663.90 Dusseldorf, Germany Dusseldorf, Germany Business 100.00% Establishment of Shanghai Yingke ECG Medical Products Co., Ltd. 2,763,127.61 Fengxian District, Shanghai Fengxian District, Shanghai Manufacturing 71.31% 28.69% Merger of companies under common control

Intco Medical Investment

175,892,315.97 Singapore Singapore Business 100.00% Established

Singapore Pte. Ltd.

Intco Medical Singapore Pte.Ltd. 35,153,280.00 Singapore Singapore Commercial 100.00% Establishment of Jiangsu Intco Medical Products Co., Ltd. 419,807,960.55 Zhenjiang City, Jiangsu Province Zhenjiang City, Jiangsu Province Manufacturing 41.33% 58.67% Merger of enterprises under common control with Shandong Haode Plastic Co., Ltd. 199,901,216.71 Zibo City, Shandong Province Zibo City, Shandong Province Manufacturing 51.00% Establishment of Intco Medical Industries Inc. 80,720,100.00 City of Ontario, U.S.A. City of Ontario, U.S.A. Commercial 100.00% Establishment of Intco Medical Supplies (Hong Kong) Co., Ltd. 25,929,948.57 Hong Kong, China Hong Kong, China Commercial 96.88% 3.12% Establishment of Shandong Yingke Medical Technology Co., Ltd. 489,094,812.26 Zibo City, Shandong Province Zibo City, Shandong Province Manufacturing 10.08% 89.92% Establishment

BASIC INTERNATIONAL

74,578,433.90 Thanh Hoa City, Vietnam Thanh Hoa City, Vietnam Manufacturing 100.00% Established

##VIETNAM CO..LTD

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 161

Section 8 Financial Report

Unit: Yuan

Shareholding ratio

Name of subsidiary company Registered capital Main place of business Place of registration Nature of business How to obtain

direct indirect

Shandong Yingke Medical Products Co., Ltd. 2,842,583,350.00 Qingzhou City, Shandong Province Qingzhou City, Shandong Province Manufacturing 13.01% 86.99% Establishment of Jiangxi Yingke Medical Co., Ltd. 1,192,371,263.18 Jiujiang City, Jiangxi Province Jiujiang City, Jiangxi Province Manufacturing 59.10% 40.90% Establishment of Anqing Intco Medical Co., Ltd. 346,828,887.50 Anqing City, Anhui Province Anqing City, Anhui Province Manufacturing 36.17% 63.83% Establishment of Anhui Yingyi Thermal Power Co., Ltd. 80,000,000.00 Anqing City, Anhui Province Anqing City, Anhui Province Manufacturing 80.00% Establishment of Intco Canada Inc. 5,210.00 Ontario, Canada Ontario, Canada Commercial 50.00% 50.00% Establishment of Shanghai Yingmai International Trade Co., Ltd. 10,000,000.00 Shanghai Free Trade Zone Shanghai Free Trade Zone Commercial 100.00% Establishment of Yiyuan Yingke Medical Protective Products Co., Ltd. 20,179,969.28 Zibo City, Shandong Province Zibo City, Shandong Province Manufacturing 100.00% Establishment of Anhui Guoyi Mold Technology Co., Ltd. 10,000,000.00 Huaibei City, Anhui Province Huaibei City, Anhui Province Manufacturing 51.00% Establishment of Anhui Kaize New Materials Co., Ltd. 415,000,000.00 Huaibei City, Anhui Province Huaibei City, Anhui Province Manufacturing 65.00% Establishment of Hainan Yingke Medical Technology Co., Ltd. 6,600,000.00 Chengmai County, Hainan Province Chengmai County, Hainan Province Commercial 100.00% Established

Intco Medical Technology

52,404,322.10 Guang'an City, Vietnam Guang'an City, Vietnam Manufacturing 100.00% Established

Vietnam Company Limited

Basic Medical Vietnam Co., Ltd. 3,312,905.90 Thanh Hoa City, Vietnam Thanh Hoa City, Vietnam Manufacturing 100.00% Establishment of Jiangsu Yingke Medical Equipment Co., Ltd. 194,565,000.00 Zhenjiang City, Jiangsu Province Zhenjiang City, Jiangsu Province Manufacturing 100.00% Establishment of Yingke Medical International (Hong Kong) Co., Ltd. 420,000.00 Hong Kong, China Hong Kong, China Commercial 100.00% Establishment of Intco Medical Japan Co., Limited 79,740,720.00 Tokyo, Japan Tokyo, Japan Commercial 100.00% Establishment of Youjia (Qingdao) Medical Technology Co., Ltd. 10,000,000.00 Qingdao City, Shandong Province Qingdao City, Shandong Province Manufacturing 100.00% Merger of enterprises not under common control Anhui Yingcai Printing Technology Co., Ltd. 69,400,000.00 Huaibei City, Anhui Province Huaibei City, Anhui Province Manufacturing 100.00% Establishment of Shandong Yingke Hygiene Products Co., Ltd. 34,960,000.00 Zibo City, Shandong Province Zibo City, Shandong Province Manufacturing 80.00% Establishment of INTCO MEDICAL SDN. BHD. 1,696,065.13 Kuala Lumpur, Malaysia Kuala Lumpur, Malaysia Commercial 100.00% Establishment of Realmax GmbH 29,872,335.00 Essen, Germany Essen, Germany Commercial 100.00% Establishment of Jiangxi Yingcai Technology Co., Ltd. 50,000,000.00 Jiujiang City, Jiangxi Province Jiujiang City, Jiangxi Province Manufacturing 100.00% Establishment of BASIC INVESTMENT PTE. LTD. 544,681,411.35 Singapore Singapore Commercial 100.00% Establishment of Anhui Yinghai Smart Energy Co., Ltd. 7,230,000.00 Anqing City, Anhui Province Anqing City, Anhui Province Commercial 85.00% Establishment of Shandong Yingcai Printing Technology Co., Ltd. 22,000,000.00 Qingzhou City, Shandong Province Qingzhou City, Shandong Province Manufacturing 100.00% Establishment

PT BASIC INTERNATIONAL

507,048,969.70 Indonesia Indonesia Manufacturing 99.00% Established

##SUMATERA

PrimeMax Medical Industries, Inc. Ontario, U.S.A. Ontario, U.S.A. Commercial 100.00% Established

PT GREEN ENVIRONMENT

8,830,528.90 Indonesia Indonesia Manufacturing 70.00% Established

MANAGEMENT SERVICES

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 162

Section 8 Financial Report

11. Government subsidies

(1) Government subsidies recognized according to the amount receivable at the end of the reporting period

Applicable √ Not applicable

Reasons for failure to receive the estimated amount of government subsidy at the estimated time

Applicable √ Not applicable

(2) Liability items involving government subsidies

√ Applicable Not applicable Unit: Yuan

Newly added in this period This period is included in the business This period it is transferred to its current period Its and assets/income accounting account Opening balance Ending balance

Subsidy amount Amount of external income Amount of other income Other changes related

Deferred income 155,840,533.57 74,015,000.00 17,867,060.19 211,988,473.38 Related to assets

(3) Government subsidies included in current profits and losses

√ Applicable Not applicable Unit: Yuan

Accounting account Amount for the current period Amount for the previous period

Amount of government subsidies included in other income 52,784,749.88 43,408,880.18 Amount of impact of fiscal discount on total profit 7,909,027.00 2,585,700.00

12. Risks related to financial instruments

(1) Various risks arising from financial instruments

The company's goal in risk management is to strike a balance between risks and returns, minimize the negative impact of risks on the company's operating performance, and maximize the interests of shareholders and other equity investors. Based on this risk management objective, the company's basic risk management strategy is to confirm and analyze the various risks faced by the company, establish an appropriate risk tolerance bottom line and conduct risk management, and supervise various risks in a timely and reliable manner to control risks within a limited range.

The Company faces various risks related to financial instruments in its daily activities, mainly including credit risk, liquidity risk and market risk. Management has reviewed and approved policies for managing these risks, which are summarized below.

(1) Credit risk

Credit risk refers to the risk that one party to a financial instrument cannot fulfill its obligations, causing financial losses to the other party.

1.Credit risk management practices

(1) Credit risk evaluation methods

The Company assesses at each balance sheet date whether the credit risk of relevant financial instruments has increased significantly since initial recognition. When determining whether credit risk has increased significantly since initial recognition, the Company considers reasonable and evidence-based information that is available without unnecessary additional cost or effort, including qualitative and quantitative analysis based on historical data, external credit risk ratings, and forward-looking information. Based on a single financial instrument or a combination of financial instruments with similar credit risk characteristics, the company determines the changes in default risk during the expected duration of the financial instrument by comparing the risk of default of the financial instrument on the balance sheet date with the risk of default on the initial recognition date.

When one or more of the following quantitative and qualitative criteria are triggered, the company believes that the credit risk of financial instruments has increased significantly:

(1) The quantitative standard is mainly that the default probability of the remaining duration on the balance sheet date has increased by more than a certain percentage compared with the initial recognition;

(2) Qualitative standards mainly include significant adverse changes in the debtor's operating or financial conditions, existing or expected changes in technology, market, economic or legal environment that will have a significant adverse impact on the debtor's ability to repay the company, etc.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 163

Section 8 Financial Report

(2) Definition of defaulted and credit-impaired assets

When a financial instrument meets one or more of the following conditions, the company defines the financial asset as having defaulted, and its standards are consistent with the definition of credit impairment:

1. The debtor encounters major financial difficulties;

2. The debtor violates the binding clauses on the debtor in the contract;

3. The debtor is likely to go bankrupt or undergo other financial reorganization;

4. The creditor grants concessions to the debtor that the debtor would not have made under any other circumstances due to economic or contractual considerations related to the debtor's financial difficulty.

2. Measurement of expected credit losses

Key parameters for measuring expected credit losses include probability of default, loss given default rate and exposure to default risk. The company considers quantitative analysis and forward-looking information of historical statistical data (such as counterparty ratings, guarantee methods and collateral types, repayment methods, etc.) to establish default probability, default loss rate and default risk exposure models.

3. Please refer to the notes to this financial statement for details of the reconciliation statement between the opening balance and the closing balance of financial instrument loss provisions.

4. Credit risk exposure and credit risk concentration

The company's credit risk mainly comes from monetary funds and accounts receivable. In order to control the above-mentioned related risks, the Company has taken the following measures.

(1) Monetary funds

The Company places bank deposits and other monetary funds in financial institutions with higher credit ratings, so its credit risk is lower.

(2) Accounts receivable

The company regularly conducts credit assessments on customers who trade on credit. Based on the credit assessment results, the Company chooses to conduct transactions with approved customers with good credit and monitors their receivable balances to ensure that the Company does not face significant bad debt risks.

Since the company's accounts receivable risk points are distributed among multiple partners and customers, as of December 31, 2025, 16.20% of the company's accounts receivable (December 31, 2024: 16.75%) originated from the top five customers with balances, and the company does not have significant credit concentration risk.

The Company's maximum exposure to credit risk is the carrying value of each financial asset on the balance sheet.

(2) Liquidity risk

Liquidity risk refers to the risk of a shortage of funds when the company fulfills its obligations to settle by delivering cash or other financial assets. Liquidity risk may arise from the inability to sell financial assets at fair value as quickly as possible; or from the counterparty's inability to repay its contractual debts; or from debts that mature prematurely; or from the inability to generate expected cash flows.

In order to control this risk, the Company comprehensively uses various financing methods such as bill settlement and bank borrowing, and adopts an appropriate combination of long-term and short-term financing methods to optimize the financing structure and maintain a balance between financing continuity and flexibility. The Company has obtained bank credit lines from a number of commercial banks to meet its working capital requirements and capital expenditures.

Financial liabilities are classified by remaining maturity

Unit: Yuan

Closing amount

Project

Book value Undiscounted contract amount Within 1 year 1-3 years More than 3 years

Short-term borrowings 16,390,414,942.75 16,530,723,260.77 16,530,723,260.77

Derivative financial liabilities 25,781,822.83 25,781,822.83 25,781,822.83

Notes payable 19,866,511.82 19,866,511.82 19,866,511.82

Accounts payable 1,236,654,739.07 1,236,654,739.07 1,236,654,739.07

Other payables 278,471,838.63 278,471,838.63 278,471,838.63

Other current liabilities

• Endorsed but not terminated 511,851.08 511,851.08 511,851.08

Confirmed bank acceptance draft

Long-term loan

1,106,834,167.24 1,140,363,677.27 715,815,473.00 259,276,094.68 165,272,109.59

(Including long-term loans due within one year)

Subtotal 19,058,535,873.42 19,232,373,701.47 18,807,825,497.20 2 59,276,094.68 1 65,272,109.59

Beginning balance

Project

Book value Undiscounted contract amount Within 1 year 1-3 years More than 3 years

Short-term borrowings 12,666,208,536.46 12,666,208,536.46 12,666,208,536.46

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 164

Section 8 Financial Report

Derivative financial liabilities 81,655,188.94 81,655,188.94 81,655,188.94

Notes payable 79,765,311.40 79,765,311.40 79,765,311.40

Accounts payable 765,617,912.37 765,617,912.37 765,617,912.37

Other payables 162,334,409.88 162,334,409.88 162,334,409.88

Long-term loan

601,776,881.61 633,017,535.93 363,864,654.65 266,435,295.33 2,717,585.95

(Including long-term loans due within one year)

Bonds payable 1,393,228.34 1,393,228.34 1,393,228.34

Subtotal 14,358,751,469.00 14,389,992,123.32 14,120,839,242.04 266,435,295.33 2,717,585.95

(3) Market risk

Market risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market prices. Market risks mainly include interest rate risk and foreign exchange risk.

1. Interest rate risk

Interest rate risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in market interest rates. Fixed-rate interest-bearing financial instruments expose the Company to fair value interest rate risk, while floating-rate interest-bearing financial instruments expose the Company to cash flow interest rate risk. The Company determines the proportion of fixed-rate and floating-rate financial instruments based on market conditions, and maintains an appropriate portfolio of financial instruments through regular review and monitoring.

As of December 31, 2025, the company's bank borrowings with floating interest rates were RMB 574,601,168.41. Under the assumption that other variables remain unchanged, assuming that the interest rate changes by 50 basis points, it will not have a significant impact on the company's total profit and shareholders' equity.

2. Foreign exchange risk

Foreign exchange risk refers to the risk that the fair value or future cash flows of financial instruments will fluctuate due to changes in foreign exchange rates. The risk of exchange rate changes faced by the Company is mainly related to the Company's foreign currency monetary assets and liabilities. For foreign currency assets and liabilities, if short-term imbalances occur, the Company will buy and sell foreign currencies at market exchange rates when necessary to ensure that the net risk exposure is maintained at an acceptable level.

For details of the Company’s foreign currency monetary assets and liabilities at the end of the period, please refer to Note (60) 1 of this financial statement.

(4) Transfer of financial assets

1. Basic information on transfer of financial assets

Transfer method Nature of financial assets transferred Amount of financial assets transferred Termination of recognition Basis for judgment of termination of recognition

Bill endorsement Receivables financing 31,351,385.29 Derecognition has transferred almost all of its risks and rewards Bill discount Receivables financing 50,000.00 Derecognition Has transferred almost all of its risks and rewards Notes receivable Notes receivable 511,851.08 Not derecognized Retained almost all of its risks and rewards Subtotal 31,913,236.37

2. Financial assets derecognized due to transfer

Item Financial assets transfer method Amount of financial assets derecognized Gains or losses related to derecognition Receivables Financing Bill endorsement 31,351,385.29

Accounts receivable financing Bill discount 50,000.00 -337.19 Subtotal 31,401,385.29 -337.19

3. The amount of assets and liabilities resulting from the transfer of financial assets and continued involvement

Item Financial asset transfer method Amount of assets formed by continued involvement Amount of liabilities formed by continued involvement Notes receivable Bill endorsement 511,851.08 Subtotal 511,851.08

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 165

Section 8 Financial Report

13. Disclosure of fair value

(1) Closing fair value of assets and liabilities measured at fair value

Unit: Yuan

Closing fair value

Project

Level 1 fair value measurement Second level fair value measurement Third level fair value measurement Total

1. Continuous fair value measurement -- -- -- --

(1) Trading financial assets 15,655,002,808.31 2,048,977,940.69 17,703,980,749.00

1. Measured at fair value and its changes

15,655,002,808.31 2,048,977,940.69 17,703,980,749.00

Financial assets included in current profit and loss

(1) Investment in debt instruments 430,631,498.27 1,668,943,700.69 2,099,575,198.96

(2) Investment in equity instruments 30,000,000.00 30,000,000.00

(3) Derivative financial assets 3,420,433.89 3,420,433.89

(4) Financial products 15,224,371,310.04 350,034,240.00 15,574,405,550.04

(5) Receivables financing 8,240,850.19 8,240,850.19

Measured at fair value on an ongoing basis

15,658,423,242.20 2,057,218,790.88 17,715,642,033.08

##’s total assets

(2) Trading financial liabilities 25,781,822.83 25,781,822.83 Derivative financial liabilities 25,781,822.83 25,781,822.83

Measured at fair value on an ongoing basis

25,781,822.83 25,781,822.83

##’s total liabilities

2. Non-continuous fair value measurement -- -- -- --

(2) Continuous and non-continuous second-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters

The financial assets/liabilities measured at the second level of fair value held by the Company are financial products, foreign exchange derivatives, interest rate derivatives and some debt instrument investments. The Company uses the valuation report provided by the financial institution as a reasonable estimate of fair value.

(3) Continuous and non-continuous third-level fair value measurement items, valuation techniques used and qualitative and quantitative information on important parameters

The financial assets measured at Level 3 fair value held by the Company are wealth management products. The Company estimates future cash flows based on the expected rate of return and discounts them to determine their fair value.

The financial assets measured at the third level of fair value held by the Company are debt instruments and equity instrument investments. If the operating environment, operating conditions and financial status of the invested enterprise have not changed significantly, the Company shall measure the equity it should enjoy as a reasonable estimate of the fair value.

The third-level fair value measurement receivable financing held by the Company is bank acceptance bill receivable, which has low credit risk and short remaining period. The Company determines its fair value based on its face balance.

(4) Fair value of financial assets and financial liabilities not measured at fair value

The Company's financial assets and financial liabilities that are not measured at fair value mainly include: monetary funds, notes receivable, accounts receivable, other receivables, short-term loans, notes payable, accounts payable, other payables, non-current liabilities due within one year, long-term loans, etc. The difference between their book values and fair values is small.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 166

Section 8 Financial Report

14. Related parties and related transactions

(1) Information about the parent company of the enterprise

Description of the parent company of this enterprise

As of December 31, 2025, natural person Liu Fangyi directly holds 35.37% of the company's equity and is the actual controller of the company.

The ultimate controller of the company is Liu Fangyi.

(2) Information about the company’s subsidiaries

For details of the company's subsidiaries, please see Note 10. Equity in other entities.

(3) Other related parties

Name of other related parties Relationship between other related parties and the enterprise

Yingke Renewable Resources Co., Ltd. is controlled by the same actual controller as the company.

Jiangsu Yingke Recycling Technology Co., Ltd. is controlled by the same actual controller as the company.

Shanghai Yingke Industrial Co., Ltd. is controlled by the same actual controller as the company.

Anhui Yingke Recycling Technology Co., Ltd. is controlled by the same actual controller as the company.

Shanghai Yingcong Enterprise Management Consulting Partnership (Limited Partnership) is controlled by the same actual controller as the company.

Intco Industries Viet Nam Co.,Ltd and the company are controlled by the same actual controller

Shanghai Yingke Charity Foundation’s subsidiary Shanghai Yingen International Trading Co., Ltd. serves as the main original donor

Zhejiang Tianchen Glue Industry Co., Ltd. A joint-stock company of our company

(4) Related transactions

1. Related transactions related to the purchase and sale of goods, provision and receipt of services

Procurement of goods/receipt of labor services table Unit: Yuan

Related parties Related party transaction content Amount incurred in the current period Approved transaction limit Whether the transaction amount exceeds the transaction amount Amount incurred in the previous period

Yingke Recycling Resources Co., Ltd. Goods 46,325.12 No 37,272.57 Shanghai Yingke Industrial Co., Ltd. Goods 3,310,309.75 No 2,174,037.19 Anhui Yingke Recycling Technology Co., Ltd. Goods 19,203.53 No 211,327.43 Jiangsu Yingke Recycling Technology Co., Ltd. Goods 608,203.11 No

Zhejiang Tianchen Plastic Industry Co., Ltd. Products 5,912,177.70 No 473,904.43

List of goods sold/labor services provided Unit: Yuan

Related parties Related party transaction content Amount incurred in the current period Amount incurred in the previous period

Yingke Renewable Resources Co., Ltd. Goods 199,302.64 229,682.60 Yingke Renewable Resources Co., Ltd. Fuel and power 208,593.58 78,539.28 Jiangsu Yingke Recycling Technology Co., Ltd. Goods 2,688.50 5,726.42 Shanghai Yingke Industrial Co., Ltd. Goods 64,747.80 51,358.74 Anhui Inco Recycling Technology Co., Ltd. Goods 15,362.83 48,654.30 Intco Industries Viet Nam Co.,Ltd Goods 50,440.51

Shanghai Yingke Charity Foundation Goods 66,991.16 267,823.03

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 167

Section 8 Financial Report

2. Related leasing situation

Unit: Yuanben Company as lessor:

Name of lessee Type of leased assets Lease income recognized in the current period Lease income recognized in the previous period

Yingke Renewable Resources Co., Ltd. Factory building 1,502,198.13 700,770.65

The company as the lessee: Unit: Yuan

Simplified short-term treatment is not included in the lease liability

Variable measurement of leases and low-value assets Lease commitments Increase in rent payments

Rental expenses for property leasing Lease payments

Lessor Lease assets Liability interest expense Right-use assets

(if applicable) (if applicable)

Name Product Category

This issue Previous issue This issue Previous issue This issue Previous issue This issue Previous issue This issue Previous issue

Amount incurred Amount incurred Amount incurred Amount incurred Amount incurred Amount incurred Amount incurred Amount incurred Amount incurred Inko Renewable Resources

Factory building 401,834.86 402,935.77

Co., Ltd.

Shanghai Yingcong Enterprise

Management Consulting Partnership Factory 160,000.08 160,000.00

Enterprise (Limited Partnership)

3. Remuneration of key management personnel Unit: Yuan

Item Amount of current period Amount of previous period

Remuneration of key management personnel 14,509,578.25 12,346,015.07

4. Other related transactions

In 2025, the Company donated RMB 370,000.00 to Shanghai Yingke Charity Foundation.

(5) Accounts receivable and payable from related parties

1. Items receivable Unit: Yuan

Ending balance Beginning balance

Project Name Related Party

Book balance Provision for bad debts Book balance Provision for bad debts

Accounts receivable Yingke Renewable Resources Co., Ltd. 34,219.58 1,710.98

15. Share-based payment

(1) Overall situation of share-based payment

√ Applicable Not applicable Unit: Yuan

Granted in this period. Exercised in this period. Unlocked in this period. Granted in this period. Objects granted.

Category Quantity Amount Quantity Amount Quantity Amount Quantity Amount

2022 Equity Incentive Plan 1,052,520.00 11,882,950.80 348,843.00 3,938,437.47 2025 Equity Incentive Plan 13,172,100.00 148,826,230.00 90,500.00 1,022,650.00 Total 13,172,100.00 148,826,230.00 1,052,520.00 11,882,950.80 439,343.00 4,961,087.47

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 168

Section 8 Financial Report

Stock options or other equity instruments outstanding at the end of the period

√ Applicable Not applicable Unit: Yuan

Stock options outstanding at the end of the period Other equity instruments outstanding at the end of the period

Grant object category

Range of exercise prices Remaining term of the contract Range of exercise prices Remaining term of the contract

Self-Grant Restricted Stock Registration

Company implementation in 2025

The 2025 Equity Incentive Plan will be completed in 21 months and 21 months respectively from the date of completion.

restricted stock incentive plan,

The first grant is 33 months, 45 months and 57 months. The grant price is 11.30 yuan/share.

Expiration

12 months, 24 months, from the date of completion of registration of the granted restricted shares,

Company implementation in 2025

2025 Equity Incentive Plan 36 months, 48 months or 2026,

restricted stock incentive plan,

Reserved grant in 2027, 2028 and 2029 with grant price of 11.25 yuan/share

Annual report disclosure date

(Whichever is later between the two)

(2) Equity-settled share-based payment

√ Applicable Not applicable Unit: Yuan Method for determining the fair value of equity instruments on the grant date The company determines the fair value of the restricted stock on the grant date based on the closing price of the company’s stock on the grant date.

Determined based on the actual number of options exercised; on each balance sheet date from the grant date to the vesting date,

Based on the latest follow-up information such as changes in the number of people who can be assigned, completion of performance indicators, etc.

Basis for determining the number of exercisable equity instruments

Revision of the estimated number of vested restricted shares: based on the latest changes in the number of vesting persons

We will wait for subsequent information to make the best estimate and revise the number of equity instruments expected to be exercisable.

Reasons for significant differences between the current period’s estimate and the previous period’s estimate None

The cumulative amount of equity-settled share-based payments included in capital reserves 42,618,853.90

Total expenses recognized for equity-settled share-based payment in the current period 31,997,687.05

(3) Share-based payment settled in cash

Applicable √ Not applicable

(4) Share-based payment expenses for this period

√ Applicable Not applicable Unit: Yuan

Category of grant objects Equity-settled share-based payment expenses Cash-settled share-based payment expenses

Managerial staff 14,917,973.25

R&D personnel 1,875,837.68

Sales staff 7,609,744.83

Production personnel 7,594,131.29

Total 31,997,687.05

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 169

Section 8 Financial Report

(5) Modification and termination of share-based payment

On May 22, 2025, the company's fourth session of the Board of Directors passed the "Proposal on Adjusting the Performance Assessment Indicators of the Company's 2022 Restricted Stock Incentive Plan". The company adjusted the fourth unlocking period of the 2022 Restricted Stock Incentive Plan and the company-level performance assessment targets in 2025.

16. Commitments and contingencies

(1) Important commitments

Important commitments existing at the balance sheet date

1. Signed foreign investment contracts and related financial expenditures that have not yet been performed or not fully performed

(1) According to the partnership agreement regarding the Guangxi Free Trade Zone Yunthuang Venture Capital Center (Limited Partnership) signed in November 2021 by the company's subsidiary Yingke Medical Supplies (Hong Kong) Co., Ltd., Yingke Medical Supplies (Hong Kong) Co., Ltd. committed to investing US$22 million. As of December 31, 2025, Inco Medical Supplies (Hong Kong) Co., Ltd. has paid an investment of US$5.8138 million.

(2) According to the partnership agreement signed by Inko Medical Supplies (Hong Kong) Co., Ltd. and other partners of Horizon Capital investment fund L.P., Inko Medical Supplies (Hong Kong) Co., Ltd. committed to invest US$50 million. As of December 31, 2025, Inco Medical Supplies (Hong Kong) Co., Ltd. has paid an investment of US$12.5 million.

(3) According to the subscription agreement signed between Intco Medical Investment Singapore Pte. Ltd., a subsidiary of the company, and the general partner of Warburg Pincus GLOBAL GROWTH 14.L.P., Intco Medical Investment Singapore Pte. Ltd. committed to invest US$100 million. As of December 31, 2025, Intco Medical Investment Singapore Pte. Ltd. has paid US$80.25 million in investment.

(4) According to the subscription agreement signed between the company's subsidiary Inko Medical International (Hong Kong) Co., Ltd. and the general partner of Warburg Pincus GLOBAL GROWTH 15.L.P., Inko Medical International (Hong Kong) Co., Ltd. committed to invest US$70 million. As of December 31, 2025, no capital has been contributed.

(5) According to the partnership agreement signed by Inko Medical International (Hong Kong) Co., Ltd., a subsidiary of the Company, and other partners of MARATHON ASSET-BASED LENDING OFFSHORE FUND IV LP, Inko Medical International (Hong Kong) Co., Ltd. committed to invest US$30 million. As of December 31, 2025, Inco Medical International (Hong Kong) Co., Ltd. has paid an investment of US$1.5 million.

(6) According to the partnership agreement signed by Inco Medical International (Hong Kong) Co., Ltd., a subsidiary of the Company, and other partners of North Haven Private Equity Co-Investment Opportunities Fund III (Cayman) LP, Inco Medical International (Hong Kong) Co., Ltd. committed to invest US$20 million. As of December 31, 2025, Inko Medical International (Hong Kong) Co., Ltd. has paid an investment of US$9 million.

(2) Contingencies

1. Important contingencies existing on the balance sheet date

As of the balance sheet date, the Company has no important contingencies that need to be disclosed.

2. If the company has no important contingencies that need to be disclosed, it should also be explained.

The company has no important contingencies that need to be disclosed.

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 170

Section 8 Financial Report

17. Events after the balance sheet date

(1) Profit distribution

The number of dividends to be distributed per 10 shares (yuan) 1 The number of dividend shares to be distributed per 10 shares (shares) 0 The number of dividends to be distributed per 10 shares (shares) 0 The number of dividends to be distributed per 10 shares (yuan) after review and approval 1 The number of dividend shares (shares) per 10 shares to be distributed after review and approval 0 The number of dividends to be distributed per 10 shares (shares) 0

According to the China Securities Regulatory Commission's "Guidelines for the Supervision of Listed Companies No. 3 - Cash Dividends by Listed Companies", listed companies are encouraged to distribute cash dividends and provide investors with guidance on stable and reasonable returns. On the premise of complying with the principle of profit distribution and ensuring the company's normal operations and long-term development, the company's profit distribution plan for 2025 is: It is planned to use the company's equity to distribute shares when the implementation is implemented

The total share capital on the right registration date after deducting the repurchased shares in the company's repurchase account shall be the base number. Every 10

Profit distribution plan

A cash dividend of RMB 1 (tax included) will be distributed on each stock, no bonus shares will be given, and no bonus shares will be issued or converted into share capital.

If the company's total share capital or the number of repurchased shares changes between the disclosure and implementation of the profit distribution plan, the company's

The total amount of distribution will be adjusted based on the principle that the amount of cash dividends distributed per share remains unchanged.

(2) Description of other post-balance sheet events

According to the resolution of the 14th meeting of the company's fourth session of the Board of Directors on April 23, 2026, the company plans to distribute a cash dividend of 1.00 yuan (tax included) to all shareholders for every 10 shares based on the total share capital on the equity registration date when the equity distribution is implemented minus the shares repurchased in the company's special repurchase account. No bonus shares will be issued for this profit distribution, and no reserve fund will be converted into share capital. The above profit distribution plan still needs to be submitted to the company's 2025 annual shareholders' meeting for review and approval.

18. Other important matters

(1) Segment information

1. Basis for determination of reporting segments and accounting policies

The Group's reportable segments are business units that provide different products or services. Since various businesses require different technologies and market strategies, the Group independently manages the production and operation activities of each reporting segment and evaluates its operating results respectively to decide to allocate resources to them and evaluate their performance.

The Group has three reportable segments, namely:

— Personal protection division, responsible for the production and sales of nitrile gloves, PVC gloves and other protective products

— Rehabilitation and nursing division, responsible for the production and sales of wheelchairs and accessories and other products

— Other divisions, responsible for the production and sales of hot and cold compress bags, electrode pads, etc.

Inter-segment transfer prices are determined by reference to the prices used in sales to third parties.

Assets are allocated based on the operations of the segment and the location of the assets, liabilities are allocated based on the operation of the segment, and expenses indirectly attributable to each segment are allocated among the segments in proportion to revenue.

2. Financial information of reportable segments

Unit: Yuan

Items Personal protective products Rehabilitation care products Others Inter-segment eliminations Total

Operating income 8,835,174,990.74 447,870,434.74 642,774,019.24 9,925,819,444.72 Operating cost 6,690,357,173.81 353,155,253.87 488,043,292.33 7,531,555,720.01

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 171

Section 8 Financial Report

19. Notes on main items of the parent company’s financial statements

(1) Accounts receivable

1. Disclosure based on age Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 263,779,156.92 246,005,800.08 1 to 2 years 94,628,786.17 15,395,249.26 2 to 3 years 9,598,229.30 1,538,630.43 More than 3 years 657,244.31

3 to 4 years 657,244.31

Total 368,663,416.70 262,939,679.77

2. Classified disclosure based on bad debt accrual method Unit: Yuan

Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book Value Book Value

Amount Proportion Amount Provision proportion Amount Proportion Amount Provision proportion Among them:

By group

It’s accurate to raise bad debts

368,663,416.70 100.00% 762,577.48 0.21% 367,900,839.22 262,939,679.77 100.00% 471,281.31 0.18% 262,468,398.46

Prepared accounts receivable

Account

Among them:

Total 368,663,416.70 100.00% 762,577.48 0.21% 367,900,839.22 262,939,679.77 100.00% 471,281.31 0.18% 262,468,398.46

Provision for bad debts on a group basis: 762,577.48

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Aging combination 15,128,651.83 762,577.48 5.04% Receivables from related parties within the company’s consolidated scope 353,534,764.87

Total 368,663,416.70 762,577.48

Description of what this combination is based on:

Account age closing amount

Book balance Bad debt provision Proportion of provision (%) Within 1 year 15,082,390.58 754,119.53 5.00 2-3 years 36,136.17 5,420.43 15.00 3-4 years 10,125.08 3,037.52 30.00 Subtotal 15,128,651.83 762,577.48 5.04

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 172

Section 8 Financial Report

If bad debt provisions for accounts receivable are made according to the general expected credit loss model:

Applicable √ Not applicable

3. Accounts receivable and contract assets with the top five closing balances by debtors

Unit: Yuan

Accounts receivable and total share of accounts receivable and contracts Bad debt provision for accounts receivable and unit name Closing balance of accounts receivable Closing balance of contract assets

Closing balance of the same assets Proportion of total closing balance of assets Closing balance of contract asset impairment provision

Unit 1 297,148,485.83 297,148,485.83 80.60%

Unit 2 27,096,732.03 27,096,732.03 7.35%

Unit 3 10,443,392.44 10,443,392.44 2.83%

Unit 4 10,045,106.49 10,045,106.49 2.72%

Unit 5 7,957,438.78 7,957,438.78 2.16% 397,871.94 Total 352,691,155.57 352,691,155.57 95.66% 397,871.94

(2) Other receivables

Unit: Yuan

Item Ending balance Beginning balance

Dividends receivable 300,000,000.00

Other receivables 646,681,147.02 252,632,129.72

Total 646,681,147.02 552,632,129.72

1. Dividends receivable

(1) Classification of dividends receivable

Unit: Yuan

Project (or invested unit) Closing balance Opening balance

Dividends receivable 300,000,000.00

Total 300,000,000.00

2. Other receivables

(1) Classification of other receivables according to nature of payment

Unit: Yuan

Nature of payment Book balance at the end of the period Book balance at the beginning of the period

Deposit security deposit 11,659,739.51 16,535,791.74

Accounts receivable from subsidiaries 637,831,579.04 226,323,994.83

Temporary payment receivable 789,187.84 20,132,198.73

Others 95,830.00 83,835.00

Total 650,376,336.39 263,075,820.30

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 173

Section 8 Financial Report

Unit: Yuan

Aging Book balance at the end of the period Book balance at the beginning of the period

Within 1 year (including 1 year) 520,464,006.21 216,206,820.42 1 to 2 years 91,110,009.09 30,454,494.72 2 to 3 years 27,352,320.12 8,020,660.00 More than 3 years 11,450,000.97 8,393,845.16 3 to 4 years 11,064,480.25 254,420.16 4 to 5 years 155,520.72 0.00

More than 5 years 230,000.00 8,139,425.00 Total 650,376,336.39 263,075,820.30

3. Disclosure by category according to bad debt accrual method

Unit: Yuan

Ending balance Beginning balance

Book balance Provision for bad debts Book balance Provision for bad debts

Category Book Value Book Value

Amount Proportion Amount Provision proportion Amount Proportion Amount Provision proportion

Among them:

By group

650,376,336.39 100.00% 3,695,189.37 0.57% 646,681,147.02 263,075,820.30 100.00% 10,443,690.58 3.97% 252,632,129.72

Provision for bad debts

Among them:

Total 650,376,336.39 100.00% 3,695,189.37 0.57% 646,681,147.02 263,075,820.30 100.00% 10,443,690.58 3.97% 252,632,129.72

Provision for bad debts on a group basis: 3,695,189.37

Unit: Yuan

Ending balance

Name

Book balance Bad debt provision Provision ratio

Receivables from related party combinations within the company's consolidated scope 637,831,579.04

Aging combination 12,544,757.35 3,695,189.37 29.46% of which: within 1 year 849,382.84 42,469.14 5.00% 1-2 years 46,128.00 3,228.96 7.00% 2-3 years 249,245.54 37,386.83 15.00% 3-4 years 11,014,480.25 3,304,344.08 30.00% 4-5 years 155,520.72 77,760.36 50.00% More than 5 years 230,000.00 230,000.00 100.00% Total 650,376,336.39 3,695,189.37

Description of what this combination is based on:

Provision for bad debts is made based on the general expected credit loss model:

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 174

Section 8 Financial Report

Unit: Yuan

The first stage The second stage The third stage

Bad debt provision for the next 12 months Expected credit for the entire duration Expected credit for the entire duration Total

Expected credit losses Loss (no credit impairment has occurred) Loss (credit impairment has occurred)

Balance on January 1, 2025 1,005,679.74 19,160.79 9,418,850.05 10,443,690.58

The balance on January 1, 2025 in this period

--Transfer to the second stage -2,306.40 2,306.40

--Transfer to the third stage -17,447.19 17,447.19

Provision for the current period -960,904.20 -791.04 -5,786,805.97 -6,748,501.21 Balance on December 31, 2025 42,469.14 3,228.96 3,649,491.27 3,695,189.37

Basis for division of each stage and provision ratio for bad debts

Changes in book balances with significant changes in loss provision during the current period

Applicable √ Not applicable

4. Bad debt provisions accrued, recovered or reversed in the current period

Bad debt provisions for the current period:

Unit: Yuan

Amount of changes in the current period

Category Beginning Balance Ending Balance

Provision Recovery or transfer Write-off or write-off Others

Provision for bad debts by combination 10,443,690.58 -6,748,501.21 3,695,189.37 Total 10,443,690.58 -6,748,501.21 3,695,189.37

5. Other receivables with the top five closing balances collected by debtors

Unit: Yuan

Accounting for other receivables at the end of the period

Unit name Nature of payment Closing balance Account age Closing balance of bad debt provision

Proportion of total balance

Unit 1 Receivables from related parties within the consolidated scope of the company 337,466,216.50 Within 1 year 51.89%

Unit 2 Receivables from related parties within the consolidated scope of the company 137,054,067.09 Within 1 year 21.07%

205,875.17 yuan within 1 year,

Unit 3 Receivables from related parties within the consolidated scope of the company 102,015,735.77 Yuan 74,706,786.02 in 1-2 years, 15.69%

27,103,074.58 yuan in 2-3 years

Unit 4 Receivables from related parties within the consolidated scope of the company 43,773,921.45 Within 1 year 6.73%

Unit 5 Receivables from related parties within the consolidated scope of the company 16,300,000.00 1-2 years 2.51%

Total 636,609,940.81 97.89%

(3) Long-term equity investment

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 175

Section 8 Financial Report

Unit: Yuan

Ending balance Beginning balance

Project

Book balance Impairment provision Book value Book balance Impairment provision Book value

Investment in subsidiaries 4,625,491,370.13 4,625,491,370.13 4,480,715,401.50 4,480,715,401.50Total 4,625,491,370.13 4,625,491,370.13 4,480,715,401.50 4,480,715,401.50

1. Investment in subsidiaries Unit: Yuan

Increases and decreases in the current period

Balance at the beginning of the period Impairment provision Ending balance Impairment provision for the investee

(Book value) Opening balance Additional investment Decrease investment Provision for impairment Others (Book value) Closing balance

Anhui Yingke Medical Products Co., Ltd. 2,221,139,543.15 5,918,194.73 2,227,057,737.88 Jiangxi Yingke Medical Products Co., Ltd. 893,984,358.00 2,080,489.04 896,064,847.04 Shandong Yingke Medical Products Co., Ltd. 516,801,269.84 7,654,999.08 524,456,268.92 Jiangsu Intco Medical Products Co., Ltd. 178,625,921.00 2,051,432.97 180,677,353.97 Intco Medical Investment 216,001,715.68 111,589,490.00 327,591,205.68

Sing apore Pte. Ltd.

Anqing Intco Medical Industries Inc. 100,451,956.88 757,443.72 101,209,400.60 Intco Medical Industries Inc. 80,720,100.00 80,720,100.00 0.00 Anhui Yingyi Thermal Power Co., Ltd. 80,015,067.00 151,672.94 80,166,739.94 Jiangxi Yingcai Technology Co., Ltd. 50,418,398.35 47,955.42 50,466,353.77 Intco Europe Gmbh 37,004,664.00 37,004,664.00 Intco Medical Supplies (Hong Kong) Co., Ltd. 24,616,210.00 24,616,210.00 Shandong Yingke Medical Technology Co., Ltd. 20,920,072.48 4,625,186.31 25,545,258.79 Shanghai Yingyan Enterprise Management Co., Ltd. 13,000,899.00 13,000,899.00 Shanghai Yingen International Trade Co., Ltd. 13,535,107.88 2,607,272.62 16,142,380.50 Hainan Yingke Medical Technology Co., Ltd. 11,938,085.45 26,182.61 11,964,268.06 Shanghai Yingke ECG Medical Products Co., Ltd. 4,475,747.35 120,277.22 4,596,024.57 Shanghai Yingke Medical Supplies Co., Ltd. 2,734,178.00 2,734,178.00 0.00 Shanghai Yingmai International Trade Co., Ltd. 10,000,000.00 10,000,000.00 Anhui Guoyi Mold Technology Co., Ltd. 345,465.89 186,231.00 531,696.89 Anhui Yingcai Printing Technology Co., Ltd. 341,512.18 161,658.97 503,171.15 Anhui Kaize New Materials Co., Ltd. 415,546.37 927,681.77 1,343,228.14 Jiangsu Yingke Medical Equipment Co., Ltd. 145,703.00 145,703.00 Shandong Yingke Hygiene Products Co., Ltd. 3,880.00 46,840.18 50,720.18 Anhui Yinghai Smart Energy Co., Ltd. 3,080,000.00 7,830,000.00 169,516.83 11,079,516.83 PT Basic International Sumatera 470,632.31 470,632.31 PrimeMax Medical Industries, Inc. 80,720,100.00 80,720,100.00 Total 4,480,715,401.50 200,139,590.00 83,454,278.00 28,090,656.63 4,625,491,370.13

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 176

Section 8 Financial Report

(4) Operating income and operating costs Unit: Yuan

Amount for the current period Amount for the previous period

Project

revenue cost revenue cost

Main business 417,179,284.77 358,506,090.17 364,651,918.95 305,004,649.82 Other businesses 23,388,193.29 22,696,349.83 24,296,660.69 8,814,524.99 Total 440,567,478.06 381,202,440.00 388,948,579.64 313,819,174.81

Breakdown information of operating income and operating costs:

Unit: Yuan

Personal protective products Total

Contract classification

Operating income Operating cost Operating income Operating cost Business type

Among them:

Personal protective products 440,567,478.06 381,202,440.00 440,567,478.06 381,202,440.00Total 440,567,478.06 381,202,440.00 440,567,478.06 381,202,440.00

Information related to the transaction price allocated to the remaining performance obligations:

At the end of the reporting period, the amount of revenue corresponding to the performance obligations that have been signed but have not been performed or have not been completed is 294,383,841.00 yuan, of which 294,383,841.00 yuan is expected to be recognized in 2026.

(5) Investment income Unit: Yuan

Item Amount of current period Amount of previous period

Long-term equity investment income calculated using the cost method 300,000,000.00 Investment income obtained during the holding period of trading financial assets and other non-current financial assets 10,081,306.24

Investment income from disposal of long-term equity investments -982,618.53

Total 9,098,687.71 300,000,000.00

20. Supplementary information

(1) Detailed statement of non-recurring profits and losses for the current period

√ Applicable Not applicable Unit: Yuan

Item Amount Description

Profit and loss from disposal of non-current assets 13,554,511.38

Government subsidies included in current profits and losses (related to the company’s normal business operations)

43,301,339.33

Closely related, in line with national policies and regulations, and in accordance with determined standards

Except for government subsidies that have a lasting impact on the company’s profits and losses)

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 177

Section 8 Financial Report

Unit: Yuan

Item Amount Description

In addition to effective hedging business related to the company’s normal business operations,

Fair value of financial assets and financial liabilities held by non-financial enterprises 698,220,162.88

Gains and losses from changes in value and gains and losses arising from the disposal of financial assets and financial liabilities

Other non-operating income and expenses other than the above items -14,382,435.77

Less: Income tax impact 125,052,599.21

Amount of impact on minority shareholders’ equity (after tax) 1,792,309.56

Total 613,848,669.05 --

Details of other profit and loss items that meet the definition of non-recurring profits and losses:

Applicable √ Not applicable

The company has no other specific circumstances of profit and loss items that meet the definition of non-recurring profits and losses.

Explanation on defining the non-recurring profit and loss items listed in the "Explanatory Announcement No. 1 on Information Disclosure of Companies that Offer Securities to the Public - Non-recurring Profit and Loss" as recurring profit and loss items

Applicable √ Not applicable

(2) Return on net assets and earnings per share

Unit: Yuan

earnings per share

Profit during the reporting period Weighted average return on equity

Basic earnings per share (yuan/share) Diluted earnings per share (yuan/share)

Net profit attributable to the company's common shareholders 5.67% 1.58 1.57 Net profit attributable to the company's common shareholders after deducting non-recurring gains and losses 2.23% 0.62 0.62

(3) Differences in accounting data under domestic and foreign accounting standards

1. Differences in net profit and net assets in financial reports disclosed in accordance with both international accounting standards and Chinese accounting standards

Applicable √ Not applicable

2. Differences in net profit and net assets in financial reports disclosed in accordance with both foreign accounting standards and Chinese accounting standards

Applicable √ Not applicable

3. Explanation of reasons for differences in accounting data under domestic and foreign accounting standards. If differences are adjusted for data that have been audited by an overseas audit institution, the name of the overseas institution should be indicated.

Applicable √ Not applicable

Yingke Medical Technology Co., Ltd. 2025 Annual Report / 178